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Abstract 
Colorectal cancer treatment and survival is improving, but deprived patients continue to 
receive less than optimal treatment and have lower survival than affluent patients. 
Population-based data on all patients diagnosed with colorectal cancer in the North 
West (n=29,563) was linked to hospital admissions (n=6 million) to provide complete 
information on cancer diagnosis, treatment and other comorbid conditions. In order to 
handle incomplete data, particularly for stage at diagnosis, multiple imputation was 
used. 
Socioeconomic inequalities in survival have been attributed to deprived patients 
presenting at a more advanced stage or with more comorbid conditions than affluent. In 
this research there were no socioeconomic variations in stage at diagnosis but deprived 
patients did have higher levels of comorbidity, which may limit their treatment options. 
Even after taking clinical and demographic factors into account, deprived patients still 
received less adjuvant therapy, surgery from high-volume surgeons and treatment in 
compliance with clinical guidance 
Socioeconomic inequalities in survival were substantial at one year after diagnosis and 
could not be explained by clinical or demographic factors, such as stage and 
comorbidity. Even when deprived patients did receive the same treatment regime or 
surgery from a higher-volume hospital or higher-volume surgeon survival was lower. 
The factors contributing to these inequalities in treatment are complex including 
physical, social, lifestyle and clinical domains. Ensuring equal access to services and 
equal improvement in survival across all social groups will be a continuing challenge 
for the NHS. Ultimately, a universal health-care system may not be able to achieve 
equal survival, because of external factors that cannot be controlled, but ensuring 
equitable access would be expected to greatly reduce the inequalities in colorectal 
cancer survival. 
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The aims of this thesis 
The aim of this thesis was to identify factors that influence socioeconomic differences 
in survival in patients diagnosed with colorectal cancer in the North West Region of 
England 1997-2004. These assessments can then be used to inform public health policy 
and other initiatives targeted to decrease inequalities in survival in the UK. 
The underlying purpose of this thesis was to investigate the use of routine data sources 
to evaluate prognosis and patterns in colorectal cancer treatment, comorbid conditions, 
and stage and the impact on survival. Equity in the provision and quality of treatment 
was assessed with the subsequent impact on inequalities in survival evaluated. 
Secondary aims were to assess and develop the methodology for i) linking cancer 
registry data to administrative datasets, ii) estimating comorbid conditions and iii) 
multiple imputation of missing data for use in relative survival analysis. 
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Introduction 
Health inequalities have long been documented between socioeconomic groups and 
these inequalities have been seen in UK cancer patients with regard to incidence, 
mortality, survival lo3 and treatment.4•5 The inequalities have frequently been attributed 
to deprived patients presenting at a later clinical stage. However, even after adjustment 
for clinical stage at diagnosis, deprivation differences in survival persist.6•7 
Treatment is a major factor influencing outcomes at any gIven stage but clinical 
treatment regimes vary by prognostic factors, including age, stage, comorbidity and 
anatomic location. Some studies have found that treatment provision also varies by 
socioeconomic factors. 8olO National guidelines set out minimum standards for treatment. 
These guidelines are applicable to all patients regardless of their socioeconomic status, 
but new treatment regimes may nevertheless be implemented more quickly in some 
areas than others, thereby contributing to socioeconomic and geographic disparities in 
outcome. More controversially, implementation of new treatment regimes could be 
made available more rapidly for patients in some socioeconomic groups than others, 
independent of where they live. This could lead to persistence of socioeconomic 
disparities in outcome. After receiving treatment, some studies report the outcomes to 
be similar among all socioeconomic groups I I while others suggest it persists. 12 Research 
on the patterns of treatment given to cancer patients, both as a function of their 
socioeconomic status and in relation to the implementation of contemporary clinical 
practice guidelines, should help elucidate the impact of differential access to optimal 
treatment on socioeconomic differences in cancer survival. 
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Summary of objectives 
• To describe and identify factors, including age, socioeconomic status and stage 
at diagnosis, that influence colorectal cancer outcomes, type and quality of 
treatment, and to set these results in the context of the current literature. 
• To identify the factors contributing to differences in survival between 
socioeconomic groups in order to inform policy and future interventions. 
• To evaluate differences in treatment type, quality and provision by 
socioeconomic group and other demographic and clinical factors, and the extent 
to which these influence inequalities in survival. 
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Cancer 
Chapter 1 
Introduction 
Cancer is a term used to describe neoplasms, or new growth, resulting from 
uncontrolled proliferation of cells. "Cancer" is a term widely used to describe all 
neoplastic growths, however many different diseases are defined as cancer, each with 
different presentation, prognosis and treatment. Cancers develop due to genetic damage, 
which may happen randomly or as a result of exposure to carcinogens. Once a tumour 
has developed it will continue to grow even if carcinogens are removed. Tumours can 
be benign, in situ, or invasive, depending on their cell growth and behaviour. 
Benign tumour cells have mutations but appear very similar to the cells from which they 
originated. The tumour itself is generally encapsulated and can be removed relatively 
easily. Benign tumours are rarely fatal except for those arising within the central 
nervous system, which can cause fatal compressions of the brain. 
In situ tumours have malignant cells but are confined to the site of origin without 
invading the organ. The localised tumour can usually be removed easily without the 
need for further treatment. However, if left untreated an in situ tumour will invade the 
local organ and become an invasive tumour. In situ tumours are pre-invasive tumours 
with malignant cells present in the epithelium but there is no invasion beyond the basal 
lamina. 
Invasive malignant tumours will infiltrate adjacent tissues to gain access to further 
blood supplies to aid growth. If left untreated they will break away and spread through 
out the body, known as metastasis, ultimately leading to death. 
18 
Colorectal tumours 
Tumours of the colon and rectum can be benign, in situ or invasive. Benign tumours, 
also known as adenomas or polyps, develop into malignant adenocarcinomas at a slow 
rate with many polyps not progressing during the patient's life-time. 13-15 Adenomas are 
thought to occur due to mutations in the mucosal epithelium cells which regulated stem 
cell renewal, proliferation and differentiation. 16 
Adenocarcinomas develop from adenoma polyps which proliferate from glandular cells 
and are the most common type of colorectal cancer accounting for 90% to 95%.17 There 
are a number of other types of tumour defined by their histology including 
adenosquamous cell and neuroendocrine but these are much rarer with each accounting 
for less than 0.5% of all colorectal cancers. Approximately 4% of patients have more 
than one primary colorectal cancer tumour diagnosed. 
Polyps and colorectal cancer tumours are slow-growing which provides the possibility 
of early identification and removal. 13,17 Polyps are asymptomatic; they tend to be 
detected either incidentally or at screening. 
Symptoms of colorectal cancer can be non-specific and may include rectal bleeding, 
weight loss, abdominal pain, anaemia, diarrhoea, constipation or change in bowel 
habits. 17-19 Many patients are asymptomatic until late in the disease and therefore may 
present at a late stage. 13 However, in a study in France most patients were diagnosed 
after presenting with symptoms (78%) with a small minority (6%) diagnosed 
incidentally.2o A significant minority (14%) presented as an emergency with an 
obstructed or perforated bowel.20 In the Merscyside and Cheshire region, within the 
North West of England, 73% of colorectal patients presented with symptoms, but it was 
not possible to determine whether presentation was as an emergency or non-
emergency.21 Only 3% of patients were diagnosed incidentally. Patients who present 
with colorectal cancer as an emergency and require urgent surgery have higher rates of 
complication, re-operation, anastomotic leakage and mortality.22 
Sites 
Colorectal cancer includes cancers of both the colon and rectum. Anal cancer (lCD-tO 
C21) is rare and is not normally included in analysis of colorectal cancer. Colon cancers 
of the right side, including cancers of the caecum, ascending colon, hepatic flexure and 
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transverse colon have been increasing in relative frequency over time in England and 
Wales,23 and the USA. 16 A higher proportion of sigmoid cancers are found in countries 
with high colon cancer incidence,16 such as the UK. 
Colorectal cancer sites are unevenly distributed along the colorectum with the majority 
being diagnosed in the rectum (29%) and sigmoid colon (18%) (Figure 1.1 ).24,25 The 
tumour sub-site could not be determined or were unspecified in 15% of colorectal 
cancers diagnosed during 1997-2000 in England.24 In some patients, even after surgery, 
the primary site of origin cannot be determined because the tumour occured on the 
border of two sub-sites (overlapping). 
Figure 1.1: Anatomic sites of the Colon and Rectum 
Source: SEER. Anatomy of Colon and Rectum, 200626 
Colorectal cancer is more common in men than women. 16,23,27 Older men (over 65) are 
more likely to have left-sided tumours and younger women (under 65 years of age) are 
more likely to have right-sided colon tumours (excluding rectum). 16 
Tumour grade 
Tumour grade describes the histologic similarity of the tumour cells to their tissue of 
origin. Tumours that are similar to the original tissue are moderately differentiated or 
low-grade, whereas tumours that are dissimilar to the tissue they developed from are 
poorly or undifferentiated and are high-grade?8,29 High-grade tumours are generally 
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aggressive and have a poor prognosis. Colorectal cancer tumours are graded under the 
histopathological grading scheme which applies to all digestive system tumours, with 
tumours given a grade from I to IV. Grade I tumours have less than 25% of the cells 
undifferentiated with the proportion increasing until grade IV with over 75% of the cells 
undifferentiated. Grade is assigned on the basis of the tumour pathology and is subject 
to variation due to the subjective nature of classification and the variability within 
individual tumours. 
Tumour stage 
Stage is a measure of the extent of disease at diagnosis and is strongly correlated with a 
patients prognosis. Three staging systems are used for colorectal cancer: Dukes' ,30 
TNM29 and contemporary versions of Dukes' including Astler-Coller.31 The TNM 
staging system is also consistent with the American Joint Committee on Cancer (AJCC) 
and International Union Against Cancer (UICC) systems. TNM and Dukes' are the most 
widely used systems but it is possible to convert from one system to another to produce 
comparable stage. Stage can be determined for all malignant tumours with benign or in 
situ tumours as stage o. 
TNM and Dukes' stage is determined by the extent of spread through the layers that 
form the wall of the colorectum (T), extent of lymphatic involvement as determined by 
positive lymph nodes (N) and spread or metastasis (M). Malignant tumours are staged 
from I to IV with patients in stage IV having metastatic disease (Figure 1.2). 
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Figure 1.2: Colorectal tumour stage 
Source: University of Pittsburgh Cancer Centers, 200632 
Complete staging can only be done through post-operative pathology, however stage 
can be estimated pre-operatively through clinical symptoms and computed tomography 
and magnetic resonance imaging. In some cases, imaging can estimate tumour size 
accurately and positive lymph nodes. 
22 
Risk factors for colorectal cancer 
Overview 
The majority of colorectal cancers are caused by environmental and lifestyle factors 
although hereditary or inflammatory diseases cause about 10%.33 Colorectal cancer is a 
multi-factorial disease with increased risk associated with lifestyle choices including red 
meat consumption,B obesity,34,35 lack of physical activity34,35 and alcoho1.36 As with 
most cancers, risk increases with age and incidence is a slightly higher in men. 
World-wide, colorectal cancer is more common in westemised countries where 
individuals have a high-risk lifestyle compared to non-westemised countries. 16,37 
Migrant studies have found the risk of colorectal cancer to be similar to the general 
population in families that have immigrated within 1 or 2 generations, thereby 
reinforcing the importance of lifestyle characteristics on risk. 16,37.38 It is estimated that 
environmental factors account for over 70% of all colorectal cancers.37,39 
Age 
Colorectal cancer rarely occurs in individuals under 40 years of age but incidence and 
mortality rates increase consistently above age 40 (Figure 1.3) with the most common 
age at diagnosis being between 70 and 79. Incidence rates increase until the 80-84 age 
group and dropped after 85 years. Colorectal cancer death rates peak in the 75-79 age 
group and consistently increase with age. Men had consistently higher age-specific 
incidence and mortality rates. 
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Figure 1.3: Colorectal cancer incidence, North West England by age at diagnosis, 
1999-2003 
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Genetic syndromes account for 5-10% of all colorectal cancers. 19,39 A large proportion 
of the young adults diagnosed with colorectal cancers have tumours that can be 
attributed to genetic syndromes. 39 Some studies have suggested that patients diagnosed 
at younger ages tend to have a more aggressive and advanced disease40 although others 
are confl icti ng. 41 
A number of specific inherited conditions, which cause aggressive colorectal cancer 
have been identified. In these cases the cancer usually presents in young adulthood. The 
most common hereditary conditions are familial adenomatous polyposis (F AP) and 
hereditary non-polyposis colorectal cancer (HNPCC). F AP results in colorectal 
adenomas in many patients by the age of 15 and in almost all by the age of 40.39 
Patients with HNPCC have a 70-85% risk of developing colorectal cancer and are at 
increased risk of cancers of the digestive and genitourinary system.39 FAP and HNPCC 
patients develop a large number of adenomas; regular colonoscopy is required to 
monitor and remove these. The high probability of developing cancer in these patients 
often leads to preventative surgery to remove colon and rectum. 
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About 15% to 20% of colorectal patients may have a familial predisposition, without 
having a specific defined syndrome. 19,39 These patients have a close relative (1 sl degree) 
or history of colorectal cancer in the family and are twice as likely to develop colorectal 
cancer. 19 They may be at higher risk because of an, as yet, undermined hereditary 
syndrome. Alternatively, families may have similar lifestyles and therefore these 
cancers may be caused by similar environmental and lifestyles. 
Obesity and physical activity 
It is estimated that 3,000 colon cancers a year (10% of the total) are caused by obesity in 
the UK.35 Obesity, independent of physical activity and other risk factors, is positively 
associated with colon cancer risk34 and lower survival in colon patients.42 Obesity is 
commonly measured as body mass index but certain types of obesity are especially 
strong risk factors. Central obesity as measured by the hip-to-waist ratio is strongly 
associated with colon cancer risk34 and inversely associated with colon cancer 
survival.42 
There is an inverse relationship between physical activity and risk for colon cancer, 
even after adjustment for obesity and diet.34 However, analyses are difficult to interpret 
as individuals who are physically active tend to smoke less, use multivitamins, consume 
more fibre and consume less fat. 34 The biological mechanism for protection is also 
unclear, but physical activity may protect via a number of biochemical mechanisms 
including reduction of insulin resistance and hyperinsulinaemia.34 In addition to 
preventing colorectal cancer, being physically active may also improve survival. A 
cohort studied in Australia found improved colorectal cancer survival in individuals 
who exercise regularly, particularly those with colon cancer stage II or stage IIL42 
Diet 
A number of studies have investigated the association of colorectal cancer with diet, but 
the majority have been case-control studies which may suffer from recall bias, with 
inconsistent results. Studies of dietary intake have found vegetables to be protective 
however, it is unclear if the vitamin or fibre content is the protective factor. Some 
hypothesise that the increased fibre bulk and increased transit time associated with fruit 
and vegetables decreases the colon's exposure to toxins in the diet. Potentially 
protective dietary factors include fruits, vegetables, fibre and a diet low in red meat.34 
Intake of multivitamins, including folate, has been shown to decrease risk of colon 
cancer.
43 
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Consumption of red meat may increase the risk of colorectal cancer although in some 
studies the results have been not significant.33 Various mechanisms for the increased 
risk associated with red meat consumption have been suggested. The majority of the 
mechanisms for increased risk were associated with the high fat content of red meat. 
However, the relationship between fat intake and colorectal cancer has not been 
consistently shown.33 
Other factors 
In a meta-analysis of 8 cohort studies an increased relative risk of 1.23 (1.07-1.42) was 
found for individuals drinking more than 2 drinks per day on average.36 There was no 
elevated risk for individuals drinking less than 2 drinks per day. Type of drink or gender 
had no effect on colorectal cancer risk. Smoking was weakly associated with colorectal 
cancer38,39 but this effect may be confounded by the association between drinking and 
smoking. 
There is increasing evidence of a protective effect of postmenopausal hormone 
replacement therapy.37,44 For women on hormone replacement therapy, there appears to 
be a 35% decreased risk of colorectal cancer, which may last for up to 5 years after 
hormone use.44 
Regular and short-term aspirin use decreased the risk of adenomas, with a relative risk 
of 0.8-0.5 depending on the dose.45 A decrease in the risk of coiorectal cancer has yet to 
be shown but is plausible. 
Prevention 
Individuals could reduce their risk by decreasing or eliminating exposure to risk factors. 
Identifying cancers at an early stage with screening or prevention in high-risk 
individuals by prophylactic surgery is estimated to reduce overall incidence by only 
1.0% and mortality by 1.0% to 2.5%.13 To have an impact on population incidence and 
mortality, interventions must reach a large number of patients. Screening is one of the 
most effective methods to identify colorectal cancer at the early stages, enabling early 
treatment and better outcomes and was initiated in the UK for people aged 60 to 69 by 
2009. 
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Reorganisation of treatment services to provide the most effective and timely treatment 
possible is estimated to decrease mortality by 10% but cannot reduce incidence.13 The 
decrease in mortality can be attributed to treatment by specialist staff, adherence to 
guidelines and collaboration of staff in multi-disciplinary teams. Increased use of 
adjuvant radiotherapy and chemotherapy will continue to improve survival and decrease 
mortality by a further 1-2% and 2-3% respectively.13 These treatment protocols are 
included in guidelines already in use, therefore a further decrease in mortality should be 
occurring now or in the near future. 
Treatment and clinical management 
Overview 
Treatment for colorectal cancer can include surgery, chemotherapy and/or radiotherapy. 
The modality and combination of treatment will vary depending on the sub-site, stage of 
disease and other clinical factors. 
Surgery 
Surgery is the most common treatment, either as the sole treatment or in combination 
with radiotherapy and/or chemotherapy. It is the only treatment with the potential of 
'cure', and up to 40% of patients achieve cure after surgery.46 In a population-based 
study in Yorkshire, during 1986 to 1993,80% of patients received surgery.47 Surgery 
removes the tumour and the associated segment of the colon or rectum, with its blood 
supply, regional lymph nodes and adjoining tissues. These are then assessed by the 
pathologist, and the pathological stage of disease ascertained, in conjunction with 
imaging. The stage of disease cannot be accurately estimated until after surgery (and 
pathology) at which point initial care plans may change. Pre-cancerous adenomas can 
be removed during colonoscopy and generally no further treatment is necessary. 
Once the tumour and adjoining tissue are removed, the colon is reconstructed with a 
reconnection of the colon (anastomosis). Where there is a bowel obstruction and an 
anastomosis cannot be done at initial surgery and a colostomy bag may be fitted. For 
many patients a colostomy is temporary and the colon can be anatomised at a later time. 
Colostomies are more common for patients presenting as an emergency. Laparoscopic 
colectomy is now being used in some cases because it reduces the chance of infection, is 
less invasive, minimises the risk to the patient and decreases postoperative pain.48.s1 
27 
Curative surgery for rectal cancer can be undertaken by anterior resection with total 
mesorectal excision or by a more extensive abdominoperineal excision. Mesorectal 
excision is now the recommended method of surgery but is dependent on the tumour 
being 5 to 9 em above the anus. If the tumour is close the anus anterior resection is the 
preferred method. However abdominoperineal excision was still used in 27% of rectal 
surgeries during 1997 to 2004.9 Generally, most of the mesentery will be removed 
during rectal surgery as it contains lymph nodes which may already be invaded by 
tumour cells and need to be checked for tumours cells in order to completely assess 
stage of disease. For some patients the rectum may be entirely removed and a colostomy 
performed however in some cases it is possible to remove the rectum and connect the 
colon directly to the anus. Surgery for rectal cancer has a high risk of leaks and less 
control over bowel function. 
Palliative8 surgery is undertaken to reduce symptoms including bleeding and blockages. 
In colorectal cancer patients, metastatases are most frequently found in adjacent organs 
or liver and these can be resected at the same time. If the tumour has invaded adjacent 
organs, removal may not be technically possible and a bypass (ileotransverse bypass) or 
faecal diversion through astoma can be done. If the patient is found to have unresectable 
late stage disease at laparoscopy, no further operative procedure may be offered (open-
and-close). For some patients the most appropriate treatment may not be surgery due to 
metastatic (stage IV) disease at diagnosis, the location of tumour, comorbidities or a 
combination ofthese.47 
Surgeon experience and specialist training may influence surgical outcomes, the choice 
of surgical technique and quality of surgery. Patients are treated by specialist colorectal 
surgeons, surgeons with high colorectal cancer case-loads or at high-volume hospitals 
II h b . I 4752-54 genera y ave etter surglca outcomes. . 
Patients presenting as an emergency have more complications, including higher 
mortality, reoperationb rates and anastomotic leakages.22 These patients tend to present 
at later stages but due to the urgent nature may not be treated by a specialist. 
• Palliative treatment or care is not aimed at curing a patient but at reducing symptoms or pain, at slowing 
rrogression. 
Re-operation describes any subsequent surgery to repair a feature of the primary surgery. It may involve 
surgery at the same site, or at another site for the same condition. 
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Potential complications from surgery include infection, bleeding and adhesions that may 
lead to bowel obstruction in the longer term. Complications with anastomosis (rejoining 
of the cut ends of the colon after tumour excision) can also be carried out. 
Radiotherapy 
Radiotherapy is mainly used for rectal cancer. It is not recommended for colon cancer 
because the small intestine, which would also be irradiated, does not tolerate radiation 
well. Radiotherapy and chemotherapy are normally given in combination for rectal 
cancer, as chemotherapy makes the tumour cells more sensitive to radiotherapy. Long-
course radiotherapy is used pre-operatively to shrink larger tumours for resection. 
Larger tumours (stage III) are generally treated for five weeks, with radiotherapy 
stopping a few weeks before surgery. For smaller tumours, a short-course of radio- and 
chemotherapy is usually performed the week before surgery which substantially 
decreases the chances of rectal cancer recurrence.55 
In some circumstances post-operative radiotherapy may be offered to patients who 
haven't had pre-operative radiotherapy. It may be recommended if the tumour was 
difficult to resect or tumour cells are considered likely to remain, and will probably be 
used in combination with chemotherapy. 
Chemotherapy 
Chemotherapy may be given pre-operatively (neo-adjuvant therapy), to reduce tumour 
size and growth, or post-operatively (adjuvant therapy C) , to decrease tumour size, slow 
tumour growth or treat and prevent metastasis. It can be given at a number of points 
during the patient pathway, including pre-operatively (to reduce tumour size), 
palliatively, post-operatively and adjuvantly. Adjuvant therapy is when a treatment is 
given to prevent potential metastatic disease but there is no evidence that metastatic 
disease is present. About 25% of patients experience a local recurrence after surgery, 
suggesting that microscopic tumours remained following surgery. These microscopic 
tumours may be eliminated with adjuvant chemotherapy. 
More appropriate use of chemotherapy, the advent of 5-fluorouracil (5-FU) and new 
chemotherapy regimes, have produced better response rates and modest improvements 
29 
in survival.56,57 For many years 5-fluorouracil (5-FU) and then 5-FU and folic acid 
given intravenously have been the standard chemotherapy treatment for colorectal 
cancer.
56 Adjuvant chemotherapy for stage III colon cancer is the standard treatment 
and improves survival but the benefit to stage II patients remains unclear. 56 Pre-
operative neo-adjuvant chemotherapy decreases tumour size, resulting in improved 
colorectal resectability and in a reduction in hepatic metastasis.56 Patients in stage I are 
not offered chemotherapy, but some stage II patients may be offered chemotherapy as 
part of a clinical trial. Rectal cancer patients may be offered chemotherapy and 
radiotherapy together pre-operatively for stage II and III tumours. 
A newer platinum-based drug called oxaliplatin is recommended only for patients with 
liver metastases that may be resected following down-sizing.58 For patients with 
advanced disease, 5FU with or without oxaliplatin or irinotecan is recommended.58 
Lymph-node sampling is vital to identify patients who will benefit from adjuvant 
chemotherapy59 but its frequency varies both internally and by hospital.55,6o The 
accuracy of stage improves with an increasing number of lymph nodes sampled61 
(usually> 12) but lymph node sampling is dependent both on the surgeon excising the 
tumour by wide margins (to maximise the number of lymph nodes), and on the 
pathologist testing and recording a large number of lymph nodes for tumour-positive 
status. 
New treatments 
A number of new treatments are aimed at reducing recurrence, including anti-
inflammatory drugs, monoclonal antibodies and vaccines. Monoclonal antibodies are 
normally produced by the immune system but are produced in very large quantities in 
the lab to induce the patients immune system to specifically target tumour cells. 
However, they are expensive and not generally approved by the National Institute for 
Health and Clinical Excellence (NICE) which provides guidance and recommends 
treatment protocols. Monoclonal antibodies are not currently approved as first line 
treatment for colorectal cancer in the NHS but are sometimes prescribed in private 
treatment.62.63 Cetuximab was one of the monoclonal antibodies NICE attempted to 
evaluate for first line treatment of metastatic colorectal cancer but the evaluation was 
terminated because the manufacturer did not submit evidence. 
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Follow-up 
There are no guidelines for follow-up after colorectal cancer in the UK but patients 
generally receive regular check-ups and colorectal screening in the first year after 
surgery and the every five years up to age 75 years; however the impact on survival is 
not clear. Recurrence occurs in 2.4% to 40% of rectal cases64 of cases. 
Epidemiology 
National 
Cancer is one of the leading causes of mortality and morbidity in England, with one in 
three people developing cancer during a typical lifetime (aged up to 74-79 years). 
Colorectal cancer is the third most common cancer in men (second in women) and the 
third most common cause of cancer death, accounting for 28,000 cases and 13,000 
deaths per year in England.65 The annual number of incident colorectal cancer cases has 
increased by 20% for men and 5% for women in England from 1971 to 1997.23 
Conversely, mortality has fallen by 24% for men and 37% for women while 5-year 
relative survival has increased from 22% for colon cancer and 27% for rectal cancer in 
1971-7523 to over 47% in 1996-99.1 These improvements have been attributed to both 
earlier diagnosis and improved treatment(s), most notably surgical techniques. 1,20,66 
However, there are still large differences in survival regionally, nationally and 
internationally. 
North West of England perspective 
Incidence & mortality 
The incidence of most cancers, including colorectal cancer, is higher in the North of 
England and Scotland, than the English average, probably due to the historic high levels 
of smoking, occupational exposures and socioeconomic deprivation.67 For colorectal 
cancer men in the North West had significantly higher incidence and mortality rates 
than the UK and Ireland average but in women only the mortality rate in the North West 
was higher.67 Colorectal cancer incidence and mortality were highest in the populated 
urban and socioeconomically deprived areas of the region, including Manchester, 
Liverpool, Salford, Sefton, Wigan and St. Helens68 (Figure 1.4). 
31 
Figure 1.4: Standardised mortality ratio and standardised incidence ratio (SMR 
and SIR, %) in the North West of England relative to England (100%), men, 2001-
2005. 
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Source: Lemon D el al. 2007.69 
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Incidence 
The North West has a population of 6.8 million with 48% men. The population 
distribution is typical of a developed country (Figure 1.5), with a small proportion in the 
younger age groups and the proportion in the older age groups increasing over time as 
the birth rate declines. Under the age of 20, there were more men than women but as 
the mortality rate in men increased with increasing age, particularly in the age range 15 
to 29, the population of men is lower than women by the 20-24 age group. The 
mortality rate in men continues to be higher than women at subsequent ages and women 
continue to out-number men, with the difference increasing substantially in age groups 
over 70. In the oldest age group (85 and over) there was almost three times the number 
of women than men. The population in the 20-24 year age group is markedly lower than 
the younger and older population because these individuals may be away in higher 
education. 
32 
Figure 1.5: Population pyramid: annual average population for the North West of 
England, 1998-2003. 
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Socioeconomic deprivation 
The North West has a high proportion of deprived areas relati ve to the Engli sh average, 
and over 50% (expected 40%) of the population in the two most deprived groups and 
33% (expected 20%) in the most deprived group alone68(Figure 1.6). Liverpool was the 
most deprived area in England with 72% of its population in the most deprived group. 
But conversely the North West also has many areas of affluence including Congiton, 
Cheshire, which had the highest proportion of the population in the most affluent group 
at 57% in England.68 Within the North West the most deprived areas were Liverpool, 
Manchester and Knowsley and the most affluent areas were Cheshire, Conglton, Ribble 
Valley and Macclesfield.68 
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Figure 1.6: Percentage of the population by socio-economic deprivation category, 
England 2001 
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The North West had historically high levels of unemployment since the decline of the 
shipping and manufacturing industry in the 1980's. In 1991 Liverpool and Knows ley 
had the highest rates of unemployment in England at 36% and 26%, respective ly.70 
Employment rates in the North West have improved to 58% compared to a national 
average of 6 1 %.71 However, the North West still has a higher than average 
unemployment rate at 5.1 % with Liverpool having the highest in the North West at 
11.1 %.71 
General Health 
Indicators of health across the North West show a clustering of negative indicators 
around the deprived communities. "Binge drinking" was highest in Liverpool (27.8%), 
Knows ley (24.9%) and Manchester (24 .8%) compared with the national average of 
18.2%.70 The prevalence of smoking mirrors that of binge drinking, with the urban 
centres of Knowsley (3 5.4%), Manchester (33.3%) and Liverpool (33 .1 %) having 
higher prevalence than the UK average.70 Obesity rates are generally high in deprived 
areas, however adult obesity levels were low in Liverpool , Manchester and 
Macclesfi e ld .7o 
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There are a number of government financial schemes for individuals out of work or 
unable to work due to ill health, which are claimed at much higher proportions in the 
NW, particularly deprived in the deprived populations. Attendance allowance, which is 
paid to those over 65 with care needs or the terminally ill, was taken up by a higher 
proportion of the population in Liverpool, St Helens, and Knowsley than the national 
average but did not vary by deprivation.68 In contrast incapacity benefit, which is paid 
to individuals who are unable to work due to disability or sickness, varies substantially 
by deprivation with those in the deprived group six times more likely to be claiming.68 
Liverpool, Manchester and Knowsley had incapacity benefit rates over twice the 
national average.68 
Summary 
The North West has higher incidence and mortality rates of cancer in general and 
colorectal cancer in particular than the English average. Part of this excess mortality 
may be attributed to the higher levels of socioeconomic deprivation, clustered in the 
urban centres. Overall health in the region is also worse than the national average, with 
the areas with the worst health also clustered in the urban centres. However, there is 
geographic and socioeconomic variation in health and cancer rates, with the rural and 
affluent areas in the region having much better health. Further quantification of the 
inequalities in survival and description of the influences on these inequalities will be 
discussed in the literature review. 
Study rationale 
Despite extensive long-term investment aimed at reducing inequalities in health, there 
remain substantial gaps in outcomes for many diseases, including colorectal cancer. The 
causes of these differences remain unclear. The remainder of this thesis will focus on 
variations in prognostic and clinical factors which may account for the socioeconomic 
differences in colorectal cancer survival. 
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Chapter 2: 
Inequalities in survival and prognostic factors 
Overview 
This chapter summarises the results of a systematic review of published literature on 
prognostic factors, d treatment and survival in colorectal cancer. The searches were 
limited to articles published since 1990. 
Search strategy 
Reproducible database searches of Pubmed, I EMBASE,2 Web of Knowledge,3 HMIC,4 
SIGLE,4 Cochrane reviewss and Google Scholar6 were conducted in January 2007. The 
title, key words and topic were searched for the terms defined in the text box below. 
Terms 3 and 4 were necessary to limit the search and were used in combination with a 
site description. Terms 1 to 4 combined were used sequentially with each of terms 5 to 
8. The first and second search terms and pseudonyms, including rectum and colorectal, 
were used in all searches. The fourth term was used to limit the search to population-
based studies, and to remove clinical trials. 
Terms 1 to 4 were entered together 
(1) Colon 
(2) Rectum 
(3) Cancer 
_____ --'r-. or Colorectal or rectal 
(4) Registry data or population-based 
Terms 1 to 4 were then combined individually with each of the following: 
(5) Grade 
(6) Treatment or surgery or chemotherapy or radiotherapy 
(7) Survival 
(8) Comorbidity or comorbid 
These searches were augmented by searches of the International Agency for Research 
on Cancer (IARC) publications list. 7 The bibliography in each reference was then 
d Prognostic factors available include: sex, age, stage, grade, sub-site of tumour, tumour 
histology, place of residence, comorbidity and socioeconomic group. 
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reviewed by hand for relevant references. This process continued until no further 
references were found. 
Survival 
Colorectal cancer survival 
Variations in survival between countries have mainly been attributed to differences in 
stage,8,9 treatment9 and socioeconomic levels. JO Colon and rectal cancer survival has 
been lower in England than Europe, II and both are substantially lower than in the 
USA. 8,9 Over the past 30 years relative survival at five years after diagnosis for colon 
rectal cancer has nearly doubled in the England and Wales from 26% in 1971-75 12 to 
47% in 1996-9913 and is expected to improve to 52% for patients diagnosed in 2000-
01. 13 Relative survival at five years for rectal cancer also increased with greater 
improvement occurring for women. There was a relative survival of 28% for rectal 
caner patients diagnosed during 1971-7512 with survival increasing to 48.7% in men and 
51.3% in women during 1996-99. 13 
In the NW health region of England, colorectal cancer survival at five years was 4% to 
5% lower than England and Wales for 1986-90, both within socioeconomic groups and 
overall. 12,14 There was variation in survival across the North West, with Greater 
Manchester and Merseyside and Cheshire health authorities continuing to have survival 
below the national average,14 whereas Cumbria and Lancashire had colon cancer 
survival similar to England for cases diagnosed in 1995-97.14 This pattern was not seen 
for other cancer types. 
There is higher incidence and mortality9,13,IS and lower relative survivaI9,J3,IS-17 for 
patients living in deprived areas compared to patients living in affluent areas. In 
England and Wales during 1996-99, five-year relative survival for colon cancer was 
5.4% higher for affluent men than for deprived. 13 For women the inequality in five year 
relative survival for colon cancer between affluent and deprived patients, or 'deprivation 
gap', was 8.3%. The deprivation gap was larger for rectal cancer patients, at 9.4% in 
men and 8.3% in women. 13 Survival has improved for colon and rectal cancer in all 
socioeconomic groups but the improvements have been greatest amongst patients from 
affluent areas. Between 1986 and 1999 the deprivation gap increased every five years 
by 1.9% for colon and 2.4% for rectal cancer in men (2.2% and 2.5% in women, 
respectively). 13 
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The North West region contains a relatively high proportion of deprived areas and as a 
result has many more incident cases in the deprived group than the affluent. The North 
West also has some of the lowest cancer survival in England mainly due to the high 
proportion of deprived patients in the North West and the association of socioeconomic 
status with lower survival. 12 
Socioeconomic variations in colorectal cancer mortality, and hence survival, have been 
attributed to a complex interaction of clinical, health system factors, social and patient 
factors (Figure 2.1).18 The inter-relationships of many of these quantifiable factors such 
as stage, age, grade and comorbidity on colorectal cancer survival have been studied 
with each having a section of the literature devoted to them. Whilst each of these factors 
directly influence survival they also influence which treatment is clinically appropriate. 
Treatment receipt may also be influenced by less quantifiable factors (e.g. general 
hea lth, health knowledge, engagement in clinical process), either through the patients or 
physicians perception of its impact. For example, patients with poorer general health 
may believe treatment will be less effective and delay seeking health care or prefer a 
less invasive treatment. Alternatively, a physician may perceive that a patient with poor 
general health is unlikely to withstand surgery or chemotherapy. The influence of these 
qualitative factors on socioeconomic inequalities in survival are difficult determine, but 
may explain some of the residual socioeconomic inequalities in survival seen in some 
studies, even after adjustment for most clinical factors. 19,20 
Figure 2.1: Oncological health disparities model 
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International and regional comparability 
Survival differences between countries and regions can be influenced by completeness 
and accuracy of registration. The impact of cancer registration completeness and 
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accuracy on the European and UK survival was evaluated by Prior et al. by modelling 
the effect on survival of excluding death certificate only (DCO)e cases, excluding 
clinically diagnosed cases and misdiagnosing in situ cases as malignant.21 By excluding 
cases with only a clinical diagnosis researchers found survival estimates close to the 
European rates and suggested that survival differences between the UK and Europe 
could be partially attributed to incomplete registration by European registries?l It was 
suggested that European registries could bias their data and produce higher survival 
estimates by under registering cases diagnosed clinically or at death, as they are likely 
to be patients with poorer prognosis. However, more recent international studies have 
consistently found colorectal survival in the UK to be lower22,23 indicating that 
differences in data collection only partially explains the lower survival, with the UK 
having a 'true' lower survival rate. For comparisons in the UK, these inconsistencies in 
data collection are not an issue as there is a nationalised standard method of registration 
which includes the registration of cases clinically diagnosed or diagnosed near death. 
Stage 
Late stage at diagnosis is strongly associated with poor survival for colorectal cancer 
patients (Figure 2.2). A population-based analysis, covering at least 14%, of US 
colorectal cancer patients diagnosed during 1996-2002 found patients with localised 
disease had a five-year relative survival of over 80% compared with 8% for patients in 
stage IV.24 In Singapore a population-based study of colorectal cancer found five-year 
survival for patients with stage I-III improved from 25% to 66% for males (23% to 
66% for females) between 1968-72 and 1988-92, but no improvement occurred for 
patients with stage IV disease.2s Improvements in colorectal cancer survival over time 
may be partially attributed to the shift in stage at diagnosis, in addition to advances in 
treatment. Clinical audits in Dijon, France, and Glasgow, Scotland, found that there was 
a shift towards earlier stage between the 1970s and 1990s.26,27 In Dijon the audit of 
2,289 colon cancer patients found the proportion of cancers diagnosed in stage I and II 
increased from 40% in 1976 to 57% in 1991. Similarly an audit of 999 patients 
diagnosed during 1974-79 or 1991-94 and treated at Glasgow Royal Infirmary the 
proportion of colorectal cancer diagnosed in stage I or II increased from 31 % in 1974-
79 to 42% in 1991-94. Diagnosis at an earlier stage improves survival both because 
treatment is more effective and it adds a lead time. For some patients, with an 
aggressive cancer or other illnesses, diagnosis at an earlier stage will not delay the time 
C Death Certificate Only (DCO) registration occurs when the only infonnation about a patient is found on 
the death certificate. 
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of death, In these patients diagnosis at an earlier time increases survival but does not 
influence the ultimate outcome or time of death thereby adding lead time, 
There is conflicting evidence on whether patients from deprived socioeconomic groups 
present at later stages,16,17,28.3I ,31.33 Some studies have found an association between 
lower socioeconomic status and late stage tumours28,29 while others have found no 
association,I6,I7,31 ,33,34 Stage at diagnosis is an important prognostic factor for 
, 183335 b f d' 'f d" d 'd ' survlva " ut even a ter a Justmg or stage at lagnosls epnve patients had lower 
survival. l6,17 A study of outcomes after colorectal cancer surgery in Central Scotland, 
for patients diagnosed during 1991-94, found that after adjusting for stage, the majority 
of the excess mortality in lower socioeconomic groups was post-operative mortality, 
most notably after curative surgery.16 
Figure 2.2: Five-year relative survival by stage at diagnosis for colorectal cancer, 
all ages, all races, 1988-2002, USA 
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D 'd ' l'k 1 17,37 P t' t t' epnve patients are more J e y to present as an emergency, a len s presen mg as 
emergencies have lower survival than non-emergency patients37 which may support the 
hypothesis that deprived patients are diagnosed at a more advanced stage or have more 
comorbid conditions, Few studies have been able to adjust for all the important 
prognostic factors; possibly due to the large sample size necessary, However, an audit 
study of patients diagnosed in Wessex, England, adjusted for most factors and found 
socioeconomic inequalities persisted after adjustment for age, sex, stage, co-morbidities 
and treatment. 17 Socioeconomic inequalities in colorectal cancer survival were also 
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found in a population-based London study during 1980-1989.38 These variations could 
not be explained by stage. 
It has been suggested that deprived patients may be more likely to have 'occult'f 
metastasis l6 which could explain why residual inequalities in survival remain even after 
adjusting for most prognostic factors. Occult metastatic disease may be more common 
in deprived patients because there is a i) biological differences in tumours ii) poorer 
general health in deprived patients iii) diagnostic assessments are less thorough in 
deprived patients and metastatic disease. There is evidence that patients from different 
socioeconomic groups do tend to have different histological and sub-sites of colorectal 
cancer, with the deprived groups having more distal cancers and adenocarcinomas, 
although no socioeconomic differences in survival were seen.31 There has been little 
published work on biological variations by socioeconomic group for colorectal cancer. 
Comorbidity has been associated with deprived patients in many studies.34,39,4o Deprived 
patients may be more likely to have poorer overall health because of higher prevalence 
of lifestyle factors, even without specific comorbid conditions, that may compromise 
the immune systems ability to fight or prevent illness.41 Lower levels of surgery may 
explain both the higher proportion of missing data for stage and lower survival in 
deprived patients however, whether lower surgical rates are clinical appropriate is 
difficult to determine. 
Treatment regimes are stage_specific.42,43 Complete staging requires both wide margins 
to be excised by surgeon and multiple lymph node sampling to be conducted by the 
pathologist. Complete staging is mainly done at the same time as surgery44 but staging 
is sometimes done clinically, by CT or MR!. For rectal cancer patients, tumour size 
from the TNM staging system was most predictive of survival whereas nodal status 
predictive of the likelihood of recurrence.45 Sufficient lymph node sampling and 
staging was most likely with specialist treatment but there is a correlation between 
specialist treatment and affluence, with affluent patients being most likely to be 
admitted to a high volume hospitals.37 In addition, the proportion of patients having 
surgery is also higher in more affluent patients.37 Consequently, deprived patients are 
more likely to have missing stage information.46 
f The spread of cancer cells from the primary site with secondary tumours that are too small to be 
clinically detected at the time of diagnosis (micrometastasis). 
46 
Missing stage 
For some patients, staging information is missing or unavailable, either because the 
information was not available to the cancer registry or because stage was not recorded. 
Frequently, patients with late stage tumours have missing data for stage because 
detailed staging was not required for curative treatment. Patients without a stage are 
older, later stage and deprived46-48 and generally have an intermediary survival 
experience between early (Stage I) and advanced stage (Stage IV) indicating there is a 
mix of stages in the unknown and missing category (Figure 2.2). Most cancer registries 
have a large portion of cancers with missing data for stage making it impossible to 
produce stage-specific survival for these patients.49 Unfortunately, colorectal cancer 
symptoms are non-specific or absent until the later stages therefore many patients will 
present late in the course of disease. 
Subdivision of stages 
Patients in stage III have a mixed prognosis, with some responding well to treatment 
and others, likely those with distant metastasis, not responding to treatment.so Some 
studies and staging systemss1 have subdivided stage III to distinguish differing 
prognosis.so Sub-division of stage III into three groups, based on tumour invasion in 
patients without metastatic disease, was found to produce substantial differences in 
survival rates of 80%, 60% and 30% at five years.so Subdivision by tumour and nodal 
status was less effective, and produced only two groups with 60% and 30% survival.so 
The three stages determined using tumour status were effective at identifying 
heterogeneity in stage III patients and may be clinically useful as the further subdivision 
identified patients in stage III who may have survival probabilities similar to stage II 
patients. 50 
Grade 
There are very few epidemiological studies of grade and survival in colorectal cancer 
patients. Poorly differentiated tumours were associated with decreased survival.52 This 
may be particularly pronounced in the elderly with post-operative mortality higher in 
patients aged over 80 and highly undifferentiated cells (grade III and IV).53 Stage is a 
stronger prognostic indicator than grade with most studies incorporating some measure 
of stage rather than grade. 
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Ethnicity 
Ethnicity is strongly associated with many factors including migration, socioeconomic 
status, culture, environmental exposure, income and childhood experience. 54 Ethnic 
groups in some regions, particularly the US, can be closely associated with lower 
socioeconomic status. Incidence, mortality and survival have been shown to vary by 
ethnicity in the US 18,20,33,55-58 but there is little published work in the UK. Certain ethnic 
groups, particularly Jewish populations, are known to be at higher risk of cancer due to 
genetic mutations59,6o but these have been related to incidence, rather than survival. A 
population-based study, covering up to 14% of the US colorectal cancer patients 
diagnosed during 1975 to 1999, identified socioeconomic differences within ethnicity 
groups, with affluent patients having survival up to 10% higher than deprived.33 
However, when ethnic groups in the USA received equivalent treatment responses are 
similar.61 ,62 
Historical diet is an important risk factor for colorectal cancer, however there is little or 
no work on the diet and ethnicity. Particularly relevant may be nutrition in early 
childhood which for many ethnic individuals would have occurred outside their current 
country of residence. As the variations in survival by ethnicity are so large and wide-
spread it is unlikely to be due only to genetics but the interplay of many factors, with 
the importance of each factor also varying by ethnic group. Data on ethnicity in UK is 
poor and in the North West only 3% are an ethnic minority making analysis by ethnicity 
not possible in this study. 
Comorbidity 
Comorbidity, or illnesses other than the colorectal cancer, may vary by demographic 
factors and are more common in patients who are 0lder39 and of lower socioeconomic 
status.17.63.64 Comorbidity may affect how clinically appropriate and effective treatments 
can be, therefore, it is necessary to adjust for comorbidity to make accurate comparisons 
of survival. Comorbidity measures are regularly recorded in clinical and audit studies 
through case note review or patient assessment at diagnosis. Measuring comorbidity for 
population-based data can be more challenging because of the number of cases. In most 
population-based cancer registry data administrative datasets are used to measure 
comorbidity, while practical these datasets may have problems with bias, inaccurate 
coding and coding or system changes over time. There is no 'gold standard' method for 
measuring comorbidity various methods based on: time spent in hospital (bed-days),64 
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previously diagnosed diseases (e.g. asthma, diabetes, arthritis)65-68 69 or scoring based on 
clinical judgement.7o The most widely used and validated method67,71 was developed by 
Charlson et al. in 198766 and is based on previously diagnosed illnesses. The Charlson 
comorbidity score is a weighted summary score originally developed to reflect the 
relative risk of death at one year for medical inpatients in a New York hospital and 
validated on breast cancer patients at another hospita1.66 It has since been validated on 
larger studies of cancer patients39,71,72 and other diseases67,68,73-76 which have found it to 
be a robust and accurate measure of comorbidity. 
Deprived cancer patients tend to have higher levels of comorbidity I 7,63,64 and emergency 
hospital admission37,64 than affluent patients. Both are independently associated with 
lower survival. In the North West region, deprivation was associated with increased 
hospitalisation rates for colorectal cancer.77 Deprived patients were twice as likely as 
affluent patients to be admitted as an emergency rather than as an elective hospital 
admission.32,37 After adjusting for comorbidity, differences in colon and rectal cancer 
survival by socioeconomic status remain,32,64 but they are larger for colon cancer and 
may be non-significant in rectal cancer.64 
Co-occurrence of colorectal cancer with other conditions, such as heart disease, 
pulmonary disease and diabetes,78 is unsurprising because the risk factors are similar or 
overlapping, with increased risk associated with environmental and lifestyle factors. The 
most commonly identified comorbid conditions for colorectal cancer patients are 
cardiovascular disease, chronic obstructive pulmonary disease (COPD), hypertension, 
diabetes and previous cancers. These associations are consistent regardless of 
methodology.34,39,79,80 Cardiovascular and COPD significantly lowered survivae9,80,81 
however, the impact of other illnesses on survival was not consistent. A case-control 
study in Hong Kong found increased risk of colorectal tumours in patients with 
coronary artery disease (CAD), metabolic syndrome and a history of smoking,78 
although it is unclear if this is solely due to the overlapping risk factors for these 
conditions. 
Comorbid conditions in colorectal cancer patients increase the complexity of treatment, 
particularly surgery, and decrease survival26 and life expectancy.80 The severity and 
number of comorbid conditions increases with age.34,39,39,7I,79,81 In a population-based 
study of colorectal patients diagnosed between 1993-95 and registered at Eindhoven 
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cancer registry, Netherlands, 26% of men (34% of women) under 70 at diagnosis had 
comorbidity, but that increased to 51 % of men (56% of women) over 70 at diagnosis.39 
The highest level of comorbidity was associated with tumours of the ascending colon at 
52% and decreased along the large colon to 44% for cancers of the rectum. Comorbidity 
did not effect surgery rates but was associated with lower short-term surviva1.39 The 
increase in comorbidity in elderly patients makes clinical management more complex 
and influences prognosis. 
A registry-based study in Eindhoven, Netherlands of colorectal patients diagnosed 
during 1993-95, found an association between stage at diagnosis and comorbidity after 
adjustment for age.39 Higher rates of comorbidity occurred in patients diagnosed at an 
earlier stage which was attributed to an incidental diagnosis of early colorectal cancer 
while receiving regular monitoring for a concomitant condition/9 or a detection bias. 
Even after adjusting for stage and age, both survival and life expectancy decreased 
consistently with increasing comorbidity.39,39,8o A population-based study in the USA 
during 1993 to 1999 which covered 14% of the country found stage-specific life 
expectancy decreased with increasing comorbidity even after adjustment for age. Men 
diagnosed at age 81 with stage I colorectal cancer and no comorbid conditions had a life 
expectancy of over 10 years (14 years for women) but this decreased to 4 years for men 
with 3 or more conditions (5 years for women).80 The strong association between 
comorbid conditions and survival highlights the importance of adjustment for 
comorbidity when evaluating other factors, such as age or stage, in epidemiological 
studies. 
Age 
Survival from colorectal cancer decreases with increasing age17,32,32,82-84 but this is 
particularly pronounced for survival at one year.25,83 Lower short-term survival in the 
elderly may be due to various factors, including late presentation and comorbidity, 
which can influence the clinical appropriateness of treatment. Clinical guidance does 
not exclude elderly patients from treatment,43,85,86 but the presence of comorbidity may 
influence whether a given treatment is appropriate. The proportion of elderly patients 
offered treatment, including adjuvant and palliative care, seems to have increased over 
time in the Cote-d'Or region, France,26 and in a meta-analysis of colorectal cancer 
treatment in the elderll7 but this may in part be due to an improvement in the general 
health of elderly patients, enabling more curative treatment. A literature review of 
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treatment concluded that curative treatment in the elderly did not lead to higher rates of 
complications or toxicity compared with younger patients,87 and that survival from 
curative surgery was similar regardless of the patient's age. There is less trial evidence 
for the appropriateness of specific treatments in elderly patients, because most clinical 
trials are limited to patients under 75.87 Although the data on older ages is limited, in a 
trial for breast cancer the effectiveness of treatment was not modified by age.88 Breast 
cancer surgery for older women has evolved over time from avoiding surgery, to 
preference for mastectomy to breast conserving surgery, which generally always 
occurred for younger patients. 
A meta-analysis of colorectal cancer treatment in the elderly concluded that older 
patients were more likely to delay appointments, and to present at a later stage.87 
Treatment delays in elderly colorectal cancer patients were also found in a survey of 
cancer patients in England and Wales during 1999 to 2000.89 However, active treatment 
may not be implemented for elderly patients due to patients' or physicians' beliefs about 
the ability to withstand treatment, or about life expectancy. A population-based study of 
colorectal cancer patients diagnosed during 1986 to 1994 in Yorkshire found lower rates 
of treatment in elderly patients,32 although some studies have found elderly patients 
were more likely to have missing data on treatment which may have influenced these 
analyses.32,48 Even if treatment is not intended as not curative, treatment substantially 
improved survival and without increasing the proportion of adverse effects in elderly 
patients.87 In a population-based study of colorectal cancer patients diagnosed between 
1976 and 1998 in the Cote-d'Or region, France, the proportion of patients receiving 
surgical resection increased from 69% to 91 % over the period with the largest increases 
in the elderly (56% to 90%).26 Increasing levels of surgery in older patients may be 
partially due to shifts toward earlier stage at diagnosis and fewer comorbid conditions 
but it is unlikely the magnitude of these changes explains the increase in surgery. 
Some degree of ageism in the treatment of the elderly likely occurs either because of 
perceived life expectancy, quality of life or the impact of comorbidity. In the UK, age 
was associated with treatment delays in the elderll9 and lower rates of treatment.32 
Elderly patients are more likely to have missing data, such as stage and treatment, 
which makes comparison of clinically appropriate treatment regimes difficult.48 The 
influence of a patient's perception of these and the influence of their physician on the 
patient's treatment choices is less clear. Most studies of patient choice have consistently 
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found most patients prefer to take a passive role in treatment decisions and relying on 
their physician to make the decision.90 This is evidence to suggest that the treatment 
decisions are not directed by patient refusal. 
Gender 
Many studies in the UK have found that women have higher survival for colon32,82,91 or 
rectal 13 cancer, although this has not been found in all studies. 1Z The survival advantage 
among women has been attributed to differences in immunological responses to 
surgery.91 Testosterone had a detrimental effect on the immune response to trauma,9Z,93 
but female sex hormones had a positive impact on the immune responses.94 
Rurality 
In rural communities the inequalities differ dramatically from those of urban because 
the organisation, availability and range of health services offered will be different from 
that of an urban or suburban area.95 Colorectal cancer patients living in rural settings 
were seen sooner, but were less likely to receive radiotherapy96 and surgery.Z6 The 
excess travel and different accessibility experienced by rural patients may influence 
diagnostic and treatment choices and living farther from a cancer centre was associated 
with lower survival82,97 and a higher chance of being a DCO.97 This is supported by the 
evidence that rural patients presented with more advanced disease at diagnosis98 and 
their treatment was not as well managed compared to urban patients.99 As a result there 
are differences in colorectal cancer survival in patients resident in urban compared with 
rural areas, even after adjustment for socioeconomic factors. 97 Patients living in a rural 
setting had 5-year survival 11 % lower than urban settings.97 However, these studies 
were based in Scotland where rural communities can be very isolated and travel times 
longer than in England, and may not be directly comparable to England. While the 
degree of difference may not be as extreme, rural and urban differences are likely to 
also exist in the North West. 
Other factors 
Lifestyle factors, such as diet and exercise, are risk factors for colorectal cancer but 
there is little work on the impact of these on survival. A case-control study of colorectal 
cancer in France found five-year survival was improved by a diet high in energy, 
however there was no effect on survival at ten years. IOO Physical activity, body mas'; 
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indexg and food type had no effect. 100 This study alludes to a possible effect of diet on 
five-year survival, but it has many methodological problems including small sample 
size, lack of cause of death information and recall bias. It is most likely that diet is 
associated with other factors, such as overall fitness and lack of co-morbidities, which 
influence treatment options and survival directly. 
Socioeconomic status 
In the UK there are wide variations in life expectancy by socioeconomic status. 
Deprived individuals have a life expectancy on average 5 years less than the most 
affluent individuals. 101 The North West has the lowest life expectancy in the UK for 
men and second lowest for women, a pattern mainly attributed to the geographic 
patterns of socioeconomic deprivation. 101 Socioeconomic status is a proxy for 
exposure(s) and lifestyle, including diet, physical activity, environmental factors, 
smoking and drinking status, which are all risk factors for colorectal cancer. Lower 
socioeconomic groups have higher exposure to disease (and cancer) risk factors, 
including smoking, obesity, high fat foods, lower fruit and vegetable consumption, 102 
higher alcohol consumption and lower levels of physical activity.77 As a result, residents 
from lower socioeconomic groups are more likely to report their health as "not good" 
than more affluent residents. l03 There may also be an association between low 
socioeconomic status and lower levels of access to health services and specialists. 
Unfortunately, variations in outcome by socioeconomic groups are widening for many 
diseases, including cancer,13 which has contributed to a widening of the life expectancy 
differences. 
Socioeconomic inequality in biological agmg has been proposed as a possible 
contributing factor to socioeconomic inequalities in surviva1.41 This could occur when 
accumulation of cellular damage, including genes, occurs as people age, but this process 
could be increased by exposure to environmental factors, like smoking and radiation. 
Patients in lower socioeconomic groups may be disproportionately exposed to these 
factors, thereby accumulating more cellular damage and having a higher risk of cancer 
and worse prognosis due to co-morbidities.41 Deprivation has been associated with 
younger age at diagnosis for colorectal cancer,41 which may support this hypothesis. 
B Body Mass Index is a measure of ideal weight 
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While patients may be interested in the absolute inequalities to compare differences 
across region and other variables it is necessary to adjust for socioeconomic status and 
other variables that differ by socioeconomic group (age, stage, comorbidity). For 
relative survival analysis, it is necessary to create socioeconomic-specific life tables to 
take account of underlying differences in life expectancy. Failure to do this would result 
in an inaccurate estimate of the survival gap as the underlying mortality would not be 
representative of the population from which patients derive. 104 Socioeconomic 
differences in relative survival are reduced when socioeconomic group specific life 
tables are used. 104 
Measuring socioeconomic status 
There are a number of ways to categorise the socioeconomic status of individuals. 
Socioeconomic measures can be based on individual level data such as employment 
type, education level and income. Historically, socioeconomic assessments were done 
using these data, but in practice, holding sensitive information like this is rarely done 
and can be easily biased by self-reporting. 
Alternatively, ecological methods for determining socioeconomic status are increasing 
in popularity. Many ecological socioeconomic measures are available including 
Carstairs' index,lOs Index of Multiple Deprivation 2000 106 and 2004,107 the Jarman 
under-privileged area score l08 and the Townsend Deprivation Score. I09 Regardless of 
the type of deprivation measure used, a deprivation gap in survival persists, but the 
magnitude of the differences varies. I 10 
Ecologically defined socioeconomic measures are based on the area in which a patient 
lives, usually at diagnosis. Routinely recorded measures associated with geography can 
be used to assign socioeconomic measures based on regular surveys including the 
decentennial census, the Health and Lifestyles Surveylll and the British Household 
Survey.112 In the past, measures based on the voter tum-out, subscribers/donors for 
charities and government surveys have all been used. ll3 Index of multiple deprivation 
is currently the most common method and is based on regularly recorded administrative 
data for the seven domains of: income, employment, health deprivation and disability, 
education skills and training, barriers to housing and services, crime and the living 
environment. Prior to 2001 socioeconomic status was measured at each census. 
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Socioeconomic inequalities in survival are influenced by the geographic area used to 
assign the index, but not by the socioeconomic index used. 11D Ecologically defined 
socioeconomic categories have been assigned at various geographic sizes and levels 
including census enumeration district (ED), lower level super-output area (SOA) and 
electoral ward, which consist of an average of 440, 1500 and 6000 residents, 
respectively. I 10 Measures based on ward are available for all census years while ED is 
available for 1991 and SOA is available for 2001. Deprivation measures based on small 
areas (ED, SOA) were highly correlated with individual level of deprivation but larger 
area measures (wards) were more heterogeneous thereby averaging the inequalities and 
diluting the final measure."4 Deprivation measures based on larger populations (wards) 
result in smaller socioeconomic differences in incidence"5 and survival"O,16 and are 
not good predictors of health."4 Additionally, ward population size varies from 100 to 
30,000 people resulting in an inconsistent measure of socioeconomic status. IIO,116 
Smaller area measures, both SOA and ED, produced socioeconomic differences which 
were 25% larger than with ward measures. IIO It is also important that the size of 
geographic unit is similar over time to avoid changes due to alteration in geographic 
groupings and the associated dilution effects. 
A comparison of ward- and SOA-based geographic units for assigning socioeconomic 
group was analysed with national incidence data. I 15 Socioeconomic score, a sum of the 
census measures, was assigned to a geographic area (SOA or ward). The geography was 
then ordered sequentially in ascending order (affluent scores to deprived scores) and 
grouped into five categories. Categories were grouped by populations, so that a one fifth 
of the population (9.8 million) is in each group, or into equal numbers of ward or SOAs. 
Grouping by population was found to produce consistent and larger deprivation 
differences for incidence. I 15 
A registry-based study in England of the methodology of ecological socioeconomic 
measures compared the use of ward- and SOA-based socioeconomic measures in 
survival analysis of colorectal cancer. Their findings were consistent with other 
studies110 based on SOA level measures producing a consistent inverse relationship with 
survival and a larger number of significant deprivation gaps. Regardless of the measure 
used, there has been consistent improvement in the survival within each socioeconomic 
group but there is no evidence that the deprivation gap is decreasing. 1 16 The deprivation 
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gap for colorectal cancer was mainly due to the large deprivation gap in patients under 
70 at diagnosis (9.3%).116 
Ecological socioeconomic groups are defined based on area of residence. As 
socioeconomic status is based on area of residence at diagnosis it may not necessarily 
be representative of the patients' current or historical socioeconomic group. Generally, 
people living in the same area have similar levels of deprivation but this may not be true 
for all individuals. Additionally, the affluence and hence socioeconomic category, a 
patient currently lives may be very different to their historic socioeconomic status. This 
is particularly relevant for cancers where exposure to risk factors occurs years or 
decades before cancer diagnosis. Some argue that patients' illness may result in 
economic hardship and cause a shift to lower socioeconomic group rather than a lower 
socioeconomic group being a risk factor for diseases. 
Treatment 
Most colorectal cancer patients receIve some form of surgery, radiotherapy and/or 
chemotherapy treatment. 52 Treatment regimes and combinations have evolved over time 
as new equipment, techniques, and drugs have become available. 
Surgery 
After adjustment for stage and socioeconomic status, differences in survival have been 
attributed to differences in surgery.I3,26,84,117 Recent improvements in surgery include 
new approaches to surgical excision (e.g. total mesorectal excision, laparoscopic 
surgery), greater standardisation of treatment protocols, improvements in surgical 
technique, and peri-operative treatment.27 Improvements in surgery have been attributed 
to increased use of in antibiotics, better management of anaesthesia and fluid balance, 
decreased blood loss, wider tissue dissection, and most notably radical resection of the 
circumferential margin.27 
A hospital-based study of colorectal cancer patients in Glasgow, Scotland, in 1974-1979 
and 1991-1994 found that more patients in 1991-94 received curative surgery and fewer 
palliative surgery, with both curative and palliative surgery patients having better 
survival.27 Post-operative mortality also decreased from 14% to 9%, due to 
improvements in peri-operative care. The study concluded that improvements in peri-
operative care had led to fewer anastomotic leakages and abscesses, possible due to 
increased use of antibiotics and treatment by specialists. 
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A population-based study of colorectal patients in the Cote-d'Or region, France, during 
1976 to 2003 found the proportion of patients resected for cure increased over time both 
for patients with localised disease and for patients with distant metastases.84 Patients 
with colon cancer were more likely to undergo resection than rectal cancer patients. 
Improvements in long-term survival were only seen in patients undergoing curative 
resection. 
Surgical outcomes may be effected by their surgeon experience and specialist training, 
which may influence the choice of surgical technique and quality of surgery. Surgical 
outcomes are improved when patients are treated by specialist colorectal surgeons, 
surgeons with high colorectal cancer case-loads or at high-volume hospitals.1 7,32,118,119 
The type of surgery received has a striking effect on patient outcomes. Patients who 
received total mesorectal excision (TME) anterior resection for rectal cancer had 
significantly lower recurrence rates, and higher survival than those who received blunt 
dissection.85,12o,121 TME decreased recurrence and anastomotic leakage, and improved 
sphincter control and survival.32,12o 
Surgeon-related factors 
Surgical outcomes are better when patients are treated by specialist colorectal surgeons, 
surgeons with high colorectal case loads and/or high-volume hospitalsy,32,118,1I9 
Patients treated by these surgeons are more likely to have a histologically confirmed 
diagnosis, and to receive surgical treatment and adjuvant chemotherapy.32,122 Active 
treatment was higher for patients treated by surgeons with high case-loads. Active 
treatment was 93% for patients treated by high-volume surgeons compared to 81.5% in 
low-volume surgeons.32 However, this may be an over-estimation because there was no 
adjustment for case-mix and patients with a particularly bad prognosis are more likely 
to be treated by a local surgeon rather than referred on to specialist services.32 
Some studies of the effect of high-volume surgeons and surgeon specialisation have 
found conflicting results,32,45,119 but these may be attributed to differences in definitions 
or sample size. A population-based study of all patients diagnosed in the Northern and 
Yorkshire region of England found that patients had better management and outcomes 
in high-volume hospitals or with high-volume surgeons.32 The study defined high-
volume hospitals as those treating more than 128 cases per year and high-volume 
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consultants were defined as those who treated more than 36 patients per year. There 
was also a gradient in post-operative mortality by socioeconomic group with deprived 
patients having from 0.4% to 2.7% higher mortality depending on the sub-site of 
cancer.32 Recurrence was not evaluated in this study. This was the largest study and had 
the highest case-load defining high-volume surgeons, therefore may be the most easily 
transferable across the NHS. 
A study based at five hospitals in Edmonton, Canada, between 1983 and 1990 found 
higher survival and lower local recurrence for patients treated by a colorectal specialist 
or high-volume surgeon. I 19 They defined high-volume surgeons as those treating more 
than 21 patients and specialists as those trained in colorectal surgery. Similarly, a case-
note review study of 673 patients in the mid-western USA with stage II or stage III 
rectal cancer45 also found high-volume surgeons, defined as over 10 cases per year, had 
lower recurrence rates.45 
A study of 927 colorectal cases diagnosed during the first half of 1993 in the Greater 
Manchester area of England found an association between hospital volume and survival, 
but consultant volume did not significantly affect survival. 118 In contrast to the other 
studies mortality increased with the increasing number of operations undertaken by 
consultants, even after adjusting for age, stage, sex and site of tumour. I IS This may be 
due to higher mortality rates for high-volume consultants because they are undertaking 
more complex cases. This study was carried out in 1993, prior to the release and 
implementation of colorectal cancer clinical guidance, and may not represent the current 
situation. 
A Swiss study of patients entered in two colorectal cancer trials during 1981 to 1993 
found surgeon training level (certified vs. in-training) and training hospital (university 
vs. non-university) were not associated with survival or local recurrence, but case-load 
at both surgeon and hospital level was associated with increased survival and lower 
probability of local recurrence. 123 In Switzerland, the majority of patients are treated by 
general surgeons, so the direct comparability with the UK's system of specialised 
treatment may not be appropriate. However, the main difficulty in the transferability of 
findings is the low threshold of 5 cases per year used to determine high-volume 
surgeons and 26 cases per year for high-volume hospitals. 
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Improved outcomes when treated by specialists and high-volume surgeons have been 
attributed to their higher likelihood of following treatment guidelines and more 
extensive lymph node harvesting which enables accurate staging and treatment. 124 
Ensuring that patients are treated by these specialists, and surgeon availability, vary by 
hospital and region. 32 It may be particularly difficult to ensure specialist treatment and 
surgery for cases presenting as an emergency, especially for initial surgery. 
The evidence on high-volume or teaching hospitals having lower post-operative 
mortality and higher long term survival is less clear, but any effect is likely to be a 
'proxy' for training and or the experience of the treating physicians. 122 The definition of 
high-volume or specialty hospital seems to be key in determining survival and treatment 
differences. Two Swedish studies identified improved survival and adherence to 
treatment protocols in university hospitals and general district hospitals. 125,126 The 
majority of studies have focussed on volume as a measure of the surgeons skill, 
expertise or quality of treatment l22 but the exact volume needed is not clear. The 
complexity of surgery was not accounted for in any of the studies but may be argued 
that surgical choice is influenced by experience. Workshops on surgical technique and 
national education programmes aimed at improving surgeon skills effectively improved 
the quality of care for rectal cancer patients and increased the use of TME.120,122 
The main limitation of all these studies is the lack of any quality of surgery data as 
volume can only ever be a proxy for experience, and whether or not this is a direct 
measure of surgical quality is not entirely clear. There is an argument for not adjusting 
for surgical technique as this is a measure of the surgeons experience and training l23 but 
the lack of data on this area is the real limitation. As volume is easily obtained it will 
likely remain the main estimate of surgical quality. 
Chemotherapy 
Chemotherapy improves prognosis and survival by decreasing tumour size before 
surgery and preventing metastases after surgery. Older colorectal patients were less 
likely to receive chemotherapy.96,96,127 The proportion of older patients receiving 
chemotherapy improved in a study of colorectal cancer patients diagnosed during 1976 
to 2003 Cote-d'Or region, France.84 
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Deprived patients are less likely to receive chemotherapy.32,96,127 A population-based 
study of colorectal cancer patients in Yorkshire during 1986 to 1994 found patients 
were most likely to receive chemotherapy if their hospital of first admission provided 
chemotherapy.32 However, no association was found after adjustment for stage.32 
A population-based national study in Scotland between 1990 and 1994 of patients 
diagnosed under age 75 found patients aged 64 to 75 were most likely to receive 
chemotherapy compared with younger and older patients, although the extremely 
elderly (over 90) were the least likely to receive chemotherapy.127 In a population-
based study the age distribution for chemotherapy treatment was attributed to 
inadequate access to health care services and fitness for treatment associated with 
patients age at diagnosis.1 27 However, stage at diagnosis was not included in the 
analysis so it is not possible to determine if lack of staging information or difference in 
stage at diagnosis played a roll in treatment provision. 
Radiotherapy 
Radiotherapy is effective at decreasing recurrence particularly for patients with rectal 
cancer in stages I or II at diagnosis.1 21 Pre-operative radiotherapy is the recommended 
treatment for rectal cancer, decreasing the chance of local recurrence by up to 40%85 
and increasing survival at 5 years by 6% to 9%.85,128 In England and Wales guidelines 
published in 1997 recommended radiotherapy is given with chemotherapy, as it makes 
the cancer more sensitive to radiotherapy.42 Post-operative radiotherapy is generally 
limited to patients at high risk for recurrence85 but has, as yet, not shown a survival or 
recurrence benefit. In a population-based cancer registry study of colorectal cancer in 
Yorkshire during 1986 to 1994 the proportion of rectal cancer patients treated with 
radiotherapy increased (8% during 1986-88 to 14% during 1992-94).32 To my 
knowledge, there have been no further population-based survival analyses of 
radiotherapy treatment for UK colorectal cancer patients since the Yorkshire study. The 
Yorkshire study did not find socioeconomic variations in radiotherapy treatment but 
further population based studies are needed. 
There is an inverse association between radiotherapy provision and age with patients 
over 85 least likely to receive radiotherapy.129 In the US, ethnic differences have also 
been found with black patients receiving less radiotherapy than other ethnic groupS.129 
In a US study of adjuvant therapy, physicians stated reasons for lack of chemotherapy 
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and radiotherapy provision were patient refusal (22% for radiotherapy), comorbidity, 
and lack of clinical indication were the main reasons. 129 
Future prevention 
Screening 
In the future, earlier diagnosis may be achieved through the national colorectal cancer 
screening programme in individuals aged 60 to 69 years old, which started in parts of 
the North West in September 2006 with national coverage by 2009. Screening for 
colorectal cancer can help to reduce mortality by identifying and treating cancers at 
earlier stage with deaths from colorectal cancer are estimated to drop by up to 16% in 
60 to 69 year 01ds.130 In the longer term incidence in the age group following the 
screening age, those aged over 70's, will decrease as tumours are detected while 
individuals are in their 60's by the screening programme. 
Reducing inequalities 
Clinical guidance in the National Health Service (NHS) aims to ensure effective and 
consistent treatment, standards and procedures across regions and services but is not 
mandatory. They can help to reduce variations across the health service that could 
contribute to inequalities. Guidance published in 1995, recommends a centralisation of 
cancer services resulting in more patients receiving treatment from specialist clinicians 
and treatment occurring at a cancer centre, which each have been shown to improve 
surgical outcomes and survival.32,118,119,123 The national cancer plan (2000)131 and the 
cancer reform strategy (2007)132 provided further resources and centralisation of 
services, including the implementation of Multidisciplinary team meetings. Both of 
these plans aimed to decrease inequalities and improve cancer treatment and survival. 
There is still regional variation but the implementation of guidance has improved 
outcomes for patients. 133,134 When interventions to improve population health are 
introduced, they improve health in all groups but larger improvements are usually seen 
in the affluent socioeconomic groups due to faster and higher take-up, resulting in a 
widening in inequalities.135 Reducing inequalities may be achieved by targeting 
resources specifically at the deprived group to obtain improvements in the deprived 
faster than in the affluent. 135,136 To address this issue, the English government initiated 
a "Programme for Action" in 2003 which was a policy across many government 
. d f . 1'" h 1 h 136 Th departments aimed at tackhng the poverty an causes 0 mequa Itles m ea t . e 
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complexity of health inequalities required the government to address many issues not 
directly related to health, such as poverty, smoking cessation, early years support for 
families, poor housing and educational development. These interventions were not 
aimed specifically at cancer but should also decrease inequalities in cancer, although the 
impact may take many years with initial results indicating the programme has not yet 
improved the gap in life expectancy.137 However, the target for decreasing mortality in 
the under 75s by 20% by 2010 wiII be reached. 137 
Inequalities have a substantial impact on mortality in colorectal cancer. An evaluation 
of the impact of inequalities estimated that by reducing rates of colorectal cancer in the 
deprived health authorities to the rates in the affluent health authorities 5,590 cases and 
2,370 deaths per year could be avoided in the UK and Ireland. 138 This identifies an area 
where major improvements can be made by reducing risk factors, encouraging healthy 
lifestyles and ensuring equal access to health services in deprived socioeconomic 
groups. 
An analysis of national cancer data in England in the 1990's quantified the impact 
improvements in cancer survival over time had on patients and found an increasing 
proportion achieved a normal life expectancy after diagnosis. 139 The largest 
improvements in survival occurred in cancers with newly introduced treatments, but 
these cancers accounted for relatively few incident cases. 139 For common cancers even 
small increases in survival had a large impact and resulted in substantial numbers of 
lives gained. 139 Improvements in survival between 1981-85 and 1986-90 in England and 
Wales resulted in 6% lower mortality (2,560 deaths) for colon cancer and4% lower 
mortality (1,090 deaths) for rectal cancer than would have been expected otherwise. 139 
Most of the avoided deaths occurred in patients aged under 75. 
Summary 
Colorectal cancer survival has been improving but continues to be lower in the UK, 
particularly the North West, than the European average and in the USA. Most of the 
recent improvements in survival have been attributed to improvements in surgical 
technique and chemotherapy regimes. Survival is influenced by lifestyle factors, 
treatment and stage at diagnosis, all of which are known to vary by socioeconomic 
status. The cause of inequalities in colorectal cancer survival remains unclear with it 
attributed to variations in stage, comorbidity, type and quality of treatment. Generally 
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population-based studies are limited by mIssmg data for stage, comorbidity and 
treatment, making plausible inferences difficult. In the following thesis I will evaluate 
the impact of comorbidity, clinical factors (including stage) and treatment have on the 
deprivation gap. 
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Overview 
Chapter 3 
Materials and data 
Data from population-based cancer registries are ideal for analysing incidence and 
survival but they are known to have incomplete treatment details and do not normally 
record details of comorbid conditions. By contrast, routine hospital discharge records, 
which are collected to evaluate activity for payment, provide in principle a complete 
record of treatment and comorbidity that can be used in population-based 
epidemiological studies. For this thesis, demographic and tumour details will be taken 
from cancer registry data. Cancer registry data will be linked to Hospital Episode 
Statistics (HES) to augment the treatment details, thereby improving the completeness 
of surgical details. Only 67% of patients were recorded as having surgery in cancer 
registry data but this increased to 82% after information from HES was also used. For 
each colorectal patient recorded at the cancer registry information on comorbidity, or 
previous illnesses, will be obtained from HES for previous hospital admissions. This 
chapter describes the type of data collected by both cancer registries and HES, and the 
methods of data management and linkage, and the creation and definition of new 
variables to create the analytical dataset. 
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Cancer Registry data 
Data collection 
Cancer registries collect information on cancer diagnosis, treatment and demographics 
(Appendix 3.1) to a consistent national standard. I Initial notification of tumours occurs 
through the provision of pathology, cytology, haematology, hospital records or death 
records. (Figure 3.1). After initial notification, hospital records, general practitioners 
and other sources are checked for information on treatment and stage. Other registries 
will provide details of a North West resident diagnosed or treated in their region. 
In the UK, death details for cancer patients, necessary to analyse survival, are relatively 
complete. The National Strategic Tracing Service (NSTS) provides death details to the 
cancer registry for patients registered with cancer and individuals with cancer 
mentioned on the death certificate. NSTS also provides missing core patient 
demographic details such as gender, name, address, date of birth for cancer 
registrations. 
Figure 3.1: Cancer registration pathways 
Pathology report or Death certificate 
.-Search for previous 
registrations for the patient 
Obtain and link demographic, diagnostic or 
treatment data 
Add death details 
(if not registered 
from death) 
Merseyside and Cheshire Cancer Registry (MCCR) and North West Cancer Registry 
(NWCR) both collect information in a broadly similar manner, although there are some 
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differences in the collection of treatment and stage data. In MCCR, during the period 
covered by this research cancer (1997-2004) registration officers collected treatment 
and staging information mainly from case-notes or electronic hospital records (mainly 
from the specialist cancer centre). At NWCR clinical coders in each hospital complete a 
registration cancer registry form providing demographic, personal, diagnostic and 
treatment details. In order to ensure accurate coding by hospital staff, a NWCR Quality 
Assurance officer regularly visits hospitals to train hospital clinical coders and audit 
case-notes. 
MCCR recorded registrations on a person- and tumour-based system providing an 
internal linkage for patients with multiple tumours. The NWCR database was only 
tumour-based. Since 2006, treatment and staging information has been collected 
electronically from hospital trusts. 
Data 
Data were extracted from NWCR (28/09/2006) and MCCR (10/02/2007) for all resident 
colorectal cancer patients (lCD-10 C 18-C20) diagnosed between 1997 and 2004 in 
separate linkable files for tumour, treatment and stage details (3 for NWCR, 3 for 
MCCR) (Appendix 3.1). The tumour and treatment data were managed separately until 
the final step because the treatment data was episode-based (Le. containing a separate 
row for each treatment episode), rather than tumour-based (Le. one record for each 
tumour). 
Demographic details 
Demographic information, such as name, address and date of birth, is obtained from 
pathology reports and confirmed by the tracing service (Appendix 3.1). Pathology 
reports do not record NHS number but this is obtained from the tracing service or other 
hospital records. 
Tumour details 
Each Cancer registration record contains the specific tumour details of cancer site, 
histology, stage, grade and date of diagnosis for every incident case. Colorectal cancer 
is normally confirmed pathologically, enabling the specific histological type of tumour 
to be determined, by microscopic verification (MV). Colorectal cancer confirmed by 
cytology was also considered microscopically verified, although this is uncommon for 
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colorectal tumours. Histology is recorded as a five digit number using the International 
Classification of Diseases for Oncology 2nd edition (ICD-02) morphology coding 
system.2 The final digit denotes the tumour behaviour (e.g. invasive, benign). When 
multiple pathology infonnation is received for the same colorectal cancer (i.e. the 
patient has more than one operation) the most recent or specific is used. Histology can 
be non-specific (e.g. neoplasm, not otherwise specified) or specific (e.g. mucinous or 
serous). Non-specific coding occurs when pathology is unavailable or insufficient to 
detennine specific histology. 
The most accurate method of staging is through a combination of pathological 
assessment of tumour tissue and of the associated lymph nodes. In order to fully assess 
stage it is necessary to comprehensively sample at least 12 lymph nodes during 
surgery.3 Cancer registries record stage at diagnosis from pathology records, clinical 
diagnosis and other sources (case-notes or electronic hospital records). 
Treatment 
Cancer registries record the date of treatment, type of procedure, surgeon and hospital 
for any surgery, chemotherapy or radiotherapy treatment within 6 months of diagnosis. 
For chemotherapy and radiotherapy, only the first instance is recorded. Surgery type 
was coded to the Office of Population, Census, and Surveys: Classification of 
Interventions and Procedures, 4th Revision (OPCS-4). Treating surgeon was recorded 
as the General Medical Council code for MCCR and HES. NWCR records the treating 
surgeon in free text, so for surgeon volume analysis, HES data will be substituted. 
Dataset cleaning 
All adults aged 15-99 years diagnosed with a first primary invasive, malignant 
colorectal cancer (lCD-to CI8-C20) between 1997 and 2004 who were resident in the 
North West of England and registered in the North West Cancer Intelligence Service 
were eligible for analysis. The dataset was then checked for incorrect or rare coding 
combinations, further checks of age and dates were conducted before excluding 
ineligible patients. 
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Quality assurance 
All tumours were checked for correct morphology and site combinations using the 
International Agency for Cancer Research checking programme (IACR tools v2.0 
IARC),4 a widely used tool for quality assuring cancer registry data. There were seven 
tumours (0.02%) identified with a rare morphology (malignant melanoma NOS, mixed 
malignant tumour and malignant teratoma) 
h but after case-note review were found to be correct. IARC checks were routinely used 
(normally every quarter) to quality assure the data, so the low proportion of errors was 
expected. Only 33 patients were under the age of 19 (0.1 %) at diagnosis. For these 
patients, registry notes were reviewed by a registration officer and no errors were found. 
NHS number was missing for some patients diagnosed during the 1990s (124 cases 
from MCCR, 852 cases from NWCR). National Strategic Tracing Service was used to 
obtain NHS number for these patients but 55 (0.2%) remained missing (42 cases from 
MCCR, 13 cases for NWCR). 
Exclusions 
Of the 30,656 eligible patients, 1,799 cases (or 6% of cases) were excluded because 
they were outside of age limits «15 or >99), death certificate only (DCO) or a second 
primary (Table 3.1). The remaining dataset included 29,563 patients who were linked to 
data for HES to provide additional clinical information. There were no significant 
differences in the probability of exclusions between NWCR and MCCR. 
Table 3.1: Exclusions by registry 
MCCR NWCR Combined 
95%CI 95%CI Significant 
Exclusions No. % lower u~~ No. % lower u~~ No. % (2S0.05} 
Age<IS or >99 3 <0.1 
° 
1.8 19 0.1 
° 
1.5 22 0.1 
Death certificate only 543 4.5 2.8 6.3 328 1.7 0.3 3.1 871 2.8 
Multiple primary 229 1.9 0.1 3.7 677 3.5 2.1 4.8 906 2.9 
Zero survivor· 561 4.7 2.9 6.4 673 3.4 2.1 4.8 1234 3.9 
·Zero survors wi! be included in the analysis with survival converted to one day 
Registrations where the only record of a cancer diagnosis is the date of death (death 
certificate only, DCO), were excluded from the analysis because the 'true' date of 
diagnosis and thus the survival time was not known. The proportion of DCO 
registrations was very low and was not significantly different between MCCR and 
h Corresponding ICO-O-2 morphology codes are 87203, 89403 and 90803, respectively 
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NWCR or socioeconomic groups. When the first record of a patient's diagnosis or 
treatment was the same as the date of death, known as zero survivors, survival time was 
converted to one day to include them in the analysis. Zero survivors include patients 
presenting late (usually as an emergency) and dying in their first diagnostic or treatment 
episode (e.g. surgery) or patients in whom a diagnosis had been made earlier but was 
not recorded at the registry. The proportion of zero survivors was non-significantly 
higher in MCCR than NWCR because NWCR will record previous treatment without a 
treatment date thereby decreasing the number of zero survivors. 
Only the first primary colorectal cancers were included because the treatment and 
outcome of any subsequent primary colorectal tumour would be influenced by the first 
colorectal cancer. MCCR had lower levels of multiple tumours than NWCR (although 
non-significant) because the data base was both person- and tumour-based making 
checks for previous (and subsequent) cancers more complete. 
Both HES and registry dates are internally quality assured for consistency of dates (e.g. 
no treatment after death, death before birth etc.). Additional checks did not find any 
discrepancies. 
Hospital Episode Statistics 
Data collection 
The Hospital Episode Statistics (HES) records include all inpatient admissions 
occurring since 1989 and all outpatient admissions since 2002 for all NHS patients. The 
lIES dataset includes demographic, clinical, administrative and geographic information. 
Information is recorded as a Finished Consultant Episode, which is a period of admitted 
patient care under a particular consultant or allied healthcare professional. Episodes 
begin at hospital admission or when the patient is transferred from another specialty 
(e.g. patient transferred from geriatrics to medical oncology). Diagnoses were coded 
according to the International Classification of Diseases, 10th Revision (I CD-l 0) and 
procedures coded to (OPCS-4). 
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The HES database includes seven diagnosis fields (DIAG_Ol to DIAG_07) and four 
operative procedure fields (OPER1N_Ol to OPER1N_04) until 2002 after which it was 
extended to 14 diagnosis fields and 12 operative fields. 
Data quality 
HES data are cleaned, validated and quality assured annually by the NHS Information 
Centre, which manages the dataset,S but there have been very few external assessments 
of HES accuracy and completeness. A study on the accuracy and completeness of death 
details for congenital heart surgery was critical of the completeness at some hospitals.6 
For this thesis, death details will be used from cancer registry data and cancer registry 
treatment will be combined with HES data on treatment. 
Data 
HES data for all cancer patient admissions in the North West between 1996/97 and 
2004/05 were received from the Information Centre7 (06/12/2006) in 21 pipe delimited 
ASCII files (Table 3.2). A further extract for 2005/06 was obtained from the National 
Cancer Action Team (NATCATSAT), because the processing time for the Information 
Centre procedures meant the most recently available year (at that time) could not be 
included. Obtaining the HES data from 1996/97 was chosen because of recording 
changes (from ICD-9 to ICD-IO), health service geography changes (District Health 
Authorities to Primary Care Trusts) and improvements in data completeness. Stat 
Transfer8 was used to convert files from ASCII into STAT A format. 
Table 3.2: liES data files 
Cancer admissions 
Financial year 
2005/06* 
2004/05 
2003/04 
2002/03 
2001/02 
2000/01 
1999/00 
1998/99 
1997/98 
1996/97 
No. of records 
219,194 
169,462 
177,337 
185,471 
189,701 
224,838 
264,788 
247,639 
223,738 
166,006 
Non-cancer admissions 
Financial year 
2005/06* 
2004/05 
2003/04 
2002/03 
2001102 
2000/01 
1999/00 
1998/99 
1998/97 
No. of records 
646,302 
324,854 
345,187 
353,363 
363,932 
410,498 
447,864 
421,369 
377,462 
*Includes patients treated in but resident outside the North West 
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Demographic and patient details 
Patients are uniquely identified by the HES patient identifier which is generated by 
internally matching records for the same patient using NHS number, hospital case 
number, postcode, sex and date of birth for the entire HES dataset (Table 3.3). Each 
discharge episode is also uniquely identified by an episode key. Demographic variables 
were confirmed with the National Strategic Tracing Service. 
Table 3.3: liES demographic variables 
Name HES field names 
HES identifier Hesid 
Episode key Epikey 
Sex* Sex 
NHS number* Newnhsno 
Postcode* Homeadd 
Date ofbirth* dob 
Format 
10 digit numeric 
8 digit numeric 
1 = men, 2= women 
10 digit numeric 
7 digit alpha-numeric (e.g. CW9 6EL) 
dd/mm/yyyy 
Description 
Unique patient identifier 
Episode identifier 
Gender 
NHS 
Postcode of residence 
Date of birth 
*used for probability linkage to cancer registry data 
Clinical and administrative 
Dates of admission and discharge were recorded along with surgery dates (Opdate_OI to 
Opdate_12), with the order corresponding to the operation order and code (Oper_Ot to 
Oper_t2) (Table 3.4). Procedure codes are recorded in decreasing importance with the 
main surgery first (Oper_Ot). Health geography codes for the treatment provider 
including hospital, primary care trust, health authority and government office region are 
recorded using the National Administrative Codes Service coding system. The national 
General Medical Council registration number is recorded for the treating surgeon, 
although this is not always complete. 
Table 3.4: liES clinical and administrative variables 
Name HES field names Fonnat DescriEtion 
Date of admission ADMINDATE ddlrnmlyyyy Date of admission (or transfer into specialty) 
Diagnosis DlAG_OI to 
-
12 lCD-1O Diagnosis for which the patient is undergoing treatment 
Operation (I to 12) OPER_OI to 
-
12 OPCS-4 coding Surgical procedure 
Date of Operation OPDATE_OI to 
-
14 ddlmm/yyyy Date of procedure (corresponds to procedure above) 
Consultant CONSULT 7 digit National unique General Medical Council clinician 
Date of discharge DlSDATE ddlmm/yyyy Date of discharge or transfer of care to another clinician 
Hopital ofadmission PROCODE S digit National hospital code (S digit) 
Hopital of admission PROCODE3ff 3 digit National hospital code (3 digit) 
Primary Care Trust PCTTREAT 3 digit Primary care trust of treatment 
of admission 
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Data management 
Probability matching 
Probability matching was conducted rather than one-to-one matching by NHS number, 
because some patients had incomplete demographic information; a significant problem 
in HES. Linkage of HES to cancer registry data was done by probability matching of 
date of birth, NHS number, sex and postcode. Preference for linkage was given to pairs 
of records with the most matches in the sequential hierarchy such as patients matching 
on more than one of NHS number, date of birth, postcode and sex, rather than a single 
match (e.g. NHS number) (Table 3.5). Each hospital attendance (from HES) was linked 
to the most complete match (lowest ranking). Only HES records that matched to the 
cancer registry and had a mention of colorectal cancer in DIAG_OI to DIAG_I4 were 
assumed to be colorectal cancer treatment. 
Table 3.5: HES and cancer registry matching 
1 2 3 4 MCCR {n=II,962~ NWCR !n=19,622~ 
NHS Date of Tumour Tumour 
Hierarch~ number Birth Postcode Sex matches % matches % 
I .,I .. .I ,/ 7,281 60.9 13,194 67.2 
2 .I .I ,/ 50 0.4 103 0.5 
3 ,/ ~ ,/ 995 8.3 1,397 7.1 
4 ,/ ,/ ,/ 159 1.3 267 1.4 
5 ,/ ,/ 32 0.3 41 0.2 
6 ,/ .I 4 <0.1 9 <0.1 
7 .I ,/ 37 0.3 54 0.3 
8 ,/ 6 0.1 7 <0.1 
9 ,/ .I ,/ 955 8 1,238 6.3 
10 ,/ .I 10 0.1 18 0.1 
Unmatched 2,433 20.3 3,294 16.8 
Total matched 9,529 79.7 16,328 83.2 
The linkage between HES and cancer registry data was very good with over 80% 
matching and the majority of cases (67% in NWCR, 61% in MCCR) matching 
completely (NIlS number, date of birth, postcode and sex). Those matching on 
hierarchy numbers 8 to 10 were more common in the earlier years, when HES and 
cancer registry recording was less accurate. For some patients an admission prior to 
diagnosis occurred, however these were mostly less than ideal matches (8 to 10). A 
small number of patients had a hospital admission with no OPCS-4 code recorded for 
any treatment procedure (4%, n=1,262). 
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Audit of linkage quality 
The HES-to-registry linkage quality was consistent with a separate linkage in Northern 
and Yorkshire Cancer Registry and Intelligence Service (NYCRIS) national colorectal 
audit (Table 3.6). The NYCRIS colorectal audit linked cancer registry and HES data for 
the same time period (1997-2004) but the NYCRIS data was extracted at different 
times. The NYCRIS audit aimed to evaluate rectal cancer patients receiving surgery, 
with surgery data solely obtained from HES.9 Despite a similar linkage method for both 
the audit and this study differences would be expected because i) of the probabilistic 
nature of the linkage and ii) differences in the registry and HES datasets (different 
extraction dates). 
Direct comparison between the NYCRIS audit and this analysis found the linkage 
quality was high and corresponded well. The majority of patients matched to HES were 
linked to the same patient HESID i (n=22,910 or 78.0%) or had no HES admission 
(2,964, 10.1 %) in both analyses. There were 172 more patients in this cancer registry 
dataset than the NYCRIS dataset because this data was extracted at a later date and 
included additional registrations (or patients where an earlier diagnosis data or treatment 
shifted the diagnosis date). The main difference between the NYCRIS linkage and this 
linkage was the HES dataset used in the NYCRIS linkage included all hospital 
admissions, regardless of whether cancer was mentioned. This resulted in an additional 
10% of patients being linked, although most of the hospital admissions will be for non-
colorectal cancer treatment. For these patients the HESIDs obtained from the NYCRIS 
linkage were used to obtain previous surgery and comorbidity for these patients. The 
miss-match rate was very low; only 1.3% of patients had a different HESID assigned in 
NYCRIS and this analysis. 
i HESID is a unique number assigned to each patient in HES. HE SID enabl.es an.alysis ~cross pa.tient 
pathways over many years or across different hospitals, without the use of Identifiable mfonnatlOn (e.g. 
NHS number). 
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Table 3.6: Comparison of HES linkage for NYCRIS Colorectal audit and NW 
Colorectal survival project (cases in both data sets N=29,391) 
Com(!arison Comment/reason No. 
SameHESID Exact match 22,910 
NYCRIS missing HESID (but in NW) NW data extracted later, patient recently added 75 
NW missing HESID (but in NYCRIS) NYCRIS linked to all hospital admissions (NW 3,074 
liked to admissiong with a mention of cancer) 
Both missing HESID Patient not admitted to hospital or not 2,964 
recorded/incomplete demographic data 
NW and NYCRIS have different HE SID Differences due to chance (probablility matching) 368 
% 
78.0 
0.3 
10.5 
10.1 
1.3 
Every effort was made to audit this dataset against the National Bowel Cancer Audit 
Programme (NBOCAP), however the NBOCAP audit did not have complete coverage 
of the North West and it was not possible to obtain individual level data. 10 
Surgery 
Before matching HES data to cancer registry treatment data there were a number of data 
management steps to prepare both datasets. First, the HES data were linked to cancer 
registry patients providing a cancer registry tumour number for later links. All surgery 
details from HES were limited to the 6 months after diagnosis to be consistent with the 
registry data. The surgery file containing registry and HES procedures was sorted by 
treatment date and reformatted into a wide file format (surgery _n, surgeon_n, 
treathosp_n, surg_code_n) and limited to the first six colorectal surgical procedures 
(Figure 3.2). Colorectal surgical procedures were limited to six for practicality and 
because they included all excision or colorectal cancer procedures. Only surgical 
procedures related to colorectal cancer treatment were retained. The relevant codes were 
identified through advice from clinicians and registry clinical coders. The selected 
colorectal procedure codes were intentionally broad to ensure procedures with a non-
specific coding were included (e.g. excision of stomach, large intestine, liver for 
metastasis, or abdomen NOS) (Appendix 3.2). All such surgery codes occurring in any 
of the first six diagnostic procedure codes in HES were included. After linkage, 82% of 
patients were found to have had at least one surgical procedure. 
Lastly, the formatted HES data were linked to registry treatment data using the cancer 
registry tumour number and date of treatment (with a 3-day variance of date allowed). 
Linkage between a cancer registry surgery and HES surgery information was in 
agreement for the majority of dates but there was less agreement for procedure codes, 
although there was usually greater specificity in HES. Surgery dates for the same 
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procedures differed between registry and HES records by up to 3 days. This was due to 
the difference between procedure and pathology date, with the latter up to 3 days later. 
In cancer registries, the pathology date is used for case registration and surgical date. 
Only 22% of the operations recorded on MCCR had coding exactly matching those 
recorded in HES, with the majority of these (85%) also matching for date, or within 3 
days (10%). The number of matching procedure codes is likely to be low, as HES 
includes data on many associated procedures (e.g. sampling of lymph nodes, opening of 
chest cavity), while registry records contain only the main surgery (excision). For 
procedures occurring on the same day in both HES and cancer registry data for which 
the OPCS-4 surgery codes did not agree HES was taken as more accurate because a) 
hospital clinical coders have access to full notes and electronic hospital files b) it is 
consistent and robust across hospital trusts and time. 
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Figure 3.2: Treatment file management 
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treatment 
+ 
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Treatment 
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HES admissions with a record of ' Continuous infusion of therapeutic subs' (OPCS-4 
X35) or 'Other intravenous injection' (OPCS-4 X29) within 6 months of diagnosis were 
considered to be chemotherapy treatment and were combined in the HES data. 
Unfortunately, HES is known to under record chemotherapy, both for X35 and X29. 
Additionally, HES will have no record of chemotherapy received orally. Chemotherapy 
regime was not recorded in either data sources. Chemotherapy receipt from HES was 
combined with chemotherapy treatment from the cancer registry to provide a record of 
chemotherapy receipt (Yes/No/missing) . Chemotherapy data in both HES and cancer 
registry data was known to be incomplete; therefore missing chemotherapy was imputed 
to take into account missing data. 
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Radiotherapy 
Radiotherapy treatment was only recorded in cancer registration data but has high levels 
of completeness. Radiotherapy treatment occurs only at three specialist treatment 
centres in the North West (Christie Hospital; Manchester, Clatterbridge Centre for 
Oncology; Wirral and Rosemere Cancer Unit; Preston) which provide treatment data 
directly to the registries. The presence or absence of radiotherapy treatment within six 
months of diagnosis was taken from the cancer registry dataset. 
Creating and defining variables 
Demographic, diagnostic and radiotherapy details were obtained from the cancer 
registry database (Appendix 3.1). Surgical and chemotherapy details were obtained 
from both cancer registry data and HES. 
Survival time and censoring 
Survival time is the time from diagnosis to death or loss to follow-up. Follow-up data 
was obtained for all patients up to 31 December 2007. Patients still alive at 31 
December 2007 were censored on that date. 
Age 
Age at diagnosis was calculated from the dates of birth and diagnosis, which are 
available for all cases (Table 3.7). Patients were grouped into 10-year age groups with 
the exception of patients aged 15 to 44, and those over 85. Patients aged under 15 and 
over 99 at diagnosis (n=22) were excluded from the analysis because they were 
childhood cancers and the life tables are only available up to age 99. 
Table 3.7: Age grouping 
Age at diagnosis No. % 
15 to 44 757 2.6 
45 to 54 2,107 7.1 
55 to 64 5,531 18.7 
65 to 74 9,224 31.2 
75 to 84 8,926 30.2 
85 to 99 3,018 10.2 
Total 29,563 100.0 
Site 
Cancer site (topography) was recorded in the International Classification of Diseases for 
Oncology 2nd edition (ICD-O-2) coding system. The International Classification of 
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Diseases version 10 (ICD-IO) coding system is normally used for cancer epidemiology 
and incorporates both tumour site and histology. ICD-O-2 codes (site and histology 
combinations) were converted to ICD-IO using the rARC conversion program. 
Colon cancers can be further stratified into the 10 sub-sites based on the 4-digit lCD-I 0 
code, while rectosigmoid (CI9) and rectum (C20) are not subdivided under ICD-IO 
coding (Table 3.S). The majority of the analysis was based on colorectal cancers 
(combined) but where there are substantial differences, such as treatment, colon and 
rectal (including rectosigmoid) was analysed individually. 
Most colorectal cancer cases were colon (61.6%) or rectal cancer (30.3%). 
Rectosigmoid cancers only accounted for 8.1 %. Within the colon, cancers were most 
likely to be located in the caecum (12.8%), sigmoid (19.3%) or unspecified site 
(13.9%). 
Table 3.8: Description of colorectal sub-sites and lCD-tO coding 
Cancer site Sub-site No. % 
Colon (CI8) 18,221 61.6 
C18.0 Caecum 3,780 12.8 
C18.1 Appendix 202 0.7 
CIS.2 Ascending colon 1,322 4.5 
C18.3 Hepatic flexure 458 1.6 
CI8A Transverse colon 1,123 3.8 
C1S.5 Splenic flexure 512 1.7 
C1S.6 Descending colon 721 2.4 
CIS.7 Sigmoid colon 5,701 19.3 
CIS.S Overlapping lesion of colon 303 1.0 
CIS.9 unspecified subsite 4,099 13.9 
Rectosigmoid (CI9) 2,400 8.1 
Rectum (C20~ 8,942 30.3 
Total 29,563 100.0 
Date of diagnosis 
Date of diagnosis was taken from cancer registry data because cancer registries have 
strict criteria for registering a definitive cancer diagnosis ll and HES records may 
include a presumptive diagnosis. For patients diagnosed by microscopic verification, 
date of diagnosis is the first date of pathology or treatment (whichever is first). The 
incidence date for patients diagnosed without pathology is the earliest of the following 
dates: 
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• first hospital attendance 
• if no hospital attendance, he date of diagnosis at GP 
• if no GP record of colorectal cancer or hospital attendance, the date of death 
Grade 
Grade is a measure of the level of cell differentiation as determined at pathology. Grade 
was obtained from the cancer registry data via pathology reports. Grade I tumours are 
well differentiated, or low grade, and progress to grade IV, or undifferentiated (Table 
3.9). Tumours in the higher grades have generally been developing for a long time or 
are aggressive tumours and have a poorer prognosis. 12 
Table 3.9: Tumour grade 
Stage 
Description 
I 
II 
III 
N 
unknown 
Total 
No. 
3,212 
16,047 
2,845 
62 
7,397 
29,563 
% 
10.9 
54.3 
9.6 
0.2 
25.0 
100.0 
Stage at diagnosis was recorded in cancer registry data in various formats, including 
TNM, Dukes' 13 and Astler-Collier,14 also known as amended Dukes' stage. These three 
coding systems convert to the widely used summary stages I to IV (Table 3.10). 
Table 3.10: Staging for colorectal cancer in TNM and Dukes' 
Swnmary TNM stage Primruy tumour Regional node Distant Dukes' Astler-Collier 
stage involvement metastasis stage 
0 In situ NO MO 
I TI NO MO A A 
T2 NO MO A A 
II IlA TJ NO MO B BI lIB T4 NO MO B B2 
IlIA TI-T2 NI MO C CI 
III IllB TJ-H NI MO C C2 
mc AnyT N2 MO C C2 
IV IV AnyT AnyN MI D D 
unknown 
Stage at diagnosis was recorded in summary stage in NWCR data, however MCCR data 
included all constituent parts to determine stage for many patients (Tumour, Nodes, 
Metastasis). Clinical coders at NWCR assessed the stage data assigning the appropriate 
stage; if the data was not complete they would assess all infonnation available 
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(including treatment) and assign the appropriate stage based on TNM-5 coding rules. 
MCCR record stage (TNM, Dukes) and constituent parts (Tumour, Nodes, Metastasis) 
which was used to determine summary stage as defined in the algorithm in Table 3.10. 
Stage was available for 60.5% of patients, which is consistent with completeness of 
other UK registries (Table 3.11).15 Stage was imputed using ICE multiple imputation 
methods16 in STATA 10.0.17 
Table 3.11: Distribution of stage at diagnosis 
Stage at diagnosis No. % 
I 2,191 7.4 
IT 7,322 24.8 
III 7,722 26.1 
IV 644 2.2 
Not known 11,684 39.5 
Total 29,563 100.0 
Population-based cancer registry datasets have high levels of completeness for many 
variables, but obtaining complete data on stage remains a challenge. For colorectal 
cancer patients diagnosed in 2003, stage was recorded for 62% in MCCR, 56% in 
NWCR and 75% in Scotland (2002) compared to a UK average of 64%.15 Registrations 
with an unknown stage fall into one of three groups.18 
a) Staged, but adequate complete information not available (e.g. missing 
pathology report) 
b) Stage could not be determined with the investigations undertaken (e.g. 
pathological sample insufficient) 
c) Investigations were not carried out (e.g. not relevant for palliative care) 
Patients with late stage tumours may be more likely to have missing data, as staging 
information may not be clinically relevant for patients receiving palliative care. Stage at 
diagnosis may also be associated with other prognostic factors, including age,19 
socioeconomic status,20,21 sub-site, and treatment. Patients with missing data for stage 
are likely to be a biased subset with regard to survival. 
Patient records were significantly more likely to have missing stage if the patient was 
aged over 75, women, more deprived, high grade tumour, not surgically treated or were 
diagnosed with rectal cancer (Table 3.12). Completeness of stage slightly improved 
with time, decreasing from 42% with missing stage in 1997 to 40% in 2004. Incomplete 
stage was very strongly associated with unknown grade, non-specific histology and 
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missing or no treatment, all of which are normally obtained (at least in part) from 
pathology reports. After adjustment, missing stage was significantly associated with 
patients over 85 at diagnosis, rectal and rectosigmoidal cancer, grade III & IV and no 
treatment. Missing stage was most strongly associated with treatment in both the 
unadjusted and adjusted analysis. This is because staging information for non-surgical 
patients is unlikely to be recorded or provided to cancer registrations, due to lack of 
pathology. 
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Table 3.12: Distribution of missing stage 
Patients with mising or 
unknown sta~e Unadjusted Adjusted-
No. % OR 95%CI OR 95%CI 
Variables lower u£~r lower u£~er 
Gender 
Men 6,612 53.9 1.0 1.0 
Women 5,666 46.2 l.l 1.J 1.2 1.0 0.9 1.0 
Age group 
15 to 44 304 2.5 1.0 1.0 
45 to 54 738 6.0 0.8 0.7 1.0 0.7 0.6 0.9 
S5 to 64 1,889 15.4 0.8 0.7 0.9 0.6 0.5 0.8 
65 to 74 3,457 28.2 0.9 0.8 1.0 0.7 0.6 0.8 
75 to 84 3,964 32.3 1.2 1.0 1.4 0.7 0.6 0.8 
85+ 1,926 15.7 2.4 2.0 2.8 1.0 0.8 l.l 
Deprivation 
I-amuent 1,901 15.5 1.0 1.0 
2 2,081 17.0 1.1 1.0 1.2 
3 2,164 17.6 l.l 1.0 1.2 
4 2,435 19.8 l.l 1.0 1.2 
5-deprived 3,697 30.1 1.2 1.I I.3 
Subsite (ICD- I 0) 
Colon (CI8) 7,163 58.3 1.0 1.0 
Rectosigmoid (CI9) 864 7.0 0.9 0.8 1.0 1.2 1.1 1.3 
Rectum (C20) 4,251 34.6 1.4 1.3 1.5 2.0 1.9 2.1 
Grade 
Low 928 7.6 1.0 1.0 
Moderate 4,129 33.6 0.9 0.8 0.9 
High 1,016 803 1.3 1.2 I.S 
Unknown 6,205 50.5 9.9 9.0 10.9 
Year of diagnosis 
1997 1,622 13.2 1.0 1.0 
1998 1,546 12.6 0.9 0.8 1.0 0.8 0.8 0.9 
1999 1,874 15.3 1.2 1.1 I.3 I.3 1.2 1.4 
2000 1,403 11.4 0.7 0.7 0.8 0.7 0.6 0.7 
2001 1,416 11.5 0.8 0.7 0.8 0.7 0.6 0.8 
2002 1,440 11.7 0.9 0.8 1.0 0.7 0.7 0.8 
2003 1,464 11.9 0.8 0.8 0.9 0.7 0.6 0.8 
2004 1,513 12.3 0.9 0.8 1.0 0.8 0.7 0.9 
Histology 
Neoplasms NOS 3,437 28.0 1.0 1.0 
Adenocarcinomas 8,117 66.1 0.0 0.0 0.0 0.1 0.1 0.1 
M usc i nous and serous 620 5.1 0.0 0.0 0.0 0.1 0.1 0.1 
Other 104 0.9 OJ 0.2 0.5 0.6 0.4 0.9 
Treatment 
surgery only 5624 46.1 1.0 1.0 
surgery & chemo 935 7.7 0.6 0.6 0.7 0.7 0.6 0.7 
surg & xrt 554 4.5 0.9 0.8 1.0 0.6 0.6 0.7 
surg. chemo & xrt 348 2.9 0.7 0.6 0.8 0.5 0.5 0.6 
chemo only 387 3.2 3.8 3.2 4.5 3.5 2.9 4.2 
chemo & radio 107 0.9 2.4 1.8 3.2 1.7 1.2 2.3 
xrt only 192 1.6 4.2 3.3 5.4 2.8 2.1 3.6 
no treat 4,056 33.2 18.2 16.5 20.1 9.7 8.7 10.8 
- Adjusted for all variables in table 
Histology 
Histological type was grouped into adenocarcinoma, neoplasms NOS, mucinous and 
serous and other (Table 3.13) based on ICD-O-2 morphology codes system (Table 
3.13). Mucinous and serous is a sub-type of adenocarcinoma and was the only sub-type 
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with sufficient numbers to analyse. The majority of colorectal cancers were 
adenocarcinomas (80.1%). Tumours with non-specific histology made up 11.6% of 
cases, with pathology unavailable for most of these patients. Mucinous or serous 
cancers accounted for 7.8% of cancers. The other category includes sarcomas (n=22), 
squamous cell (n=70) and specific epithelial (n=34) histological types. 
Table 3.13: Histological groupings of ICD-O-2 morphology 
Description Morphology ICD-O-2 
Adenocarcinoma 81403,81406,81409,81443,81453,82103, 
83113,82303,82403,82413,82433,82443, 
82453,82463,82503,82613,82623,82633, 
85103,85503,82013,82203,82213,83103 
Neoplasm NOS 80003, 80013, 80 I 03, 80 106, 80 I 09, 80043 
Mucinous or serous 84403, 84703, 84803, 84806, 84806, 84809, 
84813,84903,84906,84303 
Other 80203, 80213, 80216, 80223, 80413, 80323, 
80503,80703,80713,80726,80723,81233, 
81243,85603,87203,88003,88903,88503, 
89003,89803,90803,97203 
Total 
Deprivation 
No. % 
23,693 80.1 
3,428 11.6 
2,314 7.8 
128 0.4 
29,563 100.0 
Socioeconomic group was assigned to each patient based on their Super Output Area 
(SOA) of residence at diagnosis. Patients were grouped in categories of deprivation 
using the Index of MuItiple Deprivation (IMD) 2001 13 for patients diagnosed 1997-2004 
at SOA. Most patients were in the two most deprived socioeconomic groups (most 
deprived: 29%, group 4: 19.5%) with the remaining three deprivation groups having 
similar proportions (17.7% to 16.4%). 
Table 3.14: Distribution of cases by deprivation 
Deprivation category 
Total 
Affluent - I 
2 
3 
4 
Deprived - 5 
No. 
4,855 
5,080 
5,214 
5,774 
8,640 
29,563 
% 
16.4 
17.2 
17.7 
19.5 
29.2 
100.0 
Deprivation categories were based on ecological measures of socioeconomic status 
obtain from the 2001 censuses and other government databases available for England, 
from the Office for National Statistics (ONS).22 Socioeconomic information on income, 
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employment, health, disability, education, skills and training, barriers to housing, 
barriers to services, living environment and crime was available for geographic unit 
from the census and other government data bases. This was combined into a score for 
each small area of geography (SOA). However, only the income domain of the IMD 
was used as it is strongly associated with deprivation and excludes health-related 
variables, such as access to health services.23 The inclusion of health related measures in 
the socioeconomic measure could result in overlap between the exposure measure 
(socioeconomic status) and variables under study (treatment). 
Treatment 
Eight treatment regimes were developed from the linked HES and cancer registry data: 
surgery only; surgery and chemotherapy; surgery and radiotherapy; surgery and 
chemoradiotherapy; chemotherapy only; chemoradiotherapy; radiotherapy only and no 
treatment (Table 3.15). Surgery and chemotherapy data were combined from HES and 
registry data while radiotherapy data were available only from cancer registry data (as 
described previously). Patients with no recorded treatment who could not be linked to 
any hospital admissions were assumed to have missing treatment data and multiple 
imputation methods were used to estimate the presence or absence of surgery, 
chemotherapy and radiotherapy (separately). Clinical information on surgical intent (Le. 
curative, palliative) and chemotherapy (Le. regime, adjuvant, neoadjuvant) was not 
available in population based datasets. 
Table 3.15: Distribution oftreatment regime 
Description 
Surgery only 
Surgery and chemotherapy 
Surgery and radiotherapy 
Surgery, chemotherapy and radiotherapy 
Chemotherapy only 
Chemotherapy and radiotherapy 
Radiotherapy only 
No treatment 
Total 
No. 
17,640 
3,376 
2,023 
1,181 
514 
182 
298 
4,349 
29,563 
% 
59.7 
11.4 
6.8 
4.0 
1.7 
0.6 
1.0 
14.7 
100.0 
Absence of treatment data was significantly more common among patients who were 
older, with late stage disease, most deprived, had high grade tumours, and colon cancer 
(Table 3.16). Completeness of treatment data significantly decreased with time. 
Women were more likely to have missing data but this probably due to the later age at 
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diagnosis and this was only borderline significant after adjustment for age and other 
factors. Some of the associations with lack of treatment can be explained, at least in 
part, by clinical factors or methods of data collection. Poor prognosis is associated with 
late stage, high grade and older age. Patients with poor prognosis are less likely to 
receive surgery, chemotherapy or radiotherapy and hence their cancers are less likely to 
be pathologically confirmed. Without pathology grade and specific histological type can 
not be determined. In other studies, deprived patients have been found to have more 
incomplete data, although it is not clear why this occurS.20,21 
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Table 3.16: Distribution (No. and %) of patients with missing treatment by clinical 
factors, colorectal cancer patients diagnosed 1997-2004, North West of England 
Patients with mising Unadjusted Adjusted· 
Variables No. % OR 95% CI OR 95%CI 
lower upper lower upper 
Gender 
Men 2,160 47.7 1.0 1.0 
Women 2,369 52.3 1.4 1.4 1.5 1.1 1.0 1.2 
Age group 
15 to 44 45 0.9 1.0 1.0 
45 to 54 I17 2.58 0.9 0.7 1.3 1.1 0.7 1.6 
55 to 64 447 9.87 1.4 1.0 1.9 1.6 1.1 2.2 
65 to 74 992 21.9 1.9 1.4 2.6 1.9 1.4 2.7 
75 to 84 1,732 38.24 3.8 2.8 5.1 3.3 2.3 4.6 
85+ 1,196 26.4 9.8 7.2 13.4 5.8 4.1 8.2 
Deprivation 
l-amuent 572.0 12.6 1.0 1.0 
2 723.0 16.0 1.2 1.1 1.4 1.1 0.9 1.3 
3 823.0 18.2 1.4 1.2 1.6 1.1 1.0 1.3 
4 928.0 20.5 1.4 1.3 1.6 1.1 1.0 1.3 
5-deprived 1483.0 32.7 1.6 1.4 1.7 1.3 1.1 1.5 
Subsite (ICD-l 0) 
Colon (CI8) 3,063 67.63 1.0 1.0 
Rectosigmoid (C 19) 232 5.12 0.5 0.5 0.6 0.7 0.6 0.8 
Rectum (C20) 1,234 27.25 0.8 0.7 0.9 0.9 0.8 0.9 
Grade 
Low 194 4.52 1.0 1.0 
Moderate 887 20.68 0.9 0.8 1.1 1.0 0.8 1.1 
High 291 6.78 1.7 1.4 2.1 1.4 1.1 1.7 
Unknown 2,918 68.02 10.8 9.3 12.6 1.8 1.5 2.2 
Year of diagnosis 
1997 504 11.13 1.0 1.0 
1998 521 11.5 1.0 0.9 1.2 1.0 0.9 1.2 
1999 542 11.97 1.0 0.9 1.2 0.9 0.8 1.1 
2000 559 12.34 1.1 0.9 1.2 1.3 1.1 1.5 
2001 583 12.87 1.1 1.0 1.3 1.5 1.2 1.7 
2002 609 13.45 1.3 1.2 1.5 1.6 1.4 1.9 
2003 630 13.91 1.3 1.1 1.5 1.4 1.2 1.7 
2004 581 12.83 1.2 1.0 1.3 1.4 1.2 1.7 
Histology 
Neoplasms NOS 2,439 53.9 1.0 1.0 
Adenocarcinoma 1,939 42.8 0.0 0.0 0.0 0.2 0.2 0.2 
Mucinous and serous 126 2.8 0.0 0.0 0.0 0.1 0.1 0.3 
Other 25 0.6 0.1 0.1 0.2 0.2 1.6 2.0 
Stage 
1 42 0.93 1.0 1.0 
2 145 3.2 1.1 0.7 1.5 1.0 0.7 1.4 
3 111 2.45 0.8 0.5 1.1 0.7 0.5 1.0 
4 175 3.86 19.4 13.6 27.5 10.9 7.5 15.9 
missing 4,056 89.56 26.5 19.5 36.0 11.7 8.5 16.1 
-adjusted for all variables in table 
Surgery type 
Surgical excisions were defined through comparison with other studies,9,24 and through 
specialist clinical advice (Table 3.17). Other surgery types included a broad range of 
procedures related to lower gastrointestinal cancer excision or general cancer excision 
(e.g. OPCS-4 T8S Block dissection of lymph nodes, T86 Sampling of lymph nodes). 
For patients who had more than one surgery the most radical surgery was taken to 
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define overall patient treatment. For example, patients having another type of surgery 
followed by colorectal excision (either in the same operation or on another day) would 
be grouped into the excision group for analysis. 
The most common procedures for colon cancer patients were excision of the right 
hemicolon (25.1 %) and excision of the sigmoid colon (11.3%). Anterior resection was 
most common among rectal cancer patients (23.9%) with a similar proportion having 
abdominoperineal excision (9.7%) or Hartman's procedure (9.9%). 
Table 3.17: Type of Surgery 
Descrietion OPCS-4 No. 0/0 
Total excision of colon and rectum H04 137 0.7 
Total excision of colon H05 180 0.9 
Extended excision of right hemicolon H06 1,029 5.3 
Excision of right hemicolon H07 4,874 25.1 
c: Excision of transverse colon H08 244 1.3 0 
'0 Excision of left hemicolon H09 1,370 7.1 () 
Excision of sigmoid colon HIO 2,201 1l.3 
Excision of colon HII 791 4.1 
Extirpation of lesion of colon H12 174 0.9 
] Abdominalperineal excision of rectum H331 1,887 9.7 
() 
~ Anterior resection of rectum H332-4, H336 4,639 23.9 
Hartman's procedure H335 1,918 9.9 
Other surgery 4,776 16.2 
No surgery/missing 5,343 18.1 
Total 29,563 100.0 
Surgeon volume 
Yearly colorectal surgical work load was determined for each surgeon and assigned for 
that specific year to allow for new surgeons gaining experience with increasing surgical 
volume. For example, a surgeon may increase hislher surgery volume over time, 
conducting 15 surgeries in 1997, 25 in 1998 and 55 in 1999. They would have been 
assigned to the low-, mid- and high-volume surgeon categories for the patients they 
treated in 1997, 1998 and 1999, respectively. National guidance25 recommends that 
colorectal cancer specialists should operate on a minimum threshold of 20 colorectal 
cases per year. Thus surgical volume of less than 20 patients per year and groupings of 
20 were used to define surgeon volume (Table 3.18). Surgeons with the highest volume 
were also confirmed with local cancer registration officers. 
There was a small group (3 to 5 depending on the year) of colorectal surgeons based at 
colorectal specialist centres and teaching hospitals that each conducted over 60 
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surgeries per year however these high volume surgeons only treated 2.3% of all North 
West colorectal patients. Most patients were treated by moderate (25.6%) or low 
volume (28.0%) surgeons. A substantial proportion of patients (12.7%) were known to 
have had surgery was but the surgeon was not recorded. 
Table 3.18: Annual number of colorectal surgeries conducted for each surgeon 
Surgeon volume No. % 
very high (over 60) 676 2.3 
high (40 to 59) 3,692 12.5 
moderate (20 to 39) 7,569 25.6 
low (less than 20) 8,530 28.9 
surgery but consultant unknown 3,753 12.7 
missing 2,640 8.9 
no surgery 2,703 9.1 
29,563 100.0 
Hospital volume 
Hospital volume was assigned based on the volume of colorectal cancer surgeries 
conducted per year to take account of service changes and centralisation of some 
colorectal services. For example, a hospital may increase its surgery volume (probably 
due to centralisation) with time, conducting 35 in 1997, 65 in 1998 and 125 in 1999. 
They would have been assigned to the low-, mid- and high-volume hospital categories 
for the patients receiving surgery at that hospital in 1997, 1998 and 1999, respectively. 
Conversely, another hospital would decrease surgery volume over time, probably if 
centralisation occurred at another hospital. 
There are no recommendations for annual colorectal surgery volume per hospital. An 
average district general hospital conducts colorectal cancer surgery on 100 patients per 
year so this was taken as a moderate volume.2s Hospitals were grouped based on the 
annual volume of colorectal surgery during the study as low (less than 50), moderate 
(50 to 99), high (100 to 149), very high (more than 150) or private (Table 3.19). 
Information on private treatment was available for surgical patients and those who were 
treated at both private and NHS hospitals. Private hospitals commission the NHS to 
provide pathology reports and this is then available to cancer registries. For patients 
who are treated in the private sector and the NHS details, of treatment in private 
hospitals can be obtained from case-notes. 
Table 3.19: Annual number of colorectal cancer surgeries per hospital 
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Hoseital volume No. % 
very high (over 150) 1,402 4.7 
high (100 to 149) 4,594 15.5 
moderate (50 to 99) 8,282 28.0 
low (less than 50) 6,084 20.6 
Private 576 2.0 
Surgery but hospital not known 3,282 11.1 
missing surgery 2,640 8.9 
no surgery 2,703 9.1 
Total 29,563 100.0 
Comorbidity 
Comorbidity indices were derived from diagnostic codes associated with any hospital 
admission during 1997-2004, regardless of whether the admission was colorectal-
related. The comorbidity scores of Charlson, Ghali and Elixhauser were assigned to 
each patient, based on their 1 CD-IO admission codes. 26-28 (Appendices 3 and 4) 
Information on previous malignancies, required for calculating the Charlson index, was 
obtained from NWCIS cancer registry data by searching the database back to 1981. 
Obtaining previous diagnosis from HES and cancer registry datasets will be compared 
in Chapter 5. Surgical eligibility and outcome can be influenced by hypertension (110-
114, 120), ischaemic heart disease (125), pulmonary embolism (126) and obesity (E66), 
and therefore a 'moderated' Charlson score with these additions was also created for 
comparative evaluation as an alternative prognostic index. 
Cancer registries have strict criteria for registering a definitive cancer diagnosis, while 
HES records may include a presumptive diagnosis while patients are undergoing 
complex diagnostic tests required to determine a cancer diagnosis. The prevalence of a 
previous non-colorectal tumour, or metastasis from any tumour was obtained from HES 
and cancer registry data. Based on HES data 33.4% of patients had a previous non-
colorectal tumour and 11.8% with metastatic tumour based compared to 6% and 0.1 % 
(n=15) based on cancer registry data, respectively. Cancer registry data was taken as a 
more robust measure of previous cancer diagnosis and used for the cancer comorbidity 
in the Charlson index. 
The occurrence of comorbid conditions was calculated in three time windows in relation 
to the date of the cancer diagnosis: 18 to 6 months before diagnosis, the 6 months before 
diagnosis, in the first year after diagnosis and at any time (Figure 3.3). The impact of 
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comorbidity diagnosed at any time was evaluated, because this time-window IS 
commonly used in other studies. 
Figure 3.3: Time periods of comorbidity in relation to diagnosis 
18 
Main comorb idity measure ( 18 to 6 months prior) 
Diagnosis-re lated comorbidity (6 months prior) 
Treatmen t-related comorbid ity ( 12 months after diagnosis) .~~---=~~~~;:~==~~-----­
Comorbidity at any time 
An individual comorbid condition contributed to the comorbidity score only if it 
occurred in the time period under evaluation. Multiple admissions for the same 
comorbidity within the same time window were counted only once. 
C i = individual comorbidity 
w(' = weight (only for Charlson) , 
{ = 0 if comorbidity was not recorded in the relevant time period, or I if comorbidity was in the rele 
j = time period of comorbidity (any time, 18 to 6 months before diagnosis, 6 months before diagno~ 
12 months after diagnosis) 
Scores are all integer, with a possible range of 0 for no comorbidity to 28 for all 
possible comorbid conditions. They were grouped into four categories: 0 for no 
comorbidity and 1, 2 and 3 or more. Patients with no hospital admission (either 
colorectal or other cause) and no previous cancer were assumed to have missing data for 
the purposes of multiple imputation. 
Life table data 
The mortality and population data necessary to develop deprivation-, reglon- and 
period-specific life tables are available from the Office of National Statistics for 
England and Wales for 1991 and 2001 census data. Population and mortality data were 
available by five-year age group. Life tables are necessary for relative survival analysis 
in order to take into account of the background mortality. 
Ethical and legal approvals 
Ethical and legal approvals for this study were complex because of the overlap of this 
research and working within the NHS, and the need for identifiable data (Table 3.20). 
lOa 
Sponsorship by the host employer Christie NHS Foundation Trust, formerly the Royal 
Liverpool and Broadgreen University Hospitals Trust until May 2007 was required, 
because the study was undertaken by an employee and was required under the Research 
Governance Framework (DH 2001). Sponsorship in this context means, that the Trust 
is satisfied with the financial arrangements, that the study complies with Good Clinical 
Practice Guidelines and the Trust will take legal responsibility. The study received 
ethical approval from the Local Research Ethics Committee (Liverpool) and the London 
School of Hygiene and Tropical Medicine Ethical Committee. Approval from the 
Patient Information Advisory Group (PIAG) was obtained with the standard annual 
review (completed August 2007 and August 2008). Security and Confidentiality 
Advisory Group (SCAG) approval was required in order obtain identifiable Hospital 
Episode Statistics data (NHS number, date of birth and postcode). 
Table 3.20: List of required approvals and ethical applications 
Organisation 
Christie NIlS Trust sponsoship (former sponsorship from Royal 
Liverpool and Broadgreen University Hospitals NHS Trust) 
Liverpool Research Ethics Committee (LREC) 
Patient Information Advisory Group (PIAG) (subject to annual 
review) 
Security and Confidentiality Advisory Group (SCAG) for access 
London School of Hygiene and Tropical Medicine ethical 
approval 
Summary 
Approval date 
January 2006 
March 2006 
August 2006, renewed 
(August 2007,2008) 
September 2006 
September 2006 
Data for this thesis will be a combination of cancer registry and hospital episode data to 
provide a complete record of treatment and comorbidity. Cancer registry data are 
generally of high quality, and complete for patient demographics and tumour details, 
but less complete for treatment data. These data were augmented with HES data to 
improve completeness. Despite the use of both HES and cancer registry data, 
incomplete data remained, most notably for stage at diagnosis, and this was managed 
through multiple imputation. 
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Appendix 3.1: Registry variables and definition 
Tumour details: 
Variable Coding Categorical groupings 
Site ICD-O-2 
Morphology ICD-O-2 
Grade 1,2,3,4,9 I - well differentiated 
2 - moderately differentiated 
3 - poorly differentiated 
4 - undifferentiated 
9 - not known 
Date of diagnosis dd/mm/yyyy 
Stage 1,2,3,4,6 I - stage 1 
2 - stage II 
3 - stage III 
4 - stage IV 
6 - not known 
Dukes (or amended A, B, C, D ( or A, B I, B2, Dukes' A - tumour penetrates into the 
Dukes! Astler-Collier) CI, C2, D) submucosa of the bowel 
Dukes' B - tumour invades muscularis 
propria 
Dukes' C - tumour invasion with regional 
lymph nodes involved 
Dukes' D - tumour, has spread beyond 
the confines of the lymph nodes (to 
organs such as the liver, lung or bone) 
Amended Dukes!Astler-Collier is based 
on Dukes' but the A, B I B2, C I, C2 and 
D have slightly different defmitions. They 
have not been listed here for brevi!Y. 
T X,0,1,2,3,4 X - primary tumour can not be assessed 
0- no evidence of primary tumour 
I - tumour invades the submucosa 
2- tumour invades muscularis propria 
3 - tumour invades through the 
muscularis propria into the subserosa, or 
into non-peritonealized pericolic or 
perirectal tissues 
4 - tumour directly invades the other 
organs or structures, and/or perforates 
visceral peritoneum 
N X,O,I X - regional lymph nodes cannot be 
assessed 
o -no regional lymph node metastasis 
I - metastases in I to 3 regional lymph 
nodes 
2 - metastases 4 or more regional lymph 
nodes 
M X,O,I X - distant metastasis cannot be assessed 
o -no distant metastasis 
I - distant metastasis 
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Tumour details continued. 
Variable Coding Categorical groupings 
Basis of diagnosis 1,2,3,4,5,6,7,8,9 1 or 2 - histology 
3 - cytology 
4 - haematology 
5 - special test 
6 - imaging 
7 - observation 
8 - clinical 
9 - not known 
Source of registration 1,2,3,4,5,6,9 1 - pathology 
2 - cytology 
3 - haematology 
4 - hospital records 
5 - other registries 
6 - death certificate 
9 - not known 
Death certificate only YesINo 
(Patients for whom cancer is 
notified from death 
certificate, and first hospital 
and GP review finds no 
cancer diagnosis or cancer 
treatment.) 
Treatment details: 
Variable Coding Categorical groupings 
First reported date of diagnosis or dd/mm/yyyy 
treatment 
Date of first hospital attendance (and dd/mm/yyyy 
subsequent attendances) 
Hospital of first attendance (and Hospital reference code Corresponds to look-up 
hospital for any subsequent table with hospital name 
attendances) and address. 
Date of treatment (for each of dd/mm/yyyy 
rad iotherapy, chemotherapy or 
surgery) within 6 months of 
diagnosis 
Treatment information available for Corresponds to look-up 
each separately surgery, Code for type of surgery, table with type of 
chemotherapy, radiotherapy chemotherapy and/or treatment details. 
radiotherapy 
Consultant treating GMCcode 
Hospital of treatment Hospital reference code Corresponds to look-up 
table with hospital 
Patient details· ..
Variable Coding Categorical groupings 
Patient postcode Text 
Sex 1,2 1- male, 2 -female 
Date of birth dd/mm/yyyy 
Date of death dd/mm/yyyy 
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Appendix 3.2: OPCS-4 surgical codes for colorectal cancer surgery (either alone or in 
combination) 
No. of 
procedures 
OPCS-4 (first 
p-digiQ General descri[!tion Erocedure~ 
G07 Repair of oesophagus 3 
G27 Total excision of stomach 3 
G28 Partial excision of stomach 50 
G29 Open extirpation of lesion of stomach IS 
GJO Plastic operations on stomach I 
G33 Other connection of stomach to jejunum 33 
G47 Intubation of stomach I 
G49 Excision of duodenum I 
G58 Excision of jejunum I 
G61 Bypass of jejunum 2 
G69 Excision of ileum 99 
G70 Open extirpation oflesion ofileum 4 
G71 Bypass of ileum 18 
G72 Other connection of ileum 5 
G74 Creation of artificial opening into ileum 47 
G75 Attention to artificial opening into ileum 
HOI Emergency excision of appendix 42 
H02 Other excision of appendix 136 
H03 Other operations on appendix 2 
H04 Total excision of colon and rectum 115 
H05 Total excision of colon 156 
H06 Extended excision ofrigh hemicolon 918 
H07 Other excision of right hemicolon 4,546 
H08 Excision of transverse colon 207 
H09 Excision ofleft hemicolon 1,165 
HlO excision of sigmoid colon 1,770 
Hli other excision of colon 708 
HI2 Extirpation of lesion of colon 148 
HI3 Bypass of colon 143 
H14 Exteriorisat ion of caecum 38 
HIS other exteriorisation of colon 2,165 
HI6 I ncision of colon 8 
Hl7 Intraabdominal manipulation of colon 4 
Hl8 Open endoscopic operations on colon 3 
HI9 Other open operations on colon 17 
H2O Endoscopic extirpation oflesion of colon 613 
1/21 Other therapeutic endoscopic operations on colon 13 
1/22 Diagnostic endoscopic examination of colon 605 
1123 Endoscopic!extirpation!lesionlLower bowel using fiberoptic sigmoidoscopy 491 
1/24 Othcr therapeutic endoscopic operations on lower bowel using fiber optics 58 
1/26 Endoscopic!extirpation!lcsion! colon using rigid sigmoidoscopy 85 
1127 Other therapeutic endoscopic operations of the sigmoid colon using rigid sigmoidoscopy 21 
1130 Other operations on colon 30 
1133 Excision of rectum 4,922 
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continued. 
No. of 
procedures 
OPCS-4 (first 
P-dilliQ General descriEtion I2rocedure~ % 
H34 Open extirpation of lesion of rectum 38 0.2 
H40 Operations on rectum through anal sphincter 34 0.1 
H41 Other operations on rectum through anus 568 2.3 
H42 Perineal operations for prolapse of rectum 1 <0.1 
H44 Manipulation of rectum 269 1.1 
H46 Other operations on rectum 26 0.1 
H48 Excision oflesion of anus 23 0.1 
HS4 Dilation of anal sphincter 6 <0.1 
HS5 Other operations on perianal region 5 <0.1 
H56 Other operations on anus 18 0.1 
H58 Drainage through perineal region 10 <0.1 
H60 Other operations on pilonidal sinus I <0.1 
H62 Other operations on bowel 25 0.1 
J02 Partial excision of liver II <0.1 
J03 Extirpation oflesion ofliver I <0.1 
JOS Incision ofliver 7 <0.1 
Jl8 Excision of gall bladder 5 <0.1 
J57 Other partial excision of pancreas I <0.1 
J69 Total excision of spleen 4 <0.1 
M02 Total excision of kidney I <0.1 
M34 Total excision of bladder I <0.1 
M35 Partial excision ofbladder 2 <0.1 
M42 Endoscopic extirpation of lesion of bladder 5 <0.1 
Q07 Abdominal excision of uterus 14 0.1 
Q23 Unilateral excision ofadnexa of uterus 2 <0.1 
Q24 Other excision of adnexa of uterus I <0.1 
T28 Other repair of anterior abdominal wall I <0.1 
T29 Operation on umbilicus 1 <0.1 
TJO Opening of abdomen 138 0.6 
TJI Other operations on anterior abdominal wall II <0.1 
TJ3 Open extirpation of lesion of peritoneum I <0.1 
TJ4 Open drainage of peritoneum 10 <0.1 
TJ6 Operations on omentum 8 <0.1 
TJ8 Operations on mesentery of colon 2 <0.1 
T41 Other open operation on peritoneum 26 0.1 
T42 Therapeutic endoscopic opertion on peritoneum I <0.1 
T43 Diagnostic endoscopic examination of peritoneum 15 0.1 
T4S Image controlled operations on abdominal cavity 16 0.1 
T46 Other drainage of peritoneal cavity 87 0.3 
T8S Block dissection oflymph nodes I <0.1 
T86 Sampling of lymph nodes 3 <0.1 
T87 Excision or biopsy oflymph node 12 <0.1 
XI4 Clearance of pelvis 4 <0.1 
Z28 Large intestine 2,098 8.4 
Z29 Other Eart of bowel 2,110 8.4 
Total 25.037 
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Appendix 3.3: Charlson, amended Charlson and Ghali comorbidity lCD-tO codes 
and weights. 
Assigned 
weight Comorbidi!l: lCD-I 0 Source Charlson Ghali 
1 Myocardial infarction 12 I. X, 122.x, 125.2 HES .r ./ 
Congestive heart failure 109.9,111.0,113.2,125.5,142.0,142.5-142.9, HES .r .r 
l43.x, 1S0.x, P29.0 
Peripheral vascular disease 170.x, 171.x, 173.1, 173.S, 173.9, 177.1, 179.0, HES .r ./ 
179.2, KSS.I, K5S.S, KS5.9, Z9S.S, Z9S.9 
Cerebrovascular disease G4S.x, G46.x, F05.I, G30.x, GJI.] HES .r .,/ 
Dementia FOO.x-F03.x, FOS.I, G30.x, G31.! HES .r 
Chronic pulmonary disease 127.S, 127.9, J40.x-J47.x, J60.x-J67.x, J6S.4, HES .r 
nO.I, nOJ 
Rheumatic disease M05.x, M06.x, M31.S, M32.x-M34.x, M3S.I, HES .r 
M3S.3, M36.0 
Peptic ulcer disease K2S.x-K2S.X HES .r 
Mild liver disease BIb, K70.0-K70.3, K70.9, K71.3-K71.S, HES .r 
K7I.7, K73.x, K74.x, K76.0, K76.2-K76.4, 
K76.S. K76.9. Z94.4 
Diabetes without chronic EIO.O, EIO.I, E10.6, EIO.S, E10.9, EII.O, HES 
complication Ell.!, EI1.6, EI1.8, EI1.9, E12.0, E12.I, 
E12.6, EI2.S, E12.9, E13.0, E13.I, EIl6, 
EI3.S. E13.9. EI4.0. E14.1. EI4.6. EI4.S. 
2 Diabetes with chronic EI0.2-EI0.S, E10.7, EII.!-EII.S, EII.7, HES 
complication EI2.2-EI2.5, E12.7, EI3.2-EI3.S, EI3.7, 
EI4.2-EI4.S. E14.7 
2 Hemiplegia or paraplegia G04.I, GI1.4, GSO.I, GSO.2, GSI.x, GS2.x, HES ./ 
GS3.0-G83.4, GS3.9 
2 Renal disease 112.0,1121.1, N03.2-N03.7, NOS.2-NOS.7, HES .r 
NIS.x, NI9.x, N2S.O, Z49.0-Z49.2, Z94.0, 
3 moderate of sever liver 18S.0, IS5.9, 186.4, 198.2, K70.4, K71.!, K72.I, HES .r 
disease K72.9, K76.S, K76.6, K76.7 
6 AIDSIHIV B20.x-B22.x, B24.x HES .r 
3 Any malignancy·· COO.x-C43.x, C4S.x-C77.x, CSI.x-C97.x Cancer Registry .r 
6 Other metastatic solid C77.x-CSO.x Cancer Registry .r 
Additional disease CBte~orie5: 
1 Hypertension 110.x-1I4.x, 120.x HES Addition 
Ischaemic heart disease 125.0,125.1,125.3,125.4,125.6, 12S.8, 125.9 HES Addition 
Pulmonary embolism 126.x HES Addition 
Obesi!l: E66.x HES Addition 
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Appendix 3.4: Elixhauser comorbidity index lCD-tO codes. 
Comorbidity Elixhauser (ICD-IO) 
Congestive heart failure 109.9,111.0,1\3.0,113.2, 12S.S, 143.0, 142.S-142.9, 143.x, ISO.x, P29.0 
Cardiac arrhythmias 144.1-144.3, 14S.6, 14S.9, 147.x-149.x, ROo.o, ROO.1, ROO.S, TS2.2, Z4S.0, Z9S.0 
Valvular disease AS2.0, IOS.x-IOS.x, 109.1, 109.S, 134.x-139.x, Q23.0-Q23.3, Z9S.2-Z9S.4 
Pulmonary circulatory disorders 126.x, 127.x, 12S.0, 12S.S, 12S.9 
Peripheral vascular disorders 170.x, 171.x, 173.1, 173.S, 173.9, 177.1, 179.0, 179.2, KSS.I, KSS.S, KSS.9, 
Hypertension, uncomplicated II O.x 
Hypertension, complicated IIl.x-1I3.x, I1S.x 
Paralysis G04.1, GII.4, GSO.I, GSO.2, GSO.x, GS2.x, GS3.0-GS3.4, GS3.9 
Other neurological disorders G lO.x-G l3.x, G20.x-G22.x, G2S.4, G2S.S, G31.2, G31.S, G31.9, G32.x, G3S.x-
G37.x, G40.x, G41.x, G93.1, G93.4, R47.0, RS6.x 
Chronic pulmonary disease 127.S, 127.9, J40.x-J47.x, J60.x-J67.x, J6S.4, ]70.1, 170J 
Diabetes, uncomplicated EIO.O, EIO.I, EIO.9, EII.O, EII.I, E11.9, EI2.0, EI2.1, EI2.9, EI3.0, E13.1, 
EI3.9, EI4.0, EI4.1, E14.9 
Diabetes, complicated EI0.2-EIO.S, EI1.2-EII.S, EI2.2-EI2.S, EI3.2-EI3.S, EI4.2-EI4.S 
Hypothyrodism EOO.x-E03.x, ES9.0 
Renal failure 112.0,113.1, Nt8.x, NI9.x, N2S.0, Z49.0-Z49.2, Z99.2 
Liver disease B IS.x, ISS.x, IS6.4, 19S.2, K70.x, K71.1, K71.3-K71.5, K71.7, K72.x-K74.x, 
K76.0, K76.2-K76.9, Z94.4 
Peptic ulcer disease, excluding bleeding K2S.7, K2S.9, K26.7, K26.9, K27.7, K27.9, K2S.7, K2S.9 
HlV/AIDS B20.x-B22.x, B24.x 
Lymphoma CSl.x-CSS.x, CSS.x, C96.x, C90.0, C90.2 
Solid tumour COO.x-C26.x, C30.x, C34.x, C37.x-C4I.x, C43.x, C4S.x-CSS.x, C60.x-C76.x, 
C97.x 
Metastatic tumour C77.x-CSO.x 
Coagulopathy D6S-D6S.x, D69.1, 069.3-069.6 
Obesity E66.x 
Weight loss E40.x-E46.x, R63.4, R64 
Fluid and e1ectorlyte disorders E22.2, ES6.x, ES7.x 
Blood loss anemia OSO.O 
Oeficiencyanemia DSO.S, OSO.9, OSI.x-OS3.x 
Alcohol abuse FlO, ES2, G62.t, 142.6, K29.2, K70.0, K70J, K70.9, TSl.x, ZSO.2, Z71.4, 
Orug abuse Fll.x-FI6.x, Ft8.x, FI9.x, Z71.S, Z72.2 
Psychoses F20.x, F22.x-F2S.x, F2S.x, F29.x, F30.2, F31.2, F31.5 
Depression F20.4, F3IJ-F3IS, F32.x, F33.x, F34.I, F41.2, F43.2 
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Chapter 4 
Methodology 
Overview 
Relative survival is the 'gold standard for analysing population-based cancer registry 
data. Relative survival estimates cancer survival in the absence of other causes of death 
by taking into account the underlying mortality in the population which is particularly 
important when comparing socioeconomic groups with different underlying mortality, 
as in this thesis. By applying Poisson regression using generalized linear models (GLM) 
on estimated excess deaths multivariable analysis can be done that assesses the 
contribution of each prognostic factor and inter-relationships between prognostic 
factors. The resulting multivariable estimate is known as an excess hazard of death. 
Missing data for treatment and stage remain even after the use of both cancer registry 
data and HES. There are a number of different approaches to handling missing data 
including 'ad hoc' approaches such as excluding cases with missing data or analysing 
them in a separate category. However these approaches can introduce bias if patients 
without complete data are different (e.g. later stage) than those with complete data. 
Multiple imputation provides an alternative approach by imputing, or filling-in, missing 
data thus allowing standard analytical techniques, such as relative survival and the 
excess hazard of death. 
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Survival analysis 
Analysis of survival has become an increasingly important tool for assessmg 
improvements in patient outcome. Population-based cancer registries collect data that 
enable accurate estimates of survival for the cancer patients of the resident population. 1 
Survival is simply defined as the probability that a person with a given disease will be 
alive at a specified time (t;) since diagnosis. Survival is estimated as the product of the 
conditional survival probabilities for all time intervals (t;) in the follow-up period. 
Conditional probability is the probability of surviving the interval conditional on being 
alive at the start of the interval? Survival should not be calculated simply as the 
proportion of patients alive (out of the number of patients at risk) because it does not 
correctly account for censored lO patients. In the Kaplan-Meier3 method, survival is 
constant over each interval.1 
S(t) = Survivor function at t; 
t; = Duration of study at t, 
d, = Number of deaths occurring atf; 
n; = Number of patients at risk just prior tot, 
1 - ~ = Conditional probability of surviving to f, 
n, 
i = survival interval i 
(1) 
Survival can be conceptualised according to two main concepts: the observed survival 
and the net survival. For simplicity, we will often use the complement of survival, i.e. 
the mortality, to explain concepts. 
Main concepts in population-based survival 
Observed (or crude) survival 
According to the theory of competing risks,4,s the overall probability of death observed 
within a given population may be defined as the sum of the probabilities for each cause 
of death. Therefore, the overall observed probability of death does not reflect only the 
lethality of the disease of interest. This may lead to biased conclusions particularly if 
10 When a patient is alive at the end offollow-up, or lost to follow-up during the study, the follow-up 
time is stopped either when they are lost to follow up or at the end of complete follow-up for the 
population, or earliest. 
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many deaths within cancer patients are not cancer related, e.g. in the elderly. This is a 
particular issue with cancer survival because cancer is mainly a disease of the elderly, a 
considerable proportion of deaths in cancer patients may be due to non-cancer causes. In 
such situations, the observed mortality, and by extension the observed survival may 
reflect the background mortality rather than the mortality related to the cancer of 
interest. 
The probability of death from the cancer under study is the parameter of interest. This 
corresponds to the net probability of death, which is the probability of death from the 
cancer when all risks of death from other causes have been eliminated. The same 
definition stands with the complement of the mortality, or the survival probabilities. 
Observed mortality = L cause j mortality = L (cause j _1 mortality) + cancer mortality 
Cancer survival = 1- (observed mortality + L cause j _1 mortality) 
i = survival interval 
Net survival 
The net probability of cancer death is the probability of dying from the cancer in the 
absence of other causes of death. Its complement, the net cancer survival, is obtained if 
the risk of death from causes other than the cancer is removed. The underlying 
assumption is that the cause of death of interest is independent of other competing 
causes of death. Cause-specific and relative survival both attempt to measure net 
survival. 
Cause-specific survival 
Cause-specific survival is based on only patients dying of the disease of interest (i.e. 
cancer or colorectal cancer). Those dying of other causes are censored at death. 
In population-based data, such as cancer registries, cause of death is obtained from the 
patient's death certificate. Cause of death obtained from death certificates has been 
proven not to be reliable enough for cause-specific survival analysis.6 With only the 
death certificate information it is difficult to determine if cancer is the main or 
underlying cause of death. 1 In practice the use of cause-specific survival is usually 
limited to clinical trials where detailed and unbiased cause of death is available. Cause-
specific analysis will not be performed in this thesis for these reasons. 
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Relative survival 
Relative survival has become the 'gold standard' method for estimating cancer survival 
in population-based databases, such as the UK cancer registries. Relative survival 
attempts to estimate survival of cancer patients in the absence of other causes ob death 
(non-cancer) by taking into account the underlying mortality in the population from 
which the cancer patients are drawn (E;). It is the ratio of overall survival ('observed 
survival' as described earlier) in the cancer patient population (S;) to the survival that 
would have been expected in the cohort of patients if they had been subject to the 
mortality rate of the population from which they come from ('background' or 'expected 
survival' (Ej )). Consequently, the excess mortality risk associated with the cancer 
population may be thought to be based on the cancer deaths and cancer-associated 
deaths, such as complications related to cancer treatment, that would not have occurred 
without the cancer. 
The background mortality is obtained from life tables (see life tables section) which are 
defined at least by age, sex and calendar period. The background risk of death may vary 
with other factors such as region or socioeconomic status, and such variables may be 
included in specific life tables. Although the life tables include deaths due to cancer, this 
has little or no impact on the estimated background risks of death.2,6,7 
R; = Relative survival 
SI = Survival in the cancer population 
E; = Survival in the underlying population 
i = survival interval 
Modelling excess mortality 
(2) 
When there are several prognostic factors to compare and adjust for, univariable 
survival analysis is too simplistic and the need for more complex models arises. 
Regression models for excess mortality are the most practical method of assessing the 
impact of multiple factors on survival. 8 Various approaches have been used to model 
excess mortality with most using on the maximum likelihood model based on the 
underlying additive hazards model.2 
;lex) =;l * (x) + exp(xp) (3) 
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A{X) = observed hazard for patients diagnosed with cancer 
A * (X) = expected hazard function (estimated from external data i.e. life tables) 
exp(xfJ) = excess hazard 
x = covariate vector 
fJ = varying parameter 
The regression model (with covariate x) is estimated as the sum of the expected hazard 
(A*(X») and the excess' hazard associated with a cancer diagnosis (exp(xp». The 
expected hazard (A * (x») is obtained from life tables and has a specific subset of 
covariates which are available in the life tables (e.g. age, sex, calendar period and 
socioeconomic status) but does not depend on all covariates in the analysis (e.g. stage or 
histology).2 The excess hazard ratio estimated by such models can be thought of as the 
probability of dying from the cancer in the presence of the factor divided by those in the 
absence of the factor,9 or as a risk ratio for mortality. 
The model is estimated in the framework of GLM using a Poisson assumption for the 
distribution of the number of observed deaths. The Poisson distribution is necessary 
because observed deaths and excess mortality is skewed towards earlier time periods 
since diagnosis (or 'right skewed'). We assume the number of deaths (dj ) for a subject 
band (j) can be described by a Poisson distribution (dj - Poisson( U j» where 
uj = AjYj (Aj is the expected hazard function and Yj is person-time at risk) (Equation 3 
& 4).2 For grouped analysis of the hazard ratio of excess mortality data is aggregated by 
the variables under study (e.g. combination of age group, sex, follow-up interval) into 
subject bands. 
or 
d; = expected number of deaths (due to causes other than cancer of interest) 
YJ = person-time at risk for observation (taken from life tables) 
j = subject j (or aggregation e.g. men aged 55 to 60) 
(4) 
(5) 
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This implies a generalized linear model with Poisson error structure (link 
In(u j -d;) and offset In(yj )). The assumption that dj - Poisson(u) is introduced in 
order to use the GLM approach but is not strictly necessary. 
Excess hazards are assumed to be proportional along the analysis follow-up time.2 
Proportionality may not be true in many instances, for example patients who received 
surgery, compared to those not undergoing surgery, may have high excess hazards post-
operatively and low later. If we falsely assume proportionality, we run the risk of 
misinterpreting or over-looking significant associations across time. to When non-
proportionality occurs it is possible to model the variable with time-by-covariate 
interaction terms,2 either through stepwise functions or more flexible functions such as 
splines. \1 Currently, splines are not available in statistical software with methods for 
analysing imputed data and we opt for modelling the variables with stepwise 
approaches. 
There are a number of comparable approaches to estimating the excess hazard of death 
including full-likelihood approach,t2 Hakulinen-Tenkanen \3 and Poisson models. These 
approaches differ mainly in the way the data is presented (individual, aggregated) and 
assumptions (distributions) but produce similar estimates of the excess hazard of death.2 
Due to the similarity of estimates in practice the choice of model may guided by the 
availability of software and ease of use.2 Taking all these factors into consideration the 
generalized linear model with a Poisson error function on aggregated data using exact 
survival estimates were the recommended method for regression analysis of excess 
death.2 Some cancer registries outside of the UK record survival in complete years, 
rather than exact survival time.6 In this study exact survival time (e.g. complete date of 
death and survival time in days) was available enabling analysis at intervals narrower 
than yearly. The number of excess deaths was estimated using individual data by a 
combination of variables to be studied for Poisson analysis of excess hazard of death. 
This approach was taken, rather than the comparable poisson regression of relative 
survival, in part because it was already available within multiple imputation software in 
STAT A, however both approaches to estimating the excess hazard of death produce 
similar estimates.2.14 
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Survival analysis designs 
Cohort design 
Cohort survival requires all patients in the analysis to have a potential follow-up time 
which is equivalent to the specified time since diagnosis under study, e.g. five years. 
Patients who are lost to follow-up or die are censored, as previously described. In the 
example below (Figure 4.1), patients diagnosed in 1997 would be followed up until 
2002, at which point five years of follow-up were available and five-year survival could 
be calculated. Cohort survival requires a long period of follow-up but because the major 
influences of survival occur in the first few years after diagnosis, mostly in the first 
year, complete analysis will be used to provide more timely estimates. 
Complete design 
Complete survival includes all patients diagnosed during a specified time period. Within 
the defined period some, but not all patients would be followed up for at least five 
years. For example complete survival can be used to estimate five-year survival for 
patients diagnosed during 1997 to 2004, despite patients diagnosed in 2004 only having 
three years of follow-up. 
Period and hybrid designs 
Period survival is a method for predicting survival by incorporating the conditional 
probabilities of the most recently diagnosed patients into survival analysis. IS-IS The 
period survival approach can be though of as analogous to estimates of the life 
expectancy at birth, where the mortality in the current population is used to estimate life 
expectancy. This method enables the estimation of five-year survival before five years 
of follow-up was available for all patients. The advantage of this method is that by 
including recently diagnosed patients it produces more up-to-date and timely survival 
estimates that incorporate the effect of new advances in treatment and their impact on 
survival. 19 
Period survival 'uses the patients' survival experience in the most recent period. For 
example to estimate five-year survival in 2005 we use 0- to I-year survival experience 
for cases diagnosed in 2004, 1- to 2-year survival experience for cases diagnosed in 
2003 for patients who survived at least 1 year, and so on up to 4- to 5-year survival for 
patients diagnosed in 2001 who survived at least 4 years. Period survival is then 
estimated by multiplying these probabilities. 19 Period relative survival has been tested 
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against standard relative survival methods and was found to reliably predict short-term 
and long-term survival estimates.20,21 
When incidence data are less up-to-date than mortality data, as occurs in cancer registry 
data, survival is biased and the hybrid approach should be used.22 The hybrid approach 
combines elements of cohort, complete and period analyses to provide unbiased short-
term survival estimates and smaller variance than traditional period survival. For 
example the hybrid approach would analyse patients diagnosed 2003 and 2004, with 
patients diagnosed earlier (1997 to 2002) and still alive up-to 2007 included. 
Figure 4.1: A d iagram of the years of fo llow-up used for cohort and hybrid 
survival approaches 
Year of follow-u p 
1998 1999 2000 2001 2002 2003 2004 2005 2006 
1997 1/2 2/3 3/4 4/5 5/6 7/8 8/9 9/10 
1998 2/3 3/4 4/5 8/9 
til 1999 2/3 3/4 4/5 
til 2000 2/3 3/4 4/5 0 
t:: 
~ 2001 2/3 3/4 4/5 
-0 2002 2/3 3/4 4/5 
...... 
0 2003 1/2 2/3 3/4 .... 
C<l 
<!) 2004 0/1 1/2 2/3 >-
2005* 0/1 2/3 
2006* 0/1 
2007* 
* not yet availible due to delays in registration 
D comPlete analysis of 5-year Hybrid ana lysis of 5- and 10-
survival year urvival 
Life fables 
2007 
10/11 
9/10 
8/9 
7/8 
6/7 
5/6 
4/5 
3/4 
3/4 
2/3 
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Life tables provide estimates of the underlying population mortality necessary to 
calculate relative survival and excess mortality. The relative survival algorithm uses the 
probability of dying (q x) to estimate the expected population mortality rate. For this 
thesis, life tables by age, sex , deprivation and for the North West of England were 
developed from 1991 and 2001 census data. Population and mortality data were 
available by five-year age group. In order to estimate mortality rates for all ages (0 to 
100) and to even out random variations which may occur due to few deaths or small 
populations, particularly at the youngest and oldest ages, mortality rates were 
extrapolated and smoothed to single years of age using the Ewbank approach?3 
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Multiple imputation 
It has often been considered that the simplest, approach to analyse a dataset with 
missing data was to exclude patients with missing data, and to conduct analyses on the 
remaining cases (complete-case analysis). Limiting the analysis to patients with 
complete data would thus substantially reduce the size of the analysed dataset, waste 
data and produce inefficient estimates of the excess hazards of death and may then 
introduce bias resulting in misleading conclusions.24-27 Cases with 'missing' data for a 
given variable (e.g. stage) can also be included in the analysis by assigning a separate 
category for patients with missing data (e.g. stage not known), or by assigning the mean 
value for that variable. To avoid biasing results these 'ad hoc' methods require the 
implicit assumption that patients with missing data are not systematically different with 
regard to variables of interests (e.g. stage, survival) from those with complete data, a 
mechanism of missing ness also known as missing completely at random (MCAR).25 
Completeness of stage data and other variables in population-based registries varies by 
age,28 geography,29,30 and socioeconomic status,31 making 'ad hoc' approaches 
inappropriate. Alternatively, 'missing' data can be imputed, with regression techniques, 
and the final imputed dataset analysed with standard methods, thereby minimising bias 
compared to 'ad hoc' approaches, and increasing power.32 In the past the method of 
multiple imputation was limited by computational power and unavailability of software 
in the standard statistical packages, however multiple imputation is now established as a 
standard method of analysing data sets with missing data.24,33-36 To my knowledge it has 
been rarely used for analysis of cancer data26,37,38 and colorectal cancer patients.39 
Assumptions 
The method of handling missing data depends on the mechanism believed to underlie 
the missing values, which can follow three types:32 
a) Missing Completely at Random (MCAR) 
b) Missing At Random (MAR) 
c) Missing Not At Random (MNAR) 
MCAR occurs when the probability of an observation (r) being missing is random, and 
therefore does not depend on either the explanatory variables or outcome (z ). In these 
situations, the missing cases can be excluded from the analysis and valid inferences can 
be made, although this will result in some loss of statistical power.40 
P{rlz) = P{r) (6) 
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MAR occurs when, given the observed data, the probability of missing information (e.g. 
stage) does not depend on the unobserved data (e.g. education).41 This is the most 
commonly assumed mechanism and enables the imputation of missing observations 
using likelihood methods under the assumption that the mechanism of missigness can 
be explained by the observed data. The MAR assumptions can not be tested or 
definitively determined, without obtaining the missing data but is generally robust to 
errors in the underlying assumptions. 
p~/z) = P{r/zo) (7) 
Observations that are not MCAR or MAR are considered Missing Not at Random 
(MNAR). When data are MNAR they can not be explained by the observed data in the 
data set and depend on unrecorded observations.41 If the mechanism of missing data is 
MNAR, the probability of missing stage would depend on variables in our data set (e.g. 
age, sex, hospital) and variables which are not in our data set (e.g. education, genetic 
predisposition, health-seeking behaviour). It is difficult to determine the appropriate 
imputation model for MNAR data.41 
We can never determine whether data is MCAR, MAR or MNAR, but from analysis of 
our dataset we can never distinguish between MCAR and MAR. Most common 
statistical techniques assume that data are MAR. 
Methodology 
Multiple imputation imputes missing entries (YM ), based on observed or non-missing 
entries (Yo)' by regressing the variable (Y) with missing data on the co-variables (Q) 
(e.g. age, morphology).4o,42 When there is more than one variable with missing data the 
method of 'chained equations' can be used whereby each variable with missing data is 
imputed using a regression model conditional on all other variables and is repeated for 
each variable with missing data.27,43 Multiple imputation by chained equations is 
frequently used for imputation but another options are model-based methods (e.g. 
expectation-maximization algorithmt4 or a weighted approach.3s Model-based methods 
fit the missing data mechanism as part of the analysis model, rather than before the 
statistical analysis as occurs in chained equations. Model-based methods are complex, 
particularly for non-statisticians, and statistical software is less readily availible.33 
Multiple imputation involves three steps; imputation, analysis and pooling of final 
results (Figure 4.2). 
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Figure 4.2: Multiple imputation steps 
l 
incomplet d:n .' 
POliNG 
Source: van Burren S. Multiple Imputation Online. 2007. 42 
1m. I H' It 
The imputation step predicts (QMI) the missing entries for each level (e.g. stage I, II, III, 
IV) of the variable based on a regression of the non-missing co-variables in the dataset 
(~ ). 
(8) 
For example multiple imputation of stage predicted the missing entries (YM ) based on 
the distribution of explanatory variables (age, morphology, treatment, survival time) 
association with the non-missing entries for stage (Yo ), Imputation models should 
include all variables known to predict missingness including outcome variables 
(survival time), and all variables to be analysed in the final model should be included.34 
Imputation is repeated several times (k) using independent draws from the original 
dataset, resulting in k datasets with complete data for survival analysis and a set of k 
results pooled. The variance (Equation 9) for the final analysis will consist of a 
combination of the variance within each analysis (W) and between analysis variance 
(B). Between analyses variance is the additional variance due to the uncertainty 
surrounding imputed variables. 
1 T = W +B*(1+-) 
k 
(9) 
If the assumptions for the model and the mechanism of missing data are correct, then 
resulting inferences will be statistically valid.42 
For highly collinear variables conversion to logarithmic or orthoganal scales prior to 
multiple imputation avoids the variables being dropped from the model due to 
collinearity. Orthogonal ising creates a set of variables using a modified Gram-Schmidt 
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procedure4s which can be used for imputation and converted back after imputation with 
subsequent analysis conducted as usual. 
Imputation accuracy increases with the number of co-variates used, and the number of 
imputations carried out. However, inappropriate choice of co-variates or exclusion of 
key co-variates in the imputation model can lead to bias in the final analysis while 
inclusion of unnecessary 'co-variates can led to over fitting and reduce precision.24•34 On 
balance the risk of over fitting is less than that of bias, thus it is recommended to err on 
the side of caution and incorporate questionable co-variables.34 The importance of 
including survival time and vital status has been demonstrated in the imputation models 
when dealing with longitudinal data.27 
Multiple imputation by chained equations 
Suppose that variables x .. X2, are incomplete, and X3, ... ,Xk are fully observed, the 
method proceeds by : 
1. Filling in each incomplete (x), X2) variable by a starting value. 
2. Discard the filled-in values from the Xl leaving the original missing values. 
3. An appropriate imputation model (linear regression, polytomous regression or 
logistic regression) is specified conditionally on all other variables (observed 
and imputed (if any) combined). 
4. Regress XI. on X2, ... , Xk. 
5. Replace missing values in Xl by predicted values. 
6. Repeat for X2, and sequentially on other x's, (one iteration) 
7. The same procedure is repeated for several (in this case 10) iterations. This 
generates one completed dataset. 
8. For each completed dataset estimate relative survival Pj for each combination 
of relevant predictor variables and save the results to a file. 
9. We then fit a multivariable regression using a generalized linear model with 
Poisson erro~ to estimate the excess hazard ratio of relative survival for 
colorectal cancer patients over the background mortality. 
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10. Combine estimates from completed datasets, to obtain the mean of the estimate 
(excess hazard ratio), and variance. 
Analysis 
The degree to which socioeconomic inequalities in survival could be explained by stage, 
co morbidity and other clinical and demographic factors was evaluated through the 
excess hazard ratio of death using data after imputation. 
The method of estimating comorbidity and the most appropriate time window was first 
evaluated for use in subsequent analysis. The excess hazard of death within one year of 
diagnosis using original data (before imputation) was estimated for GhaIi, Charlson, 
'moderated' Charlson and Elixhauser comorbidity measures in order to determine the 
strength of association between each and one year survival. Charlson and Ghali 
comorbidity measures were found to be more strongly associated with the excess hazard 
of death at one year than the 'moderated' Charlson and Elixhauser measures. Multiple 
imputation was used to handle missing data for the Charlson and Ghali measures for 
each of the four time windows (i.e. multiple imputation was conducted eight times). The 
multiple imputation model will be described below and was consistent for both 
Charlson and Ghali measures (and each time window). After imputation comparisons of 
the excess hazard ratio of death were used to evaluate the Charlson and Ghali measures 
for each time window. 
The multiple imputation included variables and interactions based on documented 
knowledge of cancer registry data collection system and previous research on variations 
for missing cancer registry data.30,31,46 The associations of variables and missingness of 
data were analysed to support the assumption that the mechanism of missing data was 
MAR (see chapter 3). The imputation model included clinical factors (stage, grade, 
histology, comorbidity, colorectal cancer subsite), demographic factors (age group, 
socioeconomic status, sex) (see Table 6.8), treatment factors (surgery, chemotherapy, 
radiotherapy, surgeon volume, hospital volume) vital status and survival time. In order 
to include so many variables and decrease computation time each variable was 
categorised as outlined in Table 8.6. Interactions between follow-up time and each of 
stage, age and socioeconomic status were included because they were identified as non-
proportional in analysis of the complete dataset. 
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The excess hazard of death was estimated using Poisson model in Generalized linear 
models within the multiple imputation software in STAT A. Multiple imputation 
software (MIM) in STA TA estimates the excess hazard ratio of death and variance 
(based on between and within imputation datasets). For each clinical and demographic 
variables the socioeconomic-specific excess hazard ratio of death was initially estimated 
(or the deprivation gap) at one year after diagnosis and at five years conditional on 
surviving the first year. 
Summary generalized linear models were developed to describe the socioeconomic 
variations after adjusting for all relevant variables (end of each chapter 5 to 8). Each 
clinical, demographic and treatment variable was sequentially added to the generalized 
linear model and tested for significance, with each highly significant (p<O.OOI). Stage, 
age and deprivation were non-proportional over time. Ideally, the more advanced 
technique of splines11,47,48 would have been used to take account of non-proportionality, 
but the software for the application of splines using imputed data was not yet available. 
Non-proportionality was instead accounted for in a step-wise function including 
interactions between follow-up time and each of stage, age and deprivation. Follow-up 
time was categorised into the first year after diagnosis and second to five years after 
diagnosis. The assumption of proportional excess hazards for the first year and second 
to five years after diagnosis may be reasonable, because the excess mortality is initially 
high then decreases dramatically during the first year since diagnosis, but remains fairly 
stable at a lower level afterwards. Each time-by-variable interaction was tested using the 
likelihood ratio test and was significant at p<=O.OO I. 
Strategy 
It is clear from previous studies of registry data,28-31 and initial analysis of this dataset, 
that stage is not MCAR (Table 3.12 ). Determining whether stage is MAR or MNAR 
was not as simple, and required assessment of the mechanism underlying the missing 
data, based on associations with missing data, and knowledge of the potential reasons 
for missing data. Associations with missing data and the assumptions based on these 
will be detailed in Chapter 6. 
The aim of imputation was to estimate the underlying data, for stage, grade, 
morphology, comorbidity, surgery, chemotherapy, radiotherapy, hospital and surgeon 
volume of treatment, so that the degree of invalidity is decreased. Stage was incomplete 
for 39.5% of the available data, but other variables were recorded with high levels of 
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completeness, therefore developing a model for imputation of missing data for stage and 
other data (e.g. treatment) was the most effective method to incorporate all the data and 
avoid potential bias. 
In order to estimate the influence of stage and treatment on socioeconomic inequalities 
missing data were imputed using multiple imputation techniques. The data after 
imputation were then used to estimate the excess mortality using deprivation-, region-
and time-specific life tables to take into account differences in the underlying mortality. 
The expected excess mortality was estimated for combinations of variables to be studied 
(e.g. age, stage, comorbidity, treatment etc) and multivariable models estimated using 
generalized linear models using individual level data. 
Analysis was done in four steps I) data management 2) multiple imputation 3) final 
analysis with generalized linear models of the excess deaths (or excess mortality) 
(Figure 4.3). 
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Figure 4.3: Analysis and imputations steps 
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The first step was data management, which was detailed in the Materials and definitions 
(chapter 3). Briefly, this step involved data cleaning, applying exclusions for the cancer 
registry data and adding treatment and comorbidity information from HES. 
Step 2: Multiple imputation 
Multiple imputation by chained equations27 in STATA was used to recover missing data 
in covariates using Gibbs sampling.49 MUltiple imputation is an iterative technique, 
which deals with missing values when more than one variable is incomplete. The 
method assumes that a multivariate distribution exists, without specifying a specific 
form for it, and draws from it are generated by Gibbs sampling the conditional 
distributions. The imputation model included each incomplete variable (e.g. stage, 
Table 4.1), complete variables (e.g. age, year of diagnosis) and outcome (survival time, 
vital status). Imputation models were specified for each incomplete variable such as, 
logistic regression for binary variables (e.g. sex, vital status), normal linear regression 
for continuous variables (e.g. age in years) and ploytmous logistic regression for 
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categorical variables with more than two levels (e.g. stage). In this research it was not 
always clear when information was missing or did not occur (e.g. missing surgery, no 
surgery) 
Cancer registries attempt to improve the completeness and accuracy of data for these 
variables by case-note extraction, linkage to external datasets (screening, specialist 
registration datasets, research), and case-note audits. All these approaches are routinely 
done at MCCR and NWCR. In order to ensure the dataset was complete, further linkage 
to hospital episode statistics was done. Even after linkage of cancer registry data and 
HES some variables were not known for some patients. 
Every colorectal cancer patient must have a specific stage at diagnosis, tumour grade 
and histological tumour type, however comorbidity and treatment factors may be 
absent. For example, patients must have a stage ranging between I and IV, even if 
unrecorded, but the same is not true of treatment or comorbidity. For example, patients 
may have surgery, no surgery or have unrecorded surgery status (missing). 
Subsequently, the determination of whether a factor is missing is different for clinical 
factors and treatment factors (and comorbidity). Patients with unrecorded stage, grade 
and histology were imputed if there was no recorded stage, grade or histology. In 
contrast tumour records without comorbidity, surgery, chemotherapy, radiotherapy, 
hospital volume or surgeon volume may be a true record of the patient's experience (i.e. 
no chemotherapy, no comorbidity) and can not automatically be assumed to be missing. 
Table 4.1: Co-variates with missing data and percentage missing 
Varible with missing data 
Stage 
I Iistology 
Grade 
Comorbidity 
Surgery 
Chemotherapy 
Radiotherapy 
Surgeon volume 
Hospital volume 
% 
39.5 
11.6 
25.0 
19.3 
8.9 
63.9 
19.6 
21.6 
20.0 
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In the absence of actively recording if treatment or comorbidity is not presentll it was 
necessary to make some assumptions about when treatment factors and comorbidity did 
not occur (e.g. no surgery, no comorbidity) or were missing (e.g. unknown surgery 
status, unknown comorbidity). These assumptions were developed based on data 
collection methods, completeness and accuracy of cancer registry and HES treatment 
data. 
Linkage of colorectal cancer patient's in the cancer registry data to HES achieved a 
good linkage (82%, see chapter 3), unlinked patients with no registry record of surgery 
were assumed not to have had surgery. In the simplest situation patients had surgery 
recorded in the cancer registry (Figure 4.4). For patients without surgery recorded in 
the cancer registry, and for whom linkage to HES was obtained, surgery was assumed to 
be unknown (or missing) and was imputed. This assumption was made because 
individual inspection identified OPCS-4 codes that could be associated with colorectal 
cancer surgery for many of these patients (e.g. opening of the abdominal cavity, or 
anaesthesia) but no colorectal cancer surgery code. Additionally, in the earlier time 
periods HES was known to under record surgery. 67% of patients were recorded as 
having surgery in the cancer registry data. The addition of HES data improved the 
proportion of patients receiving surgery to 82% and imputation further increased the 
proportion of patients having surgery to 90%. 
Figure 4.4: Surgery data and determination of missingness 
Cancer Registry data 
I Coloreclal surgery recorded 
~ ~ 
Surgery received 
(surgery-yes) 
Surgery received 
(Iurgery=yes) 
linkage to HES 
/~ 
Petient luccessfully Patient OQjsuccessfully 
linked to HES linked to HES 
cOlorecL surgery I 
rd d' HES No hospital admissiOns ;? · .~ ('"~'"'ool 
lurgery=missing 
II Active negative recording occurs when a non-occurrence is recorded (e.g. no surgery = 0). Any patients 
without positive or negative information recorded would be truly missing data. 
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Hospital and surgeon volume was categorised based on the number of colorectal cancer 
surgeries conducted per year (see chapter 3). Patients who did not have surgery were 
assigned no surgeon volume and hospital volume (Table 4.2). Hospital and surgeon 
volume was imputed for patients who had surgery but missing data on hospitaVsurgeon 
volume, or who had missing surgery status. Inspection of individual surgical codes and 
comparison to cancer registry data appeared to show improvements in surgery coding 
between 1997 and 2004 .. 
Table 4.2: Relation between surgery status and hospital volume and surgeon 
volume 
Surgery 
Yes 
No 
missing 
Hospital/Surgeon volume 
Yes missing 
vi' Impute 
None 
Impute 
The determination of when chemotherapy data was missing followed a similar model to 
surgery data. Patients with chemotherapy recorded in either the cancer registry or HES 
data were assumed to have had chemotherapy, although this constituted a small 
proportion of patients (17.8%). Chemotherapy data is known to be under recorded in 
HES, because HES records procedures, such as chemotherapy received intravenously, 
but does not record chemotherapy received orally. Patients who were linked to HES but 
did not have chemotherapy data recorded in the cancer registry or HES were assumed to 
have missing chemotherapy data (Figure 4.5). Only patients without a record of 
chemotherapy in the cancer registry, and who were not linked to HES were assumed to 
have no chemotherapy. This method of assigning missingness might be considered 
conservative, however there are known biases in the data recorded in HES that must be 
taken into account. Hospital attendance and surgery is important for charging and 
measuring activity level. There is therefore a financial incentive to record attendance at 
hospital and it appears well recorded. Non-surgical treatment is less important for 
charging and measuring activity and is often not recorded (such as chemotherapy). 
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Figure 4.5: Chemotherapy data and determination of missingness 
Cancer Registry data 
! 
Chemotherapy recorded 
~ ~ 
Chemotherapy received 
(chemotherapy=yes) 
Linkage to HES 
/~ 
Patient successfully 
linked to HES 
1 
Chemotherapy 
recorded in HES 
Patient not successfully 
linked to HES 
1 
/~ 
No hospital admissions 
(chemotherapy=no) 
Chemotherapy received 
(OPCS-4 X35 or X29) 
(chemotherapy=yes) 
chemotherapy=unknown 
Chemotherapy very under 
recorded in HES 
The method of assIgnmg mlssmgness for radiotherapy data was different to 
chemotherapy and surgery because i) the data in the cancer registry was accurate and 
complete and ii) there was no other source (HES does not record radiotherapy 
treatment). Radiotherapy treatment information was only available from the cancer 
registry, but is well recorded. However, HES should still have a hospital admission (in-
patient or out-patient) for radiotherapy treatment. Each of the three radiotherapy centres 
in the North West provide highly complete radiotherapy information to the cancer 
registry. Patients were assumed not to have received radiotherapy if they had no record 
of radiotherapy and had no hospital admissions. Patients without radiotherapy treatment 
recorded but had no hospital admissions were assumed to be missing radiotherapy 
information. 
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Figure 4.6: Radiotherapy and determination of missingness 
Cancer Registry data 
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~ 
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(RadiotherapFmissing) 
All three radiotherapy centres in the North West provide highly complete radiotherapy data to the 
cancer registry. Patients admitted or attending hospital for rad iotherapy should have a hospital 
admission (although rad iotherapy treatment would not specifically be recorded). 
It was assumed any patient no recorded radiotherapy treatment in the cancer registry and 
without a hospital admission were missing radiotherapy data. 
The level of comorbidity for each patient was estimated based on their previous hospital 
admissions and any previous cancer diagnosis for Ghali, Charlson, 'moderated' 
Charlson and Elixhauser comorbidity measures (see chapter 3). The comorbidity 
information for patients linked to HES was derived from the diagnosis fields recorded 
during hospital admission (see Table 3.4). Patients for whom cancer registry records 
could not be linked to HES were assumed to have no information with which to 
estimate comorbidity and were assumed to have missing data. Comorbidity levels for 
both Ghali and Charlson comorbidity measures for each of the four time windows were 
imputed in order to evaluate the measures (i.e. eight imputed data sets). 
The multiple imputation model included the variables: age, sex, deprivation, 
comorbidity, stage, grade, histology, chemotherapy, radiotherapy, surgery, hospital 
volume and surgeon volume and the outcome variables of vital status and follow-up 
time. The completeness of variables to be imputed ranged from 37.5% for 
chemotherapy to 88% for morphological type (Table 4.1). Interaction terms were 
included for stage and follow-up time; age and follow-up time; deprivation and follow-
up time; and comorbidity and age. 
To avoid problems with small numbers and non-convergence, age and time were 
grouped. Age was grouped into 15 to 44, 45 to 54, 55 to 64, 65 to 74, 75 to 84 and 85 to 
99. Follow-up time was grouped into less than 6 months, 6 months up to 1 year and 
yearly intervals up to five years. Stage, age and comorbidity were highly collinear and 
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were orthoganised before imputation to avoid being dropped (due to non-convergence); 
they were reverted back before estimating survival and excess mortality. 
Hospital and surgeon volume were both imputed conditionally on surgery status (both 
imputed and complete). This was achieved by including an interaction between the 
surgery flag (OIl) separately for hospital volume and surgeon volume, such that if 
surgery did not occur then surgeon volume and hospital volume were forced to zero. For 
example, for a given patient if it was imputed that no surgery occurred the patient must 
also have no hospital and surgeon volume. However if surgery occurred (known or 
imputed) then hospital and surgeon volume must be estimated (low, mid, high or very 
high). 
Except when large proportions of data are missing, five to ten iterations have been 
deemed sufficient.24,50 Ten iterations were used in this study. 
Step 3: Multivariable analysis of excess hazard ratio of death 
For each of the ten imputed datasets, excess mortality were e:;timated for each 
combination of relevant predictor variables with the results saved to 10 separate files. 
Excess mortality was calculated using the strs algorithm on individual data, as it allows 
the application of generalized linear models (GLM) of excess mortality2 with a Poisson 
error structure as described in step 3. For the excess hazard of death, follow-up time was 
defined into a number of intervals. The follow-up interval structure was every three 
months for the first three years, then six monthly up to five years and yearly after five 
years. 
Multiply-imputed software in STAT A was used to analyse the imputed data because it 
enables analysis of imputed data using standard analysis such as multi variable GLM 
modelling.43 Each dataset was analysed independently with the final estimate an average 
of the analyses for each dataset.43 Standard errors ~ere estimated as defined by Rubin24 
(Equation 9) by incorporating variation within and between datasets. 
Treatment was then combined into one variable as previously outlined in the materials 
section (e.g. surgery only, surgery and chemotherapy, .. no treatment). 
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To compare and evaluate comorbidity measures, the multiple imputation was used to 
estimate missing data for Charlson and Ghali scores for comorbid conditions occurring 
18 to 6 months before diagnosis, the 6 months before diagnosis, in the first year after 
diagnosis and at any time (Figure 3.3). 
Summary 
The methods used to analyse colorectal cancer survival were complex but necessary to 
ensure the results were not biased by missing data. Relative survival is the gold standard 
method for analysing survival in population-based cancer registry data. When adjusting 
for multiple factors, Poisson models for excess mortality provide the most practical 
method to assess the impact and relationship of multiple variables. Population-based 
cancer registry data have high levels of completeness and accuracy for tumour details 
but even after HES is used to further improve data, treatment and staging data were 
incomplete. Multiple imputation was used to handle missing data, thus allowing 
analysis of relative survival or the excess hazard of death with a completed dataset. 
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Chapter 5 
Colorectal cancer survival and comorbidity: does the choice of 
comorbidity indicator matter? 
Overview 
Comorbidity, or illnesses other than the primary illness under treatment, is more 
common in patients who are older and of lower socioeconomic status. I-3 Comorbid 
conditions may influence both the clinical appropriateness of a given treatment and its 
effectiveness, particularly for cancer patients who may need intensive surgery or 
prolonged chemo- or radiotherapy treatment.4 Comorbidity measures are regularly 
recorded in clinical and audit studies using case-note review or patient assessment at 
diagnosis. Recording comorbidity for all patients in a population-based cancer registry 
is more challenging. Population-based cancer registry data include all patients, even 
those who are not eligible for active treatment because of late stage or severe 
comorbidity, and who are normally excluded from clinical or audit studies. Clinical 
trials, by contrast, are often restricted to patients meeting strict criteria, usually under 75 
years of age and in good overall health. S 
Aim 
This chapter contains an evaluation of various approaches to assigning overall 
comorbidity scores that incorporate the number and severity of comorbid conditions to 
cancer patients in population-based data. Hospital Episode Statistics (HES) data6 were 
used to estimate the variation in one-year survival associated with different levels of the 
Charlson, Elixhauser and Ghali comorbidity measures. A 'moderated Charlson' 
measure was developed that included other conditions known to be contra-indicators for 
surgery and was compared to the other comorbidity measures. Comorbidity scores for 
each measure were categorised into four levels (none, 1,2 and 3 or more). Conditions 
diagnosed at or around the time of cancer diagnosis may have been initiated or 
increased in severity by the cancer and/or its treatment. The impact on survival of 
comorbid conditions was therefore assess in relation to various time windows around 
the cancer diagnosis and in order to elucidate the best method of measuring comorbidity 
as a prognostic factor in cancer survival analysis. The four time windows evaluated 
were; 18 months to 6 months before cancer diagnosis, 6 months before cancer 
diagnosis, the first 12 months after cancer diagnosis and any comorbidity between the 
financial years of 1996/07 and 2005106. 
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For the Charlson and Ghali measures multiple imputation was used to estimate the level 
of comorbidity when the underlying score was missing. Evaluation of the multiple 
imputation model and its impact on the comorbidity levels associated with other 
variables and survival will be evaluated in Chapter 6. The imputation model used for the 
Charlson measure at 18 months to 6 months before diagnosis was also applied to the 
Charlson and Ghali comorbidity measures for each time window. The Elixhauser and 
moderated Charlson measures were evaluated as only weak measures of comorbidity 
analysis, and were not no imputation were done for these measures. 
The analysis presented in this chapter will mainly be based on data after imputation, 
unless otherwise specified. 
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Choice of index and time window 
Comorbid conditions may increase in severity due to the presence of colorectal cancer 
and the diagnostic procedures and treatment procedures for colorectal cancer. The 
association of the timing (or 'time window') of comorbid conditions in relation to the 
diagnosis of colorectal cancer was evaluated based on comorbid conditions recorded in 
hospital admissions at: any time during the financial years 1996/97 to 2005/06; in the 18 
to 6 months before colorectal cancer diagnosis; 6 months before colorectal cancer 
diagnosis; or the first year after colorectal cancer diagnosis. The excess hazard of death 
for each level of the Charlson and Ghali measure for each of the four time windows 
were compared. For most time windows the Charlson and Ghali measures were 
associated with a similar excess hazard ratio of death for each level of comorbidity 
(Table 5.1, Figure 5.1). The excess hazard ratio was higher for Charlson measure in the 
18 to 6 months before diagnosis (4.1, 95% CI 3.8-4.5) than with the Ghali measure (2.2 
95% CI 1.8-2.6). In the six months before a colorectal cancer diagnosis the Charlson 
comorbidity measure were consistently higher than Ghali measure. In the year 
following a colorectal cancer diagnosis and any time between 1996/07 and 2005/6 the 
Ghali measure was marginally higher than the Charlson measure, although this was not 
significant. This pattern remained at five years after diagnosis although the association 
was moderated because the impact of comorbidity mainly occurred in the first year after 
diagnosis (Appendix 5.1). Comorbidity diagnosed at any time was not associated with 
an excess hazard except for patients with 3 or more for both Charlson and Ghali 
measures. There was only a weak association between the excess hazard ratio for 
increasing levels of comorbidity in the Elixhauser and moderated Charlson measures 
(Appendix 5.2). 
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Table 5.1: Distribution of patients (%) and excess hazard ratio of death within one 
year diagnosis by level of comorbidity (Charlson and Ghali comorbidity measures) 
and time window within which comorbidity was recorded: colorectal cancer 
patients diagnosed 1997-2004, North West of England (after imputation) 
Charlson Ghali 
EHR EHR 
% of 95% cr % of 95% CI 
level eatients lower uEEer eatients lower uEEer 
18 months to 6 months before diagnosis 
0 77.9 1.00 97.8 1.00 
I 5.2 1.73 1.54 1.93 0.4 1.56 1.12 2. 18 
2 8.9 2.78 2.56 3.02 0.9 1.60 1.30 1.95 
3+ 7.9 4.11 3.77 4.48 0.9 2.15 1.80 2.57 
6 months before diagnosis 
0 65 .6 1.00 89.6 1.00 
I 13 .1 1.74 1.51 1.99 1.7 1.72 1.44 2.05 
2 9.0 2.80 2.53 3.11 2.6 2.41 2.09 2.77 
3+ 12.5 4.12 3.71 4.59 6.1 3.11 2.83 3.41 
First 12 months after diagnosis 
0 65.5 1.00 88.6 1.00 
I 12.9 1.38 1.28 1.48 1.6 1.23 1.02 1.49 
2 9.2 1.49 1.33 1.66 3.2 2.06 1.80 2.34 
3+ 12.4 2.20 1.87 2.59 6.6 2.29 2.08 2.51 
An~ time 
0 49.5 1.00 78.2 1.00 
12.8 1.17 1.09 1.25 9.0 0.62 0.46 0.83 
2 11.4 1.09 1.0 I 1.18 3.8 1.07 0.94 1.23 
3+ 26.3 1.35 1.26 1.44 17.1 1.59 1.49 1.70 
140 
Figure 5.1: Direct comparison of the excess hazard ratio of death at one year after 
diagnosis for colorectal cancer by the four levels of Charlson and Ghali measures 
and time window within which comorbidity was recorded: colorectal cancer 
patients diagnosed 1997-2004, North West of England (imputed) (reference = no 
comorbidity score) 
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Charlson measure 
·Patients diagnosed with comorbidity between 1997/06 and 2005106 
Two moderations to the Charlson comorbidity measure were evaluated for their impact 
on survival patterns. The moderated Charlson included the standard 16 Charlson 
comorbid conditions plus hypertension, ischaemic heart disease, pulmonary embolism 
and obesity each with of the additional comorbid conditions given a severity weight of 
one. Another moderation to the Charlson measure obtained previous cancer diagnosis 
from hospital admissions rather than from cancer registry data. The addition of 
hypertension, ischaemic heart disease, pulmonary embolism and obesity to Charlson 
comorbidity measure identified substantially more patients with comorbidity but had a 
weak association with survival (Appendix 5.2). Hypertension and ischaemic heart 
disease occurred in a large proportion of patients but were not significantly associated 
with an excess hazard of death (Table 5.4). Obesity identified very few patients (n=I13, 
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0.4%). Of the four additional diagnoses only pulmonary embolism (n=311, 1.1%) 
diagnosed at any time was significantly associated with the excess hazard of death (1.28 
95% CI 1.08-1.52). 
The Charlson and Ghali measures had similar excess relative survival for most time 
windows, while the Elixhauser and modified Charlson measures were weakly associated 
with survival (Appendix 5.2). The weak association of the modified Charlson measure 
with survival was mainly due to the inclusion of hypertension which was associated 
with a large number of patients but an apparently protective effect (excess hazard ratio 
0.64). 
The comorbidity scores in all time windows were highly skewed. Most patients had no 
recorded comorbidity score at any time (Charlson: 68.5%, modified Charlson: 65.9%, 
Ghali: 85.9% Elixhauser: 55.5%). A small proportion of patients had high levels of 
comorbidity (Table 5.2, Appendix 5.2). The time window identifying the most 
comorbidity was consistent for all methods and occurred in decreasing order in the 
comorbidity window of anytime, during treatment, 6 months prior to diagnosis and at 18 
months to 6 months prior to diagnosis, respectively. 
Table 5.2: Distribution of weighted comorbidity scores by time window: Charlson 
comorbidity measure: colorectal cancer patients diagnosed 1997-2004, North West 
of England 
18 months to 6 
months before 6 months before to First 12 months 
An:z: time diagnosis diagnosis after diagnosis 
Comorbidit:z: score No. % No. % No. % No. % 
0 20,248 68.5 28,244 95.5 26,076 88.2 25,625 86.7 
I 4,523 15.3 833 2.8 2,552 8.6 2,742 9.3 
2 3,095 10.5 403 1.4 705 2.4 912 3.1 
3 1,055 3.6 66 0.2 181 0.6 216 0.7 
4 385 1.3 16 0.1 42 0.1 53 0.2 
5 156 0.5 3 0.0 8 0.0 8 0.0 
6 56 0.2 0 0.0 3 0.0 
7 19 0.1 I 0.0 0 0.0 
8 18 0.1 6 0.0 
9 8 0.0 
10 0 0.0 
II 2 0.0 
Linkage quality 
Linkage of HES data to cancer registry data obtained for this study was 82%, which was 
consistent with linkages in other registry-based studies in London and South West 
England (63%),7 teenagers and young adults (86%),8 and rectal cancer patients 
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undergoing abdominoperineal excision (92%).9 Patients whose cancer registry data 
could not be linked to a HES record included those without any prior hospital admission 
and with no comorbid conditions, patients with a hospital admission but no recorded 
comorbidity (missing in HES) and those treated outside of the NHS. Patients that could 
not be linked to HES data were significantly more likely to have colon cancer (than 
rectal cancer), no treatment (rather than any other treatment), to be aged over 75 at 
diagnosis, and to be diagnosed at an advanced stage (data not shown). 
Patients for whom cancer registry data could not be linked to HES may be 
systematically different with regards to survival and/or comorbidity than patients for 
whom a cancer registry to HES linkage was obtained. Patients with no hospital 
admissions may include patient who i) 'truly' have a comorbidity that is well managed 
(hence no hospital admissions), ii) have no comorbid conditions or iii) hospital 
admission data may be missing from HES. The impact of these scenarios on the excess 
hazard ratio of death for each level of the Charlson measure (at 18 to 6 months before 
diagnosis) were evaluated by excluding patients without a hospital admission, assuming 
patients not linked to HES had no comorbidity (0) and assuming patients not linked to 
HES had the highest level of comorbidity (3+). These three scenarios showed no 
significant difference in the excess hazard ratio at each comorbidity level, although 
limiting the estimates to patients linked to HES increased the excess hazard for scores 1 
and 2 compared to the other estimates (Table 5.3). The impact of assuming patients that 
were not linked to hospital admission data had a Charlson comorbidity measure level of 
3 or more being a biased toward higher comorbidity was evaluated by assuming they 
had higher levels of comorbidity (3 or more), increased the excess hazard ratio of death 
moderately and non-significantly to 2.92 (95% CI 2.79-3.05) for patients with a 
comorbidity level of 3 or more. 
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Table 5.3: Sensitivity analysis for excess hazard ratio of death for Charlson 
comorbidity measure at 18 to 6 months before diagnosis: colorectal cancer patients 
diagnosed 1997-2004, North West of England 
Patients for whom cancer All patients, with patients not All patients, with patients not 
registry record and HES data linked to HES assumed to have linked to HES assumed to have 
were linked (n=23,868) comorbidi!l: level 0 (n=29,563) comorbidi!l: level 3+ (n=29,563) 
excess hazard ratio excess hazard ratio excess hazard ratio 
95%. CI 95% CI 95%. CI 
level lower u~~er lower u~~er lower u~~er 
0 1.00 1.00 1.00 
1 1.46 1.25 1.72 1.32 1.16 1.50 1.32 1.16 1.50 
2 1.47 1.15 1.87 1.38 1.16 1.64 1.38 1.16 1.64 
3+ 2.83 1.96 4.08 2.85 2.12 3.83 2.92 2.79 3.05 
Despite the lack of significant difference in the excess hazard of death between the three 
scenarios patients that did not link with HES were assumed to have missing data and 
multiple imputation was used to estimate the comorbidity level in the Charlson 
comorbidity measure at 18 to 6 months before diagnosis. Imputed estimates of the 
excess hazard ratio of death for patients with a comorbidity level of 3 or more were 
slightly higher (3.295% CI 2.6-3.9) than all of the scenarios evaluated in the sensitivity 
analysis. Multiple imputation will be evaluated in Chapter 6 for all clinical and 
demographic variables. 
Individual comorbid conditions 
Among colorectal cancer patients diagnosed with between 1997 and 2004 in the North 
West the most common of the 17 conditions which make up the Charlson comorbidity 
measure (diagnosed at any time between the financial year 1996/97 and 2005/06) were 
chronic pulmonary disease (n=2,338, 7.9%), prior invasive malignancy (COO-C97 excl 
C44, n=I,788, 6.0%) and congestive heart failure (n=I,086, 3.7%) (Table 5.4). Nine 
conditions were associated with an excess hazard ratio of death above 1.0 (reference is 
no comorbidity). Due to small numbers individual comorbid conditions were analysed 
regardless of whether they occurred pre- or post-operatively. Only six conditions were 
significantly associated with an increased excess hazard ratio of death (congestive heart 
failure, cerebrovascular disease, dementia,· hemi/paraplegia, renal disease, 
moderate/severe liver disease) and three significantly protective (previous malignancy, 
mild liver disease, rheumatic disease). Liver disease l was strongly associated with an 
excess hazard ratio of death (3.72 95% CI 1.90-7.30) however there were only 10 
patients with recorded liver disease. Liver disease was strongly associated with an 
I Moderate/severe liver disease (ICD-IO 185.0, 185.9, 186.4, 198.2, K70.4, K71.1, K72.1, K72.9, K76.5, 
K76.6, K76.7), Liver metastasis is excluded. 
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excess hazard ratio of death (3.72 95% CI 1.90-7.30) however there were only 10 
patients with recorded liver disease. Liver disease did not include metastatic liver 
cancer (C76-C80). It is plausible that some patients with this comorbid condition were 
diagnosed prior to diagnosing late stage colorectal cancer with liver metastasis thus 
explaining the poor prognosis in these patients. Congestive heart failure occurred in a 
large number of patients and predicted a 53% excess mortality. Only one patient had an 
HIV / AIDS diagnosis so this could not be evaluated as an individual comorbid condition 
but was included In the overall measures with a weight of SIX. 
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Table 5.4: Number (%) and excess hazard ratio of death at one year, for comorbid 
conditions included in the Charlson and modified Charlson measure at any time: 
colorectal cancer patients diagnosed 1997-2004, North West of England 
Excess hazard ratio 
Relative 95%CI 
Weight Comorbidity Patientst frequency lower upper 
I Myocardial infarction 780 2.6 1.04 0.92 1.17 
I Congestive heart failure 1,086 3.7 1.53 1.40 1.67 • 
I Peripheral vascular disease 498 1.7 0.88 0.75 1.04 
I Cerebrovascular disease 867 2.9 1.19 1.07 1.33 • 
I Dementia 295 1.0 1.22 1.01 1.46 • 
I Chronic pulmonary disease 2,338 7.9 0.95 0.88 1.02 
I Rheumatic disease 232 0.8 0.72 0.55 0.95 • 
I Peptic ulcer disease 468 1.6 0.92 0.78 1.09 
I Mild liver disease 188 0.6 0.66 0.48 0.91 
I Diabetes without chronic complication 797 2.7 0.73 0.63 8.84 
2 Diabetes with chronic complication 46 0.2 0.98 0.57 1.69 
2 Hemiplegia or paraplegia 234 0.8 1.42 1.18 1.71 • 
2 Renal disease 470 1.6 1.18 1.02 1.37 • 
3 Moderate or severe liver disease 10 <0.1 3.72 1.90 7.30 • 
3 Any malignancy: 1,788 6.0 0.73 0.66 0.81 • 
6 Other metastatic solid tumour 15 0.1 1.44 0.32 6.39 
Additions: 
Hypertension 5,902 20.0 0.64 0.60 0.68 • 
Ischaemic heart disease 2,106 7.1 0.96 0.89 1.04 
Pulmonary embolism 311 1.1 1.28 1.08 1.52 • 
Obesit~ 113 0.4 0.76 0.53 1.10 
• p-value<0.05 
tSome patients will have more than one type of comorbidity and are included in each category 
: Excluding benign tumours and non-melanoma skin cancer (C44). only first colorectal diagnosis included. 
Hypertension, ischaemic heart disease, pulmonary embolism and obesity were evaluated 
as potential additions to the Charlson measure (or 'modified Charlson'), because they 
are potential contra-indications for some cancer treatment as well as increasing the 
overall risk of mortality. Patients with ischaemic heart disease should not receive some 
chemotherapy regimes (particularly 5FU) because of the cardiotoxicity. The modified 
Charlson measure did not improve the association between each level of comorbidity 
and the excess hazard of death, compared to the standard Charlson measure. 
Hypertension (n=5,902), ischaemic heart disease (n=2,1 06), pulmonary embolism 
(n=311) and obesity (n=I13) occurred in 20.0%,7.1%,1.1%, and 0.4% of patients, 
respectively. Pulmonary embolism (1.28, 95% CI 1.08-1.52) was significantly 
associated with excess mortality while ischaemic heart disease (0.96, 95% CI 0.89-
1.04), and obesity (0.76, 95% CI 0.53-1.10) were not. There was a significantly lower 
excess hazard associated with hypertension as a comorbidity (0.64, 95% CI 0.60-0.68). 
Distribution of comorbidity 
Higher levels of comorbidity are known to be associated with some clinical and 
demographic factors. The Charlson comorbidity measure for comorbid conditions 
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diagnosed between 18 and 6 months before diagnosis was used to evaluate clinical and 
demographic variations in the proportion of patients with each comorbidity level and 
the odds ratio for any comorbidity (compared to none). Comorbid conditions occurring 
in the time window of 18 to 6 months before colorectal cancer diagnosis were evaluated 
because this time window was the least likely to include the colorectal cancer diagnosis 
or treatment procedures. The prevalence (and adjusted odds ratio) of comorbidity at 18 
to 6 months before diagnosis, was higher for patients aged over 55 at diagnosis, for 
more deprived and for those treated non-surgically. Increasing age was strongly 
associated with increasing levels of comorbidity increasing from 7.0% for patients aged 
15-44 to 26.2% for patients 85-99 (Table 5.5). Women had a higher levels of 
comorbidity than men but were diagnosed at an older age than men (men 69.2 years, 
women 72.0 years). Women had apparently lower comorbidity levels than men after 
adjustment for clinical and demographic factors. 
Deprived patients were more likely to have a comorbidity recorded than affluent 
patients (14.8% and 11.8%, respectively). Comorbidity was significantly higher in the 
three most deprived groups before adjustment comorbidity was only significant in the 
most deprived group after adjustment for age, subsite, diagnosis year stage and 
treatment. 
The prevalence of comorbidity among colorectal cancer patients appears stable between 
1999 and 2003, but is lower at the beginning of the study period probably because of 
artefact in the collection of HES data (1997, 1998). The collection and compilation of 
lIES was refined and improved from the financial year 1996/97 with continued 
improvement over time. This reorganisation and further refinement of HES likely 
explains the lower comorbidity in 1997 to 1999. This is further supported by the lower 
levels of less severe comorbid conditions (level 1) recorded in 1997 and 1998 (possibly 
1999) which might be expected to improve as data colle~tion processes were refined. 
Patients diagnosed in 1997 would also have a shorted time period within which 
comorbid conditions could be recorded (only 1996/97 financial year) with this having a 
differential impact on less severe comorbid conditions. 
Patients diagnosed with colon cancer had a higher prevalence of comorbidity than 
rectosigmoid or rectal cancer patients. The higher levels of comorbidity for colon cancer 
patients may be associated with the older age diagnosis for colon cancer patients, with 
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43.1 % of patients over age 75 compared to 35.2% and 36.3% for rectosigmoid and 
rectal cancer, respectively. Before adjustment for clinical and demographic variables, 
cancers of the rectum or rectosigmoid were associated with a significantly lower level 
of comorbidity at 18 to 6 months than colon cancer patients but these differences were 
fully explained after adjustment for age, year of diagnosis, deprivation, stage and 
treatment. 
Increasing levels of Charlson comorbidity at 18 to 6 months before diagnosis were 
strongly associated with advanced stage, rising from 7.1 % of patients in stage I to 
17.5% in stage IV. Patients in with stage IV colorectal cancer also had a high proportion 
of patients with level two (8.4%) and three or more (6.9%) comorbidity. Advanced 
stage at diagnosis (IV) was significant association with increasing comorbidity 
measures at 18 to 6 months. 
Patients receIvmg only chemotherapy and/or radiotherapy had significantly higher 
levels of comorbidity than surgical patients. Variations in treatment regime and 
associations with clinical and demographic variables, including comorbidity, will be 
examined in detail in Chapter 7. 
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Table 5.5: Distribution (%) of Charlson comorbidity measure at 18 to 6 months 
before diagnosis and odds ratio for any comorbidity (baseline = no comorbidity) by 
clinical and demographic variables (imputed): colorectal cancer patients diagnosed 
1997-2004, North West of England 
level of the Charlson comorbidit~ measure Odds ratio Odds ratio 
zero I 2 3+ {unadjusted! {adjusted!f 
Gender 
Men 87.1 4.0 1.I 3.8 1.00 1.00 
Women 85.9 4.0 6.0 4.2 1.I1 • 0.72 • 
Age grouping 
15 to 44 93.0 1.9 3.7 1.2 1.00 1.00 
45 to 54 93.8 1.9 3.2 l.l 0.90 1.22 
55 to 64 90.8 2.9 4.3 2.1 1.40 • 1.97 • 
65 to 74 89.1 3.6 4.6 2.8 1.68 • 2.51 • 
75 to 84 83.3 5.1 6.5 5.1 2.74 • 3.32 • 
85 to 99 73.8 6.1 9.6 10.7 4.86 • 3.94 • 
Subsite (lCD-tO) 
Colon (CI8) 85.4 4.3 5.9 4.4 1.00 1.00 
Rectosigmoid (CI9) 89.8 3.7 4.1 2.4 0.66 • 0.94 
Rectum (C20) 88.1 3.5 4.9 3.6 0.79 • 0.92 
Morphological type 
Adenocarcinoma 86.4 4.0 5.5 4.0 1.00 
Mucinous and serous 88.5 3.6 4.5 3.3 0.82 • 
Other 77.1 5.4 10.6 6.9 1.88 • 
Grade 
I 87.7 4.1 5.0 3.2 1.00 
II 87.0 3.9 5.2 3.9 1.06 
III 82.8 4.5 7.2 5.5 1.48 • 
IV 85.2 2.2 7.0 5.6 1.21 
Year of diagnosis 
1997 89.4 1.4 5.2 4.0 0.66 • 0.39 • 
1998 87.9 3.5 4.8 3.8 0.77 • 0.74 • 
1999 86.7 4.3 5.2 3.8 0.85 • 0.85 
2000 86.2 4.5 5.6 3.8 0.90 0.92 
2001 84.8 5.2 5.9 4.1 1.00 1.00 
2002 84.4 5.3 6.0 4.3 1.03 0.98 
2003 84.7 5.1 6.0 4.3 1.01 1.03 
2004 88.2 2.8 5.J 3.9 0.74 • 0.55 • 
Deprivation group 
Amuent-I 88.2 3.5 5.2 3.1 1.00 1.00 
2 87.7 3.6 5.2 3.5 1.04 0.98 
3 86.6 3.7 5.8 3.5 1.15 • 1.08 
4 86.2 4.5 5.1 4.2 1.20 • 1.21 
Deprived-5 85.2 4.3 5.8 4.7 1.30 • 1.30 • 
Stage 
I 93.9 3.2 2.3 0.7 1.00 
II 93.3 3.5 2.3 0.9 1.11 
III 94.1 3.1 2.0 0.8 0.97 
IV 80.5 4.2 8.4 6.9 3.74 • 
Treatment 
surgery only 94.9 3.6 1.3 0.3 1.00 
surgery and chemo 95.5 3.2 1.1 0.2 0.88 ).00 
surgery and radiotherapy 97.6 1.9 0.3 0.2 0.41 0.48 
surgery and chemoradiotherapy 98.0 1.7 0.3 0.1 0.39 • 0.50 • 
chemotherapy only 17.5 17.9 45.5 19.1 88.20 • 133.15 • 
radiotherapy only 47.2 17.0 25.5 10.4 20.75 • 24.70 • 
chemoradiotherapy 42.1 16.9 29.4 11.6 25.46 • 38.1 • 
no treatment 11.1 9.9 41.6 37.5 149.40 • 172.16 • 
86.5 4.0 5.5 4.0 
• Significant at p-value <=0.05 
t adjusted for age group, deprivation, subsite, diagnosis year and treatment, excluding the variable being studied 
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Comorbidity and survival 
Stage and age both substantially moderated the excess hazard ratio of death within one 
year of diagnosis for each level of the Charlson comorbidity measure at 18 to 6 months 
before diagnosis. Stage had a much weaker effect on the excess hazard for each level of 
the Ghali comorbidity measure (Table 5.6). Adjustment for deprivation had little impact 
on the excess hazard ratio of death for either Charlson or Ghali measures. Adjustment 
for treatment fully explained the excess hazard of death for each level of the 
comorbidity for both the Charlson and Ghali measures (not shown) highlighting the 
impact of comorbidity on treatment eligibility and the further validating association 
between the Charlson and Ghali measures with survival and treatment. Treatment was 
not included in the final adjusted model because stage, comorbidity and other clinical 
factors were predictors of treatment; thus treatment was on the causal pathway between 
these factors and outcome. 
Increasing levels of the comorbidity at 18 to 6 months before colorectal cancer 
diagnosis were still associated with excess mortality at five years after diagnosis 
regardless of whether the Charlson or Ghali comorbidity measure -was used (Appendix 
5.3). The pattern was similar to that at one year after diagnosis, but moderated. The 
moderating impact of treatment on the excess hazard for each level of comorbidity was 
also weaker at five years after diagnosis than at one year. 
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Table 5.6: Excess hazard ratio for death at one year and for Charlson and Ghali 
comorbidity measures at 18 to 6 months, adjusted for age, stage, deprivation and 
treatment (imputed): colorectal cancer patients diagnosed 1997-2004, North West 
of England 
Charlson measure Ghali measure 
EHR EHR 
95%CI 95%CI 
level Adjusted for lower uQQer lower uQQer 
0 1.00 1.00 
1 follow-up 1.73 1.54 1.93 1.56 1.12 2.18 
2 2.78 2.56 3.02 1.60 1.30 1.95 
3+ 4.11 3.77 4.48 2.15 1.80 2.57 
0 Age and 1.00 1.00 
1 1.52 1.36 1.69 1.41 1.02 1.94 
2 follow-up 2.47 2.28 2.67 1.36 1.12 1.65 
3+ 3.25 2.99 3.53 1.60 1.35 1.90 
0 1.00 1.00 
1 Stage and 1.68 1.48 1.90 1.68 1.16 2.42 
2 follow-up 2.34 2.13 2.57 1.53 1.23 1.92 
3+ 3.18 2.88 3.53 2.20 1.81 2.68 
0 1.00 1.00 
1 Deprivation and 1.70 1.52 1.89 1.53 1.11 2.13 
2 follow-up 2.77 2.56 3.00 1.54 1.25 1.87 
3+ 4.04 3.72 4.39 2.08 1.75 2.48 
0 Age, stage, 1.00 1.00 
1 1.44 1.27 1.62 1.40 1.02 1.91 
2 
deprivation, and 2.03 1.86 2.22 1.33 1.09 1.61 
3+ follow-up 2.45 2.22 2.70 1.57 1.32 1.85 
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Summary 
Increasing levels of the comorbidity, particularly in the 18 months to 6 months before 
diagnosis of the colorectal cancer diagnosis were strongly associated with increasing 
excess hazard ratio of death within he first year after colorectal cancer diagnosis. This 
time window for comorbidity would be expected to exclude illnesses that may either 
have increased in severity or were due to a complication of colorectal cancer diagnosis 
or treatment. The Charlson comorbidity measure has been widely used and validated, 
but no other studies have assessed the time window of comorbid conditions in relation 
to cancer diagnosis (or other diseases). Increasing levels of comorbidity were associated 
with increasing age, increasing deprivation and more advanced stage at diagnosis. Even 
after adjusting for clinical and demographic factors, comorbidity, stage and age were the 
strongest predictors of excess mortality. 
The estimated prevalence of previous cancers obtained from registry data was consistent 
with other studies,I,2 but obtaining evidence of a presumptive previous cancer diagnosis 
from HES data greatly overestimated the prevalence. HES data may include suspected 
cancer, where results of diagnostic procedures are still pending, thus overestimating the 
true prevalence (e.g. suspected stomach later determined to be colorectal). Hospital 
administrative databases undoubtedly under-estimate the frequency of diseases which 
would not normally require hospital treatment, such as diabetes without complications, 
and other common chronic conditions, such as obesity, may also be under-recorded. 
The use of hospital admissions for estimating comorbidity will result in some degree of 
residual confounding, due to under-ascertainment of comorbid conditions. Despite this, 
lIES and cancer registry data remain a good source of comorbid conditions from which 
to construct comorbidity measures. 
For simplicity, in the analyses a single measure of comorbidity was selected. For the 
remainder of this thesis the Charlson comorbidity measure for illnesses diagnosed 
between 18 and 6 months before a colorectal cancer diagnosis will be used, with 
previous cancer diagnosis obtained from cancer registry information. 
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Appendix 5.1: Distribution of patients (%) and excess hazard ratio of death within 
five years of diagnosis by level of comorbidity (Charlson and Ghali comorbidity 
measures) and time window within which comorbidity was recorded: colorectal 
cancer patients diagnosed 1997-2004, North West of England (imputed data) 
Charlson Ghali 
EHR EHR 
% of 95% CI %of 95% CI 
level Eatients lower upper Eatients lower uEEer 
18 months to 6 months before diagnosis 
0 84 .5 1.00 98 .2 1.00 
I 4.4 1.61 1.48 1.77 OJ 1.48 1.13 1.95 
2 6.2 2.43 2.27 2.60 0.8 1.63 1.38 1.92 
3+ 4 .9 3.65 3.39 3.94 0.7 2. 16 1.86 2.51 
6 months before diagnosis 
0 75 .0 1.00 93.4 1.00 
I 11.0 1.61 1.46 1.77 1.2 1.60 1.37 1.85 
2 6.4 2.44 2.27 2.64 1.6 2.13 1.89 2.41 
3+ 7.6 3.66 3038 3.97 3 .2 2.82 2.59 3.06 
First 12 months after diagnosis 
0 73 .1 1.00 91.4 1.00 
I I 1.9 1.41 1.33 1.49 1.5 1.27 1.09 1.48 
2 7.1 1.61 1.48 1.75 2.3 2.04 1.82 2.27 
3+ 7.9 2.21 1.92 2.54 4.8 2.31 2. 14 2.50 
An;y time 
0 53.9 1.00 80.2 1.00 
I 12.6 1.20 1.14 1.27 1.1 0.81 0.67 0.99 
2 12 .0 1.17 1.10 1.25 3.8 1.17 1.06 1.30 
3+ 2 1.5 1.46 1.38 1.53 14 .9 1.64 1.56 1.73 
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Appendix 5.2: Relative distribution and excess hazard ratio of death for comorbidity measures of Charlson, Charlson with additions, 
Elixhauser and Ghali measure by time window (original 'complete' data): colorectal cancer patients diagnosed 1997-2004, North West of 
England 
18 months to 6 months bdorc diagnosis 
Charlson modified Charlson Ehxhauser Ghah 
EHR EHR EHR EHR 
Patients 95°"CI Patients 95%CI Patients 95%CI Patients 95%CI 
level No. % lower ~~r No. % lower ul!~r No. % lower ul!~r No. % lower upper 
0 28,244 95.5 1.00 28,110 95.1 1.00 27,759 93.9 1.00 29,014 98.1 1.00 
1 833 2.8 1.32 1.16 1.50 850 2.9 \.19 1.06 1.34 1,068 3.61 1.17 1.04 1.32 88 0.3 1.20 0.80 1.78 
2 403 1.4 1.38 1.16 1.64 476 1.6 1.23 1.07 1.42 596 2.02 1.45 1.26 1.67 226 0.8 1.37 1.08 1.73 
3+ 85 0.3 285 2.12 3.83 127 0.4 1.78 145 2.17 140 0.47 1.53 \.15 2.03 237 0.8 2.06 1.70 2.5\ 
6 months before to diagnosis 
Charlson modified Charlson Ehxhauser Ghali 
EHR EHR EHR EHR 
Patients 95%C1 Patients 95%CI Patients 95%CI Patients 95%CI 
level No. 0;' lower ul!~r No. % lower ul!~r No. % lower ul!~r No. % lower upper 
0 26,076 88.2 1.00 25,630 86.7 1.00 23,738 80.3 1.00 28,212 954 1.00 
1 2,552 8.6 1.52 1.41 1.63 2,651 9.0 1.27 1.18 1.35 3,930 13.3 1.27 \.19 1.35 279 0.9 1.26 1.10 1.68 
2 705 2.4 2.32 2.08 2.60 970 3.3 1.56 1.43 1.71 1,551 5.3 1.59 1.45 1.74 355 1.2 2.18 1.85 2.55 
3+ 232 0.8 2.86 2.37 346 312 1.1 2.17 1.91 2.47 344 1.2 2.25 1.90 2.65 719 2.4 3.14 2.85 3.48 
Fint 12 months after diagnosis 
Charlson modified Charlson Elixhauser Ghali 
EHR EHR EHR EHR 
Patients 95%C1 Patients 95%CI Patients 95%CI Patients 95%CI 
level No. % lower uI1l~r No. 0/0 lower u~r No. % lower ul!~r No. % lower upper 
0 25,625 86.7 1.00 24,878 84.2 100 22,823 77.2 100 27,900 94.4 100 
1 2,742 9.3 1.21 1.12 130 3,044 10.3 0.85 0.78 0.90 4,483 15.2 0.89 0.84 0.96 328 1.1 0.94 0.75 \.18 
2 912 3.1 1.32 1.17 1.49 1,233 4.2 106 0.97 \.16 1,793 6.1 107 0.98 \.18 448 1.5 1.98 1.72 2.28 
3+ 286 10 2.28 1.92 2.70 408 1.4 1.54 1.36 1.73 464 1.6 1.43 1.23 1.68 889 3.0 2.28 2.07 2.52 
Anl:time 
Charlson modified Charlson Ehxhauser Ghali 
EHR EHR EHR EHR 
Patients 95%CI Patients 95%CI Patients 95%CI Patients 95%CI 
level No. % lower !!I2:r No. % lower ul!~r No. % lower ul!~r No. % lower ul!~r 
0 20,248 68.5 1.00 19,487 65.9 1.00 16,405 55.5 1.00 25,405 85.9 1.00 
1 3,313 11.2 0.96 0.89 1.03 3,420 11.6 0.75 0.69 0.80 4,833 16.4 0.82 0.77 0.88 295 1.0 0.37 0.25 0.54 
2 2,813 9.S 0.83 0.77 0.91 2,833 9.6 0.76 0.70 0.82 3,658 12.4 0.70 0.65 0.76 844 2.9 0.86 0.74 100 
3+ 3,191 10.8 1.12 104 nO __ ..,3,823 12.9 092 0.87 0.98 4,667 158 092 086 0.98 3,021 10.2 1.45 1.36 1.55 
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Appendix 5.3: Excess hazard ratio for death at five years and for Charlson and 
Ghali comorbidity measures at 18 to 6 months, adjusted for age, stage, deprivation 
and treatment (imputed data): colorectal cancer patients diagnosed 1997-2004, 
North West of England 
Charlson measure Ghali measure 
EHR EHR 
95%CI 95%CI 
level Adjusted for lower uQper lower uQ~r 
0 1.00 1.00 
1 follow-up 1.61 1.48 1.77 1.48 1.13 1.95 
2 2.43 2.27 2.60 1.63 1.38 1.92 
3+ 3.65 3.39 3.94 2.16 1.86 2.51 
0 Age and follow- 1.00 1.00 
1 1.49 1.37 1.62 1.38 1.05 1.80 
2 up 2.28 2.13 2.44 1.44 1.23 1.70 
3+ 3.17 2.94 3.41 1.74 1.50 2.02 
0 1.00 1.00 
1 Stage and 1.59 1.44 1.75 1.64 1.24 2.18 
2 follow-up 2.05 1.90 2.12 1.53 1.29 1.82 
3+ 2.82 2.59 3.07 2.26 1.93 2.64 
0 1.00 1.00 
1 Deprivation 1.60 1.46 1.74 1.46 1.11 1.91 
2 and follow-up 2.43 2.27 2.60 1.57 1.34 1.85 
3+ 3.61 3.35 3.89 2.10 1.81 2.44 
0 Age, stage, 1.00 1.00 
1 1.43 1.31 1.57 1.36 1.04 1.78 
2 
deprivation, 1.90 1.76 2.04 1.41 1.20 1.66 
3+ and follow-up 2.38 2.19 2.60 1.71 1.47 1.98 
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Chapter 6 
Do clinical and demographic variables explain socioeconomic 
inequalities in colorectal cancer survival? 
Overview 
Colorectal cancer survival decreases with increasing deprivation. I-3 Some authors 
attribute these inequalities to deprived patients presenting with higher levels of 
comorbidity4,5 or more advanced stage at diagnosis.6,7 Comorbid conditions or advanced 
stage at diagnosis limit treatment options for treatment of curative intent. Very few 
patients with advanced colorectal cancer at diagnosis are amenable to curative 
treatment. Population-based evaluations of comorbidity and stage in cancer patients are 
difficult because data on stage and comorbidity are rarely complete in population-based 
data sources. Additionally, comorbidity and age are associated with other factors, such 
as treatment. Population-based assessments of the impact of stage, comorbidity and 
socioeconomic status on incidence and survival have usually been based on data in 
which stage and/or comorbidity are incomplete.5,7,8 Alternatively, audits may have 
complete stage or comorbidity data but may not be representative of the general 
population. 
Aim 
Inequalities in colorectal cancer survival in the North West of England between 1997 
and 2004 were evaluated to determine if they could be explained by stage, comorbidity 
and other clinical and demographic variables. The excess hazard ratio of death was 
estimated at one year after diagnosis, five years conditional on surviving the first year 
after diagnosis and at five years after diagnosis to determine if excess mortality 
occurred mainly during specific follow-up times thereby suggesting possible causal 
mechanisms. The excess hazard ratio of death in the most deprived compared to the 
most affluent (or 'deprivation gap') was evaluated for each clinical and demographic 
variable to determine the impact on the overall deprivation gap. 
In order to assess inequalities in survival using complete data, particularly for stage, 
missing data were handled using multiple imputation. The impact of multiple 
imputation on associations and survival, particularly stage at diagnosis, was also 
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quantified. The analysis presented in this chapter will mainly be based on data after 
imputation, unless otherwise specified. 
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Imputation 
Socioeconomic status was available for all patients, but many other variables which 
may explain inequalities were incomplete (e.g. stage, grade, histology and comorbidity, 
treatment). Multiple imputation methods were used to estimate missing data based on 
the observed dataset under the Missing at Random assumption. Multiple imputation did 
not substantially alter the distribution of stage, grade or histology compared to analysis 
of the original dataset for patients who were not missing data (or 'complete' analysis) 
but had a greater influence on the proportion of patients in each level of comorbidity, 
treatment regime, hospital and surgeon volume. Imputation did influence the stage-
specific distribution for each variable, because deprived patients had higher levels of 
missing data. The similarity of distributions and excess mortality between the 
'complete' and imputed analysis might supports the imputation methods. without 
obtaining the missing data it is not possible to determine (or test) if the assumption that 
unobserved data is missing at random (MAR).9 
The proportion of patients with missing grade increased from 22.4% of affluent patients 
to 26.7% of deprived patients with a corresponding decrease in the proportion of grade 
II and III cancers in deprived patients (Table 6.1). Similarly, the proportion of patients 
with unspecified histology increased with deprivation. After imputation there was no 
significant variation in grade or histological type by socioeconomic status. Grade IV 
and other histological types were very rare and imputation had very little effect on the 
distribution of these. The higher proportion of incomplete grade and histology in 
deprived patients was associated with a slightly lower proportion of colorectal cancers 
diagnosed in deprived patients being confirmed by pathologically. Colorectal cancer 
was confirmed by pathology (tissue diagnosis) in 92.6% of deprived patients compared 
to 94.3% of affluent patients with the remainder diagnosed by imaging (affluent 2.0%, 
deprived 2.9%) or clinically (without imaging or tissue diagnosis) (affluent 3.6%, 
deprived 4.4%). 
Affluent patients were more likely to have missing comorbidity data (21.1%, n=1,022) 
but after imputation, affluent patients were more likely to have no comorbidity (88.2%) 
than deprived patients (85.2%) (Table 6.1). Higher levels of comorbidity in deprived 
patients were associated with an increased risk of hospital admissions and a slightly 
lower level of missing comorbidity measures than affluent. After imputation patients 
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with comorbidity level two were more prevalent than level one or three, but the excess 
hazard ratio of death increased consistently with each level of comorbidity (Table 6.1, 
Table 6.4). The higher proportion of patients with a comorbidity in level two, compared 
to comorbidity levels of one or three or more is probably because of the close 
relationship between diseases with a weight of two and poor survival. Patients with a 
comorbidity level of two either had two low level comorbid conditions (each with 
weight of one) or,as is more likely to occur, had diseases with a· weight of two 
(paraplegia, renal disease or diabetes with complications). Paraplegia and renal disease 
were both individually associated with a significant excess mortality (see Table 5.4), 
therefore resulting in comorbidity level two having an excess hazard ratio of death for 
each comorbidity level intermediate between level one and level three or more. 
Comorbidity was more strongly associated with increasing deprivation after imputation 
(Table 6.1), because there was a higher proportion of missing co morbidity data for 
affluent patients (after imputation: no comorbidity in 88.2% of affluent and 85.2% of 
deprived). The odds ratio of having any comorbidity, compared to none, increased with 
deprivation and was significant, even after adjustment for clinical and demographic 
factors (see Table 5.5). 
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Table 6.1: Distribution (%) of clinical and treatment factors by deprivation among 
observed 'complete' data and after imputation colorectal cancer patients 
diagnosed 1997-2004, North West of England 
Original "complete" dara Imputed 
5 - 1- 5 -1-
amuent 2 3 4 deprived all amuent 2 3 4 deprived aU 
Clinical factors 
Stage 
I 13.2 12.8 12.0 11.5 11.4 12-3 
41.0 
43_2 
11.7 11.9 10.9 10.2 10.2 10.8 
II 38~ 4~2 4 1 ~ 422 42.0 36 .8 37.6 38.4 38.7 383 38.0 
III 
IV 
Not known 
Gmde 
I 
II 
III 
IV 
Not known 
lI is tology 
Adenocarcinoma 
Mucinous and serous 
Other specified 
Neoplasm NOS 
ComortJidity 
none 
I 
2 
3+ 
Unknown 
Treatment 
surgery only 
surgery and chemo 
surge ry and radiotherapy 
surgery and chemorad io 
chemotherapy only 
radiotherapy onl y 
chemoradiotherapy 
no treatment 
mi ssing 
110 pila1 vo1umc 
very high (over 150) 
high (100 to 149) 
moderate (50 to 99) 
low (less than 50) 
Private 
none 
miss ing 
urgcon volume 
very high (over 60) 
high (40 La 59) 
moderate (20 to 39) 
low (less than 20) 
n ne 
miss ing 
442 43~ 42.8 433 
4 .0 3.1 4.2 3.0 
(37 .2) (38.4) (39.1) (403) 
13.2 15.2 14.7 14.5 
73 .1 71.8 72. 1 72. 1 
13.3 12.8 12.9 13.0 
0.4 0.2 0.3 0.3 
(22.4) (24.4) (25 .1) (253) 
90.8 90.8 
8.9 8.7 
03 0.5 
(8 .8) ( 103) 
95 .7 95.4 
2.7 3.0 
1.4 1.4 
0.2 03 
(2 1.0) ( 18.8) 
9 1.3 90.0 
8.2 9.6 
0.5 0.4 
(12.1) ( 12.7) 
94 .8 
3.1 
1.9 
0.2 
(18.6) 
94.1 
4.1 
1.4 
0.4 
(18.0) 
42.8 
3.7 
(41.2) 
14 .7 
72.7 
12.4 
0.2 
(26.7) 
90.6 
8.8 
0.6 
(12 .9) 
93 .5 
3.9 
2.1 
0.6 
(19.8) 
3.6 
(39.5) 
14.5 
72.4 
12.8 
0.3 
(25.0) 
80.1 
7.8 
0.4 
(I 1.6) 
94.5 
3.5 
1.7 
0.4 
(19.3) 
Treatment factors 
62.2 
14 .2 
7.5 
4.4 
2.0 
0.9 
1.1 
7.7 
(4 .5) 
22 .2 
27.5 
2 1.1 
4 .6 
5.9 
18.9 
(24 .2) 
62.7 64 .8 63.5 
14.0 10.8 12.0 
7.1 7,64 7.7 
4.4 3.9 4.5 
2.0 2.0 1.8 
0.6 0.6 0.7 
0.9 1.2 1.1 
83 9.0 8.7 
(5 .8) (63) (7 .2) 
25.3 23.2 20.6 
30.2 33.4 3 1.0 
16.4 16.5 17.8 
5.3 4.1 5.5 
3.3 1.7 0.9 
19.6 21.2 24.3 
(25 .7) (2 7.9) (31.2) 
4.6 2.7 2.1 
13.0 
29.2 
3 1.6 
24 .2 
(18.4) 
23 
13.0 
28 .9 
32.0 
23 .8 
( 18.6) 
13.4 14.0 
27.5 28 .2 
28 .6 30.5 
25 .8 24 .6 
( 15.7) ( 16.9) 
100.0 100.0 100.0 100.0 
65 .1 
11.0 
6.9 
4.2 
1. 7 
0.5 
1.1 
9.6 
(7 .7) 
22.2 
31.3 
15.0 
6.1 
0.4 
25.1 
(32.3) 
1.6 
14.6 
27.2 
24 .0 
22 .5 
(19.6) 
100.0 
63.8 
12.2 
7.3 
4.3 
1.9 
0.7 
1.1 
8.8 
(6.5) 
22.6 
30.8 
17.1 
5.2 
2.1 
22.2 
(28.9) 
2.S 
13.7 
28.1 
31.7 
24.0 
(18.1 ) 
100.0 
46.6 
4.9 
12.9 
72.5 
14.2 
0.4 
90. 7 
8.9 
0.4 
88.2 
3.5 
5.2 
3.1 
36.6 
37.2 
1.0 
16.0 
0.5 
0.5 
0.7 
7.5 
24 .8 
3 1.4 
23 .0 
5.3 
5.8 
9.7 
5.0 
12 .9 
33 .3 
35 .3 
10.0 
100.0 
46.1 
4.3 
14 .2 
71.7 
13 .8 
0.3 
90.7 
8.7 
0.5 
87.7 
3.6 
5.2 
3.5 
36.7 
37.8 
0.8 
15.5 
0.4 
0.3 
0.4 
8.1 
27.9 
34.1 
18.6 
5.9 
3.5 
10. 1 
3.1 
16.3 
33 .3 
37.1 
10.2 
100.0 
45 .8 
4.9 
14.0 
71. 8 
13.9 
03 
9 1.2 
8.3 
0.5 
86.6 
3.7 
5.8 
3.9 
39.6 
34.6 
0.7 
15.5 
0.3 
0.3 
0.3 
8.8 
26.3 
37.5 
19.0 
4.8 
2.0 
10.5 
2.5 
14.9 
33.8 
38. 1 
10.8 
100.0 
46.9 
4.3 
13.9 
72.0 
13.8 
0.3 
90. 1 
9.5 
0.4 
86.2 
4.5 
5. 1 
4.2 
40.2 
33 .9 
0.9 
15.6 
0.3 
0.3 
0.4 
8.4 
25 .1 
36.2 
20.7 
6.2 
1.3 
10.5 
2.7 
15.0 
33 .2 
38.7 
10.5 
100.0 
46. 7 
4.8 
13 .9 
72.5 
133 
0.3 
90.5 
8.9 
0.6 
85 .2 
4.3 
5.8 
4.7 
4 1.3 
33.2 
0.8 
14 .7 
0.4 
0.2 
0.2 
9.3 
26.6 
36.7 
17.9 
6.8 
0.9 
11.2 
1.9 
16.0 
3 1.2 
39.8 
11.1 
100.0 
After imputation patients with miss ing stage were more likely to have an advanced 
stage than patients with known stage at diagnosis (Table 6.1 and 6.2). After imputation 
there were a much higher proportion of patients with missing stage diagnosed in stage 
III (53%) and stage IV (6.3%) compared to the overall distribution of stage. The most 
common stage at diagno is before imputation was stage II and III (41 %, 43%) but after 
161 
46.8 
4.8 
13.8 
72.1 
13.7 
0.3 
90.6 
8.9 
0.5 
86.5 
4.0 
5.5 
4.0 
39.2 
35.1 
0.8 
15.3 
0.4 
0.3 
0.4 
8.5 
26.2 
35.4 
19.6 
5.9 
2.4 
10.5 
2.9 
15.7 
32.7 
38.2 
10.6 
100.0 
imputation for all patients this shifted towards more advanced disease (stage II 38%, 
stage III 46%). Obviously, unstaged patients were predominantly patients who were not 
treated surgically and where therefore associated with missing grade and histology; 
10.3% (n=3,059) of patients were missing all three (stage, grade and histology). 
Increasing deprivation was associated with a higher proportion of patients with missing 
stage (Table 6.1), although this was explained by variations in age, sex, subsite, year of 
diagnosis and treatment (see Table 3.14). The proportion of patients in each stage at 
diagnosis was similar across all socioeconomic groups both before and after imputation. 
Stage I was slightly more common in more affluent patients whereas stage II was 
slightly less common possibly reflecting the impact of private health checks and 
opportunistic screening. 
Table 6.2: Distribution (%) of stage for patients with known (observed 'complete' 
data) stage, imputed stage and for patients with missing but imputed stage: 
colorectal cancer patients diagnosed 1997-2004, North West of England 
Imputedt 
Stage complete stage missing stage All {n=11,684~ 
No. % % % 
I 2,191 12.3 8.7 10.8 
II 7,322 41.0 33.5 38.0 
III 7,722 43.2 51.5 46.8 
IV 644 3.6 6.3 4.8 
unknown 11 z684 {39.4l 
100.0 100.0 100.0 
t Analysis of 10 imputed datasets 
Imputation is expected to produce distributions that are more representative of the 'true' 
underlying data and provide more plausible (and interpretable) estimates than the 
incomplete (original) data. 
Patients with missing stage had poorer survival than staged patients but were estimated 
to be from a heterogeneous mix of 'true' stages, with a higher proportion of advanced 
disease than patients with known stage. Therefore, before imputation patients with 
missing stage had a relative survival at five years in between (32.4%) that of stage III 
(42.8%) and IV (10.5%) (Figure 6.1). After imputation one-year and five-year relative 
survival for each stage was lower than before imputation (Table 6.3). The poorer 
prognosis for patients with missing stage resulted in large decreases in survival 
compared to 'complete' survival analysis for stage III and IV, particularly at one-year. 
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Figure 6.1: Relative survival (%) up to five years after diagnosis for unimputed 
and imputed data by stage at diagnosis: colorectal cancer patients diagnosed 1997-
2004, North West of England 
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Table 6.3: Relative survival (%) up to five years after diagnosis for original 
data and data after imputation by stage at diagnosis: colorectal cancer 
patients diagnosed 1997-2004 
unimEuted imEuted 
Stage one-~ear five-~ear one-~ear five-~ear 
96,5 93.3 90. 1 87.2 
II 89.8 74.7 78.3 66.5 
ill 77.3 42.8 52.8 32.8 
IV 39.2 10.5 20.8 9.4 
missing 49.5 32.4 
The three approaches used to handle missing data included i) limiting analysis to 
patients with complete data ('complete' analysis), ii) analysis with a separate category 
for missing data (or ' interval' analysis) and iii) using the imputed 'complete ' dataset 
created by multiple imputation. All three approaches produced relatively similar excess 
hazard ratios of death (or 'excess mortality') for each level of grade, comorbidity and 
histology. Wider differences occurred for each level of stage (Table 6.4). 
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Stage 
In the complete analysis, the excess hazard ratio of death for stage increased rapidly to 
3.89 in stage II, 11.65 in stage III and 30.13 in stage IV, compared with stage I 
(reference category) (Table 6.4). The excess hazard ratio for stages I to IV increased 
consistently and moderately for the interval analysis compared to the complete analysis. 
Patients with missing stage in the interval analysis had an excess hazard ratio of 12.64 
(95% CI 9.47, 16.86) intermediate between stage III and IV. After imputation, the 
excess hazard ratio of death in relation to stage increased less rapidly with stage than 
either complete or interval analysis. 
Grade 
Complete and interval analysis had similar excess hazard ratios for grades I to IV. The 
excess hazard ratio for patient with missing grade was between grade III and IV (Table 
6.4). In the imputed analysis the excess hazard for grade IV was higher but otherwise 
imputed analysis was broadly similar to the complete and interval analysis. 
Histology 
Patients with adenocarcinoma consistently had the best survival regardless of the 
approach to handling missing data. The excess hazards of death for adenocarcinoma and 
mucinous and serous histological types were similar in complete, interval and imputed 
analysis (Table 6.4). It was difficult to interpret analyses of the other specified 
histological type because there was a very small proportion of patients (complete 
analysis: n=128) which resulted in wide variations between complete, interval and 
imputed analysis. It is unsurprising that survival was very low for patients with an 
unspecified histology (Neoplasm, not otherwise specified) because they were unlikely 
to undergo surgery and, therefore unlikely to have pathological confirmation of their 
colorectal cancer (as described previously for missing stage). 
Comorbidity 
Interval and complete analysis produced similar estimates of the excess hazard ratio of 
death for each comorbidity level (none to 3 or more) whereas after imputation the 
excess hazard for each comorbidity level was higher (Table 6.4). Patients with missing 
comorbidity had higher survival (0.85 95% CI 0.74, 0.96) than those without 
comorbidity possibly indicating a 'true' lack of comorbidity in these patients. After 
imputation a high proportion of patients with missing comorbidity were imputed to have 
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no comorbidity, thereby improving the survival in the no comorbidity group (reference 
category) and systematically increasing the excess hazard ratio in levels one to three or 
more. 
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Table 6.4: Excess haza rd ratio (EHR) of death at five years after diagnosis for 
records no missing da ta (or iginal ' complete' analysis), with a separate 'missing' 
category (interval analysis) and with data after imputation adjusted fo r fo llow-up 
and age: colorectal cancer patients diagnosed 1997-2004, North West of England 
Complete Interval Imputed 
(16.223) (n=29.563) (n=29,563) 
EHR EHR EHR 
95%C I 95%C I 95%CI 
lower u~~e r lower u~~e r lower u~~er 
Clinical factors 
Stage 
I 1.00 1.00 1.00 
II 3.89 2.81 5.40 3.66 2.73 4.90 2.69 2.32 3. 11 
III 11. 65 8.44 16.08 9.76 7.3 1 13.04 6.87 6.05 8.02 
IV 30.13 2 1.42 42.38 2 1.69 16.07 29.28 15.30 12. 12 17.85 
missing 12.64 9.47 16.86 
G rade 
I 1.00 1.00 1.00 
II 1.38 1.24 1.55 1.34 1.20 1.49 1.46 1.37 1. 57 
III 3.29 2.90 3.73 3 .08 2.74 3.47 3.00 2.77 3.24 
IV 3.38 1.66 6.87 3.43 2.19 5.37 3.68 2.82 4.8 1 
missing 2.6 1 233 2.93 
Comorbidity 
0 1.00 1. 00 1.00 
I 1.54 1.31 1.80 1.50 1.3 1 1.7 1 1. 62 1.48 1.77 
2 1.55 1.2 1 1.98 1.5 1 1.24 1. 85 2.43 2.27 2.60 
3+ 2.84 1.76 4.58 2.94 2. 12 4.08 3.65 3.39 3.94 
missing 0.85 0.74 0.96 
iii tology 
Adenocarcinoma 1.00 1.00 1. 00 
Muc inous and scrous 1.29 Ll 6 1.42 1. 22 Ll 4 1.3 1 1.20 Ll 2 1.27 
Other specified 2.74 1.50 5.01 1.07 0.85 1.35 1.78 1.44 2.2 1 
Neoplasm NOS 2.29 2.15 2.43 
Treatment factors 
Hospital volume 
very high (over 150) 1.00 1.00 1. 00 
high ( 10010 149) 0.98 0.92 1.04 0.98 0.92 1.04 0.97 0.92 1. 02 
modera te (50 to 99) 1.00 0.93 1.07 1.00 0.93 1.07 0.97 0.9 1 1.03 
low (less than 50) 1.2 1 1.10 1.33 1.2 1 Ll O 1.33 1. 11 1.02 1.2 1 
private 0.47 0.38 0.57 0 .47 0.38 0.57 0.55 0.46 0.65 
none 1.88 1.78 1.99 1.88 1.77 1.99 2.86 2.70 3.03 
missing 3.4 1 3.20 3.63 
Con ullanl volume 
very high (60 and over) 1.00 1.00 1.00 
high (401059) 1.02 0.87 1.20 1.02 0.87 1.21 1.03 0.89 Ll 9 
moderate (20 to 39) 1.06 0.90 1. 23 1. 08 0.92 1.27 1.11 0.97 1.27 
low ( less than 20) 1.53 1.3 1 1.78 1.55 1.33 1.8 1 1.57 1.37 1.79 
none 2.43 2.08 2.83 2.5 1 2.15 2.93 3.8 1 3.32 4.37 
missing 5.26 4.49 6.16 
T reatment 
surgery only 1.00 1.00 1.00 
surgery and chemotherapy 1.27 1.20 1.35 1.27 1.20 1.35 0.95 0.90 1.00 
surgery and radiothe rapy 0.87 0.79 0.95 0.87 0.79 0.95 0.69 0.51 0.92 
surgery and chcmoradiotherapy 1.33 1.22 1.45 1.33 1.22 1.45 0.9 1 0.85 0.97 
radiotherapy only 2.69 2.40 3.0 1 2.69 2.40 3.0 1 1.12 0.82 1.56 
chemotherapy only 1.79 1.47 2.18 1.79 1.47 2 .18 1.20 0.82 1.75 
chcmoradiothcrapy 2.2 1 1.89 2.59 2 .21 1.89 2 .59 1.09 0.8 1 1.46 
no treatment 8.98 8.48 9.5 1 8.98 8.48 9.51 3.37 3.17 3.59 
missi ng 5.27 4.98 5.57 
Analyses of treatment factors were included in tables for reference but the results will 
be described in Chapter 7. Unless otherwise specified all subsequent analysis wi ll be 
based on the imputed dataset. 
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Socioeconomic status 
Higher levels of deprivation were associated with poorer survival at all follow-up times 
(3 months to 5 years) (Figure 6.2). The inequality in survival between deprived and 
affluent, also known as the 'deprivation gap', was established and significant by one 
year after diagnosis with the magnitude of the deprivation gap stable at two, three, four 
and five years after diagnosis (7.3%-7.9%). The consistently lower survival in deprived 
patients culminated in some startlingly wide inequalities. For example deprived patients 
have a median survival 40% shorter than affluent patients (deprived: 2.10 yrs 95% CI 
2.10,2.21, affluent: 3.49 yrs 95% CI 3.21, 3.89). Some of the deprivation gap may be 
explained by other factors, particularly those influencing prognosis (e.g. stage) or 
appropriateness of treatment (e.g. age, comorbidity), however if a deprivation gap 
occurs for each variable (e.g. stage, comorbidity) the deprivation gap will not be 
moderated after adjustment for these factors. 
Figure 6.2: Relative survival (%) up to five years after diagnosis by deprivation 
group: colorectal cancer patients diagnosed 1997-2004, North West of England 
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Inequalities in survival were estimated using the excess hazard ratio of death for the 
deprived compared to the affluent (reference category) at one year after diagnosis and 
conditional at five years after diagnosis (conditional on surviving the first year) (Table 
6.5 and 6.6). These time periods were chosen because i) stage and comorbidity strongly 
influence the first year after diagnosis, ii) treatment has a greater effect on survival after 
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the first year of diagnosis and iii) the deprivation gap was established in the first year 
after diagnosis. The excess hazard ratio of death was estimated for each socioeconomic 
group and assuming a linear deprivation gap. In order to easily compare the excess 
hazard ratio in the most deprived to the linear deprivation gap the linear coefficient of 
the continuous deprivation gap was multiplied by the four gaps between each 
deprivation groups. The linear deprivation gap and the excess hazard for the most 
deprived were similar for most analysis, therefore unless otherwise stated the linear 
deprivation gap will be discussed. 
Significant deprivation gaps (based on the linear estimate) occurred for 20 of 24 
categories at one year but only 11 of the 24 categories following the first year of 
diagnosis (or 'conditional' survival). At one year after diagnosis the deprivation gap 
was substantial (EHR 1.33) but narrowed to an excess hazard of death of 1.18 for five 
year conditional survival (Table 6.6). 
The deprivation gap narrowed at for one-year and conditional survival for factors 
associated with a poor prognosis, although the trend was more pronounced in the first 
year. For example increasing age was associated with a narrowing of the deprivation 
gap in the first year from an excess hazard of death of 1.73 for patients aged 45 to 54 to 
1.16 for patients aged 85 to 99 (Table 6.5). There was also a narrowing of the 
deprivation gap with increasing age for five-year conditional survival but it was less 
pronounced than in the first year (1.32 in patients aged 45 to 55 to 1.00 in patients aged 
85 to 99). Similarly, increasing levels of stage, grade and increasing specificity of 
histology were associated with a narrowing of the deprivation gap for one year and 
conditional survival. 
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Table 6.5: Excess hazard ratio of death at one year after diagnosis by deprivation 
group for clinical and demographic variables, adjusted for age and follow-up 
(reference = affluent) (data after imputation): colorectal cancer patients diagnosed 
1997-2004, North West of England 
Linear coefficient 
I - 5- of deprivation 
affluent 2 3 4 deprived gapt 
All 1.00 1.03 l.l5 1.23 1.35 1.33 • 
Gender 
Men 1.00 0.96 l.l7 1.23 1.35 1.36 • 
Women 1.00 1.11 l.l4 1.22 1.35 1.29 • 
Age group 
15 to 44 1.00 0.68 0.62 0.97 1.17 1.08 
45 to 54 1.00 1.05 1.56 1.89 1.85 1.73 • 
55 to 64 1.00 1.08 1.27 1.39 1.74 1.61 • 
65 to 74 1.00 1.00 l.ll 1.22 1.42 1.41 • 
75 to 84 1.00 1.00 1.07 l.l2 1.17 l.l8 • 
85 to 99 1.00 1.11 1.25 1.22 1.21 1.16 • 
Subsite (lCD-tO) 
Colon (CI8) 1.00 1.04 l.l5 1.27 1.36 1.34 • 
Rectosigmoid (C 19) 1.00 0.95 0.88 l.l3 1.31 1.35 • 
Rectum (C20) 1.00 1.00 1.25 1.16 1.35 1.32 • 
Stage 
I 1.00 1.09 l.l9 l.ll 1.39 1.48 
II 1.00 1.02 l.l8 1.31 1.42 1.40 • 
III 1.00 1.04 l.l5 1.23 1.35 1.32 • 
IV 1.00 1.13 1.22 1.23 1.29 1.23 
Grade 
I 1.00 0.81 l.l0 1.21 1.27 1.37 • 
II 1.00 1.06 l.l9 1.27 1.43 1.38 • 
III 1.00 1.08 l.ll 1.20 1.27 1.24 • 
IV 1.00 0.94 1.27 0.84 1.48 1.32 • 
Histology 
Adenocarcinoma 1.00 1.02 1.15 1.21 1.34 1.32 • 
Mucinous and serous 1.00 1.00 1.22 1.44 1.39 1.40 • 
Other specified 1.00 1.63 l.l5 0.79 1.14 0.82 
Comorbidity 
0 1.00 1.00 1.13 1.23 1.33 1.33 • 
I 1.00 0.99 1.24 1.03 1.11 1.09 
2 1.00 1.14 1.18 1.27 1.33 1.27 • 
3+ 1.00 1.25 1.28 1.25 1.38 1.25 
• p-value<0.05 
t Regression for linear change in EHR between successive socioeconomic groups (estimated by multiplying the linear 
coefficient by 4 to obtain entire deprivation gap), 
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Table 6.6: Excess hazard ratio of death at five years conditional on surviving the 
first year after diagnosis, by deprivation group, for clinical and demographic 
variables, adjusted for age and follow-up (reference = affluent) (data after 
imputation): colorectal cancer patients diagnosed 1997-2004, North West of 
England 
I - 5- Linear coefficient of 
affluent 2 3 4 deprived deprivation gap! 
All 1.00 1.00 1.04 1.13 1.17 1.18 • 
Gender 
Men 1.00 1.08 1.12 1.16 1.26 1.22 • 
Women 1.00 0.90 0.95 1.10 1.05 1.09 
Age group 
15 to 44 1.00 0.75 0.55 1.23 1.40 1.32 • 
45 to 54 1.00 0.88 0.81 1.23 1.00 1.12 
55 to 64 1.00 0.93 0.91 0.96 1.23 1.22 • 
65 to 74 1.00 1.23 1.37 1.20 1.32 1.21 • 
75 to 84 1.00 0.96 1.04 1.06 1.04 1.06 
85 to 99 1.00 0.76 0.89 1.02 0.87 1.00 
Subsite (lCD-I 0) 
Colon (CI8) 1.00 1.04 0.96 1.08 l.ll 1.10 
Rectosigmoid (CI9) 1.00 0.89 1.11 1.18 1.42 1.44 • 
Rectum (C20) 1.00 0.97 1.19 1.22 1.21 1.24 • 
Stage 
I: 1.00 1.34 1.91 1.91 2.37 1.76 
II 1.00 l.ll 1.16 1.24 1.35 1.29 • 
III 1.00 1.00 1.00 1.12 1.12 1.16 • 
IV: 1.00 1.08 1.01 1.07 1.27 1.27 
Grade 
I 1.00 1.03 0.99 1.09 1.11 1.11 
II 1.00 1.01 1.05 1.15 1.22 1.22 • 
III 1.00 1.08 1.23 1.36 1.15 1.21 
IV: 1.00 
Histology 
Adenocarci noma 1.00 1.02 1.07 1.18 1.21 1.21 • 
Mucinous and serous 1.00 2.67 1.65 1.48 1.46 1.11 
Other specified 1.01 
Co morbidity 
0 1.00 1.01 1.04 1.15 1.17 1.19 • 
I 1.00 0.92 0.95 1.00 1.29 1.31 
2 1.00 1.19 1.19 1.09 1.21 1.12 
3+ 1.00 1.02 1.62 1.59 1.44 1.42 
• p-value<0.05 
t Regression for linear change in EIIR between successive socioeconomic groups (estimated by multiplying the linear 
coefficient by 4 to obtain entire deprivation gap), 
: Not adjusted for age due to low numbers of deaths, 
Demographic factors 
Sex 
Overall survival at one year and conditional survival at five years was slightly lower in 
women than men even after adjustment for clinical and demographic factors (Table 6.7). 
The average life expectancy for women in the general population is higher than men 
however the use of relative survival and adjustment for age and other factors (stage, 
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comorbidity, etc.) accounts for these differences. Some authors have suggested that 
women may have better biological responses to trauma I 0, 11 and therefore better survival 
after surgery, although the main impact of this would be expected post-operatively and 
in the first year after diagnosis. Higher survival and lack of inequalities in survival in 
women than men after the first year of diagnosis is more likely to be because of gender 
differences in colorectal cancer subsite. Men are more likely to have rectal (and 
rectosigmoidal) cancer than women (colon: men 57%, women 67%; rectosigmoidal: 
men 9%, women 7%, rectal: men 34%, women 26%). 
In the first year after diagnosis socioeconomic inequalities in survival were similar for 
both men and women (EHR 1.36 in men and 1.29 in women). For women there was no 
socioeconomic trend for five year conditional survival, in particular women from group 
2 and 3 had better survival than affluent women. For men there was still a deprivation 
gap in conditional survival at five years, although it was narrower than the deprivation 
gap at one year. 
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Table 6.7: Excess hazard ratio of death at one year after diagnosis and five year 
survival conditional on surviving the first year after diagnosis, for clinical and 
demograpbic variables (data after imputation): colorectal cancer patients 
diagnosed 1997-2004, North West of England 
Deprivation group . 
1 - affluent 
2 
3 
4 
5 - deprived 
Comorbidity 
o 
1 
2 
3+ 
Gender 
Men 
Women 
Age group 
15 to 44 
45 to 54 
55 to 64 
65 to 74 
75 to 84 
85 to 99 
Subsite (lCD-tO) 
Colon (CI8) 
Rectosigmoid (CI9) 
Rectum (C20) 
Stage 
I 
II 
III 
IV 
Histological type 
Adenocarcinoma 
Mucinous and scrous 
Other specified 
Grade 
I 
II 
III 
IV 
One year 
95%CI 
1.00 
1.03 0.94 1.14 
1.14 1.04 1.26 
1.22 1.11 1.34 
1.34 1.23 1.46 
1.00 
1.54 1.39 1. 70 
1. 72 1.54 1.92 
2.02 1.66 2.47 
1.00 
0.97 0.92 1.03 
1.00 
1.22 0.95 1.58 
1.64 1.30 2.07 
2.20 1.76 2.76 
3.25 2.59 4.07 
4.88 3.87 6.15 
1.00 
0.83 0.75 0.92 
0.77 0.73 0.82 
1.00 
2.11 1.75 2.54 
4.84 4.04 5.80 
9.96 8.17 12.14 
1.00 
0.93 0.85 1.02 
1.17 0.89 1.53 
1.00 
1.05 0.95 1.15 
2.07 1.87 2.31 
2.55 1.86 3.49 
• Adjusted for all variables in the table 
Five year survival 
conditional on surviving 
the first yeat 
1.00 
1.03 
1.03 
1.14 
1.16 
1.00 
1.52 
1.63 
1.89 
1.00 
0.91 
1.00 
1.17 
1.16 
1.23 
1.27 
1.52 
1.00 
1.06 
1.14 
1.00 
4.04 
11.70 
24.83 
1.00 
1.20 
0.76 
1.00 
1.14 
1.43 
1.34 
95%CI 
0.92 1.15 
0.92 1.15 
1.02 1.27 
1.05 1.29 
1.30 1.77 
1.36 1.94 
1.32 2.71 
0.85 0.97 
0.96 1.44 
0.96 1.41 
1.02 1.49 
1.05 1.55 
1.18 1.94 
0.94 1.20 
1.06 1.23 
2.93 5.57 
8.53 16.04 
17.65 34.93 
1.08 1.34 
0.45 1.28 
1.03 1.27 
1.25 1.64 
0.71 2.53 
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Age at diagnosis 
Survival decreased with increasing age, with a rapid decline (or high excess mortality) 
occurring within the first 3 months after diagnosis for patients aged over 75 (Figure 
6.3). There were substantial age-specific differences in relative survival at five years 
after diagnosis ranging from 62.3% (95% CI 58.4, 66.0) for patients aged 15 to 44 to 
35.6% (95% 32.1-39.2) for patients aged 85 to 99 at diagnosis. Wide variations in age-
specific survival at five years after diagnosis were mainly explained by age-specific 
differences in the first year after diagnosis with very little difference in age-specific five 
year conditional survival (Table 6.7). For example at one year after diagnosis patients 
aged 85 to 99 had an adjusted excess hazard ratio of death of 4.88, compared to patients 
age 15 to 44, while for conditional survival at five years the excess hazard of death was 
only 1.52 for patients age 85 to 99. 
Inequalities in survival decreased with increasing age for both one year survival and 
conditional survival at five years, however the inequalities were wider at one year than 
for five year conditional survival (Table 6.5 and 6.6). Patients aged over 75 had a small 
deprivation gap at one year but this disappeared after the first year. For patients over 75 
higher levels of comorbidity and lower survival are stronger influences and may cancel 
out any inequalities in survival. The only age to see an increase in the deprivation gap 
between one year survival and conditional five year survival was patients age 15 to 44 
although they had a very high overall survival. A higher proportion of younger patients 
may have colorectal cancer with a genetic aetiology, therefore they may be diagnosed 
earlier through familial screening or have preventative treatment decreasing the 
likelihood of mortality and the deprivation gap within the first year after diagnosis. 
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Figure 6.3: Relative survival (%) up to five years after diagnosis by age group: 
colorectal cancer patients diagnosed 1997-2004, North West of England 
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Clinical factors 
Stage 
Advancing stage was very strongly associated with poorer survival. After the first year 
of diagnosis the excess hazard of death was more strongly associated with stage than at 
one year after diagnosis (Table 6.7). This may be because in the first year after 
diagnosis post-operative mortality contributes substantially to excess mortality. Post-
operative mortality was associated with all stages, although most frequently in patients 
with comorbidity. Colorectal cancer in patients with advanced stage generally causes 
death after the first year. Trends in treatment and survival will be further discussed in 
chapter 8. 
A narrowing of the deprivation gap was associated with advancing stage at diagnosis at 
one year and five year conditional survival (Table 6.5 and 6.6). The socioeconomic 
inequality in survival narrowed for moderate stage tumours (stage II and III) conditional 
on surviving the first year after diagnosis, but remained significant. For example, the 
linear deprivation gap (or excess hazard of death) for stage III was 1.32 at one year after 
diagnosis, but decreased to 1.16 for five year survival conditional on surviving the first 
year after diagnosis. It may be unsurprising that inequalities are significant for moderate 
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stage because the inter-relationship of other factors (e.g. comorbidity) and treatment 
choices may have the biggest impact on survival for these stages. Whereas, there is less 
ambiguity or influence of other factors (e.g. comorbidity) in the treatment regimes for 
early and advanced stage tumours. For stage I and IV the excess hazard of death could 
not be adjusted for age because of the small number of patients by age group and for 
stage I the low number of deaths. 
Specific site 
Variations in survival by specific cancer site were evaluated to determine if specific site 
could elucidate further socioeconomic variations in survival. Specific cancer site was 
only available for colon cancer, with a large proportion of colon cancer patients having 
unspecified (n=4,099, 13.9%) or overlapping sites (n=303, 1.0%). Cancers of the 
caecum, colon unspecified, and overlapping lesion had the lowest relative survival at 
both one and five years and were associated with non-surgical treatment and older age 
(Figure 6.4). 
Within the colon, relative survival at one year after diagnosis was highest for distal 
tumours (descending colon, rectosigmoid, sigmoid colon and rectum) and cancer of the 
appendix (Figure 6.4). At five years after diagnosis, relative survival was highest for 
cancers of the ascending, transverse and descending colon, rectosigmoid and appendix. 
For colon cancer the narrowest deprivation gap in survival at five years between 
affluent and deprived was 13.5% for the appendix but was widest at 21.0% for the 
sigmoid colon. There were only 202 cancers of the appendix, mostly in young patients 
(52% under age 55). 
Further analysis will be based on the wider groupings of colon, rectosigmoid and 
rectum because they are more widely used and identify the main associations between 
deprivation and survival. Additionally, the large proportion of colon cancers without a 
specific site makes interpretation difficult. 
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Figure 6.4: Relative survival (%) at one and five years after diagnosis by specific 
colorectal cancer site: colorectal cancer patients diagnosed 1997-2004, North West 
of England 
One year 1ransverse colon 
o.terlapping lesion of colon (63.0%), Colon, unspecified (52.0%) 
Five years 
Descendln~ colon 
"'A(-- 51 .8% 
44.0% 
Overlapping lesion of colon (45.2%), Colon, unspecified (37.8%) 
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Subsite 
Colon cancer patients had lower survival at one year than rectal cancer patients, 
however this reversed for conditional five year survival with survival lower in rectal 
cancer patients than colon (Table 6.7). Rectosigmoidal cancers had survival in between 
colon and rectal cancer for both one year and conditional five year survival. 
Colon, rectosigmoid and rectal cancer patients had very similar deprivation gaps in 
survival at one year (1.34, 1.35, 1.32, respectively). For rectal and rectosigmoidal 
cancer the socioeconomic inequalities in survival in five year conditional survival were 
similar to those found in one year survival. There were no significant inequalities in 
colon cancer survival for five year conditional survival. The difference in survival 
inequalities after the first year of diagnosis for colon, rectosigmoidal and rectal cancer 
may be attributed to differences in treatment and time to cure; colon cancer has higher 
post-operative mortality and excess mortality in the first year, reaching statistical 'cure' 
earlier. 12 
Grade 
Ilighcr grade was associated with lower survival but this was largely explained by the 
close association between advanced stage and high grade. The excess hazard of death 
for gradc IV comparcd to grade I decreased by almost half after adjustment for stage 
from 3.89 (95% 2.98,5.09) to 2.13 (95% 1.64,2.77) after adjustment for stage and age 
(data not shown). 
Inequalitics in survival during the first year after diagnosis were similar for all grades 
(1.24 to 1.3 8) (Table 6.5). Contrary to the trends seen for stage and age, increasing 
grade was associated with an increase in the socioeconomic inequalities for conditional 
five year survival (Table 6.6). As with grade-specific survival the deprivation gaps may 
bc strongly influcnced by stage. Additionally, there were very small numbers of patients 
in grade III (14%) and grade IV (0.3%) resulting in inconsistent trends over 
socioeconomic groups at onc year and socioeconomic-specific estimates not possible 
for five year conditional survival. 
Ilis/%gy 
Adenocarcinoma was the most common histological type (90.5%) and had the highest 
survival at five years after diagnosis (Table 6.3). Mucinous and serous cancers had 
bcttcr survival than adcnocarcinomas at one year (Table 6.7) but conditional five year 
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survival was lower. Factors associated with a poorer prognosis, such as advanced stage 
(10.0% in stage IV) and higher grade tumours (16.5% in grade IV), were more common 
for muscinous and serous cancers. 
The one year deprivation gap in survival was similar for adenocarcinoma and mucinous 
or serous cancers (Tabel 6.5). There were only socioeconomic inequalities in five year 
conditional survival for adenocarcinoma (Table 6.6). There were no significant 
socioeconomic variations in survival for other specified histological types at for one 
year or five year conditional on survival. 
Comorbidity 
Increasing levels of comorbidity were associated with a decrease in survival (Figure 
6.5). At five years after diagnosis patients with a comorbidity level of 3 or more had 
excess hazard of death at five years of 4.11 (95% CI 3.77, 4.48), compare to patients 
with no comorbidity. Higher levels of comorbidity were associated with increasing 
deprivation, age and stage. After adjusting for deprivation, age and stage the excess 
hazard of death for patients with a comorbidity score of 3 or more decreased to 2.45 
(95% CI 2.22,2.70) (see Table 5.1 & 5.6). 
At one year after diagnosis the socioeconomic inequalities in survival were similar for 
most levels of comorbidity (EHR 1.25 to 1.33), with the exception of patients with a 
comorbidity level of one (EHR 1.09). The deprivation gap in survival was narrower for 
five year conditional survival for patients with a comorbidity level of one, but increased 
after the first year (EIIR 1.31). Patients with a comorbidity level of one had single 
comorbidity with low severity weight (see Appendix 4.3), which may have had a larger 
effect on mortality after the first year of diagnosis (Le. chronic, rather than acute). 
Inequalities in survival at five years conditional on surviving the first year, occurred for 
each comorbidity level although they were highest for patients with a comorbidity level 
of3 or more. 
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Figure 6.5: Relative survival (%) up to five years after diagnosis for each level of 
Charlson measure (data after imputation): colorectal cancer patients diagnosed 
1997-2004, North West of England 
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Impact of clinical and demographic variables on the deprivation gap 
There were substantial socioeconomic inequalities in survival at one year after diagnosis 
but socioeconomic inequalities narrowed substantially for patients who survived the 
first (Table 6.8). In the first year after diagnosis, adjusting for age and comorbidity had 
the biggest impact on narrowing the deprivation gap (EHR adjusted for age 1.37; 
adjusted for age and comorbidity 1.34). Stage explained some of the excess hazard of 
death in the first year after diagnosis decreasing the excess hazard ratio from 1.41 
(unadjusted) to 1.38. Together age, stage and comorbidity were strongly correlated and 
decreased the excess mortality at one year (excess mortality for deprived: 1.3695% CI 
1.26, 1.46). The addition of subsite, sex, grade and histology did not further explain the 
deprivation gap compared to the age, stage and comorbidity model. The fully adjusted 
modcl explained very little of the deprivation gap with an excess hazard of 1.37 (95% 
CI 1.28, 1.48). Between two and five years after diagnosis there were no significant 
deprivation gaps in any of the models. 
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Table 6.8: The impact adjusting for each variable on the excess hazard ratio of 
death by deprivation group (reference = affluent) (data after imputation): 
colorectal cancer patients diagnosed 1997-2004, North West of England 
Deprivation group 
I - arnuent 
one year "~o to five year 
EHR EHR 
9S%CI 9S%CI 
lower upper lower upper 
adjusted for follow-up time 
Significance level 
2 
1.00 
1.05 
1.23 
1.3 1 
IA I 
0.97 
I. I 3 
1.2 I 
1.32 
1.1 4 
1.33 
IA2 
1.52 
1.00 
1.00 
1.0 I 
1. 12 
1.16 
0.90 
0.91 
1.0 I 
1.05 
1. 11 Interaction of time « = 
3 I . I 3 1 year, > 1 year) 
4 1.25 pvalue=O.0047 
5 - deprived 
Deprivation group 
I - arnuent 
2 
3 
4 
5 - deprived 
Deprivation group 
I - arnuent 
2 
3 
4 
5 - deprived 
Depriva tion group 
1 - arnucnt 
2 
3 
4 
5 - deprived 
Depriva tion group 
I - arnuent 
2 
3 
4 
5 - deprived 
1.00 
1.03 
1.18 
1.25 
1.37 
1.00 
1.04 
1.1 7 
1.24 
1.34 
1.00 
1.06 
I. I 8 
1.26 
1.38 
0.95 
1.09 
1.1 6 
1.28 
Age and follow-up time 
1.1 2 
1.27 
1.35 
IA7 
1.00 
0.99 
0 .98 
1.08 
1.1 3 
0.89 
0.89 
0.98 
1.02 
Age, comorbidity and follow-up time 
0.96 
1.08 
1.1 5 
1.25 
1.1 3 
1.27 
1.34 
1.44 
1.00 
0.99 
1.00 
1.09 
I. I 3 
0.90 
0.90 
0.99 
1.02 
Age, tage and follow-up time 
0.97 
1.09 
1. 17 
1.29 
1.1 5 
1.28 
1.36 
IA8 
1.00 
1.0 I 
0.99 
1. 10 
1.1 4 
0.9 1 
0.89 
1.00 
1.03 
Age, tage, comorbidity and follow-up time 
1.00 
1.06 
I. 18 
1.25 
1.36 
0.97 
1.08 
1. 16 
1.26 
1.1 5 
1.27 
1.35 
1.46 
1.00 
1.0 I 
1.00 
I. I I 
0.9 1 
0.90 
1.00 
1.03 
1.28 
1.09 
1.09 
1.20 
1.24 
1.10 
1.1 1 
1.2 I 
1.24 
1.1 2 
I. I 0 
1.22 
1.25 
1.1 2 
I. I I 
1.23 
1.25 
Adjustement for age 
p<O.OO l t 
Adjusunent for 
comorbidity p<O.OO I t 
Adjustment for stage 
p<O.OO l t 
Adjustment for 
comorbidity p<O .OO 1 t 
Age, tage, comorbidity, hi tology, grade, ex and follow-up time 
Depriva tion group 
I - arnucnt 1.00 1.00 
2 1.07 0 .98 1.1 6 1.02 0.92 I. I 3 
3 1.18 1.09 1.28 1.0 1 0.9 1 1.1 2 
4 1.26 1.1 6 1.36 1.1 2 1.0 I 1.24 
5 - deprived 1.3 7 1.28 I A 8 I. I 5 1.05 1.27 
Adju tment for 
histology, grade, 
sub ite and sex 
p<O.OO lt 
Age, tage, comorbldlty, hi tology, grade, ub ite, ex and follow-up time, interatlon between 
tage and follow-up time and age and follow-up time 
Depriva tion J: roup 
I - amuent 
2 
3 
4 
5 - deprived 
1.00 
1.05 
1.15 
1.22 
1.34 
0.96 
1.07 
1. 14 
1.25 
1. 14 
1.25 
1.33 
IA4 
: Significance leve l ofaddll ional variable compared to previous model 
1.00 
1.03 
1.03 
1.15 
1. 17 
0 .93 
0.93 
1.04 
1.06 
1. 15 
1. 15 
1.28 
1.29 
Fully adjusted 
p<O.OO It 
Lowcr urviva l wa associated with increasing levels of tage, age grade comorbidity 
and deprivation wi th deprivation having the weakest a sociation of these (Table 6.7). 
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The inequality in the excess hazard ratio for the deprived was particularly high in the 
first year after diagnosis (1.34 95% CI 1.23, 1.46) than in subsequent years (1.16 95% 
CI 1.05, 1.29) (Table 6.8). The excess hazard was higher at one year than for 
conditional excess hazard for all variables except subsite, stage and mucinous or serous 
histology. After adjustment for all factors and non-proportionality the deprivation gap 
was wider than in the unadjusted one year and conditional survival models. There was a 
significant excess hazard for deprived patients in the fully adjusted model at one year 
(1.3495% CI 1.25, 1.44) but not at two to five years after diagnosis. 
Age at diagnosis and stage had the strongest impact on survival, although age was not 
significant at two to five years in the fully adjusted model (which included interactions 
with time) (data not shown). The fully adjusted model decreased the excess hazard for 
deprivation, age and stage at one year and two to five years (compared to conditional). 
Adjustment for all factors, after imputing missing data, only accounted for a small 
proportion of the socioeconomic inequalities in colorectal cancer survival at one year 
after diagnosis but fully explained the inequalities after the first year of diagnosis. 
Colon cancer patients had lower relative survival than rectosigmoid or rectal cancer. 
Factors associated with a poor prognosis were higher in colon patients such as 
unspecified histology, aged over 75 at diagnosis, and men but there was no significant 
difference in deprivation, stage or grade. 
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Summary 
The deprivation gap in survival at one year after diagnosis was substantial and it was 
only slightly moderated by adjustment for clinical (stage, grade, histology, comorbidity, 
subsite) and demographic variables (age, sex). For patients who survived the fIrst year 
after diagnosis, there was no signifIcant difference in survival between those from 
affluent and deprived backgrounds for most categories. Inequalities in survival were 
generally wider for factors associated with a good prognosis, such as early stage at 
diagnosis and low grade (highly differentiated). There were no socioeconomic 
differences in stage at diagnosis, although more deprived patients generally had more 
comorbidity. Comorbidity was associated with poor survival but the deprivation gap 
was not substantially narrowed by adjustment for comorbidity or any other factors. 
The presence of a significant deprivation gap in the fIrst year indicates that the cause(s) 
of the deprivation gap are associated with factors particularly related to the fIrst year 
after diagnosis. Variations in access to treatment and post-operative mortality may 
particularly influence survival in the fIrst year, although curative treatment will 
influence longer-term survival. These issues will be explored in the next two chapters. 
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Chapter 7 
Are there socioeconomic variations in colorectal cancer treatment? 
Overview 
Treatment regimes, particularly surgery, are mainly determined by clinical factors, such 
as stage at diagnosis. Not surprisingly treatment is also strongly associated with 
survival. Geographic variations in the quality and type of treatment received, described 
in the popular media as the 'postcode lottery', are known to exist in the UK, and these 
may have contributed to socioeconomic gradients in survival. These geographic 
variations primarily influence the availability of chemotherapy drugs, however there are 
also variations in surgical type and quality by hospital and/or surgeon.· Surgical 
outcomes are better when patients are treated by specialist colorectal surgeons, by 
surgeons with high colorectal case-loads and at high-volume hospitals2-S but deprived 
patients may be less likely to receive surgery under these conditions. Inequalities in 
access, type and quality of treatment could contribute to inequalities in survival, but it 
remains unclear if patients from deprived and affluent backgrounds do receive similar 
treatment, after clinically relevant factors are taken into account. 
Aims 
Socioeconomic inequalities in the type and quality of treatment received for colorectal 
cancer patients in the North West of England diagnosed between 1997 and 2004 were 
evaluated, after adjusting for clinical and demographic factors. In the previous chapter, 
socioeconomic inequalities, particularly in the first year after diagnosis, could not be 
explained by clinical or demographic factors. In this chapter, differences in treatment 
receipt between deprived and affluent will be assessed after taking into account clinical 
and demographic factors thus providing the basis for assessing socioeconomic 
variations in survival and treatment (Chapter 8). The impact of multiple imputation for 
missing data on the distribution of patients receiving surgery, chemotherapy and 
radiotherapy, and hospital and surgeon volume will first be evaluated. Secondly, 
treatment regimes will be analysed separately for colon and rectal cancer, because of 
differences in surgery type, treatment regimes and outcome were evaluated. 
Socioeconomic variations in the type of surgery received will be evaluated, particularly 
for anterior resection in rectal cancer patients. Variations in hospital and surgical 
volume were also evaluated as 'proxy' measures of surgical quality and surgeon 
experience. Treatment in accordance with clinical guidance improves survival and 
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decreases reoccurrence.6,7 A crude measure of whether treatment was in accordance 
with stage-specific guidelines was also evaluated. 
The analysis presented in this chapter will mainly be based on data after imputation, 
unless otherwise specified. 
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Imputation 
Treatment 
Despite the use of both cancer registry and HES data information on treatment was 
incomplete. Missing treatment data were imputed separately for surgery, chemotherapy and 
radiotherapy and combined after imputation to create eight treatment regimes; surgery only; 
surgery and chemotherapy; surgery and radiotherapy; surgery and chemoradiotherapy; 
chemotherapy only; radiotherapy only; chemoradiotherapy; and no treatment. In the 
original data increasing deprivation was strongly associated with missing treatment 
(missing surgery, chemotherapy and radiotherapy) and was strongly associated with 
missing data for other clinical and demographic variables (e.g. stage, age, comorbidity). 
The biggest contributor to missing treatment in deprived patients was chemotherapy, which 
was received by only 16.0% of deprived patients and 20.5% of affluent patients (missing 
for deprived 64.6%; affluent 60.0%). 
In the original dataset increasing age and more advanced stage were strongly associated 
with non-surgical treatment regimes (and missing treatment information), both before and 
after adjustment for clinical and demographic factors (see Table 3.16). Lower levels of 
surgery, radiotherapy and/or chemotherapy might be expected in elderly patients or for 
paticnts with advanced stage who may be too frail to endure invasive procedures, or for 
whom treatmcnt would not be curative. The association between older age, more advanced 
stage and missing treatment data in the original dataset was partially explained by the 
interaction of age and stage, but it persisted even after adjustment for sex, deprivation, 
histology, subsite and year of diagnosis. For example, the unadjusted odds ratio for missing 
treatment data for patients aged 85 to 99 was 9.8 (95% CI 7.2, 13.4) and but fell to 5.8 
(95% CI 4.1, 8.2) after adjustment. 
High grade and unknown grade were associated with missing surgery, chemotherapy and 
radiotherapy. This association is probably because of lack of pathology (and no surgery 
occurred). Additionally, missing grade and unknown grade would be associated with a poor 
prognosis and a 'true' lack of active treatment. 
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Surgical treatment was the most common (and complete) treatment both in the original data 
(81.9%) and after (90.4%) imputation (Table 7.1). The recorded proportion of patients 
given chemotherapy was low and as a result imputation had the biggest impact on 
chemotherapy. Chemotherapy is the most difficult treatment information for cancer 
registries to obtain because it is rarely recorded in electronic datasets. Frequently 
chemotherapy is prescribed at non-specialist hospitals or off-site clinics run by the 
specialist centre, which makes access to case notes or electronic datasets difficult. HES 
linkage was used to improve the completeness of chemotherapy and surgery data. However, 
the linkage improved surgery more than chemotherapy. 
Radiotherapy treatment is given at only three centres in the North West. Each centre 
provided radiotherapy treatment information directly to the cancer registry thereby 
achieving higher completeness than chemotherapy or surgery (see chapter 4). In the 
original dataset radiotherapy was missing for 19.7% of colorectal patients, but was more 
complete for rectal (16.0% missing) than colon cancers (21.1 % missing); radiotherapy is 
not normally provided for colon cancer patients. After imputation radiotherapy was 
substantially more common for rectal cancer patients (including rectosigmoid) (38.2%) 
than colon cancer patients (6.2%). 
The cancer registry shifted toward obtaining information from electronic data sources and 
away from reviewing patient case notes to obtain treatment information between 1997 and 
2004 (see Table 3.16). This shift away from case note review and toward electronic 
datasets, correlated with a dccrease in the proportion of patients with complete treatment 
over time. Electronic datasets designed for recording all patients (i.e. non-cancer and 
cancer patients) rarely record dctailed cancer treatment and stage. 
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Table 7.1: Distribution (%) of surgery, chemotherapy and radiotherapy for patients 
with known (original 'complete' data) treatment and data after imputation: colorectal 
cancer patients diagnosed 1997-2004, North West of England 
ComElete ImEuted 
Treatment No treatment Missing· Treatment No treatment 
No. % No. % No. % % % 
Surgery 24,220 81.9 2,703 9.1 2,640 8.9 90.4 9.6 
Chemotherapy 5,253 17.8 5,429 18.4 18,881 63.9 51.1 48.9 
RadiotheraE~ 3,061 12.5 3,684 67.9 5,818 19.7 17.0! 83.0 
·Treatment was assumed to be missing if there was no record of treatment in registry or HES and the patient 
could not be linked to any HES records. 
t34.3% of rectal (and rectosigmoidal) cancer patients had radiotherapy 
Surgery only, followed by surgery and chemotherapy were the most common treatment 
regimes, both in the original data and after imputation (after imputation 39.2% and 35.5%, 
respectively) (Table 7.2). The third most common regime shifted from surgery and 
radiotherapy in the original dataset to surgery and chemoradiotherapy after imputation, 
because the proportion of patients receiving chemotherapy increased substantially after 
imputation (see Table 6.1). These treatment regimes correspond to clinical guidance 
recommending that patients with early stage colon and rectal cancers receive surgery only, 
with moderate stages (stage II or III) receiving surgery and chemotherapy for colon cancer 
and surgery and chemoradiotherapy for rectal cancer.8,9 The proportion of patients 
receiving no treatment increased slightly after imputation to 8.5% from 8.2% in the original 
dataset and was higher in deprived patients in both imputed and original datasets. Very few 
patients had chemotherapy and radiotherapy either alone or in combination (without 
surgery). Patients with missing treatment data for all three modalities (no surgery, 
chemotherapy and radiotherapy) were associated with poorer prognostic factors and were 
morc Iikcly to have no treatment (61.7%) or surgery only (21.4%) after imputation (Table 
7.2). Treatment without surgery is generally palliative thus it is unsurprising that after 
imputation no treatment (no surgery, chemotherapy or radiotherapy) and non-surgical 
treatment were associated with poor prognostic factors, such as older age and advanced 
stage. 
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Table 7.2: Distribution (%) of known (original), IDlssmg and imputed data by 
treatment regime: colorectal cancer patients diagnosed 1997-2004, North West of 
England 
Treatment 
surgery only 
surgery and chemotherapy 
surgery and radiotherapy 
surgery and chemoradiotherapy 
chemotherapy only 
chemoradiotherapy 
radiotherapy only 
no treatment 
Complete' data (%) 
(patients with no 
missing data) 
63.S 
12.2 
7.3 
4.3 
1.9 
0.7 
1.1 
8.S· 
Imputed data 
Patients with 
missing treatment 
(%) 
21.4 
12.4 
0.3 
4.2 
0.1 
<0.05 
<0.05 
61.7 
All 
patients 
(%) 
39.2 
35.1 
0.8 
15.3 
0.4 
0.3 
0.4 
8.5 
In the original dataset deprived patients were more likely than affluent patients to have 
surgery only, or no treatment, and were less likely to receive adjuvant therapy. These 
inequalities widened after imputation (Table 7.3). The association between increasing 
deprivation and lack of treatment was stronger after imputation, although it is difficult to 
directly compare untreated patients before and after imputation. In the original data patients 
were assumed to have no treatment if they had no known surgery, radiotherapy and 
chemotherapy, but surgery, chemotherapy and radiotherapy were imputed separately and 
then combined to create an amalgamated record with the best available data on treatment 
(see chapter 4). Therefore, an imputed treatment for eaeh of surgery, chemotherapy or 
radiotherapy could substantially change the distribution of the combined treatment regimes. 
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Table 7.3: Distr ibution (%) of treatment regime by deprivation in the or iginal data 
and data after imputation : colorectal cancer patients d iagnosed 1997-2004, North 
West of England 
Origina l "com~lete" data Im~uted 
I · 5 · I . 5· 
amuent 2 3 4 deprived a ll amuent 2 3 4 de~rived all 
Clinical factors 
Treatment 
surgery onl y 62.2 62 .7 64 .8 63.5 65 .1 63.8 36 .6 36.7 39.6 40.2 41.3 39.2 
surgery and chemo 14 .2 14.0 10.8 12.0 11.0 12.2 37.2 37.8 34 .6 33 .9 33 .2 35.1 
surgery and radiotherapy 7.5 7.1 7,64 7.7 6.9 7.3 1.0 0.8 0.7 0.9 0.8 0.8 
surgery and chemoradto 4A 4A 3.9 4.5 4.2 U 16.0 15 .5 15 .5 15 .6 14 .7 15.3 
chemotherapy only 2.0 2.0 2.0 1.8 1.7 1.9 0.5 OA OJ OJ OA 0.4 
radiotherapy onl y 0 .9 0.6 0.6 0.7 0.5 0.7 0.5 OJ OJ OJ 0.2 0.3 
chemoradiotherapy 1.1 0.9 1.2 1.1 1.1 J.J 0.7 OA 0.3 OA 0.2 0.4 
no treatment 7.7 8.3 9.0 8.7 9.6 8.8 7.5 8.1 8.8 8A 9J 8.5 
miSSing (4.5 ) (5 .8) (6J) (7.2) (7.7) (6.5) 
1000 100.0 100.0 100.0 100.0 100.0 100 .0 100.0 100.0 100.0 100.0 100.0 
Hospital volume 
The overall distribution of surgeon volume or hospital volume was similar in the original 
dataset and after imputation. After imputation most patients receiverl surgery at a high- or 
very high-volume hospital , by a moderate- to low-volume surgeon (Table 7.4), Surgeon 
vo lume and hospital volume were imputed for patients known to have received surgery (for 
which surgeon and/or hospital volume were missing) or estimated to have received surgery 
after imputation (see chapter 4) . Most pati ents with missing surgery data were estimated not 
to have had surgery after imputation. A large proportion of patients with missing data on 
hospital volume in the original dataset were imputed not to have had surgery and thus no 
hospital of surgery vo lume (37.2%). 
In the original data et, 24.8% of patients had miss ing data on hospital volume, while only 
18.3% of patient had miss ing data on surgeon volume. The difference in completeness of 
ho pital and surgery volume data were because 10.7% of patients had the place of surgery 
recorded a primary acute trust or primary care trust, rather than a pecific hospital (e.g. 
Pennine Acute Trust, rather than one of the four hospitals within the trust). 
Private hospitals conducted only 2.4% of the surgery (0.4% in the original dataset) with 
most of these patient resident in affluent areas (see Table 6.1). olorectal cancer patients 
treated in the private ect r were generally younger at diagnosis diagnosed at an earlier 
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stage and had lower levels of comorbidity than colorectal cancer patients treated at NHS 
hospitals. 
Table 7.4: Distribution (%) of known (original), missing and data after imputation by 
surgeon and hospital volume (colorectal surgeries per year): colorectal cancer patients 
diagnosed 1997-2004, North West of England 
ImEuted data 
Original 'complete' data Patients missing (%) (patients with no surgery, All 
missing data) chemotherapy and patients 
radiotheraE~ {%} {%} 
Hospital volume 
(n=20,938) (n=8,625) 
very high (over 150) 23.2 18.7 26.2 
high (100 to 149) 31.4 24.9 35.4 
moderate (50 to 99) 17.5 13.7 19.6 
low (less than 50) 2.S 4.0 5.9 
Private 0.4 1.6 2.4 
none· 24.S 37.2 10.5 
Surgeon volume 
(n=20,467) (n=9,096) 
very high (over 60) 2.7 1.9 2.9 
high (40 to 60) 14.4 10.3 15.7 
moderate (20 to 39) 30.7 23.1 32.7 
low (less than 20) 33.9 30.2 38.2 
none· IS.3 34.4 10.6 
·Includes patients with no surgery for complete analysis and no known or imputed surgery for imputed 
analysis 
Surgeon volume 
Imputation did not substantially alter the distribution of patients who had their surgery 
conducted by a moderate- or low-volume surgeon (Table 7.4). As described previously in 
relation to hospital volume, a large proportion of patients with missing surgeon also had 
missing surgery status. After imputation most patients with missing surgeon in the original 
data were estimated not have undergone surgery (34.4%). After imputation the proportion 
of patients who had their surgery conducted by a low-volume surgeon increased (33.9%, to 
38.2%). Patients who had missing surgeon volume in the original data generally had a 
poorer prognosis so it is logical that they might have non-curative or emergency surgery 
from a low-volume surgeon. 
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Analysis of data after imputation, complete data and data with a category for missing data 
had very similar excess hazard ratios of death for both surgeon and hospital volume (Table 
6.3). The only substantial difference after imputation was an increase in the excess hazard 
for patients who received no surgical treatment and for whom obviously, no surgeon or 
hospital volume analysis could be done. Variations in survival and treatment patterns will 
be discussed in chapter 8. 
Access to treatment 
Treatment 
The proportion of patients receIvmg surgery (of any kind) slightly decreased with 
increasing deprivation, from 89.5% for affluent patients to 87.8% for deprived patients 
(Table 7.5). After adjustment for clinical and demographic factors, however increasing 
deprivation was associated with a higher odds ratio of receiving surgery (deprived odds 
ratio 1.63). This suggests that deprived patients generally have higher levels of clinical and 
demographic factors that may be contra indicators for surgery than affluent patients. This 
may highlight the large influence of clinical and demographic factors as contra indicators of 
surgery. 
The proportion of rectal cancer patients receiving radiotherapy decreased slightly with 
increasing deprivation but this was explained by variations in clinical and demographic 
factors (OR for deprived: 0.90, 95% CI 0.77, 1.04). Deprived patients were less likely to 
receive chemotherapy treatment and this could not be explained by associations with 
clinical and demographic factors (OR for deprived: 0.84). These socioeconomic trends in 
surgery and radiotherapy highlight the higher levels of factors which may be potential 
contra-indicators for treatment (e.g. comorbidity, age) in deprived patients, and the 
importance of imputing missing data and then fully adjusting for these factors in the 
analysis. The lack of significant socioeconomic variation in chemotherapy may be because 
of the impact of imputing data with such a large proportion missing. 
Over 99% of patients with no comorbidity received surgery compared with only 6% of 
patients with a comorbidity score of 3 or more (Table 7.5). Older age was also associated 
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with a decrease in the proportion of patients receiving surgery after age 75, but this was 
explained by variations in clinical and demographic factors (OR 2.78 and 1.85). Patients 
aged between 55 and 84 were significantly more likely to have surgery after adjusting for 
clinical and demographic factors (compared to 15 to 44 year olds). Increasing age and 
comorbidity were both independently associated with a rapid decrease in chemotherapy and 
radiotherapy provision. The lower prevalence of chemotherapy and radiotherapy may 
suggest that surgery in older patients were not intended as curative. 
Advanced stage was negatively associated with surgical treatment. Conversely, advanced 
stage was positively associated with chemotherapy or radiotherapy probably because they 
were received actively in moderate to advanced stages (Stage II and III) and palliatively for 
advanced disease (stage IV). Radiotherapy was significantly more likely to be received by 
rectal cancer patients, as it is the current recommended guidance. 
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Table 7.5: Distribution (%) and adjusted odds ratios for recelvmg surgery, 
chemotherapy and radiotherapy by clinical and demographic variables (data after 
imputation): colorectal cancer patients diagnosed 1997-2004, North West of England 
Surgery Chemotherapy Radiotherapy· 
{reference = surge!):} {reference = chemothera~:r:} {reference = radiothera~~} 
Odds Ratio! Odds Ratio! Odds Ratiot 
95%CI 95%CI 95%CI 
--L lower u~r --L lower u~~r % lower u~~ 
overall 90.4 51.1 17.0 
sex 
men 91.6 1.00 55.9 1.00 20.0 1.00 
women 89.0 0.54 0.43 0.67 45.0 0.76 0.70 0.82 13.2 0.80 0.72 0.89 
age 
15 to 44 92.9 1.00 73.0 1.00 30.2 1.00 
45 to 54 94.4 1.45 0.65 3.24 76.6 1.18 0.88 1.58 31.2 0.89 0.64 1.24 
55 to 64 93.2 2.13 \.03 4.37 69.5 0.84 0.65 1.09 26.2 0.67 0.49 0.91 
65 to 74 92.9 2.89 1.43 5.86 57.7 0.51 0.40 0.66 18.4 0.47 0.35 0.64 
75 to 84 88.8 2.78 1.37 5.62 36.3 0.23 0.18 0.29 9.7 0.25 0.18 0.34 
85 to 99 79.4 1.85 0.89 3.83 17.2 0.09 0.07 0.12 3.8 0.09 0.06 0.14 
deprivation 
1 - affluent 89.5 1.00 54.5 1.00 18.2 1.00 
2 89.0 1.14 0.78 1.67 54.0 1.05 0.92 1.20 17.1 1.00 0.85 1.18 
3 88.5 1.34 0.93 1.94 50.6 0.97 0.85 1.11 16.8 1.00 0.85 \.18 
4 88.5 1.47 \.02 2.11 50.2 0.95 0.84 1.08 17.3 1.04 0.89 1.23 
5 - deprived 87.8 \.63 1.17 2.26 48.3 0.84 0.74 0.94 16.1 0.90 0.77 1.04 
subsite 
colon 89.6 1.00 48.1 1.00 6.2 
rectosigmoid 93.9 \.36 0.88 2.11 54.4 1.10 0.96 \,27 19.5 
rectum 9\,2 0.81 0.63 1.03 56.3 1.29 1.18 1.41 38.2 
stage 
I 96.2 \.00 45.7 1.00 14.8 1.00 
II 94.4 0.76 0.49 1.19 48.3 1.33 1.17 1.52 14.3 1.52 1.30 1.78 
III 87.7 0.29 0.19 0.45 54.7 1.88 1.65 2.14 19.5 2.21 1.89 2.58 
IV 72.0 0.10 0.06 0.18 49.5 1.73 1.38 2.16 18.3 2.31 1.72 3.09 
comorbklity 
none 99.3 1.00 55.8 1.00 18.4 1.00 
1 76.0 0.02 0.01 0.03 40.3 0.64 0.53 0.78 11.2 0.63 0.47 0.84 
2 22.5 <0.01 16.2 0.15 0.12 0.19 7.8 0.32 0.24 0.43 
3+ 6.0 <0.01 6.9 0.07 0.05 0.09 4.2 0.18 0.12 0.29 
• Analysis for radiotherapy was limited to rectosigmoid and rectal cancers 
fAdjusted for all variables in table 
The combination of surgery, chemotherapy and radiotherapy in treatment regimes is a more 
clinically relevant description of treatment, since clinical guidance recommends specific 
treatment regimes. The following section combines individual treatments into treatment 
regImes. 
Treatment regimes 
Most patients receive surgery (90.4%), either alone (39.2%) or in combination with 
chemotherapy (35.1%) or chemoradiotherapy (15.3%) (Table 7.6). The proportion of 
patients treated with chemotherapy only, chemoradiotherapy only or radiotherapy only 
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were lower in the deprived than the affluent, but there was a very small proportion of 
patients treated with these regimes, regardless of socioeconomic status. Deprivation was 
positively associated with treatment by surgery only, and inversely associated with 
treatment with both surgery and chemotherapy, and surgery and radiotherapy (Table 7.7). 
Surgery was evaluated as a binary variable (yes/no) but will in fact be a heterogeneous 
group with regard to surgical type (e.g. emergency, non-emergency) and intent (curative 
and non-curative). Patients treated with surgery only for early-stage colorectal cancer may 
be treated with curative intent, whereas treatment by surgery alone for advanced stage is 
generally palliative (e.g. debulking). The higher proportion of deprived than affluent 
patients receiving surgery alone after adjustment may be due to differences in the type and 
intent of surgery. Stage at diagnosis after imputation was the same between affluent and 
deprived patients, possibly suggesting that curative surgery and the type of surgery should 
be similar between socioeconomic groups. However, deprived patients did have higher 
levels of comorbid conditions than affluent patients possibly suggesting that a larger 
proportion of the surgical procedures in deprived patients may be non-curative, either 
because the comorbidity is a contra-indicator for surgery or life expectancy is perceived to 
be limited by comorbidity. However, the lack of specificity of coding (e.g. TME), lack of 
specific surgical information (e.g. curative, emergency) and the necessity to impute missing 
surgery data made it impossible to sub-divide surgery in these analyses. There was also a 
higher proportion of deprived patients receiving no treatment (no surgery, chemotherapy or 
radiotherapy), but this was explained by associations with stage, comorbidity, age, subsite 
and sex (Table 7.6 and 7.7). 
Increasing comorbidity was very strongly associated with a lack of treatment, and 
consequently negatively associated with other treatment regimes (Table 7.7). Comorbid 
conditions may limit the possibility of offering some treatments, particularly surgery. 
Advanced stage also influences treatment options with chemotherapy, radiotherapy and 
adjuvant therapy becoming more common. Increasing stage was associated with a decrease 
in surgery only, and in no treatment, but increasing proportions of patients who were 
treated with surgery and adjuvant therapy (chemotherapy and chemoradiotherapy). 
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Women were less likely than men to receive surgery, chemotherapy or radiotherapy, but 
women had slightly better survival at five years (EHR for women compared to men: 0.89 
95% CI 0.80, 0.99). Men were more likely to receive adjuvant therapy than women whilst 
women were more likely to have surgery only, or no treatment, which may suggest that 
treatment for some is focused on those who are most likely to benefit from treatment. Men 
were more likely to have rectal cancer than women but even after adjustment for subsite, 
age and other clinical factors, women had slightly better survival. 
Lower levels of adjuvant therapy and higher proportions of surgery only were associated 
with increasing age (Table 7.6). The high proportion of surgery only in older patients is 
probably attributed to more non-curative surgeries, with this hypothesis supported by the 
consequently lower levels of adjuvant treatment. A substantially higher proportion of older 
patients received no treatment but this was explained by factors such as advanced stage, 
and comorbidity (Table 7.7). 
Colon cancer patients were most likely to receIve surgery only or surgery and 
chemotherapy while rectal cancer patients were most likely to received surgery only or 
surgery and chemoradiotherapy (Table 7.6). Patients with a rectosigmoidal cancer had a 
distribution of treatment that was intermrdiate between both rectal and colon cancers. 
196 
Table 7.6: Distribution (%) of treatment regime by clinical and demographic 
variables (data after imputation): colorectal cancer patients diagnosed 1997-2004, 
North West of England 
surgery surgery and surgery and surgery and radiotherapy chemotherapy chemoradio no 
only chemotherapy radiotherapy chemoradio only only therapy only treatment 
therapy 
overall 39.2 35.1 0.8 15.3 0.4 0.3 0.4 8.5 
sex 
men 35.6 36.9 0.8 18.3 0.4 0.3 0.4 7.3 
women 43.8 32.8 0.8 11.6 0.3 0.3 0.4 10.0 
age 
15 to 44 21.1 43.3 0.3 28.2 0.6 0.3 l.l 5.2 
45 to 54 18.7 46.0 0.7 29.1 0.4 0.5 l.l 3.6 
55 to 64 24.2 44.1 0.7 24.3 0.5 0.5 0.7 5.2 
65 to 74 35.0 40.3 0.9 16.7 0.4 0.3 0.4 6.0 
75 to 84 51.8 27.7 0.9 8.3 0.3 0.1 0.2 10.7 
85 to 99 61.4 14.4 0.8 2.8 0.2 0.1 <0.1 20.3 
deprivation 
I· amuent 36.6 37.3 1.0 16.0 0.5 0.5 0.7 7.5 
2 36.7 37.8 0.8 15.5 0.4 0.3 0.4 8.1 
3 39.6 34.6 0.7 15.5 0.3 0.3 0.3 8.8 
4 40.2 33.9 0.9 15.9 0.3 0.3 0.4 8.4 
5· deprived 41.3 33.2 0.8 14.7 0.4 0.2 0.2 9.3 
suhsite 
colon 42.0 41.9 0.2 5.5 0.2 0.4 0.3 9.S 
rectosigmoid 39.4 35.7 0.8 18.1 0.1 0.2 0.5 5.3 
rectum 33.5 21.0 2.0 34.7 0.8 <0.1 0.6 7.3 
.tage 
I 49.4 32.5 1.2 13.0 0.4 <0.1 0.1 3.3 
11 45.5 35.0 0.9 12.9 0.3 0.1 0.2 5.0 
\11 33.3 36.0 0.7 17.8 0.4 0.4 0.6 10.9 
IV 23.7 31.7 0.4 16.1 0.7 0.6 1.1 25.7 
comorbidity 
none 42.7 38.4 0.9 17.3 0.1 <0.1 <0.1 0.5 
38.1 30.4 0.4 7.1 1.7 0.8 2.0 19.6 
2 11.9 9.4 0.1 1.1 3.2 2.3 3.4 68.7 
3+ 3.0 2.5 <0.1 0.5 1.9 2.1 1.8 88.2 
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Table 7.7: Odds ratio for treatment with: surgery only; surgery and chemotherapy; and surgery and chemoradiotherapy 
(reference = any other treatment not under evaluation), by clinical and demographic variables (data after imputation): 
colorectal cancer patients diagnosed 1997-2004, North West of England 
sur!!~OIlI! su!:!~ and chemotheT3Q:Z: surge!): and radiochemotheraQ:Z: no treatment 
Oddsrauo' OddsraIlO' Odds ratio' Odds ratio' 
95%CI p-value 95%CI p-va\ue 950;. CI p-value 95%CI p-value 
% lower u~ '/0 lower u~ 0;. lower u~ % lower ul2~ 
.venD 39.2 3S.I IS.3 8.S 
sex 
men 3S.6 1.00 
<0.001 36.9 1.00 0.04 18.3 1.00 0.04 7.3 1.00 0.07 
lMlIIIen 43.8 122 111 1.34 32.8 0.88 0.80 0.96 11.6 0.81 0.73 0.90 10.0 1.37 0.98 1.91 
a,e 
15to44 21.1 1.00 43.3 1.00 28.2 1.00 5.2 1.00 
451054 18.7 1.20 0.80 1.80 46.0 1.11 0.82 LSI 29.1 0.73 0.54 0.99 3.6 0.87 0.25 306 
551064 24.2 1.94 1.33 2112 
<0001 44.1 0.96 0.73 1.28 0.02 24.3 0.57 0.43 0.75 5.2 0.71 0.23 2.23 0.11 6S 1074 35.0 3.14 2.17 4.54 40.3 0.81 0.61 1.07 16.7 0.38 0.29 0.51 6.0 0.79 0.26 2.43 
75 to 84 51.8 694 4.79 1006 27.7 047 0.35 0.62 8.3 0.18 013 0.24 10.7 1.03 0.33 3.15 
851099 61.4 15.84 10.59 23.68 14.4 0.24 0.17 0.33 2.8 0.04 0.02 0.07 0.01 20.3 1.22 0.37 4.00 
deprintio. 
1- affiuenl 36.6 1.00 fitted 37.3 1.00 16.0 1.00 fitted 7.5 1.00 2 36.7 0.97 0.83 1.13 deprivation 37.8 LOS 0.90 122 fitted deprivation 15.5 \.01 0.85 1.21 deprivation 8.1 1.12 0.65 \.92 fitted deprivation 3 39.6 1.05 0.90 1.23 34.6 0.94 0.80 1.09 gap=O 96 15.5 1.10 0.92 1.30 8.8 0.99 0.58 1.70 gap=O.96 
" 
402 1.06 0.91 \.23 
gap=1.06 
33.9 0.92 0.79 1.06 p-vaIue=O.02 15.9 1.11 0.94 1.32 
gap=O.99 
8.4 0.83 0.47 1.45 p-value=O.44 
5 -deprived 41.3 1.25 1.08 L44 
p-vaIue=O .002 
33.2 0.87 0.76 1.00 14.7 0.93 0.79 1.09 
p-value=O .02 
9.3 0.92 0.57 1.48 
subsite 
colon 42.0 1.00 41.9 100 5.5 1.00 9.5 1.00 
rectosigmoid 39.4 092 0.79 1.08 <0.001 35.7 0.60 0.51 0.71 0.02 18.1 3.65 3.07 4.35 5.3 0.69 0.37 1.30 0.02 
rectum 33.5 0.67 0.60 0.75 21.0 0.27 0.24 0.31 34.7 10.94 9.73 12.30 0.10 7.3 0.60 0.40 0.92 
staze 
I 49.4 1.00 32.5 1.00 13.0 1.00 3.3 1.00 
II 45.5 0.74 0.64 0.86 
<0.001 35.0 0.97 0.83 1.\3 0.04 12.9 1.69 1.42 2.01 5.0 0.86 O.SO 1.47 0.003 III 33.3 0.48 0.41 055 36.0 1.14 0.98 1.32 17.8 2.80 237 3.32 10.9 0.63 0.37 1.09 
IV 23.7 0.41 0.31 0.55 31.7 0.99 0.75 \.31 16.1 2.61 191 3.58 0.06 25.7 5.17 2.72 9.83 
comorbidity 
none 42.7 1.00 38.4 1.00 17.3 1.00 0.5 1.00 
1 38.1 0.77 0.60 0.99 <0.001 30.4 0.80 0.62 \.04 0.04 7.\ 0.49 0.33 0.72 19.6 16.17 9.82 26.60 <0.001 2 11.9 031 0.22 0.44 9.4 0.29 0.20 0.41 1.1 0.09 0.04 0.19 68.7 113.59 76.28 169.14 
3+ 3.0 0.10 005 0.21 2.5 0.11 005 0.25 OS 0.05 001 0.26 0.04 88.2 302.95 176.78 519.14 
• adjusted for all factors in the table 
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Type o/surgery 
The specific type of surgery received can have a huge influence on a patient's survival, risk 
of recurrence, and probability of a colostomy, but operation type is also influenced by 
prognostic factors, such as stage and comorbidity. Whilst patients with early and advanced 
stage were equally likely to have surgery (known or imputed) there are stage-specific 
differences in the surgical options. Specific operation type was not included in the 
imputation model because of the large number of specific operation types and overlapping 
operation code definitions (e.g. excision of colon NOS, excision of transverse colon). 
Univariate analysis of specific operation type was evaluated but could not include imputed 
data, such as complete stage. 
There were very few significant socioeconomic trends in specific operation type because of 
the small numbers for most specific operation types (Table 7.8). Deprived patients were 
less likely to have a surgery than affluent patients (no surgery: 15.7% and 19.6%, 
respectively) and were more likely to have operations associated with emergency treatment 
or non-curative treatment (e.g. Hartman's). For colon cancer surgery, affluent patients were 
significantly more likely than deprived patients to have an excision of the left hemicolon, 
sigmoid colon or colon (unspecified). For rectal cancer surgery, affluent patients were 
significantly more likely to have anterior resection than deprived patients. Deprived 
patients were less likely to have abdominoperineal excision for rectal cancer or Hartman's 
procedure (although neither was significant). A substantial minority of patients (16.2%) had 
colorectal surgery that was not recorded as an excision, but this was consistent across 
socioeconomic groups. Deprived patients were more likely to have no surgery recorded 
than affluent patients (15.7% and 19.6%). The higher proportion of missing data for 
deprived patients compared to affluent may suggest that some of the socioeconomic 
variations are because of missing surgery information. This could be further investigated if 
specific surgery information were available (e.g. emergency, intent, complications). 
Information on chemotherapy adherence and prevision prior to treatment may also help to 
elucidate the socioeconomic variations in treatment type. 
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Table 7.8: Distribution of surgical type (%) by socioeconomic status (original data): 
colorectal cancer patients diagnosed 1997-2004, North West of England 
All 
I - 5-
OPCS-4 affluent 2 3 4 de~rived No. % 
Total excision of colon and rectum H04 0.6 0.6 0.5 0.4 0.4 138 0.5 
Total excision of colon HOS 0.7 0.7 0.6 0.5 0.6 180 0.6 
Extended excision of right hemicolon H06 3.4 3.7 3.5 3.7 3.2 1,029 3.5 
Excision of right hemicolon H07 16.1 17.1 17.2 16.9 15.9 4,894 16.6 
iii Excision of transverse colon H08 0.8 1.0 0.9 0.8 0.7 244 O.S 
.S! 
C> Excision ofleft hemicolon H09 4.9 S.S S.O 4.4 4.1 1,384 4.7 .. 
Excision of sigmoid colon HIO S.I 7.S 7.6 6.7 7.4 2,211 7.5 
Excision of colon HII 3.4 2.S 2.3 2.4 2.7 792 2.7 
Extirpation of lesion of colon HI2 0.6 0.6 0.7 0.5 0.6 182 0.6 
:; Abdominoperineal excision H33.1 6.0 S.9 6.7 6.9 6.4 1,888 6.4 
~ Anterior resection H33.2-H33.4, H33.6 17.5 16.9 15.6 14.S 14.6 4,639 15.7 ... 
Hartmans H33.S S.7 5.6 5.8 7.0 7.6 1,920 6.5 
Other surgery 16.7 15.3 15.5 16.7 16.4 4,776 16.2 
None 15.7 16.9 IS.4 IS.6 19.6 5,343 IS.1 
Hospital and surgeon volume 
There were moderate socioeconomic variations In the proportion of patients having 
operations at each level of hospital and surgeon volume. Deprived patients were more 
likely to have surgery at a high-volume or very high-volume hospital, but to have their 
surgery conducted by a low-volume surgeon (Table 7.9). In the absence of individual 
measures of hospital and surgical quality, surgical volume may provide an indication of the 
quality of peri-operative care and surgical expertise. Complex, curative and planned 
surgeries may also be completed by higher volume surgeons and hospitals. For rectal 
cancer patients, anterior resection and abdominoperineal resection were positively 
associated with both high-volume surgeon and high-volume hospitals, and inversely 
associated with Hartman's procedure (Appendix 7.1 and 7.2) There were no clear trends 
for colon cancer patients. Operations other than excisions were very common for low-
volume hospitals. These trends clearly point towards differential surgery types but the lack 
of specificity of coding and missing data (both for treatment and prognostic factors) makes 
further interpretations difficult. For example, a large proportion of private patients were 
recorded as not receiving excisions (other non-curative surgery) but this was probably due 
to non-specific surgery codes. Most of the surgery information for private patients treated 
during 1997 to 2004 was obtained from pathology reports, rather than directly from private 
hospitals. In most cases it is therefore possible to determine if a patient had surgery but not 
the surgical procedure. 
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Surgeon and hospital volume were positively correlated, although even at high-volume 
hospitals a substantial proportion of patients were treated by low-volume surgeons (Table 
7.10). This initially seems counter-intuitive but the majority of the very high-and high-
volume hospitals in the North West are teaching hospitals, with trainee surgeons in these 
hospitals likely to have lower volumes. In the later years (after 2003) most of the hospitals 
designated to specialise in colorectal cancer surgery were teaching hospitals. Surgeon and 
hospital volume undoubtedly influence the specific surgery type a patient received, but this 
could not be assessed directly because of small numbers (as described previously). If 
surgeon and hospital volume effectively measure the quality of treatment, compliance with 
clinical guidance and provision of adjuvant therapy, then we would expect each of these to 
be positively associated with increasing hospital and surgeon volume. Even after 
adjustment for clinical and demographic factors higher-hospital volume and surgeon 
volume were positively associated with a higher odds of patients receiving of adjuvant 
therapy, or compliant treatment (Table 7.11 and 7.13). 
Table 7.9: Distribution (%) of hospital and surgeon volume (colorectal surgeries per 
year) by socioeconomic status (data after imputation): colorectal cancer patients 
diagnosed 1997-2004, North West of England 
I - affluent 2 3 4 5 - dCErivcd AII 
Hospital volume 
very high (over 150) 24.8 27.9 26.3 25.1 26.6 26.2 
high (100 to 149) 31.4 34.1 37.5 36.2 36.7 35.4 
moderate (50 to 99) 23.0 18.6 19.0 20.7 17.9 19.6 
low (less than 50) 5.3 5.9 4.8 6.2 6.8 5.9 
Private 5.8 3.5 2.0 1.3 0.9 2.4 
none 9.7 10.1 10.5 10.5 11.2 10.5 
Surgeon volume 
very high (60 and over) 5.0 3.1 2.5 2.7 1.9 2.9 
high (40 to 59) 12.9 16.3 14.9 15.0 16.0 15.7 
moderate (20 to 39) 33.3 33.3 33.8 33.2 31.2 32.7 
low (less than 20) 35.3 37.1 38.1 38.7 39.8 38.2 
none 10.0 10.2 10.8 10.5 11.1 10.6 
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Table 7.10: Distribution (%) of surgeon volume by hospital volume (colorectal 
surgeries per year) for surgical patients only (after imputation): colorectal cancer 
patients diagnosed 1997-2004, North West of England 
Hos(!ital volume 
surgeon volume very high high moderate low private 
{more than 150} {100toI49} {50 to 99} {less than 50} {~rivate} 
very high (60 and over) 4.1 3.2 3.6 2.0 3.3 
high (40 to 59) 26.0 16.3 9.9 12.5 17.9 
moderate (20 to 39) 32.0 39.7 37.4 35.1 34.2 
low {less than 20} 37.9 40.8 49.2 50.3 44.6 
The proportion of patients receiving surgery and adjuvant therapy (either chemotherapy or 
chemoradiotherapy) was positively associated with hospital and surgeon volume (Table 
7.11). Conversely, the proportion of patients receiving only surgery increased with 
decreasing hospital and surgeon volume and was highest for private patients (78.3%). 
Private patients were least likely to receive adjuvant therapy, although this may be mainly 
attributed to their case-mix and very good prognosis, including earlier stage at diagnosis. 
Hospital volume was more strongly associated with treatment regime than surgeon volume. 
Increasing deprivation was still associated with an increase in treatment with surgery only, 
and less in surgery and chemotherapy, even after adjusting for hospital volume. Adjustment 
for hospital volume actually increased the inequality in treatment for surgery only, and 
surgery with chemoradiotherapy, possibly because of socioeconomic variations in hospital 
volume and the inclusion of private hospitals (Table 7.7). Deprived patients and patients 
treated privately were both most likely to receive surgery only. The good prognosis and 
case-mix for private patients suggested they were generally treated curatively were as 
deprived patients receiving surgery alone were treated curatively and palliatively. 
Treatment regimes as a whole appear to be influenced by both hospital and surgeon 
volume, presumably because more experience or skill and adherence to guidance is 
associated with high-volume hospitals and high-volume surgeons. The consistent pattern 
could be attributed to centralisation of services, access to multidisciplinary expertise & 
oncology services and a better knowledge of and adherence to the most recent clinical 
guidance. 
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Table 7.11: Odds ratio for and distribution (%) of treatment with: surgery only; surgery and chemotherapy; and surgery and 
chemoradiotherapy (reference = any other treatment not under evaluation), by socioeconomic status, hospital and surgeon 
volume (colorectal surgeries per year) (data after imputation): colorectal cancer patients diagnosed 1997-2004, North West of 
England 
surgery only· surgery and chemotherapy· surgery and chemoradiotherapy· 
odds ratio p-value odds ratio p-value odds ratio p-value 
95%CI 95%CI 95%CI 
% lower upper % lower upper % lower upper 
Hospital volume 
very high (over 150) 32.8 1.00 49.2 1.00 17.2 1.00 
high (100 to 149) 42.1 1.65 1.47 1.85 40.4 0.69 0.62 0.76 16.9 0.96 0.86 1.07 
moderate (50 to 99) 48.5 2.23 1.95 2.56 <0.001 31.2 0.46 0.41 0.52 <0.001 19.2 1.11 0.97 1.26 <0.001 
low (less than 50) 66.0 4.39 3.51 5.48 18.1 0.24 0.19 0.30 13.8 0.88 0.70 1.10 
Private 78.3 13.40 9.47 18.96 10.3 0.10 0.07 0.16 8.8 0.35 0.24 0.53 
Surgeon volume 
very high (60 and over) 45.4 1.00 29.2 1.00 24.0 1.00 
high (40 to 59) 39.7 1.30 0.96 1.77 0.03 42.7 0.94 0.72 1.23 0.2 16.7 0.82 0.62 1.07 <0.001 
moderate (20 to 39) 41.5 1.20 0.89 1.62 38.1 0.85 0.65 1.11 19.5 1.06 0.81 1.37 
low (less than 20) 46.9 1.44 1.07 1.94 37.4 0.91 0.70 1.19 14.8 0.73 0.56 0.95 
deprivation 
1 - affiuent 36.6 1.00 37.3 1.00 16.0 
2 36.7 1.07 0.91 1.26 37.8 0.97 0.84 1.13 15.5 0.96 0.82 1.12 
3 39.6 1.19 1.01 1.41 <0.001 34.6 0.84 0.72 0.98 <0.001 15.5 1.05 0.90 1.23 0.82 4 40.2 1.16 0.99 1.36 33.9 0.84 0.72 0.98 15.9 1.06 0.91 1.24 
5 - deErived 41.3 1.41 1.21 1.64 33.2 0.76 0.66 0.88 14.7 0.94 0.81 1.08 
*adjusted for all variables in the table and age, sex, stage and comorbidity, 
tOdds ratio could not be estimated due to small numbers 
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Compliance with guidance 
Treatment regimes were assigned by stage at diagnosis based on the National Institute 
for Clinical Excellence guidance published in 1997, and up-dated in 2004.8 A simple 
stage-specific estimate of compliance was generated, using the imputed treatment 
categories of surgery, chemotherapy, and radiotherapy. Treatment for stage IV colon 
and rectal cancer is generally non-curative and any treatment combination could be 
clinically appropriate; it was excluded from further analysis. This estimate of adherence 
with clinical guidance is an alternative method of assessing treatment receipt and 
quality, rather than a 'true' estimate of adherence to guidelines. Compliance in 
accordance with guidance was higher for colon cancer (72.5%) than for rectal cancer 
(64.6%) (Table 7.12). Treatment in accordance with clinical guidance was high for 
stage I and II but poor for stage III cancers, both for colon cancer and rectal cancer. 
Table 7.12: Proportion of patients (%) treated in accordance with clinical guidance 
by subsite and stage (data after imputation): colorectal cancer patients diagnosed 
1997-2004, North West of England 
Stage Treatment regime recommended by current guidance 
Colon 
I Surgery only 
II Surgery only or surgery and chemotherapy 
III Surgery and chemotherapy 
IV any combination except radiotherapy (will depend on patients diagnosis 
and overall health) 
Rectal and rectosigmoidt 
I Surgery only 
II Surgery only or surgery and chemoradiotherapy 
III Surgery only or surgery and chemoradiotherapy 
IV any combination (will depend on patients diagnosis and overall health) 
Patients treated in 
accordance with 
guidance (%) 
58.7 
96.0 
57.6 
99.1 
67.0 
97.4 
40.8 
100.0 
tTotal mesorectal excision should be used for tumours in early stage but this does not have a specific 
code in OPCS-4 therefore any surgery was used in imputation and analysis 
Compliance with guidelines measured in this way, was generally similar for both colon 
and rectal cancers (Table 7.13). Increasing deprivation was associated with lower 
compliance for colon cancer (deprived odds ratio 0.72), but there was no socioeconomic 
difference in rectal cancer. 
Increasing age, deprivation and comorbidity were correlated with much lower 
compliance, even after adjustment, however this could be because of lower levels of 
adjuvant therapy identified earlier. 
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Rectal cancer surgery can reqUIre more specialist training, especially for total 
mesorectal excision (TME). It is therefore unsurprising that the patterns of treatment 
compliance for each hospital volume and surgeon volume were different for colon and 
rectal cancer patients. Rectal cancer patients treated at moderate- to low-volume 
hospitals had the highest proportion of patients treated in accordance with guidance but 
there was no difference after adjustment (Table 7.13). High surgeon volume for rectal 
cancer was associated with compliance but ideally information on anterior resection or 
TME would be used to assess compliance further. For colon cancer, increasing hospital 
and surgeon volume were associated with higher levels of treatment in accordance with 
guidance, even after adjustment. Private hospitals had the lowest adherence to guidance 
possibly because of the case-mix of patients treated privately. Surgeon volume had little 
impact on treatment compliance with guidance for colon cancer patients, decreasing 
from 83% for high-volume surgeons to 79% for low-volume surgeons. 
Despite the limitations of this analysis it is still useful to see a general trend for higher 
compliance with higher volume hospital and higher surgeon volume. However, hospital 
and surgeon volume did not explain socioeconomic variations in treatment that was 
given in accordance with clinical guidance and warrants further investigation. 
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Table 7.13: Odds ratio for treatment in accordance with clinical guidance 
(reference = compliance) by clinical, demographic and treatment factors for colon 
and rectal cancer, excluding stage IV (data after imputation): colorectal cancer 
patients diagnosed 1997-2004, North West of England 
colon* rectal and rectosigmoidal* 
95%CI 95%CI 
lower upper lower upper 
sex 
men 1.00 1.00 
women 0.84 0.71 0.99 0.89 0.75 1.07 
age 
15 to 44 1.00 1.00 
45 to 54 0.93 0.46 1.87 0.67 0.37 1.21 
55 to 64 0.61 0.33 1.14 0.55 0.32 0.96 
65 to 74 0.43 0.24 0.80 0.43 0.25 0.75 
75 to 84 0.20 0.11 0.36 0.28 0.16 0.48 
85 to 99 0.09 0.05 0.18 0.18 0.09 0.36 
deprivation 
I - affiuent 1.00 1.00 
2 0.96 0.72 1.29 0.97 0.73 1.30 
3 0.86 0.64 1.14 1.01 0.75 1.36 
4 0.88 0.66 1.16 1.06 0.80 1.41 
5 - deprived 0.72 0.56 0.93 0.95 0.73 1.24 
comorbidity 
none 1.00 1.00 
1 0.60 0.39 0.93 0.42 0.21 0.81 
2 0.21 0.11 0.41 0.29 0.11 0.81 
3+ 0.26 0.06 1.21 0.26 0.02 3.88 
Hospital volume 
very high (over 150) 1.00 1.00 
high (100to149) 0.69 0.57 0.85 1.01 0.83 1.23 
moderate (50 to 99) 0.60 0.48 0.76 1.40 1.11 1.76 
low (less than 50) 0.61 0.38 0.97 1.43 0.95 2.16 
Private 0.66 0.25 1.78 0.79 0.44 1.41 
Surgeon volume 
very high (over 60) 1.00 1.00 
high (40 to 60) 0.80 0.43 1.49 0.69 0.42 1.11 
moderate (20 to 40) 0.77 0.42 1.42 0.92 0.58 1.48 
low {less than 20~ 0.68 0.38 1.25 0.86 0.53 1.38 
* adjusted for sex, age, stage, deprivation and comorbidity 
Summary 
Inequalities in access to treatment may partially explain socioeconomic inequalities in 
survival. Deprived patients were less likely than affluent patients to have adjuvant 
therapy and more likely to receive their surgery from low-volume surgeons. Deprived 
rectal cancer patients were more likely to receive surgery types associated with poor 
outcomes (Hartman'S procedure) and less likely to receive anterior resection. A broad 
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measure of whether treatment was given in accordance with guidance further identified 
some variations by socioeconomic group and this actually widened after adjustment for 
hospital and surgeon volume. Imputation managed missing stage, treatment and 
comorbidity data enabling analysis without large proportions of data missing, but 
required some grouping of information resulting in a loss of some specificity. For 
example, surgery was categorised into the occurrence or non-occurrence, rather than the 
specific type and quality measures (e.g. TME, emergency, curative, complications). It is 
always preferable to have full information without missing data, which could explain 
some of the socioeconomic variations. 
Overall, deprived patients received lower levels of adjuvant therapy and may have 
received less than optimal surgical type and/or surgical quality than affluent patients. 
The apparent socioeconomic variations in access to treatment are a concern. They may 
not be the only cause of socioeconomic variations in survival, however if, survival for 
any given treatment is similar in all socioeconomic groups. The relationship between 
socioeconomic status, treatment and survival will be evaluated in the next chapter. 
207 
Appendix 7.1: Distribution (%) of surgery type by hospital volume (colorectal 
surgeries per year) for surgical patients only (unimputed data): colorectal cancer 
patients diagnosed 1997-2004, North West of England 
very high high moderate low private Total (more than 150) (100 to 149) (50 to 99) (less than 50) (Erivate) 
Total excision of colon and rectum 0.7 0.7 0.5 0.3 0.4 0.6 
Total excision of colon 0.7 0.8 0.6 0.8 1.0 0.7 
Extended excision of right hemicolon 4.5 4.3 3.8 4.9 3.3 4.1 
Excision of right hemicolon 20.1 20.2 20.4 22.4 17.9 19.6 
c Excision of transverse colon 0.8 1.1 0.9 1.1 1.6 1.0 0 
'0 Excision ofleft hemicolon 5.8 5.7 5.6 5.4 5.2 5.8 u 
Excision of sigmoid colon 10.1 8.6 8.8 8.6 9.7 9.2 
Excision of colon 2.8 3.0 3.2 4.0 14.6 2.7 
Extirpation of lesion of colon 0.8 0.6 0.5 2.2 2.6 0.4 
'Ei Abdominoperineal excision 
0 
8.5 7.8 7.9 4.2 3.3 8.6 
II) Anterior resection 7.5 7.7 7.9 3.8 2.6 8.3 r:r:: 
Hartman's 8.5 8.4 8.1 7.0 1.9 8.1 
Other non-curative sur~ery 29.2 31.2 31.8 35.3 35.9 30.8 
100.0 100.0 100.0 100.0 100.0 100.0 
Appendix 7.2: Distribution (%) of surgery type by surgeon volume (colorectal 
surgeries per year) for surgical patients only (unimputed data): colorectal cancer 
patients diagnosed 1997-2004, North West of England 
very high high moderate low Total ~more 60~ ~40 to 59~ ~40 to 19~ ~Iess than 20~ 
Total excision of colon and rectum 1.3 0.8 - 0.8 0.3 0.6 
Total excision of colon 1.0 0.8 0.7 0.8 0.7 
Extended excision of right hemicolon 2.2 3.7 3.7 4.9 4.1 
Excision of right hemicolon 18.8 19.3 18.8 20.6 19.6 
c Excision of transverse colon 1.2 0.7 0.9 1.2 1.0 
..2 
-0 Excision ofleft hemicolon 6.8 4.8 6.5 5.5 5.8 U 
Excision of sigmoid colon 11.4 9.3 8.9 9.2 9.2 
Excision of colon 2.1 2.9 2.4 3.0 2.7 
Extirpation of lesion of colon 0.7 0.5 0.4 0.4 0.4 
S Abdominoperineal excision 10.4 10.1 10.5 6.3 8.6 
~ Anterior resection 7.0 8.8 9.8 6.7 8.3 Hartman's 5.9 7.9 7.2 9.3 8.1 
Other non-curative sur~e!! 31.2 30.5 29.6 32.0 30.8 
100.0 100.0 100.0 100.0 100.0 
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Chapter 8 
Are there socioeconomic differences in survival when deprived and 
affluent patients receive equivalent treatment? 
Overview 
Surgery, either alone or in combination with chemotherapy and/or radiotherapy, is the 
only curative treatment for colorectal cancer. Surgical outcomes have improved during 
the 1990s and 2000s because of improvements in post-operative care, the introduction 
of surgical techniques (e.g. total mesorectal excision and laparoscopic surgery), 
centralisation of services, and the increased use of neoadjuvant chemotherapy. 1.2 
Regional variations in treatment in accordance with guidelines, surgeon factors (e.g. 
high-volume or specialist) and centralisation of treatment (e.g. high-volume or specialist 
centres) have been proposed as possible causes of the variations in survival.3 However, 
the relationship of guidance, hospital volume and surgeon volume on inequalities is not 
known. Associations between treatment, clinical and demographic factors could explain 
socioeconomic inequalities in colorectal cancer survival. Yet it remains unclear if 
patients from deprived and affluent backgrounds have similar survival from the same 
treatment, after adjusting for clinically and demographically relevant factors. 
Aims 
The previous chapter highlighted socioeconomic variations in type and quality of 
treatment, particularly lower levels of adjuvant therapy among deprived patients. This 
chapter will report the analyses of inequalities in survival for specific treatment regimes 
for colorectal cancer patients, after adjusting for relevant clinical and demographic 
factors. Post-operative mortality will also be evaluated because it has a substantial 
impact on survival at one and five years and is strongly influenced by other factors, 
such as comorbidity. The influence of hospital and surgeon volume on survival will be 
analysed with adjustment for variations in case-mix. The impact of a broad measure of 
adherence to clinical guidance on the socioeconomic gap in survival will be assessed. 
Finally, socioeconomic variations will be evaluated after adjustment for treatment type, 
hospital and surgeon volume and case-mix to determine if socioeconomic inequalities in 
survival persist. 
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The analysis presented in this chapter will mainly be based on data after imputation, 
unless otherwise specified. 
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Treatment regimes 
Socioeconomic inequalities in survival for each treatment regime persisted, even after 
adjustment for age, stage and comorbidity. For each treatment regime, socioeconomic 
inequality in survival at one year after diagnosis and was consistent across treatments (EHR 
1.30 to 1.33), and generally higher, than for five year conditional survival (EHR 1.13 to 
1.28) (Table 8.1). For example, the survival inequalities for patients treated with surgery 
and chemotherapy or with, surgery and chemoradiotherapy narrowed by about half after the 
first year of diagnosis (EHR at one year 1.33 and 1.32, five year conditional 1.16 and 1.13). 
Inequalities in survival decreased very little for patients treated with surgery only and no 
treatment between one year after diagnosis and five year conditional survival. The excess 
hazard ratio could not be analysed for surgery and radiotherapy, radiotherapy alone, 
chemotherapy alone and chemoradiotherapy alone because of the small number of patients 
by socioeconomic groups. These summary measures of treatment regime capture the 
overall trends but lack the specificity to determine if variations in the quality of treatment, 
particularly surgery explain these inequalities in survival. 
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Table 8.1: Excess hazard ratio of death at one year after diagnosis and at five years 
conditional on survival to one year, by treatment regime and socioeconomic status, 
adjusted for age, stage and comorbidity (data after imputation): colorectal cancer 
patients diagnosed 1997-2004, North West of England 
I - 5 -
affluent 2 3 4 deprived 
One year 
Treatment 
surgery only 1.00 1.06 1.13 1.30 1.32 
surgery and chemotherapy 1.00 0.95 1.12 1.20 1.31 
surgery and radiotherapy: 
surgery and radiochemotherapy 1.00 1.01 1.28 1.14 1.38 
radiotherapy only 
chemotherapy only 
chemoradiotherapy only 
no treatment 1.00 1.30 1.27 1.38 1.47 
Five year survival conditional on survivin~ the first year 
Treatment 
surgery only 1.00 1.03 1.13 1.36 1.36 
surgery and chemotherapy 1.00 1.00 1.07 1.15 1.28 
surgery and radiotherapy 1.00 
surgery and chemoradiotherapy 1.00 1.01 1.04 1.10 1.17 
radiotherapy only 1.00 
chemotherapy only 1.00 
chemoradiotherapyonly 1.00 
no treatment 1.00 1.27 1.27 1.42 1.55 
It was not possible to calculate estimates for surgery and radiotherapy, radiotherapy only, chelIDtherapy only, or 
chelIDradiotherapy because of small numbers in these groups. 
• p-vaIue <0.05 
Linear 
coefficient of 
deprivation 
gaEt 
1.31 • 
1.33 • 
1.30 
1.32 • 
1.32 • 
1.28 • 
1.16 
1.13 
1.26 
t Regression for linear change in EHR between successive socioeconomic groups (estimated by multiplying the linear coefficient 
by 4 to obtain entire deprivation gap), 
: Adjusted for age and stage 
Surgery, either alone or in combination with radiotherapy and/or chemotherapy, is the only 
curative treatment for colorectal cancer. Most colorectal patients had surgery (90.5%). 
Further analysis will focus on inequalities in survival after surgical treatment, including the 
influence of hospital volume and surgeon volume. The annual number of colorectal cancer 
operations per year at the hospital and surgeon level will be evaluated as a measure of 
surgical quality (or expertise). Type and quality of surgery are different for colon cancer 
and rectal (including rectosigmoid), therefore socioeconomic variations in survival and 
surgery will be evaluated separately for each subsite. 
213 
Post-operative mortality 
Post-operative mortality, or mortality within 30 days of surgery, was higher in deprived 
than affluent colorectal cancer patients. The risk of death for deprived patients compared to 
affluent fell from 1.35 to 1.22 after adjustment for age, stage, comorbidity, hospital volume 
and surgeon volume (Table 8.2). Post-operative mortality in colon cancer patients was 
almost double the post-operative mortality in rectal cancer patients (9.6%, 5.0%). 
Inequalities in post-operative mortality were wider for colon cancer and post-operative 
mortality was substantially higher for each socioeconomic group than rectal cancer. For 
example, 8.4% of affluent colon cancer patients died post-operatively compared to 11.0% 
of deprived patients (OR 1.24). For rectal cancer patients, only 4.3% of affluent patient died 
post-operatively increasing to 5.6% of deprived patients (OR 1.18). The disparities between 
socioeconomic groups and by subsite were not explained by differences in stage and 
comorbidity but may be partially attributable to differences in the type of operation 
received. The type of surgery a patient receives will be influenced by patient factors such as 
cancer subsite, and whether they presented with comorbidity or with advanced stage. 
Patients treated by higher volume surgeons have lower post-operative mortality, even after 
adjustment for these factors, but this may be partially because a higher proportion of 
patients received adjuvant therapy and planned surgery. Post-operative mortality was also 
influenced by the volume of colorectal cancer operations conducted by a hospital, but there 
was little variation between hospitals conducting a very-high (over 150 surgeries per year), 
high-volume (100 to 149 surgeries per year) and moderate-volume (50 to 99 surgeries per 
year). Higher post-operative mortality occurred for hospitals conducting a low-volume of 
surgeries per year (less than 50) (OR colon: 1.10, rectal: 1.28). Those patients treated in 
private hospitals had very low post-operative mortality (colon 3.8%, rectal 4.1 %) because 
treatment at a private hospital was associated with better prognostic factors. In contrast, 
patients who had surgery at low-volume hospital may have been more likely to have 
presented as emergencies. Furthermore, complex surgery conducted by higher-volume 
surgeons or higher-volume hospitals would be expected to result in lower post-operative 
mortality than similar surgery conducted by low-volume surgeons, but the influence of this 
on socioeconomic inequalities in one-year and five-year survival conditional on surviving 
the first year is less clear. 
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Post-operative mortality decreased by about 30% between 1997 and 2004, even after 
adjusting for deprivation, stage and other factors (Table 8.2). This may provide a 
quantitative description of the positive impact of improvements in peri-operative care and 
the introduction of new surgical techniques, such as laproscopic surgery. Laproscopic 
surgery decreases th~ risk of infection and leakage and has lower post-operative mortality 
than open surgery.4-7 The impact on longer term survival is yet to be quantified. but is 
expected to prove higher with laproscopic than open surgery. 
There were very few socioeconomic trends in post-operative mortality for each type of 
surgery due to the small numbers (Table 8.3). Each type of operation is specifically for 
either colon or rectal cancer and will be discussed separately. 
Colon 
For colon cancer patients, post-operative mortality increased with increasing levels of age, 
deprivation and stage. There were substantial inequalities in post-operative mortality for 
colon cancer patients, with 11.0% of deprived patients dying post~operatively compared to 
8.4% of affluent patients. The inequalities in post-operative mortality were higher for colon 
cancer than rectal cancer, and were not explained after adjustment. Age was most strongly 
associated with post-operative mortality, particularly for patients who were over age 75 at 
diagnosis who had a post-operative mortality of over 12%. Post-operative mortality was 
very high for colon cancer patients with a comorbidity level of 3 or more (36.3%), but was 
similar for patients with comorbidity levels of none to two (9.5% to 10.2%). 
High post-operative mortality for colon cancer patients was mainly attributed to four 
surgical procedures: total excision of the colon (15.0%); extended right hemicolon (10.9%); 
transverse colon (12.3%); and sigmoid colon (12.9%) (Table 8.3). These procedures are 
generally more invasive. For each of these four surgery types post-operative mortality was 
higher in deprived than affluent patients. There was a consistent trend for higher post-
operative mortality for most operations, however because of small numbers only excision 
of the right hemicolon and left hemicolon had significantly higher post-operative mortality. 
The proportion of colon cancer patients dying post-operatively was similar for very high-, 
high- and moderate-volume hospitals (9.2% to 10.2%). Post-operative mortality was higher 
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for colon cancer patients who had surgery at low-volume hospitals (11.5%), even after 
adjustment for clinical and demographic factors (Table 8.2). Private hospitals had very low 
levels of post-operative mortality probably because all surgeries were elective. Higher 
surgeon volume was significantly associated with better post-operative mortality for colon 
cancer patients, even after adjustment for stage. Differences in post-operative mortality by 
surgeon volume may be partially attributed to case-mix, however this should be largely 
accounted for by adjusting for stage and comorbidity. For example, colon cancer patients 
presenting as an emergency with an obstruction may be more likely to be treated by a low-
volume surgeon. Higher levels of adjuvant therapy associated with elective surgery would 
also be associated with higher volume surgeons, further influencing post operative 
mortality (see Table 7.11). 
Rectal 
Post-operative mortality for rectal cancer patients was less strongly associated with 
deprivation and stage compared to colon cancer. For example 5.6% of deprived rectal 
cancer patients died post-operatively compared to 4.3% of affluent (1.18), whereas 11.0% 
of deprived and 8.4% of affluent colon cancer patients died post-operatively (1.24), 
respectively. Surgical intent (curative, palliative, elective or emergency) may explain some 
of the differences between rectal and colon cancer but this information was not available 
for this study. Advanced stage was associated with a large post-operative mortality (8.8%, 
OR 3.6) for rectal cancer patients, although this may be partially explained by differences 
in procedure type (emergency, type of surgery). Post-operative mortality for rectal cancer 
patients increased with comorbidity but was accounted for after adjustment. Post-operative 
mortality for patients with a comorbidity level of 3 or more could not be estimated due to 
small numbers. 
Most of the post-operative mortality for rectal cancer patients occurred following other 
(non-excision) surgeries (11.2%) (Table 8.3). Post-operative mortality for colon and rectal 
cancer patients was particularly high for Hartman's procedure (12.4%). Anterior resection 
and abdominoperineal excision for rectal cancer had very low post-operative mortality 
(3.8% and 1.7%, respectively). The very good post-operative outcomes for anterior 
resection and abdominoperineal resection may be attributed to both the curative intent of 
the surgery and case-mix. 
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Post-operative mortality for rectal cancer patients was similar for very high- to moderate-
volume hospitals (4.5% to 5.2%) and private hospitals (4.1%). Similarly, post-operative 
mortality for rectal cancer patients was consistent for very high- to moderate-volume 
surgeons (3.6% to 3.7%). Rectal cancer patients who had surgery at a low-volume hospital 
(6.3%) or a low-volume surgeon (7.3%) had much higher post-operative mortality. The 
high post-operative mortality in low-volume hospitals and surgeons was associated with a 
higher proportion of patients having Hartman's procedure and lower proportion having 
received adjuvant therapy. 
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Table 8.2: Post-operative mortality: Distribution (%) of patients dying within 30 days 
of surgery and Odds ratio for death within 30 days of surgery by clinical and 
demographic factors (data after imputation): colorectal cancer patients diagnosed 
1997-2004, North West of England 
colorectal colon rectal 
(n=26,162~ (n=15,942~ (n=10,220~ 
Odds ratio· Odds ratio' Odds ratio' 
~ 95%CI 95%CI 95%CI 
Total 7.8 9.6 5.0 
Sex 
Men 7.4 1.00 9.4 1.00 4.8 1.00 
Women 8.4 0.91 0.88 0.94 9.9 0.91 0.88 0.95 5.3 0.89 0.84 0.95 
Age 
15 t044 0.8 1.00 1.1 1.00 0.4 1.00 
45 to 54 2.S 3.37 2.56 4.45 2.9 2.76 2.03 3.77 2.1 5.59 2.96 10.59 
55 to 64 4.0 5.55 4.26 7.24 5.3 5.49 4.10 7.36 2.4 6.20 3.31 11.61 
65 to 74 6.3 8.88 6.83 11.54 7.9 8.51 6.37 11.37 3.9 10.72 5.75 20.02 
75 to 84 10.8 16.11 12.39 20.94 12.4 14.73 11.03 19.66 7.8 22.38 12.00 41.74 
85 to 99 18.3 30.68 23.57 39.92 21.6 29.04 21.71 38.84 11.8 37.74 20.19 70.58 
DepriVition 
I -amuent 6.8 1.00 8.4 1.00 4.3 1.00 
2 6.2 0.84 0.80 0.89 7.4 0.81 0.76 0.86 4.3 0.93 0.84 1.04 
3 7.9 1.05 1.00 1.10 9.9 1.09 1.02 1.15 4.8 0.96 0.86 1.06 
4 8.4 1.11 1.06 1.17 10.4 1.13 1.07 1.20 5.2 1.07 0.97 \.18 
5 - deprived 8.9 1.22 \.17 1.28 11.0 1.24 1.\7 1.31 5.6 1.18 1.08 1.29 
Diagnosis yeu 
1997 9.5 1.00 11.9 1.00 5.7 1.00 
1998 9.3 1.00 0.95 1.06 11.4 0.98 0.92 1.04 6.2 1.05 0.94 \.17 
1999 7.3 0.73 0.69 0.78 9.0 0.72 0.68 0.77 . 4.6 0.78 0.70 0.88 
2000 7.8 0.82 0.77 0.86 9.6 0.80 0.7S 0.85 5.1 0.88 0.78 0.98 
2001 7.3 0.75 0.71 0.80 9.0 0.73 0.68 0.78 4.6 0.81 0.72 0.91 
2002 6.7 0.69 0.65 0.74 8.0 0.66 0.61 0.70 4.7 0.82 0.73 0.92 
2003 7.6 0.79 0.75 0.84 9.S 0.78 0.73 0.83 4.8 0.86 0.77 0.96 
2004 6.7 0.71 0.66 0.75 8.S 0.70 0.6S 0.7S 4.1 0.74 0.66 0.84 
Subsile 
colon 9.6 1.00 
recotsigmoid 5.7 0.63 0.60 0.67 
rectum 4.8 0.54 0.52 0.56 
Stage 
I 3.5 1.00 4.1 1.00 2.9 1.00 
II 6.5 1.61 \.SO 1.72 7.8 1.82 1.66 1.98 4.3 1.38 1.24 1.53 
III 9.7 2.76 2.S8 2.94 12.0 3.20 2.94 3.50 6.0 2.16 1.96 2.39 
IV 12.5 4.27 3.91 4.67 14.6 4.84 4.33 5.41 8.8 3.64 3.12 4.24 
Comorbidity 
none 7.7 1.00 9.5 1.00 4.9 1.00 
I 9.6 0.98 0.91 1.06 10.5 0.91 0.83 0.99 7.9 US 1.08 1.44 
2 9.1 1.02 0.89 1.17 10.2 0.99 0.84 1.16 7.0 1.14 0.88 1.47 
3 or more 10.8 2.33 1.89 2.86 36.3 4.16 3.29 5.26 
lIospUal volume 
very high (over 150) 8.0 1.00 10.2 1.00 4.8 1.00 
high (100 to 149) 7.6 0.96 0.93 1.00 9.2 0.91 0.87 0.95 5.2 1.11 1.04 \.19 
moderate (SO to 99) 7.7 0.91 0.87 0.95 9.8 0.91 0.87 0.96 4.5 0.88 0.81 0.96 
low (less than 50) 9.8 1.15 1.08 1.22 11.5 1.10 1.03 \.18 6.3 1.28 1.13 1.44 
Private 3.9 0.56 0.49 0.63 3.8 0.44 0.38 0.52 4.1 1.03 0.83 1.28 
Surgeon volume 
very high (over 60) 5.5 1.00 6.7 1.00 3.8 1.00 
high (40 to 60) 5.7 0.99 0.89 \.10 7.4 1.01 0.89 1.14 3.6 0.93 0.77 1.12 
moderate (20 t040) 6.3 1.09 0.98 1.20 8.3 1.15 1.02 1.29 3.7 0.93 0.78 \.II 
low (less than 20~ 10.2 1.61 1.46 1.78 11.6 1.57 140 1.77 7.3 1.76 1.48 2.10 
'Adjusted for all variables in the table 
87.6% or colon cancer patients and 90,,°;' or rectal cancer patients recieved surgery 
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Table 8.3: Post-operative mortality: Number and percentage of (%) of patients dying 
within 30 days of surgery for each type of surgery and socioeconomic group (original 
'complete' data): colorectal cancer patients diagnosed 1997-2004, North West of 
England 
Post-operative Affluent De£rived Absolute 
mortali!r deprivation 
OPCS-4 No. % No. % No. % gap 
Total excision of colon and rectum H04 5 3.6 2 7.1 2 5.6 -1.6 
- Total excision of colon HOS 27 15.0 4 12.5 II 21.6 9.1 
Extended excision of right hemicolon H06 112 10.9 15 9.0 29 10.5 1.4 
Excision of right hemicolon H07 425 8.7 58 7.5 132 9.6 2.2 • 
§ Excision of transverse colon HOB 30 12.3 5 12.5 8 12.7 0.2 8 Excision ofleft hemicolon H09 102 7.4 IS 6.4 37 10.5 4.1 • 
Excision of sigmoid colon HIO ISO 6.8 21 5.3 41 6.5 1.2 
Excision of colon Hit 102 12.9 18 10.9 36 15.7 4.7 
_ Extirpation of lesion of colon HI2 10 5.7 2 7.1 4 8.0 0.9 
~ Abdominoperineal excision H33.1 71 3.8 8 28 19 3.4 0.7 
-=:.. Anterior resection H33.2-H3H, H33.6 77 1.7 9 \.I 21 1.7 0.6 
Hartman's H3B 238 12.4 39 14.1 83 12.7 -1.4 
Other non-curative surgery 533 1\.16 80 9.9 167 11.8 1.9 
Total 1,882 8.6 276 8.2 590 10.0 1.8 
• p-value <0.05 
Hospital and surgeon volume 
Patients receiving surgery at high-, moderate- or low-volume hospitals patients had similar 
survival at one year (73.3% to 74.2%) with survival positively associated with hospital 
volume by five years after diagnosis (52.3% to 53.2%) (Figure 8.1). 
Patients receiving surgery at a private hospital had substantially higher relative survival at 
one (93.3%) and five years after diagnosis (69.5%) than other patients, but treated only 
2.4% of patients. Non-surgical patients had the poorest survival and largest excess mortality 
in the first months after diagnosis but there was still a substantial minority alive at five 
years after diagnosis (one year 32.7%; five years; 21.0%). 
Surgeon volume was also positively associated with survival at five years, although up to 
five years after diagnosis moderate-, high- and very high-volume surgeons had similar 
survival (Figure 8.2). Low-volume surgeons had consistently lower relative survival at all 
follow-up times (one year: 67%, five years: 47.0%). Five-year relative survival was 61.3% 
(95% CI 60,0, 62.6) for very high-volume surgeons (over 60),59.2% for high-volume and 
56.9% for moderate-volume surgeons. Non-surgical patients had the lowest relative 
survival at all follow-up periods. 
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Survival variations by hospital and surgeon volume are mostly explained by case-mix, 
which will in turn impact on surgical options and adjuvant therapy. The type of surgery 
received for rectal cancer varied widely by surgeon volume and hospital volume, but there 
was little variation for colon cancer. As identified earlier, high-volume surgeons and high-
volume hospitals were generally associated with curative surgery with better outcomes (see 
Appendix 7.1 and 7.2). However, socioeconomic differences in colorectal cancer survival 
by surgeon volume or hospital volume still exist even after adjustment for factors that 
might be associated with surgery type (comorbidity, stage and other factor). 
Figure 8.1: Relative survival up to five years after diagnosis by hospital volume 
(colorectal surgeries per year) (data after imputation): colorectal cancer patients 
diagnosed 1997-2004, North West of England 
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Figure 8.2: Relative survival up to five years after diagnosis by surgeon volume 
(colorectal surgeries per year) (data after imputation): colorectal cancer patients 
diagnosed 1997-2004, North West of England 
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Socioeconomic inequalities in survival were observed for all hospital and surgeon volumes 
at one year after diagnosis, but they were slightly narrower for five year survival 
conditional on surviving the first year, even after adjustment (Table 8.4). In the first year 
after diagnosis, survival inequalities were very similar for all hospital volumes, ranging 
from an excess hazard ratio of death of 1.26 in high-volume to 1.41 for moderate volume. 
For patients who survived the first year after diagnosis, a substantial deprivation gap in 
survival remained for patients treated at high- and moderate-volume hospitals but none 
occurred for very high- or low-volume hospitals. For private hospitals the number of 
operations (and patients) was too low, particularly in the most deprived, to estimate the 
deprivation gap. 
There was no consistent pattern in the socioeconomic inequalities in survival by surgeon 
volume for both one year or five year survival conditional on surviving the first year. 
Deprived patients treated by very high-volume surgeons had an extremely high excess 
mortality (EIIR 1.70) which was narrowed after the first year following diagnosis. 
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Moderate and low-volume surgeons had similar levels of inequality at one year after 
diagnosis; survival inequalities persisted only for low-volume surgeons for five year 
survival conditional on surviving the first year. 
Table 8.4: Excess hazard ratio of death for one-year survival and five year conditional 
survival by hospital and surgeon volume (colorectal surgeries per year), adjusted for 
age, stage and comorbidity (data after imputation): colorectal cancer patients 
diagnosed 1997-2004, North West of England 
Linear 
1 - 5- coefficient of 
affluent 2 3 4 deQrived deQrivation gaQ! 
One !ear 
Hospital volume 
very high (over 150) 1.00 0.97 1.27 1.21 1.32 1.31 • 
high (100 to 149) 1.00 0.95 1.02 1.19 1.21 1.26 • 
moderate (50 to 99) 1.00 1.06 1.17 1.19 1.50 1.41 • 
low (less than 50) 1.00 1.11 0.96 1.30 1.39 1.28 
no surgery 1.00 1.25 1.27 1.26 1.43 1.30 • 
Surgeon volume 
very high (over 60) 1.00 1.25 1.22 1.63 1.92 1.70 • 
high (40 to 60) 1.00 0.89 1.13 1.13 1.06 1.13 
moderate (20 to 39) 1.00 0.96 1.12 1.25 1.40 1.38 • 
low (less than 20) 1.00 1.03 1.12 1.19 1.32 1.30 • 
Five !ear survival conditional on survivin~ the first !ear 
Hospital volume 
very high (over ISO) 1.00 1.01 0.94 0.99 0.92 0.92 
high (100 to 149) 1.00 0.93 1.00 1.16 1.16 1.22 • 
moderate (SO to 99) 1.00 1.04 1.07 1.19 1.40 1.35 • 
low (less than 50) 1.00 1.18 1.25 1.02 1.17 1.07 
no surgery 1.00 1.05 1.07 1.20 1.28 1.25 
Surgeon volume 
very high (over 60) 1.00 1.01 1.49 1.48 1.51 1.52 
high (40 to 60) 1.00 0.91 0.83 1.00 1.00 0.80 
moderate (20 to 39) 1.00 1.10 1.11 1.09 1.12 1.08 
low {less than 20~ 1.00 0.99 1.00 1.22 1.27 1.28 • 
It was not possible to calculate estimates patients receiving colorectal surgery at private hospitals because 
of small numbers in these groups. 
• p-value < 0.05, 
t Regression for linear change in EHR between successive socioeconomic groups (estimated by 
multiplying the linear coefficient by 4 to obtain entire deprivation gap), 
Private hospitals 
Patients receiving private surgery had significantly higher survival even after adjustment 
for age, stage, subsite and comorbidity. Higher survival for private patients was largely due 
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to these patients being generally younger, diagnosed at an earlier stage, and with lower 
levels of comorbidity than colorectal cancer patients in the North West. Most private 
patients received surgery alone (79%), compared with 39.2% for patients treated at an NHS 
hospital. After adjustment for age, stage, subsite and comorbidity, survival was 
significantly better in private patients. 
Private surgical patients were also more affluent than the North West colorectal cancer 
population, with 65% from the two most affluent groups compared to 33% of colorectal 
cancer patients in NW. The specific type of surgery received by private patients was 
difficult to assess because of lack of access to case notes, but based on their earlier stage, 
and low levels of comorbidity, the surgical procedures were likely to have been curative. In 
short, private patients are a tiny but highly selected sub-set of patients, with a lower risk of 
death. 
Guidance 
Treatment in accordance with clinical guidelines for colon and rectal cancer patients was 
associated with better survival at one and five years. Patients with very advanced disease 
(stage IV) were excluded from these analyses (consistent with analysis in chapter 7) 
because most treatment regimes could be considered clinically appropriate, although 
inclusion of patients diagnosed in stage IV produced very similar trends. Compliance was 
associated with a much higher survival at five years (unadjusted EHR: 0.41 95% CI 0.38, 
0.44, data not shown). The protective effect of compliance was still significant after 
adjustment for sex, age, subsite, stage, comorbidity, diagnosis year and deprivation (EHR: 
0.66, 95% CI 0.61, 0.70, data not shown). 
Inequalities in survival were observed for both compliant and non-compliant treatment 
(Table 8.5). Survival inequalities for colon and rectal cancer were higher in the first year 
after diagnosis than at five years conditional on surviving the first year after diagnosis, a 
pattern similar to that observed for treatment and other variables (stage, comorbidity) (see 
chapter 6). For rectal cancer patients treated in compliance with guidance the inequality in 
survival narrowed after the first year of diagnosis (from IAI to 1.22) but widened for non-
compliance (from 1.23 to 1.33). After the first year of diagnosis, there were no inequalities 
in compliant or non-compliant treatment for colon cancer. Variations in treatment 
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(emergency, complications, compliance) may explain the pattern of inequalities in survival 
for compliant treatment because of the overlap between treatment regimes and compliance. 
The consistent pattern of lower survival in deprived patients, for each treatment regime and 
compliant treatment raises the question of whether fuller details of treatment type 
(complications, chemotherapy toxicity and adherence) and quality could help to explain 
these disparities further. 
Table 8.5: Excess hazard ratio of death for treatment in accordance with clinical 
guidance for one-year survival and conditional survival at five years, adjusted for age 
and stage, excluding stage IV (data after imputation): colorectal cancer patients 
diagnosed 1997-2004, North West of England 
Linear 
coefficient of 
1 -
affluent 
5- deprivation 
One year 
Colon 
2 3 
Compliance 1.00 1.00 1.16 
Non-compliance 1.00 1.1 5 1.16 
Rectal (and rectosigmoid) 
Compliance 1.00 1.00 1.29 
Non-compliance 1.00 0.96 1.09 
Five year survival conditional on survivinf! the first year 
Colon 
4 
1.26 
1.33 
1.30 
1.11 
deprived 
1.42 1.41 
1.39 1.33 
1.44 1.41 
1.23 1.23 
Compliance 1.00 1.1 0 0.99 1.07 1.11 1.11 
Non-compliance 1.00 1.03 0.91 1.21 I.IS 1.19 
Rectal (and rectosigmoid) 
Compliance 1.00 0.98 1.02 1.19 1.19 1.22 
Non-compliance 1.00 1.12 1.36 1.35 1.40 1.33 
Patients in stage IV were not included (see text) 
gapt 
t Regression for linear change in EIIR between successive socioeconomic groups (estimated by multiplying 
the linear coefficient by 4 to obtain entire deprivation gap), 
• p-value < 0.05, 
• 
• 
• 
• 
• 
• 
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The relationship between deprivation, clinical guidance, hospital and surgeon volume 
In the first year after diagnosis, there was a substantial deprivation gap in survival for colon 
cancer (39%) and rectal cancer (29%), which could not be explained after accounting for 
differences in hospital volume or clinical and demographic factors (Table 8.6). 
Socioeconomic inequalities were minimal for five year survival conditional on surviving 
the first year after diagnosis. Compliance was not adjusted for in analysis of deprivation 
because it is on the causal pathway to survival (Figure 9.2). 
The basic estimate of whether treatment was in accordance with clinical guidance was 
associated with a markedly reduced excess hazard of death for both colon and rectal cancer 
(EHR: 0.82 and 0.81, respectively). Treatment in accordance with guidance did not, 
however explain the deprivation gap in survival for either colon or rectal cancer (colon: 
1.36, rectal 1.28, data not shown). Excess hazard of death was not adjusted for treatment 
regime because it was closely associated with survival and is on the causal pathway (Figure 
9.1). 
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Colon cancer 
For colon cancer patients, increasing deprivation was positively associated with the excess 
hazard of death in the first year after diagnosis but only slightly associated after the first 
year. After adjustment for age, stage and comorbidity hospital and surgeon volume had 
very little impact on moderating the excess hazard of death by socioeconomic group. There 
was a significant trend towards higher survival with increasing hospital volume, although 
there was no significant excess mortality for patients receiving surgery at any hospital 
volume within the NHS. Similarly, the excess risk of death increased with decreasing 
surgeon volume but was significant only for low-volume surgeons. Survival was 
substantially higher for privately treated patients than patients in NHS hospitals. 
Rectal cancer 
Socioeconomic inequalities were narrower for one year and five year conditional survival 
for rectal cancer patients than colon cancer patients. The general pattern of excess mortality 
for each level of surgeon and hospital was similar for both rectal cancer and colon cancer 
patients. However, rectal cancer patients had a slightly lower excess mortality than colon 
cancer patients at most hospital and surgeon volumes. For example rectal cancer patients 
who had surgery from a low-volume surgeon had an excess mortality of 1.33, compared to 
1.43 for colon. Patients who did not have surgery had an excess mortality of 1.61, 
compared to 2.37 for colon). This moderation in the association between hospital volume in 
rectal cancer resulted in no significant association between hospital volume and excess 
mortality. 
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Table 8.6: Excess hazard of death by hospital and surgeon volume, treatment in accordance with guidance and socioeconomic status 
(data after imputation): colorectal cancer patients diagnosed 1997-2004, North 'Vest of England 
Colon Rectal 
up to Five years after 
First ~ear diagnosist First~ear up to Five years after diagnosist 
95%CI 95%CI 95%CI 
Hospital volume* 
more than 150 1.00 
100 to 150 0.98 0.92 1.04 
50 to 99 1.03 0.95 1.10 
less than 50 1.12 0.98 1.27 
private 0.70 0.57 0.87 
none 1.77 1.50 2.09 
Surgeon volume* 
more than 60 1.00 
40 to 60 1.00 0.81 1.22 
20 to 39 1.10 0.91 1.33 
less than 20 1.43 1.18 1.73 
none 2.37 1.85 3.03 
Guidance* 
Non-compliance 1.00 
Compliance 0.82 0.74 0.90 
Deprivationt 
1 - affluent 1.00 1.00 1.00 
2 1.07 0.97 1.19 1.01 0.88 1.16 1.00 0.86 1.17 
3 1.18 1.07 1.30 0.93 0.81 1.07 1.16 1.01 1.34 
4 1.29 1.18 1.42 1.03 0.90 1.18 1.15 1.00 1.32 
5 - deprived 1.39 1.27 1.52 1.08 0.95 1.22 1.29 1.14 1.47 
• adjusted for age, stage, grade, comorbidity, deprivation and interaction between deprivation and time. 
t Estimates for second to fifth year after diagnosis for deprivation, 
95%CI 
1.00 
0.98 0.89 
0.96 0.87 
1.14 0.96 
0.71 0.53 
1.35 1.09 
1.00 
0.98 0.78 
0.99 0.79 
1.33 1.06 
1.61 1.32 
1.00 
0.81 0.74 
1.00 
1.00 0.84 
1.08 0.92 
1.19 1.02 
1.18 1.02 
t adjusted for hospital volume, surgeon volume, age, stage, comorbidity, and interactions between deprivation and time. 
1.07 
1.06 
1.36 
0.95 
1.69 
1.24 
1.23 
1.66 
2.13 
0.89 
1.18 
1.28 
1.38 
1.37 
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Summary 
Even when deprived patients received the same treatment regime or surgery in a high-
volume hospital or from a high-volume surgeon, they had lower one year and post-
operative survival. Excess mortality was similar for patients treated at very high-, high-
and moderate-volume surgeons and hospital volume but was significantly higher for 
low-volume surgeons and hospitals. Patients treated at private hospitals had 
significantly higher survival but they were younger, diagnosed at an earlier stage and 
had fewer comorbid conditions than colorectal cancer patients in the North West. 
Provision of optimal treatment is the aim of clinical guidance, but even when deprived 
patients receive treatment in line with guidance colon and rectal cancer patients survival 
was still lower than affluent patients. The continued inequality in colorectal survival, 
even within a specific treatment regime or hospital/surgeon volume may be due to 
socioeconomic differences in treatment quality or other factors that could not be fully 
investigated in this data set. However, these inequalities in survival, combined with the 
lower levels of adjuvant therapy, highlights issues of equality, a particular concern in a 
NationallleaIth Service based on equal access to optimal treatment for all patients.s 
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Chapter 9 
Discussion and conclusions 
Overview 
Wide socioeconomic inequalities in survival for colorectal cancer were found in the 
North West for patients diagnosed between 1997 and 2004, particularly in the first year 
after diagnosis. These inequalities were not explained by variations in stage, 
comorbidity or other clinical and demographic factors. Deprived patients, were less 
likely to receive adjuvant therapy and more likely to have had surgery, particularly 
surgery alone, than affluent patients. Deprived patients, were also less likely to receive 
curative surgery, particularly anterior resection for rectal cancer, and more likely to die 
within 30 days of colorectal cancer operation than affluent patients. Substantial 
inequalities in survival persisted even when deprived and affluent patients received 
similar treatment regimes. Determining the appropriate treatment regime involves many 
clinical factors, such as stage and comorbidity. However, even after adjusting for many 
of these factors, adjuvant therapy and survival remained lower for deprived patients. 
The inter-relationship between type and quality of treatment, clinical factors and 
demographic factors is complex (Figure 9.1). The main influences on treatment regime 
were taken into account (stage, comorbidity, age, surgeon volume and hospital volume), 
but they explained very little of the socioeconomic disparities in treatment. A large 
number of factors that are weakly associated with treatment and survival could not be 
evaluated in this study (lifestyle factors, biological differences, complications, 
adherence to treatment). Ilowever, it seems unlikely that any of these factors could 
explain the wide socioeconomic inequalities in treatment and survival that are reported 
here. 
The Nationalllealth Service in the UK is founded on principles of equity, and persistent 
socioeconomic inequalities in treatment access and survival are therefore a source of 
concern. Inequalities in survival and access to treatment for colorectal cancer patients 
occurred in the North West region between 1997 and 2004 and given the higher take-up 
of colorectal screening in affluent populations may actually widen. Evidence-based 
strategies, to address socioeconomic inequalities in treatment access and to ensure 
consistent outcomes regardless of socioeconomic position are, likely to be the most 
effective way to address survival disparities. 
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Socioeconomic status 
Socioeconomic inequalities in survival existed for up to five years after diagnosis, but 
the widest disparity was observed in the first year after diagnosis. Adjustment for 
clinical and demographic factors explained very little of this inequality in survival. 
Survival for colon and rectal cancers improved substantially in England and Wales 
between 1986 and 1999, yet the socioeconomic inequalities continued to increase. I 
Whilst factors such as stage, comorbidity, age and treatment regime have the biggest 
impact on survival, survival is also influenced by other factors, either directly or 
through influences on the eligibility for and effectiveness of treatment. Figure 9.1 is a 
schematic diagram showing the likely direction of the influence of the complex inter-
relationship of factors influencing socioeconomic inequality in both the type and quality 
of treatment and subsequent survival. Treatment is at the centre of this model, which is 
influenced directly by layers of clinical and patient decisions. Clinical decisions are 
strongly influenced by quantifiable clinical factors (e.g. stage, comorbidity) but these 
clinical factors may also explain most of the socioeconomic variations in survival. Each 
of these quantifiable factors will be discussed separately. Clinical decisions may also be 
influenced by 'softer' factors, such as the patient's health knowledge, lifestyle and 
characteristics. These 'softer' influences incorporate the personal interactions, lifestyle 
factors and characteristics that are difficult to quantify but may well influence decisions, 
both consciously and subconsciously. 
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Figure 9.1: Influences on inequality in colorectal cancer treatment and survival 
(based on an original concept from Polite et aL 2006, see Figure 2.1) 
Other clinical/ 
factors 
Type of treatment 
(regime or type of surgery) 
I 
Quality of treatment 
(particularly surgery) 
Survival 
Socioeconomic 
group 
--Lifestyle factors 
_ Adherence to regime 
(particularly 
chemotherapy/radiotherapy) 
\ 
Complications 
A recurring explanation for health inequalities is that affluent patients play a more 
active role in treatment decisions and that as a result they are more likely to receive 
optimal treatment and have higher survival than deprived patients.2 A sociological 
theory, known as the 'Fundamental cause theory', takes this a step further, suggesting 
that people of higher socioeconomic status have a 'broad range of flexible and multi-
purpose resources that can be used to the advantage of their health, including 
knowledge, money, power and social connections'. 3 The theory suggests that affluent 
patients may have better psychological and physical resources to request and obtain 
optimal treatment, or to obtain optimal treatment privately. Furthermore. affluent 
patients may be better able to remove potential barriers to treatment (e.g. transportation, 
financial, time off work) and to gain access to oilier resources (e.g. private medical 
advice, home support, external information on treatment options), than deprived 
patients. Individually, these may have little impact, but the combined influences on 
treatment, and ultimately survival could be substantial (Figure 9.2). 
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Figure 9.2: Proposed hierarchy of factors contributing to the inequalities in 
survival in the UK 
No deprivation gap in survival (EHR 1.0) 
Other factors (e.g. lifestyle factors) 
Optimal treatment type and quality 
Comorbidity 
Stage 
Histology, grade, age 
Deprivation gap in survival (EHR 1.41) 
Tow rds fully 
expl nin the 
depri tio gap 
In a universal-access health system that aims to provide equal access to treatment to all 
members of society, it seems counterintuitive that inequalities in outcome should 
persist. However, when risk factors that cause health inequalities are removed, social 
disparities in health have remained.4 Rather than suggesting that reducing health 
disparities is futile, the fundamental cause theory suggests an alternative approach to 
ensure equitable access, by focusing on redressing inequalities through overtly ensuring 
optimal treatment for all socioeconomic groups. Actively empowering deprived patients 
with health knowledge could further serve to remove barriers to optimal treatment 
(including adherence). 
tage 
Advanced stage at diagno i was strongly associated with lower survi ai, but it 
explained very little of the socioeconomic inequalities in survival. At each tage, 
deprived patien had lower survival than affluent patients, although there were no 
ocioeconomic variations in stage at diagnosis. By contrast, other re earchers propo e 
that a higher proportion of deprived than affluent patients pre ent at a more ad anced 
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stage contributed substantially to the socioeconomic inequalities in both colon and 
rectal cancer surviva1.2,s The impact of stage on socioeconomic inequalities in survival 
has been difficult to quantify, because population-based colon and rectal cancer data are 
often missing data on stage at diagnosis for between 15% and 40% of patients.6-11 
Missing data on stage were associated with older age, lower levels or quality of 
treatment,S poor prognosis and lower socioeconomic status12 for colorectal patients in 
this study, and in other studies of population-based cancer registry data. Variations in 
the case-mix of patients with missing data on stage could explain some of the 
deprivation gap. Without the 'true' stage at diagnosis, it is impossible to adjust for stage 
because 'ad hoc' methods for adjustment (e.g. exclusion of missing data, inclusion of 
cases with missing data as a separate category) would not fully adjust for stage. In this 
study, stage-specific socioeconomic inequalities in survival remained at one year after 
diagnosis and for five-year conditional survival. With the presence of stage-specific 
inequalities, it is unsurprising that adjustment for stage after imputation did not 
significantly narrow the deprivation gap in survival. The wide stage-specific inequalities 
in survival may be attributed to i) differential staging by socioeconomic groups ii) 
incomplete adjustment for other patient characteristics (e.g. comorbidity, patient choice) 
or iii) differential treatment, for which stage is the main predictor. 
Earlier stage at presentation of affluent colorectal cancer patients who, therefore 
achieved longer survival ('lead time'), has been suggested as a possible explanation for 
survival inequalities?,13 Earlier stage at diagnosis has been seen in audit studies for 
affluent colorectal cancer patients,14 but results from population-based studies have 
been inconsistent.9.13.1S This discrepancy is unsurprising, given that case ascertainment 
for population-based cancer data is less biasedl6 than audit studies, which are biased 
towards patients who are actively treated. Earlier presentation in affluent patients for 
other cancer types9.17.18 may be due to higher symptom awareness, whilst the non-
specific nature of colorectal cancer symptoms may make it less likely that affluent 
patients would present at an earlier stage. Deprived colorectal cancer patients were 
more likely to have missing data for stage in, this and other studies8.12 which may 
explain the reported association between advanced stage and deprivation. The records of 
affluent patients were more likely to have complete staging information, thereby biasing 
the observed stage distribution toward an earlier stage at diagnosis, because patients 
with missing data for stage generally had more advanced disease. There do not appear 
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to be any population-based studies of survival for colorectal cancer with either data on 
stage for all patients or in which missing stage data have been adequately imputed. 
Stage at diagnosis can be further sub-divide within stage (e.g. Stage IIA and IIB)!9 If 
these sub-divided stage varies systematically by socioeconomic status it could 
contribute to socioeconomic inequalities in survival, and this differences would not be 
accounted for by imputation. Subdivision of stage II and III (e.g. Stage II: B 1, B2; Stage 
III: C 1 C2) was only available for 22% of patients (n=6,450), therefore it was necessary 
to use the less specific stage groupings (I-IV). Heterogeneity within stage is therefore 
plausible, but it is unlikely to cause the large stage-specific socioeconomic differences 
in survival. 
Accurate staging is clinically important to determine if adjuvant therapy should be 
provided. Specialist centres are more likely to accurately stage patients and provide 
adjuvant therapy to their patients.20,21 Stage-specific clinical guidelines for colorectal 
cancer encourage the recording of high-quality stage data, but they may have also 
contributed to inter-hospital variations. In this study, high-volume hospitals and high-
volume surgeons were more likely to stage patients fully. This probably reflects better 
recording systems, a greater familiarity with clinical guidance and higher proportions of 
patients given active treatment. 
Ideally, stage should be obtained from pathology to ensure accuracy and comparability, 
but for non-surgical patients stage must be obtained from clinical assessment, or 
preferably by imaging (also known as clinical stage). The accuracy of stage improves 
with an increasing number of lymph nodes sampled22 (usually > 12) but this is 
dependent both on the surgeon excising the tumour by wide margins (to maximise the 
number of lymph nodes), and on the pathologist testing and recording a large number of 
lymph nodes for tumour-positive status. Clinical stage is unlikely to be recorded in 
routine electronic datasets that are not cancer-specific, such as lIES, and therefore to be 
captured by cancer registries or other data organisations (e.g. NBS Information Centre). 
The metastatic status of cancer is diagnosed from imaging (e.g. CT) and is therefore 
also less likely to be recorded in the cancer registry. Further research to elucidate the 
variations in staging methods and completeness between socioeconomic status could 
clarify differences in 'true' stage and why stage data are less complete for deprived 
patients. 
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Survival for each stage at diagnosis decreased in the North West after imputation of 
missing data on stage. This is because patients with missing data on stage had a poorer 
prognosis, were generally older and had more comorbidity than patients whose stage 
was recorded. For example, patients with missing stage data and who were assigned to 
stage I after imputation of stage, had a poorer prognosis than those with stage I recorded 
in the original data: This reduced the overall relative survival estimate at five years for 
patients in stage I from 93.3% in the original data to 87.2% after imputation. This may 
be thought of as an example of the Will Rogers phenomenon, in which an undefined 
group, after assignment to specific categories, can reduce survival for all groupS.23,24 As 
comedian Will Rogers would say 'When the Okies left Oklahoma and moved to 
California, they raised the average intelligence of both states,.23,24 
It is impossible to know the 'true' population-based distribution of stage for colorectal 
cancer patients. Multiple imputation was used to impute missing data, particularly stage, 
resulting in a pattern of stage-specific relative survival comparable with that of the 
Surveillance Epidemiology and End Result programme in the USA (1998 to 2002) 
(Figure 9.3). For example, five year relative survival was 90.5% for the US and 87.2% 
in the North West after imputation (Stage IV; 9.1 % in US and 9.4% in NW). Colorectal 
cancer survival in the North West of England is generally below that of the USA, 
although lower stage-specific colorectal cancer survival in England, than the USA has 
been previously identified and mainly attributed to a lower proportion of patients 
receiving surgery.25 The distribution of cases by stage, after imputation, was also 
consistent with other population-based studies in which colon cancer patients are mostly 
diagnosed in stage II and rectal cancer patients in stage III (Table 9.1 ).8,25.28 There is 
wider variation in the distribution of stage I and IV between studies. Stage I generally 
accounts for between 4% and 14% of colorectal patients,8,25.28 which was consistent 
with this study (11%). 
Ilospital-bascd audits generally found a higher proportion of patients with advanced 
disease, probably because patients had more thorough assessment for curative treatment. 
Additionally, patients with early-stage cancers may be treated at non-specialist centres 
where hospital-based audits rarely occur. In particular, one study found 27% of patients 
with stage IV, but this was a hospital audit of patients receiving adjuvant therapy and 
therefore biased as described above.28 The proportion of patients in stage IV at 5% (2% 
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in original data) was lower in this study than other studies. This is attributed to the 
application of the standard exclusion used in survival analyses; to exclude patients 
without a date of diagnosis (death certificate only). 'Death certificate only' (DCO)m 
patients generally had a poor prognosis, most likely because of advanced stage. Death 
certificate only patients accounted for 2.8% of all patients, which would make the 
estimated proportion of patients diagnosed in advanced stage (7.8%) consistent with 
other population-based studies (ranging from 4% to 21%).8.25.28 Additionally, 
population-based studies had lower proportions of advanced stage because when staging 
is done by imaging or from inadequate pathological specimens, stage tends to be 
underestimated.26 This is more likely to occur in population-based data because they 
include patients who do not receive curative treatment. Despite the lower proportion of 
stage IV patients in this study, the stage-specific survival is consistent with other 
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Figure 9.3: Stage-specific survival up to five years after diagnosis for the North 
West of England 1997 to 2004 and Survival and Epidemiology End Results 
(SEER), USA, 1998 to 2002 
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Table 9.1: Distribution (%) of stage at diagnosis for selected studies of colorectal, 
colon and rectal cancer in population-based or large hospital-based audits. 
Stage 
II III IV unknown 
Colorectal 
This study· No rth West of England, population-based, 1997-
2004 (n=29,563) 
Original data 7 25 26 2 40 
After imputation 11 38 47 5 
Tilney et al. 2006 England-wide surgical audi t (NBOCAP), 2005 . 14 36 32 18 
KeJsal el al. in press Melbome, Australia, nested cohort study (Melbome 23 28 28 17 3 
Collaborative cohort study) 1990-1994 (n=526) 
Nur et al. 2008 England and Wales, Clinical trial of adjuvant 12 39 31 8 10 
radiotherapy and chemotherapy (5-FU), 1996-97 
(n= 2,48 1) 
Brcwsteretal. 2001 Scotland, case-note audit, 1993 (n=2,778) 9 34 23 21 13 
Munro et al. 2004 Dundee, Scot land, hospital-based audit, 1997- 1999 4 25 43 27 
(n=483) 
Ciccolallo el al. 2004 USA & Europe, but will present the UK data avai lible, 
1990-91 
Mersey and Cheshi re region, case-note audit, (n=207) II 29 23 23 14 
Thames region case-note audit, (n= 176) 12 30 24 23 II 
Colon 
Jestin el al. 2005 Uppsala region, Sweden, audit of rescected patients 12 42 31 15 
bass:d OD I:lIDm [!:l!iSI[Y dala 1221-2002 ([)=) 13 5) 
Recta l 
Morri s el al. 2008 England-wide population-based, 1998 to 2004 17 24 30 4 26 
(n=3 1 ,223~ 
Comorbidity and lifestyle factors 
Comorbidity in colorectal cancer patients was associated with poor survival. After 
adjustment, comorbidity explained very little of the deprivation gap in survival. The 
prevalence of comorbid conditions was higher in patients who were deprived, older and 
at an advanced stage, each of these being independently associated with poor survival. 
The severity and number of comorbid conditions was particularly associated with 
increasing age, both in this and other studies. IO,30-34 omorbid conditions reduced 
clinical eligibility for certain treatments and increased the complexity of treatment 
particularly surgery, and are consequently associated with lower urvival31 and horter 
life expectancy after diagnosis.35 
Increa ing levels f c morbidity were associated with a higher excess hazard ratio of 
death in the fir t year after a colorectal cancer diagnosi , especially when comorbid 
conditi n occurred with 18 to 6 month before colorectal cancer diagnosis. After 
adju tment ~ r age, deprivation, stage and duration of follow-up, the excess hazard ratio 
at one year after diagnosi was slightly higher for a given Ie el of the har! on measure 
than th hali mea ure. The har! on comorbidity mea ure identified more comorbid 
c nditi n and had a stronger association with the exce s hazard ratio at one year 
despite the comorbid conditions in Iha li being a subset f the harl on. Additional 
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conditions, such as chronic pulmonary disease, liver disease, previous cancer, that are 
included in the Charlson measure improved its association with survival. 
The use of administrative databases to derive the data for measures of comorbidity 
introduces many limitations and challenges, particularly relating to the lack of specific 
data (e.g. complication of cancer treatment), accuracy of clinical coding and system or 
coding changes over time. Although HES data quality and accuracy have been 
questioned, comparisons with audit data36,37 have found they produce representative and 
comparable results for post-operative mortality following cardiac, bowel cancer or 
abdominal aortic aneurysm surgery, and surgical volume for bowel cancer. Some gaps 
in completeness remain, particularly at individual Trust level. For example, in some 
records only the acute care trust of treatment was recorded, rather than the specific 
hospital (e.g. Pennine acute trust, rather than one of the four specific hospitals within it). 
The prevalence of previous tumours and metastatic tumours in this research obtained 
from registry data was consistent with other studies,IO,34 whilst HES data overestimated, 
this possibly due to recording of suspected cancer (e.g. suspected stomach later 
determined to be colorectal). liES may be very good at recording illnesses that are 
contra-indicators for treatment. For example Ischemic Heart Disease is a contra-
indicator for some chemotherapy treatments and was detected in 7% of colorectal 
cancer patients. Hospital administrative databases undoubtedly under-estimate the 
frequency of diseases which do not normally require hospital treatment, such as diabetes 
without complications. Alternatively, liES may not record when patients have other 
common chronic conditions, such as obesity, In this study, for example, the prevalence 
of obesity recorded in lIES data was 0.4% in colorectal patients, compared with a 
population prevalence of 24% for men and 36% for women during 2003 in the North 
West of England.38 
Co-occurrence of colorectal cancer with other conditions, such as heart disease, 
pulmonary disease and diabetes, is to be expected, because they share some 
environmental and lifestyle risk factors,39 Cardiovascular disease, chronic obstructive 
pulmonary disease (COPD), hypertension, diabetes and one or more previous cancers 
have been consistently identified in other studies as the most frequent comorbid 
conditions among the colorectal cancer patients, regardless of the methods used in the 
study,I0.3J.3,,4o In particular, cardiovascular disease and COPD significantly affected 
survival.32,34,J,,40 The frequency of comorbidity observed in this study, was lower than 
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In many clinical studies, but it was consistent with other population-based 
studies. 10,28,30,32,34 
With the exception of diabetes and chronic obstructive pulmonary disease, the 
prevalence of specific comorbid conditions was similar, to a population-based study of 
comorbidity (using medicare claims) in colorectal cancer patients aged over 66 without 
missing data on stage (I-IV) and diagnosed in the USA between 1992-1996.40 The 
prevalence of diabetes among the general population in England at 3.3%,41 was 
comparable to the prevalence of2.9% for colorectal patients in this study (diabetes with 
complications 2.7%; diabetes without complications 0.2%). In contrast, the US 
comorbidity study in colorectal cancer patients found the prevalence of diabetes with 
complications to be 6.4% in men and 5.4% in women (diabetes without complication 
0.6% for both men and women) but this may be partially explained by the study 
selection criteria, which excluded patients under the age of 66, those with unusual 
histology and with missing data on stage. The prevalence of chronic obstructive 
pulmonary disease was estimated to be between 4% and 10% based on an international 
meta-analysis.42 This range of COPD prevalence is consistent with the prevalence 
observed in the present study for colorectal cancer patients in North West of England 
(7.9%). It is unclear whether differences in risk factors or health systems might explain 
these differences. One hypothesis is that patients in the USA receive more thorough 
assessments and treatment, particularly in the case of those likely to require surgical 
procedures.25 
There is increasing evidence that lifestyle choices may improve survival and decrease 
recurrence for cancer patients.43-45 Studies of the influence of lifestyle choices on 
colorectal cancer have mainly focused on lifestyle choices and recurrence, although it 
may logically follow that lower recurrence rates are likely to improve survival. Whilst 
comorbidity was measured and adjusted for in the present study, data on lifestyle 
choices and general health were not available. Adverse lifestyle factors, such as 
smoking, obesity, poor diet and low levels of exercise38 are all consistently more 
common in deprived communities. All of them are negative prognostic factors for 
diagnostic procedures, treatment options and survival; both through poorer general 
health and specific comorbid conditions. A high body mass index (BMI) has been 
associated with poorer prognosis after adjuvant therapy.46 Low levels of exercise and a 
diet high in red meat and fat, and low in vegetables, have been associated with lower 
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survival for colon and colorectal cancers but not for rectal cancer.47 Taken together the 
increased risk of poor diet, low levels of exercise and obesity put deprived patients at a 
further disadvantage, with deprived patients less likely to improve these factors after 
diagnosis. 
In cancer patients, smoking significantly increases post-operative mortality, and the risk 
of complications.48,49 Prevalence of smoking is higher among deprived socioeconomic 
groups and in manual occupations, although smoking has recently become less common 
in the these groups, particularly since the introduction of the smoking ban in England in 
2008.50 The higher smoking prevalence among deprived patients could substantially 
contribute to post-operative mortality and in tum influence inequalities at both one year 
(and possibly five years). It is unclear how much of the socioeconomic inequalities in 
post-operative mortality could be explained by variations in smoking. Quitting smoking, 
even after a cancer diagnosis, could well improve survival. 
Tumour biology and genetics 
There were no socioeconomic variations in the distribution of grade or histology at 
diagnosis. Patients diagnosed with a non-specific subsite or non-specific morphology 
had a poorer prognosis than others, while adenocarcimoma was associated with a better 
prognosis. Socioeconomic inequalities in survival occurred for both adenocarcinomas 
and mucinous and serous histological types (EHR at one year: 1.32, and 1.40, 
respectively), but socioeconomic inequalities in grade narrowed with increasing grade 
(EUR at one year: 1.37 to 1.32). A study of colorectal cancer survival differences in 
Europe and the USA found that adjustment for morphology partially explained 
variations in survivaLS I However, as in the present study of the North West of England, 
the European cancer registries had a significantly higher proportion of patients with 
unspecified subsite (10%) and morphology (15%) than the USA (North West of 
England: 13.9% and 11.6%, respectively). Higher proportions of patients with specific 
histology and subsite might be because of the higher proportion of colorectal patients 
receiving surgery in the US.S2 In order to detect the small differences in survival implied 
by variations in histology large scale studies scale studies such as these (Europe 
n= 151 ,244; USA n=53,884) were required. 
Biological differences in invasive breast cancer between socioeconomic groups have 
been recorded, such as lower oestrogen receptor status in deprived women,S3 but there 
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has been no evidence of biological differences for colorectal cancer. A number of 
inherited or acquired genetic abnonnalities are associated with colorectal cancer in 
particular ethnic groupS.54,55 In order for these to affect socioeconomic survival the 
genetic abnonnalities would need to influence survival and the ethnic group would also 
have to be strongly associated with socioeconomic status, both of which may occur. A 
recent study found that colorectal cancers in African Americans had higher levels of 
microsatellite instability.56 There is some evidence that cancers with microsatellite 
instability are less likely to respond to fluorouracil-based chemotherapy. 57 There is still 
too little infonnation on genetic abnonnalities and survival to assess the magnitude of 
these genetic and ethnic relationships, although the impact on socioeconomic variations 
in survival is probably very small. 
Access to treatment 
Socioeconomic variations in treatment regIme and the quality of surgery partially 
explain socioeconomic inequalities in survival. Deprived patients received less 
adjuvant chemotherapy and/or radiotherapy than affluent patients. Increasing 
deprivation was associated with surgical procedures that were conducted by less 
experienced surgeons (low-volume surgeons). Receipt of sub-optimal surgery was also 
associated with increasing deprivation; deprived patients were more likely to receive 
Hartman's procedure and less likely to receive anterior resection than affluent patients. 
If different socioeconomic groups are diagnosed at the same stage and level of 
comorbidity, why do they receive different treatment? Factors related to the patient, the 
treating physician and the health service may each influence the treatment regime 
received by the patient. Even after adjusting for the major patient influences on 
treatment (age, stage, comorbidity, subsite), substantial socioeconomic differences in 
treatment remained. Patient factors may still explain some of the socioeconomic 
variation, but it is unlikely that they alone can explain the large magnitude of 
inequalities. Deprived patients may be more likely to have other factors making them 
less likely to take-up treatment or attend treatment appointments. Lower levels of 
education may decrease the ability to play an active role in treatment planning and 
increase apprehension. Additionally, incomplete or outdated knowledge of cancer 
prognosis would result in an expectation of a poor outcome. Despite treatment being 
free incidental costs (e.g. transportation, time off work) may influence receive 
radiotherapy and chemotherapy and/or adhere to the full regime. The fundamental cause 
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theory summarises the influence of patient factors on inequalities and highlights the 
greater ability affluent patients may have to obtain psychological and physical resources 
to request and obtain optimal treatment (see page 226). These factors are outside of the 
direct control of clinicians and health service control but would be expected to decrease 
the proportion of deprived patients receiving treatment. 
Affluent patients may benefit from fewer comorbid conditions, thereby influencing the 
treatment, but even after adjusting for comorbidity there were still socioeconomic 
variations in treatment. The comorbidity measure may under-represent illness, 
particularly diseases that do not require hospital admission, but this under-estimation is 
not likely to be biased by socioeconomic status. Clinical treatment plans must take into 
account the whole person, including non-quantifiable factors. Even a small bias toward 
less than optimal treatment regimes for deprived patients based on the perceived 
presence of risk factors for outcome (e.g. poorer general health) may result In a 
substantial contribution to systematic socioeconomic differences in treatment. 
Chemotherapy 
Inequitable access to chemotherapy, known in the popular media as the 'postcode 
lottery' is a controversial issue in the UK. Increased use of adjuvant therapy for stage III 
tumours has occurred over the past decade,58 contributing to improvements in colorectal 
cancer survival during the 1990s and early 2000s. There was a slight increase in the 
proportion of stage III patients in the North West treated with adjuvant chemotherapy 
(either before or after surgery), from 11.4% in 1997 to 12.7% in 2004 (data not shown). 
The proportion of stage III patients receiving adjuvant chemotherapy increased for 
affluent patients between 1997 and 2004, but not for deprived patients (data not shown). 
It is not clear if these temporal changes may be explained by other factors (stage, 
comorbitity) but is a further example of highlight differential treatment by 
socioeconomic groups. Other countries have seen greater improvement in adjuvant 
therapy than in the England, partially explaining the lower colorectal cancer survival in 
England.59 In a population-based study of colorectal cancer patients in the Cote-d'Or 
region, France, the proportion of patients receiving adjuvant chemotherapy for stage 1111 
cancers increased from 0.8% in 1976-1987 to 6.4% in 1988-1999, and for stage III 
cancers from 3.9% to 27.7%.58 Centralisation of diagnostic and treatment services can 
ensure consistent provision of adjuvant therapy. In Scotland, a study of adjuvant therapy 
between 1992 and 1996 found patients admitted to a non-cancer centre were half as 
243 
likely to receive adjuvant therapy than if they were treated at a specialist centre.21 Since 
this study a number of policies including the Calmine-Hine report,60 the NHS Cancer 
Plan 200061 and the most recent Cancer Reform Strategy 2007,62 have improved access 
to cancer treatment and further centralised cancer services. The introduction of 
multidisciplinary team meetings has resulted in most patients benefiting from specialist 
clinical oncology. However, it is clear that there are still socioeconomic disparities in 
access to chemotherapy. 
Chemotherapy toxicity, or adverse effects associated with chemotherapy treatment, 
influences a patient's likelihood of completing a chemotherapy regime. Adherence to 
chemotherapy treatment would also be influenced by patient factors, such as 
transportation, ability to obtain time off work, and general health. The impact of other 
influences, such as diet, vitamins, positive attitude and fitness, is less tangible, although 
it is plausible that they could influence adherence to treatment. Cancer registry and HES 
information on chemotherapy treatment was not detailed enough to determine either the 
duration of chemotherapy or its timing in relation to surgery (before or after surgery) 
which is strongly related to both stage and outcome. Patients receiving at least one 
chemotherapy treatment were designated as having had chemotherapy. As a result. it 
would be expected that some patients would not complete their full chemotherapy 
regime, due to side-effects or complications. There is little evidence of socioeconomic 
variations in adherence and completion of chemotherapy. A population-based study of 
women with breast cancer in the US between 1998 and 2002 found that adverse events 
were more likely in women from lower socioeconomic groupS.63 Lower adherence 
among women from lower socioeconomic groups was attributed to their poorer general 
health. No variations in chemotherapy toxicity have been found for other patient 
characteristics, such as ethnicity64 or age6's. Socioeconomic variations in chemotherapy 
toxicity and adherence remain an area for further research. 
Surgery type and quality 
Over the past decade, rectal cancer survival has improved more rapidly than for colon 
cancer, mainly due to improvements in surgical techniques. Notable improvements to 
the quality of treatment in the 1990s and 2000s include the introduction of the 
multidisciplinary team approach, increasing specialisation of cancer surgeons, the 
introduction of laparoscopic surgery and the introduction of total mesorectal excision 
(TME) for rectal cancer. Anterior resection (AR) is the type of surgery for which TME 
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is a specific technique. Unfortunately, TME is not specifically coded for in HES or 
cancer registry data. An England-wide study of rectal cancer surgical patients found that 
the use of AR increased between 1998 to 2004, and coincided with decreased use of 
abdominoperineal excision (APE) and Hartman's procedure.8 The England-wide trend 
reflect the patterns seen in this study, with larger shifts toward the use of AR in affluent 
than deprived patients (17.5% and 14.6%, respectively). Similarly, in both England and 
the North West, patients were less likely to receive anterior resection if they were 
treated at a low-volume hospital or by a low-volume surgeon (data not shown). Trends 
toward centralisation of services and increased use of anterior resection probably reflect 
the introduction of multidisciplinary team meetings (MDT). MDT meetings currently 
discuss most patients and ensure specialist oncology input into treatment plans from a 
range of specialities (surgery, medical oncology, specialist nurse). A large cancer-
registry based study in California found that rectal cancer patients having their surgery 
at high-volume hospitals were less likely to have had colostomy, and had better 
survival, than patients treated at other hospitals.66 A lower proportion of anterior 
resections would be expected at low-volume hospitals and by low-volume surgeons, 
because a higher proportion of these patients will receive non-curative and emergency 
surgery. Despite this, there were still a substantial proportion of patients receiving 
surgery, particularly anterior resection, at low-volume hospitals and by low-volume 
surgeons. Poorer survival among low-volume surgeons and low-volume hospitals is a 
concern for all colorectal cancer surgeries, but particularly for anterior resection (and 
TME) for which specialist training and teams are necessary to achieve satisfactory 
surgical results. 
Despite equitable access to surgery, in analysis of data after imputation (affluent 89.5% 
and deprived 87.8%) it is clear there were still socioeconomic variations in the type and 
quality of surgery. Deprived colorectal cancer patients may be more likely to receive 
emergency surgery for which outcomes are worse than affluent patients.8,67 
Socioeconomic inequalities in the type of surgery, either emergency or elective, may 
explain some of the inequalities in outcome. Adjustment for stage (imputed) should 
have taken into account some, although not all, of the late stage at presentation. Patients 
presenting as an emergency could be more likely to have blockages which are more 
common in later stages but can occur at any stage, or due to complications. 
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Annual hospital case-load and surgeon case-load may not be the ideal measure to 
evaluate hospital or surgeon patient care, because they may not correlate precisely with 
the quality of patient care.66 For example, there may be some very good small surgical 
units that are categorised along side other low-volume, but poorer-performing, 
hospitals. In the absence of patient level quality of care data, hospital and surgeon 
volume provides a reasonable estimate of a surgeons experience and a hospitals peri-
operative care. High-volume hospital and surgeon volume has been associated with 
better survival after colorectal cancer surgery in many studies66,68,69 although not all.70,71 
Reductions in socioeconomic variation in the type of operation that a patient receives 
could be achieved through further centralising treatment in specialised or high-volume 
centres,66 thus enabling more equitable access to state-of-the-art treatment (key-hole 
surgery, TME).72 Even within specialist centres, it is important to ensure that services 
are equitable, because variations in treatment type and quality are known to vary within 
a given hospitaL73 In this research even at very high-volume hospitals, colorectal cancer 
surgery was conducted by low-volume surgeons in 37.9% of surgeries. Concentrating 
services may not be possible in all geographies due to logistic' barriers66 but in most 
Cancer Networks in the UK, it should be achievable. 
Survival for elderly cancer patients in the UK has improved, but it remains below that 
seen in Europe.74 Despite increasing evidence that elderly patients do not have higher 
chemotherapy toxicity or surgical complication rates,6S they are substantially less likely 
to receive surgery and chemotherapy.s8 In the North West of England the proportion of 
patients aged 15 to 44 receiving chemotherapy was 73.0% and decreased to 17.2% for 
patients aged 85 to 99 (Odds ratio after adjustment 0.09). Increasing age was associated 
with higher levels and severity of comorbid conditions, and with lower survival in the 
North West of England. Even after adjusting for age and comorbidity older patients 
were less likely to receive chemotherapy or radiotherapy treatment (Odds ratio for 
patients aged 85 to 99 after adjustment 0.09 and 0.09, respectively). In other countries, 
colorectal cancer survival among older patients is much higher than in the UK, raising 
the question of whether there is some ageism in treating older patients in the UK. 
Treatment benefits and survival 
Why do deprived patients have lower survival than affluent patients when they are 
receiving equivalent treatment? In the UK, a randomised controlled trial of 
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chemotherapy and radiotherapy for colorectal cancer patients diagnosed between 1989 
and 1997 found relative survival at five years was the same across all stage, comorbidity 
and age,75 but they also ensure consistent and optimal treatment for all patients. Most of 
the population-based research on inequalities in survival and treatment has been done in 
the USA, where Medicare databases provide complete treatment data. Clinical trials of 
survival by ethnic group, which is closely associated with socioeconomic status, have 
also found that where there is equal access to treatment, the outcomes are similar.76 
Conversely, population-based studies generally find differences in colorectal cancer 
survival by socioeconomic status (or ethnicity) when patients receive equivalent 
treatment or after adjusting for treatment.77•77-79 
Taken together these, studies suggest that the factors associated with inequalities in 
survival are eliminated in clinical trials, either because of entry criteria (selection) or the 
consistency of optimal treatment. Furthermore, the similarity of survival by 
socioeconomic group in clinical trials suggests that once treatment is received (when 
clinically appropriate), survival is similar in all socioeconomic groups. Ultimately, there 
is a balance to be met to encourage optimal treatment, whist ensuring over-treatment 
does not occur. 
Greater hospital and surgeon specialisation have been associated with a lower 
probability of recurrence and better outcomes for colorectal cancer.66•80 Poorer 
outcomes for patients treated by low-volume surgeons and low-volume hospitals could 
be attributed to case-mix. However, socioeconomic inequalities in survival were found 
at each level of case-load for hospital or surgeon volume, therefore adjustment did not 
explain socioeconomic inequalities in survival. Post-operative (30-day) mortality was 
higher for low-volume hospitals and surgeons (9.8%, 10.2%), probably because patients 
in those settings were more likely to be emergency admissions treated at low-volume 
hospitals or by low-volume surgeons. Emergency colorectal cancer surgery is associated 
with advanced disease and bowel obstruction.BI Even after adjustment for stage, which 
should account for much of the impact of emergency treatment on survival, and for 
comorbidity, low-volume hospitals and low-volume surgeons had lower one year and 
five-year conditional survival. This might suggest that case-mix accounted for some of 
the excess mortality, whilst surgical type and quality accounted for some. Deprived 
patients were more likely to have their surgery with a low-volume surgeon, probably 
either by a low-volume trainee at a high- volume hospital or by a general surgeon at a 
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low-volume hospital. Temporal patterns of referral and treatment may explain some 
socioeconomic disparity in survival, particularly if deprived patients have more delays 
(and longer time). Socioeconomic differences in referral patterns and delay in treatment 
would be an area of further research. 
Private treatment had very little influence on socioeconomic inequalities, because only 
2% of patients were treated in the private sector. Relative survival was higher for 
private patients, although it was only significantly higher for colon cancer patients in 
the first year after diagnosis. Private patients were a highly biased group: on average 
younger, and with earlier stage than NHS treated patients. Most private patients 
received surgery alone (79%) from a moderate-volume NHS surgeon, probably because 
some surgeons also work both privately and in the NHS. This is an advantage for 
private patients, because the surgeons experience and training will be maintained by a 
sufficient range of complexity and volume of surgeries, which would not be available if 
they operated only in the private sector. 
Ideally, ensuring that surgical treatment is optimal for all socioeconomic groups should 
improve survival for all patients and reduce socioeconomic inequalities in survival. In 
reality, however there are complex socia], resource and health mechanisms which make 
this unlikely. Support and treatment targeted at deprived patients may be the only way 
to reduce inequalities in survival, although these would be difficult to implement. 
Ilealth promotion programmes aimed at the more deprived patients to improve health 
awareness, decrease obesity and smoking prevalence, and to improve general health 
could also decrease inequalities, and comorbidity prior to colorectal cancer diagnosis. 
Compliance with guidance: access and benefit 
Ana]ysis of whether the treatment received was in accordance with clinical guidance 
was necessarily crude. It was intended as an alternative evaluation of treatment quality, 
rather than a 'true' reflection of the application of guidance. Receiving treatment in 
accordance with clinica] guidelines is the idea] but individual patient characteristics that 
could not be measured in this study may influence treatment options (e.g. patient 
choice, lifestyle), making evaluation of the impact of guidance more complex. Even in 
this simplistic analysis, however treatment in accordance with guidance identified 
striking patterns of disparity. Treatment that was compliant with guidance for both 
colon and rectal cancer patients was progressively less received with increasing 
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deprivation and age. Higher hospital and surgeon volume was associated with higher 
levels of treatment in accordance with guidance. Despite being treated in compliance 
with clinical guidance, there were socioeconomic gaps in survival for both colon and 
rectal cancer at one year (EHR 1.41 and 1.41). After the first year of diagnosis the 
socioeconomic inequalities in survival reduced but persisted for colon but not for rectal 
cancer (EHR 1.22 and 1.11, respectively). 
Patients in stage II were most likely to be treated in compliance with clinical guidance 
for both colon and rectal cancers (96.0%, 97.4%). This may reflect the lower 
invasiveness of surgery and better general prognosis which could encourage higher 
levels of active treatment. Alternatively, it may be a artefact of the broad range of 
treatment regimes clinically appropriate for stage II cancers (e.g. surgery alone, surgery 
and adjuvant therapy). 
The possible reasons for the wide socioeconomic inequalities in survival for patients 
receiving treatment compliant with clinical guidance mainly relate to treatment type and 
quality or to external factors (e.g. general health). The inequalities in survival and 
access for patients who received treatment in compliance with clinical guidance is 
comparable to those identified in the evaluation of treatment regimes. It is clear that 
affluent patients receive surgery from higher-volume surgeons and optimal types of 
surgery than deprived patients, which could contribute to inequalities in survival by 
treatment regime and clinical guidance. Furthermore if similar type and quality of 
treatment was received by each socioeconomic group very narrow socioeconomic 
inequality in survival would be expected, as has been achieved in clinical trials.82 
Whilst, the influence of external factors and means to address these have been described 
previously. 
Future and screening 
Improvements in colorectal cancer survival since the mid-1990s have been attributed to 
better surgical techniques, post-operative care and adjuvant therapy. In the next decade, 
survival is likely to improve further with increased use of laparoscopic (key-hole) 
surgery. Deprived patients in the North West were less likely to receive treatment in 
accordance with guidance and optimal treatment. If inequitable access to the most 
modem treatment regimes persists, socioeconomic inequalities in survival are likely to 
occur in the future.6o.s3 
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Lower up-take of colorectal screening among the deprived than the affluent is evident in 
the UK piIot84 and the North West colorectal screening programmes.85 The national 
colorectal screening programme for 60 to 69 year olds, based on the faecal occult blood 
test (FOB), began in April 2006 and will achieve national coverage by 2009. 
Merseyside and Cheshire was one of the first regions to begin screening in 2006 
(achieving regional coverage in 2008). So far screening has detected 292 cancers with 
50% in stage I (as at 3 Nov 2008). However, there are large socioeconomic variations in 
FOB up-take, from 28% in deprived areas to 60-70% in wealthy areas. Variations in the 
socioeconomic up-take of population-based breast cancer screening programmes have 
resulted in increases in inequalities in survival in Eindhoven, Netherlands86 but a 
narrowing occurred in Scotland.87 Mammographic screening up take rates are much 
higher (up to 76%)86.88 and show less variation between deprived and affluent areas 
(58% to 80%) than in the Merseyside and Cheshire colorectal screening programme. 
Such large inequalities in FOB up take are likely to widen inequalities in survival 
among the screening age group, and the 70 to 79 age group at least in the period 
immediately after the introduction of screening. 
In the absence of screening, the deprivation gap in five-year relative survival for the 
North West is expected to increase from 7.7% of patients diagnosed in 1997-99 to 9.2% 
of patients diagnosed in 2003-05 (Figure 9.3). The initial analysis plan for this research 
included evaluation of time trends, developing methods for excess hazard models for 
the hybrid survival approach, and future estimates of survival, but shifted toward more 
in depth analysis of treatment patterns. Brief hybrid survival estimates are presented 
here in order to support hypothesis about future socioeconomic inequalities in survival. 
Estimates for patients diagnosed during 2003-05 were based on the hybrid approach 
(with follow-up to 2007).89 Improvements in surgery and adjuvant therapy may 
continue to improve survival for all socioeconomic groups but the largest increases in 
five-year relative survival will occur in the affluent, improving from 52% in 1997-99 to 
58% in 2003-05 (from deprived 44.7% in 1997-1999 to 49% in 2003-2005) in the 
deprived. Even ten years after diagnosis, a deprivation gap of 7% was predicted for 
patients diagnosed between 2003 and 2005 (based on hybrid relative survival approach). 
The socioeconomic inequalities in survival in the North West are similar to those 
expected for England for the same time periods.2·90 
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Figure 9.3: Relative survival at 5 years by period of diagnosis (cohort survival for 
1997-2002, hybrid survival approach 2003-07), colorectal cancer, North West of 
England 
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Limitations to the interpretabi lity of this research and to its generalisability, have been 
addressed throughout the discussion. The following remarks will focus solely on data 
limitations. Demographic and diagnostic information held by cancer registries is 
generally very robust and complete, but information on stage, grade and treatment is 
less complete, particularly for older patients. 12,91 For example, increasing age was 
associated wi th a higher proportion of Death Certificate Only (DCO) registrations in 
cancer registry data. The lack of a diagnosis date ( r record of treatment) has been 
attributed both t lower level of treatment and to incomplete registry data.91 xclusion 
f 0 regi trations and age adjustment within survival analysis can decrease but not 
remove the inOuence f age-specific differences in under-ascertainment.92 The number 
and pr porti n f DC ca e has been decreasing since the mid 1990s because of 
impr ved collection and linkage of treatment and death data (improved I and database 
capabi lities). In the early 2000s receipt of palliative care data decreased the number of 
regi trations in the N rth West of ~ ngland cancer registry WI). 
In order t impr ve the c mpletene s of treatment information, cancer registry and H 
dat w re linked thereby achie ing a linkage fI r 82% of c I rectal cancer patient. 
ompl te linkage (1 0%) b tween H and cancer regi try data i unreali tic becau e 
f mi ing dem graphic information, particularly NH number in H ~ . Demographic 
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information was generally less complete in HES, but it has been improving with time, 
probably because of improvements in training and knowledge of clinical coding 
personnel, improvements in information technology and emphasis on measuring activity 
through HES (and its precursor, the patient administration system). The overall linkage 
of 82% achieved in this study was similar to that achieved in other studies of testis and 
prostate cancer in London and South West England (63%),93 teenagers and young adults 
in England (86%),94 and rectal cancer patients undergoing abdominoperineal excision in 
England (92%).8 Cancer patients who could not be linked to HES included both those 
with incomplete demographic information and patients who did not attend hospital. 
The method of multiple imputation was used to provide a dataset for analysis with 
estimates of the missing data, particularly for stage and treatment data. Imputation is a 
widely used method for handling datasets with missing data in order to improve the 
interpretability of results,95.99 although survival analysis was rarely been done with 
imputed data.82,96 Imputation requires assumptions about the mechanism of missingness 
and the patterns and associations of missingness. For cancer registry data, the variables 
associated with missing stage and treatment are well documented I 2,9 I ,100, 10 I providing 
support to the assumption that the mechanism of missing data was Missing at Random 
assumption (MAR), but it is not possible to test these assumptions. Most variables with 
missing data generally had a moderate level of missing data (10% to 40%), but the 
proportion of patients with missing chemotherapy data was high (63%). Whilst this is 
far from ideal, the imputation method appeared to manage these missing data for 
chemotherapy well, resulting in logical overall analyses consistent with other 
studies,8.66.102 probably because of the close association between chemotherapy and 
stage. Overall, the improvement of data completeness by linkage to lIES and multiple 
imputation appears to have adequately managed missing data. 
Obtaining complete treatment information would enable more detailed analysis and 
useful conclusions. Information on the type of chemotherapy regime (neo-adjuvantly, 
adjuvantly and adherence) and surgical intent (curative, palliative, emergency, elective) 
would be invaluable in disentangling inequalities in treatment and survival. While 
cancer treatment information is increasingly being obtained from liES or Cancer 
registry data (but rarely both) this does not provide the detailed information necessary 
for analysis of surgical intent and chemotherapy regime. It is very difficult to obtain this 
information in a standard and comparable format from multiple hospitals however there 
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are currently a number of initiatives to improve data completeness and quality. The 
main limitation is obtaining timely treatment information in electronic format with 
consistent information from all trusts. This is being addressed by i) mandating 
electronic data provision ii) collection of data at MDT through real time computer 
systems. It will take a few years before this dataset will be complete. 
Geographic (ecological) measures of socioeconomic status will always result in some 
misclassification of individuals because one socioeconomic status may not be 
representative of all individuals living in that geography, commonly known as the 
'ecological fallacy'. This would result in attenuation of socioeconomic gradients in 
survival, thus raising or lowering the socioeconomic-specific survival. Additionally, 
exposure to risk factors for colorectal cancer may also occur decades before diagnosis 
and at a time when the patient was in another socioeconomic group (and geography). 
However, any temporal shifts probably have a small influence, because of the strong 
association between socioeconomic status and cancer incidence. The use of geographic 
measures of socioeconomic status is a practical choice for epidemiological studies and 
measures are generally consistent over time. 103 
Summary 
This research appears to be the first population-based analysis of inequalities in 
colorectal cancer with complete stage and treatment information obtained through a 
combination of both multiple data sources and multiple imputation. This unique 
analysis highlighted the less than optimal outcomes and survival in deprived patients 
compared to affluent. 
Colorectal cancer treatment and survival is improving, but deprived patients continue to 
have less than optimal treatment and worse survival than affluent patients. Deprived 
patients appear to have higher levels of factors that may limit their treatment options, 
such as comorbid conditions. Even after taking these factors into account, however 
deprived patients still received less optimal treatment (e.g. less adjuvant therapy). The 
factors contributing to these inequalities in treatment are complex including physical, 
social, lifestyle and clinical domains. The most effective way to reduce socioeconomic 
disparities in treatment and survival may be targeted health programmes aimed at 
mandating optimal treatment for all patients rather than preferential treatment for 
deprived patients. 
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How could socioeconomic inequalities in survival be reduced?: recommendations 
for policy and service developments 
The socioeconomic variations in surgery type and adjuvant therapy reported above 
could not be explained by clinical or demographic factors. Initiatives to encourage 
equality of treatment are probably the only way to reduce socioeconomic variations in 
treatment, and ultimately socioeconomic inequalities in survival. Policies to ensure that 
deprived patients receive optimal treatment, possibly through systems that required 
justification of treatment plans that were not in accordance with clinical guidance could 
reduce socioeconomic inequalities. Centralisation of services and the implementation of 
the current clinical guidance have improved survival, but have not reduced inequalities 
in treatment or survival. Requiring justification of exceptions to optimal treatment and 
clinical guidance would ensure all patients are receiving optimal treatment, except when 
not clinically appropriate. Entering a higher proportion of deprived patients in clinical 
trials may also narrow inequalities and ensure consistent optimal treatment. However, 
any increases in entry to clinical trials may occur more rapidly in affluent patients. 
Furthermore, inclusion criteria (particularly comorbidity) may mean higher proportions 
of affluent than deprived patients are eligible for entry. Despite the difficulties 
increasing the proportion of deprived patients in clinical trials may narrow inequalities 
because there were no socioeconomic inequalities in survival for colorectal cancer 
patients treated in clinical trials. Further studies would be helpful in supporting policy 
development, particularly detailed evaluations of treatment type and quality, specifically 
with details on chemotherapy toxicity, adherence, type of surgery and complications. 
Delays in access to treatment within the patient pathway should be investigated. 
Deprived patients were more likely than affluent patients to receive surgery from a low-
volume surgeon. It is likely that most of the surgery by low-volume surgeons is 
emergency surgery, highlighting the need for greater symptom awareness and earlier 
stage at diagnosis among deprived patients. Symptom awareness may be improved 
through general health campaigns (e.g. 'five a day') and the bowel screening 
programme, but further effort is probably needed to target deprived communities. 
Patient- or system-led delays in the patient pathway may contribute to delays in 
diagnosis, increased levels of complication and decreased adherence to treatment 
regime. Reducing delays could be a relatively simple way to improve the timeliness of 
treatment: although this is of benefit to the individual patient, the impact (if any) on 
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population-based survival remains unquantified. From the data available, it is not 
possible to evaluate patient pathways or referral patterns to determine if there were 
socioeconomic variations in referral to a specialists or delays. For deprived patients the 
referral pathway (and any delays) is of particular importance to treatment at a specialist 
hospital, but more importantly by a high-volume surgeon. 
Further analysis of patients pathways is possible if the data quality and completeness of 
treatment and staging information is improved. There is strong support from clinician 
groups to collect detailed treatment information (e.g. emergency surgery, curative 
surgery, neo-adjuvant and adjuvant therapy) but in order for large population based 
studies to be conducted this data must be consistent across all trusts and in an electronic 
format. The cancer reform strategy62 mandated data provision of electronic by trusts to 
cancer registries by 2011 but did not clearly define the completeness of submissions. 
Many trusts are making good progress towards submitting but the information is 
frequently incomplete. For example a submission might include the name and address 
of a patient seen at MDT but no information on treatment plan, or stage. In order to 
collect detailed treatment information clear targets and resources must be applied with 
the support of clinical groups. Regular and timely feedback also be done to ensure 
continued interest. 
The introduction of population-based screening may Increase inequalities, at least 
temporarily, through earlier stage at diagnosis in affluent rather than deprived patients. 
Affluent people were at least 10% more likely to complete and return the Faecal Occult 
Blood test.S4,8S Although, population-based bowel screening is currently limited to 60-
69 year olds, (with over 70s upon request) screening will influence both the incidence 
and mortality rates in older age groups, because cancers are detected earlier in a 
younger age group. Initiatives to increase the proportion of deprived people completing 
the FOB are vital to restrict this probable widening of socioeconomic inequalities in 
diagnosis and survival. 
Conclusion 
• This appears to be the first large population-based study on colorectal cancer to 
include data on comorbidity and stage data. Complete data on stage and 
treatment have always been difficult to obtain for population-based cancer 
registries. By using both cancer registry and hospital episode data, to obtain 
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infonnation on surgery and chemotherapy data, the proportion of patients 
receiving surgery was more complete and comparable with clinical studies. 
• The use of administrative databases to measure comorbidity in population-based 
data, such as cancer registry data, is a choice of practicality and feasibility. Some 
residual confounding is likely to remain due to under-ascertainment of 
comorbidity. The comorbidity measures and the time period within which the 
comorbid conditions are identified in relation to the cancer diagnosis should also 
be considered and evaluated in relation to the disease under study. The Charlson 
comorbidity measure derived from the period 18 months to 6 months before 
colorectal cancer diagnosis strongly predicted cancer-related mortality in the 
first year after a diagnosis. Even after adjusting for comorbidity, the strongest 
predictors of cancer-related mortality were stage and age. Adjustment for 
comorbidity should generally be encouraged, to enable more realistic and 
clinically appropriate and comparable estimates of survival for cancer. 
• The survival advantage in affluent patients has generally been attributed to 
earlier stage at diagnosis and fewer comorbid conditions, but both are 
incompletely recorded in most population-based data. A major strength of this 
study is the lack of missing stage and comorbidity data, obtained by a 
combination of data linkage and imputation. This allowed complete adjustment 
and evaluation of survival for 29,563 colorectal cancer patients diagnosed in the 
North West of England between 1997 and 2004. Advanced stage and greater 
comorbidity were both strongly associated with poor survival, but they did not 
explain the socioeconomic inequalities in survival. Most of the excess mortality 
occurred in the first year after diagnosis and was frequently attributed to post-
operative mortality, late stage at diagnosis, comorbid conditions and other 
complications. The deprivation gap in survival appeared to be 'set' in the first 
year after diagnosis, remaining similar up to five years after diagnosis. 
Inequalities in colorectal cancer survival have been found in other countries. 
Whilst these findings were based on patients diagnosed in the North West the 
underlying pattern is likely to be generalisable to the UK, and possibly Europe. 
• Equitable access to treatment is a fundamental principle of the NHS and was a 
central conclusion of the Calmine-Hine report. It is difficult to ascertain if equal 
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access is occurring, because whether treatment was clinically appropriate can't 
be assessed without complete infonnation (stage, comorbidity and treatment). In 
this study, there was considerable socioeconomic inequality in treatment, with 
deprived patients receiving less adjuvant therapy than affluent, and a higher 
proportion receiving no treatment. More modem surgical techniques, such as 
anterior resection, were less likely to be perfonned on deprived patients. Modem 
surgical type, lower post-operative mortality and higher survival are associated 
with surgery conducted by high-volume surgeons and in high-volume hospitals, 
but the chance of receiving surgery from a high-volume surgeon reduced with 
increasing deprivation. Overall, deprived patients were less likely to receive 
optimal treatment, even after adjustment for stage and comorbidity. This raises 
the key questions: i) What are the barriers to treatment for deprived patients? 
And ii) are there other factors which could not be evaluated in this study, but 
which may explain the treatment differences? 
• Even if deprived and affluent patients received equivalent treatment, there was 
still a deprivation gap in survival at one year. Deprived patients had higher post-
operative mortality and excess mortality for high-volume surgeon and high-
volume hospitals. Even when deprived patients received the same treatment type 
as affluent patients, inequalities in survival were observed. This could be 
because of treatment factors that could not be measured in this study (e.g. 
chemotoxicity, timeliness of treatment) or other risk factors for mortality or 
complications (e.g. obesity, smoking). Evaluation of treatment regimes using 
population-based data may not have the depth of detail to account for the 
complexity of the entire treatment pathway, but it does provide a population-
based analysis that can be studied with more in-depth clinical audits. 
• Ideally, population-based data should be complete, avoiding the need for the 
arduous linkage process and the use of multiple imputation. Cancer registry data 
is known to be of high quality for demographic and tumour details, but the data 
quality of hospital episode data is of lower quality and completeness. Multiple 
imputation is a widely used and robust technique, but it is always preferable to 
have original data that are complete. This enables more in-depth analysis than 
was possible here for surgery types. 
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• Throughout the study period of 1997 to 2004 clinical guidelines for the 
treatment of colon and rectal cancer have existed, and remained similar during 
the entire period. Therefore, with the optimal treatment regimes clearly 
identified it is particularly disappointing to find socioeconomic inequalities in 
survival during this period. This research adjusted for patient factors and still 
found socioeconomic variations in treatment and survival still persisted. The 
persistence of socioeconomic variations suggests intervention to mandate 
optimal treatment for all patients involving both health policy and clinical 
guidance may narrow the inequalities. 
• The treatment a colorectal cancer patient receives appears to depend, in part, on 
socioeconomic status. This may be due to the treating physician judgements of 
the patients perceived ability to withstand a given treatment regime. Ensuring 
equal access to services and equal improvement in survival across all social 
groups will be a continuing challenge for the NHS. The introduction of a 
colorectal cancer screening programme will probably increase inequalities in 
survival, because up-take rates are higher among the affluent. Ultimately, a 
universal health-care system may not be able to achieve equal survival, because 
of external factors that cannot be controlled, but ensuring equitable access would 
be expected to greatly reduce the inequalities in colorectal cancer survival. 
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3. The following papers are currently being drafted: 
a. Estimates of 'cure' after colorectal cancer: variations by stage and age. 
b. Socioeconomic inequalities in colorectal survival are not explained by 
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4. I also intend to write papers based on the main results of Chapters 7 and 8 
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